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ABSTRACT 
The aim of this thesis was to examine the use of modelling techniques in 
the economic evaluation of selective decontamination of the digestive tract 
(SDD), used to prevent intensive care unit (ICU) acquired pneumonia. The 
need for evidence for the effectiveness and cost effectiveness of 
technologies used in intensive care was highlighted through an 
examination of the literature. The clinical and economic issues pertinent to 
ICU-acquired pneumonia and SDD were described. It was suggested that 
an economic evaluation of SDD was required. An evaluation using 
modelling techniques was proposed. A secondary economic evaluation of 
SDD was carried out, utilising a decision-analytic model and published 
clinical and economic evidence to derive cost/outcome ratios. This 
analysis showed that SDD could be a dominant therapy, but improved 
economic and long term outcome evidence was required to increase the 
robustness of conclusions. This thesis concentrated on improving the 
economic evidence. A national survey of SDD use provided information on 
clinical practice. A prospective observational study was carried out at two 
British ICUs to obtain evidence on the economic impact of ICU-acquired 
pneumonia. The impact of infection and confounding factors on resource 
use was handled quantitatively, using regression techniques. It was found 
that ICU-acquired pneumonia significantly increased length of ICU stay. 
These two sets of empirical data were used in a revised economic 
evaluation of SDD. SDD was found to be a dominant therapy at both 
centres. Uncertainty around cost/outcome ratios was considered to be 
decreased, or at least quantified, by this primary economic evidence. This 
thesis concludes that modelling has a place in economic evaluation in 
intensive care, if rigorous methods are used. It has also demonstrated that 
current, reliable and applicable economic evidence is a prerequisite to any 
economic evaluation, if it is to be included in the decision-making process. 
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GLOSSARY 
Aspiration 
Bacterial resistance 
to drugs 
Blind antibacterial 
treatment 
Pathologic inhalation of vomitus or mucus into 
the respiratory tract which may occur when 
the patient is unconscious or anaesthetized. 
The ability of a microorganism to withstand 
effects of a drug that is lethal to most 
members of its species. 
Use of antibiotics to treat an infection when 
there is no positive microbiological culture to 
direct therapy. 
Gram-negative bacteria Group of bacteria identified by a chemical stain 
test, often implicated in nosocomial infection. 
Members include Pseudomonas aeruginosa and 
Escherichia coli. 
Gram-positive bacteria Group of bacteria identified by a chemical stain 
test, often implicated in nosocomial infection. 
Members include Staphylococcus aureus and 
Streptococcus faecalis. 
ICU-acquired pneumonia Pneumonia that is not present or incubating on 
admission to ICU. 
Early onset pneumonia Pneumonia that becomes clinically evident 
within the first 48 hours of the ICU stay. 
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Late onset pneumonia Pneumonia that becomes clinically evident 
after the first 48 hours of the ICU stay. 
Mechanical ventilation Ventilation of the lungs accomplished by 
extrinsic means (mechanical ventilator). 
Minor infection Infections originating from the urinary tract, 
skin, superficial wounds, gastrointestinal tract 
and vagina. 
Nosocomial infection Infection that is not present or incubating on 
admission to hospital. 
Oropharyngeal Relating to the area of the pharynx between 
the soft palate and the epiglottis. 
Pulmonary artery Catheter inserted into the pulmonary artery to 
catheter measure pulmonary capillary wedge pressure 
(PCWP) and thus evaluate cardiac function in 
cardiogenic, hypovolaemic and septic shock. 
Serious infection Infections originating in the lungs, central 
nervous system, abdominal cavity or 
bloodstream. (Also 'major infection') 
Tracheal aspirate Fluid withdrawn from the trachea ('windpipe') 
by suction, for microbiological culture. 
Tracheostomy Creation of an opening into the trachea 
through the neck, with insertion of an 
indwelling tube to facilitate passage of air or 
evacuation of secretions. 
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Abbreviations 
ADHs Additional doctors' hours 
APACHE Acute physiology and chronic health evaluation 
CPAP Continuous positive airways pressure 
(artificial ventilation mode) 
CCU Coronary care unit 
CSSD Central sterile supplies department 
DGH District general hospital 
DRG Diagnosis-related group 
g Gramme 
GNAB Gram negative aerobic bacteria 
HDU High dependency unit 
ICS Intensive Care Society 
ICU Intensive care unit 
iv Intravenous 
LTH London teaching hospital 
LYG Life years gained 
mg Milligrammes 
ml Millilitres 
MPM Mortality prediction model 
MRSA Multiresistant Staphylococcus aureus 
MU Mega units 
NHSME National Health Service Management Executive 
NST No significance test reported 
OFS Organ failure score 
PA Pulmonary artery 
PMH Previous medical history 
PTA Polymixin E, tobramycin and amphotericin-based SDD 
regimen 
QALY Quality adjusted life year 
QoL Quality of life 
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Abbreviations (cont. ) 
RCT Randomised controlled trial 
qds Four times a day 
SAPS Simplified acute physiology score 
SCARRF Severe combined acute renal and respiratory failure 
sd Standard deviation 
SDD Selective decontamination of the digestive tract 
SEM Standard error of the mean 
tds Three times a day 
TISS Therapeutic intervention scoring system 
WFI Water for injection 
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Chapter 1: Introduction 
This thesis explores the issue of economic evaluation in intensive care 
medicine, in general, and the economic evaluation of prevention of ICU- 
acquired pneumonia with selective decontamination of the digestive 
tract (SDD), in particular. 
Intensive care medicine dates from the 1950s when long term artificial 
ventilation was developed for polio victims [Hulstaert et al, 1990]. 
Since that time it has developed into a discrete clinical discipline. 
Intensive care has many different interpretations in society, as most 
people have no first hand experience of it. To the layman, it is regarded 
as the 'winning technology, through which miracles of modern medicine 
may be performed' [Hulstaert et a/, 1990]. To clinicians, the intensive 
care unit is where the most serious cases are sent in the hope that 
medicine will win against heavy odds. To policy-makers, intensive care 
is the endless consumer of non-budgeted resources, making constant 
financial demands, often supported by subjective and emotional 
arguments from clinicians and patients. 
Modern intensive care medicine is a rescue therapy, rather than 'cure' or 
'care' [Jennett, 19861. Its widely accepted aim is the 'restoration to 
normal of vital organ function in order to gain time to treat an underlying 
disease and provide an appropriate quality of life for the future' 
[Hulstaert et al, 1990]. To achieve this, there are three categories of 
intensive care, defined by the European Society of Intensive Care 
Medicine [Miranda et al, 1990]. The recovery room is where patients 
are observed and treated in the immediate postoperative period. The 
high dependency unit (HDU) provides a higher level of nursing care and 
medical consultation than is required on a normal ward. The intensive 
care unit (ICU) is where continuous specialised nursing and medical 
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care, combined with dedicated equipment, is available for the 
normalisation of vital organ function, without time limit. 
ICUs were developed with the aim that concentration of resources 
would lead to economies of scale and improvements in quality of care 
[Hulstaert et al, 1990]. In the last thirty years there has been 
unrelenting expansion and development of intensive care medicine. One 
day on an ICU can cost up to four times as much as a day on a normal 
ward. Reported average costs per day on British ICUs can exceed 
£1000 [Singer, 1991]. 
The UK has a lower level of ICU provision than the rest of Europe and 
the USA. In the UK, only 2.6% of adult acute hospital beds are 
allocated to ICUs. Denmark has the highest European provision of 4.1 % 
[Miranda et al, 19901. In comparison, 7 to 11 % of acute care beds in 
the US are ICU beds [Osborne et a/, 1994]. In 1992, intensive care 
medicine accounted for 15-20% of US hospital costs, or 1% of their 
GDP [Osborne et a/, 19941. In Britain, only 0.05% of GDP is spent in 
intensive care medicine. It is, of course, difficult to draw direct 
comparison between British and American health care provision due to 
differences in medical culture and health service funding methods. 
However, the presence of a twenty-fold divergence between the UK and 
the USA warrants further investigation into reasons for existing 
provision levels. 
Achieving the optimal or most 'efficient' level of ICU provision requires 
information on resource use associated with ICU provision, and the level 
of benefit incurred by the target patient population. In the UK, there is a 
growing awareness that purchasers require information about how best 
to allocate their resources in an NHS increasingly focusing on cost- 
effectiveness. However, optimising ICU resource allocation is limited by 
the lack of cost effectiveness evidence available [Metcalfe et a/, 1995]. 
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This is because, like many high technology medicines, and health 
technologies in general, intensive care medicine was introduced without 
prior evaluation. There is no overriding legislation to control the 
purchase and use of heath care technology in the UK, and until recently, 
little evidence of a coherent policy for health technology assessment. 
However, in recent years, the need to control the introduction of new 
technologies has become more widely appreciated, partly due to more 
organised activity overseas [Spiby, 19941. The response to this in the 
UK is the creation by the NHS management executive (NHSME) of a 
standing group on health technology assessment [NHSME, 19941. Their 
recommendations for evaluations of interventions are based on the 
premise that 'without reliable information about the effects of health 
technologies, soundly based decisions cannot be made about the 
deployment of resources' [NHSME, 19911. 
To date, there has been only sporadic clinical and economic evaluation 
of intensive care. A major barrier is that it is established (in the minds 
of the medical profession and society) as a 'life saving' technology and 
it would now be considered unethical to randomise patients to receive 
intensive care, or not [Miranda et al, 19901. There is no doubt that 
many severely ill patients benefit from admission to an ICU. However, 
intensive care medicine consists of many technologies used in a wide 
range of patients. To achieve the optimal level of provision, it is 
necessary to evaluate whether individual interventions and technologies 
used in intensive care are being directed at patient groups most likely to 
benefit, and whether those technologies are being used optimally in 
those patients. This divides the issue of efficiency into allocative and 
technical efficiency. Allocative efficiency exists when there is the most 
efficient, or optimal, level of ICU provision within health care provision 
in general [Drummond et a/, 1987]. Technical efficiency exists where 
those resources provided for intensive care are used to produce the 
largest net benefit possible. 
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Neither of these efficiency targets can be achieved without evidence on 
effectiveness. However, there is little published research in 
effectiveness of technologies used within intensive care. This is usually 
attributed to difficulties associated with doing randomised controlled 
trials (RCTs) in an intensive care environment. Due to the critically ill 
nature of ICU patients, it is more difficult to obtain ethical approval or 
patient consent. Patient groups are frequently either homogeneous but 
too small, or large but heterogeneous. Assessment of technical 
efficiency of many interventions may be precluded if economic 
evaluation is only conducted as part of an RCT. The NHSME advisory 
group on health technology assessment suggested that alternative 
methods, such as use of observational data, could be used to 
'demonstrate the effects of health technologies ... in some 
circumstances where randomised trials are not feasible' [NHSME, 1991 ]. 
Alternative methods of economic evaluation incorporate the 
development of models that have clinical and economic evidence 
attached to them from multiple sources, rather than from one RCT. The 
main difference is that data derived from multiple sources, rather than 
one source, are combined for use in analysis. These sources can be 
primary or secondary. Primary economic or clinical data are collected 
either within the framework of an RCT or from an observational study. 
The analysis is carried out on the same patient group that was used to 
obtain the data. Secondary data consists of published evidence. It is 
used in analysis of patient groups other than those originally used to 
collect the data. The use of modelling techniques for economic 
evaluation is used as an alternative to economic evaluations attached to 
RCTs. This alternative methodology could be particularly useful in 
intensive care medicine. Investigation is required into whether the 
methods are applicable to intensive care. 
This thesis examines the application of modelling techniques in the 
economic evaluation of SDD, used to prevent ICU-acquired pneumonia. 
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The primary aim is to examine whether SDD can be demonstrated to be 
cost effective, using these techniques. The secondary aim is to 
examine whether alternative modelling methods of economic evaluation 
allow the derivation of cost/outcome ratios that can be used with as 
much confidence as those that would be derived from RCT-linked 
economic evaluations. 
Chapter Two introduces the issue of economic evaluation of intensive 
care medicine. Drawing on published British and foreign evidence, the 
need for research into both allocative and technical efficiency is 
demonstrated. The methods used in economic evaluation are described. 
The evidence available on technical efficiency on intensive care and its 
technologies is examined. 
Chapter Three focuses the issues raised in Chapter Two onto the 
specific clinical and economic issues surrounding ICU-acquired 
pneumonia and its prevention by SDD. The highly significant economic 
and clinical impact of ICU-acquired infection, particularly pneumonia, is 
described through a consideration of published evidence. Although SDD 
is a resource-intensive intervention, it may result in decreased resource 
use due to fewer episodes of pneumonia. To assess the cost 
effectiveness of SDD, economic evidence is required on the resource 
use and patient outcome implications of SDD and ICU-acquired 
pneumonia. This chapter concludes that the evidence available 
precludes making conclusions about the cost effectiveness of SDD. A 
formal assessment of costs and benefits is recommended. 
Chapter Four, therefore, develops the framework for the economic 
evaluation of SDD. This chapter defines the economic question to be 
asked and employs decision analysis to develop a decision-analytic 
model upon which to base a formal economic analysis [Weinstein, 
19801. When the model has been designed, it is necessary to attach 
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clinical and economic evidence to it. This evaluation uses secondary 
data sources for this evidence. Systematic review techniques are used 
to extract evidence to derive incremental cost/outcome ratios. The 
sensitivity of conclusions drawn to variation in underlying parameters 
are tested using sensitivity analysis. This analysis suggests that, in 
general, the clinical data available is of high quality, but it is not always 
presented in such a way that allows direct application to economic 
evaluation. Also, improved economic and patient outcome data is 
required to improve the conclusions on the cost effectiveness of SDD. 
This thesis concentrates on the impact of the quality of economic data 
on the uncertainty around cost/outcome ratios. Collection of primary 
economic data should only be recommended under two conditions. The 
first is that there will be sufficient added value from the evidence 
collected in a primary study to improve upon the conclusions drawn by a 
secondary analysis. The second condition is that there is sufficient use, 
clinical interest or controversy surrounding the therapy that the results 
from a primary study will have an impact on decision makers. 
Chapters Five to Seven report the acquisition of primary data on the 
economic impact of ICU-acquired pneumonia and SDD. To carry out an 
economic evaluation of SDD applicable to British practice, it is necessary 
to have information about clinical practice of SDD in Britain. Chapter 
Five describes the identification of British practice patterns and resource 
use associated with SDD through a national postal survey. Chapter Six 
describes the acquisition of primary bottom-up economic data arising 
from ICU-acquired pneumonia in two British ICUs, one at a London 
teaching hospital and one at a district general hospital. Identification of 
the impact of infection, particularly ICU-acquired pneumonia, on 
resource use is investigated in Chapter Seven. The impact of infections 
and confounding factors is handled quantitatively, using linear and 
logistic regression techniques, with reference to the effect on resource 
use and patient mortality. 
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Chapter Eight describes an economic evaluation of SDD that models the 
clinical and economic impact of SDD if it was to be implemented at the 
two ICUs investigated in Chapter Six. Economic evidence obtained in 
Chapters Five to Seven is applied to the decision-analytic model 
developed in Chapter Four. Conclusions on the cost effectiveness of 
SDD are derived for the two ICUs described. Sensitivity analysis is used 
to assess the robustness of conclusions to variation in underlying 
parameters. The 'added value' obtained from devoting resources to 
obtaining primary economic data is examined in this chapter. The 
realisable cost savings arising from the possible implementation of SDD 
at the two ICUs studied, compared with the theoretical values derived 
by this economic evaluation, are discussed. 
Chapter Nine draws together the main points of the thesis. The extent 
to which the thesis has met its objectives through the methods used is 
discussed. The policy implications of the results reported in this thesis 
for the use of SDD in ICUs are examined. Finally, the wider implications 
of the use of modelling in economic evaluation in intensive care are 
considered. 
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Chapter 2: The Economics of Intensive Care 
2.1 INTRODUCTION 
Health care costs in general are rising for a number of reasons, including 
increase in population size and age, rising levels of service, new 
technologies and society's growing expectations of health services 
[Miranda et a/, 19901. There is a steadily increasing awareness that 
resources for health care are limited. Unfortunately, the possible uses of 
those resources far exceed their capacity. In this climate it is essential 
that intensive care provision should represent a balance between 
resource use and likelihood of benefit to patients. 
The clinical objective of intensive care medicine is to maximise the 
incremental health gain it imparts upon the population it serves. This 
objective is achieved by increasing life expectancy and quality of life 
through clinically effective intervention. Clinical effectiveness exists 
where an intervention can be shown to improve either quantity or 
quality of life, or both, in research and practice. However, clinical 
effectiveness is a 'counsel of perfection in a real world which can never 
afford to be all things to all persons' [Reisman, 1993]. The scarcity of 
health care resources means that treating one patient necessarily means 
leaving another on the waiting list. In this context it is unethical not to 
ensure that these resources are used as efficiently as possible. 
Therefore, the economic objective of intensive care medicine is to meet 
the effectiveness objective, given the level of provision deemed 
affordable by the host hospital and the funding health service at large, 
thus achieving efficiency at the same time. 
The aim of this chapter is to introduce the issue of efficiency in 
intensive care medicine and examine whether there is a need for 
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economic evaluation. The social opportunity cost of using scarce 
resources in one activity is the benefit forgone by not using them in the 
best alternative activity [Friedman, 1984]. The use of scarce resources 
in intensive care to improve the health of a group of individuals 
necessarily precludes their use in an alternative group of individuals. 
The benefit forgone by these individuals is the true opportunity cost of 
intensive care. The economic efficiency of intensive care can broadly be 
divided into allocative and technical efficiency. Intensive care can be 
considered to show allocative efficiency if diverting resources away 
from intensive care would result in more 'disbenefit' occurring in the 
intensive care population than benefit would be gained in other health 
care target populations. Allocative efficiency is considered more 
specifically within the context of an examination of the level of provision 
of intensive care in the UK, compared with other industrialised countries 
in section 2.2. 
The second component of efficiency is technical efficiency. The need 
for investigation into technical efficiency is demonstrated in section 2.3. 
Technical efficiency in intensive care arises from the efficient interaction 
between inputs (intensive care patients), health care intervention 
processes and outputs (health outcomes). These are examined in the 
context of their impact on one another and on technical efficiency in 
sections 2.4 to 2.6. The economic evaluation of intensive care 
medicine is complicated because it is composed of a range of 
technologies. Therefore, section 2.7 examines the published evidence 
on the technical efficiency of these technologies. The evidence 
available is assessed in terms of quality. Reasons for the lack of 
economic evidence are suggested. Finally, the implications of the 
findings from this chapter for economic evaluation in intensive care are 
discussed in section 2.8. 
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2.2 ALLOCATIVE EFFICIENCY IN INTENSIVE CARE: AN 
INTERNATIONAL COMPARISON 
Allocative efficiency exists on a number of levels [Williams, 19861. In 
the British context, there are decisions to be made about allocation of 
Government resources between different public services, such as health, 
social services, education or defence. Within the health service, 
resources can be allocated to the primary, secondary or tertiary sectors. 
Within a hospital, different specialities compete for resources. Within 
each speciality there is a decision to be made about which patients 
should be treated [Drummond et a/, 1987]. At each level of resource 
allocation, allocative efficiency is only achieved if the benefits incurred 
maximally exceed the opportunity cost. In practice, deciding on optimal 
levels of intensive care provision is very complex, due to arbitrary 
budget constraints, use of unevaluated technologies precluding 
assessment of cost effectiveness, pressures from clinicians, patients 
and families who may not recognise or accept when medical 
intervention is futile and the increasing threats of litigation. Varying 
influences of these factors have resulted in the level of provision being 
highly disparate in different countries [Miranda et a/, 1990]. 
The UK has the lowest reported level of ICU provision of an 
industrialised country, and the USA has the highest. Table 2.1 
illustrates the twenty-fold difference between the two countries in 
proportion of monies spent on intensive care in 1990. 
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Table 2.1 Intensive Care Costs per Person in Selected Industrialised 
Countries in 1990 [Metcalfe et a/, 1995] 
Country HC' (% 
GDP2) 
GDP 
/CAP3(£) 
HC costs 
/CAP(E) 
IC4 (% HC) IC costs 
/CAP(E) 
USA 12.4 11634 1443 10 144.3 
France 8.9 11805 1050 ?5 (52.5)6 
NZ 7.2 7211 519 ?5 (26.0)5 
Japan 6.5 13164 856 ?5 (42.8)6 
UK 6.1 9540 582 1 5.8 
' Health care 
2 Gross domestic product 
3 Gross domestic product per person at 1990 market prices 
Intensive care 
6 Estimated intensive care costs as 5% of all health care costs 
This section compares the levels of intensive care provision in the UK 
and USA to identify where the differences in resource allocation lie, why 
intensive care provision is so different, and to what extent more general 
health care provision structures impact upon this provision. An 
assessment of whether allocative efficiency in intensive care medicine is 
achieved by the two countries is not within the scope of this review. 
However, whether British or American levels of ICU provision can be 
considered more closely to approach allocative efficiency, on the 
strength of evidence available, is briefly examined. 
The USA devotes twice as much of its GDP to health care provision as 
the UK (see Table 2.1). Therefore the difference in intensive care 
spending may reflect significant differences in health care provision in 
general. These differences in health care expenditure are usually 
attributed to methods of funding and provision of services. In the USA, 
health care costs are met largely by third party insurance. The 
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combination of third party payment, tax relief for health insurance and 
strong patient autonomy dominating the clinician/patient agency 
relationship effectively reduces barriers to resource intensive 
interventions like intensive care [Osborne et a/, 1994]. Standard 
economic theory suggests that when people pay less than the full cost 
of what they buy, they will consume more than is socially optimal 
(unless their consumption benefits other individuals in the process) 
[Aaron, 19911. This theory suggests that insurance payment systems 
induce excessive health care expenditure. Insurance is purchased to 
avoid the risk of unexpected expenditure but, because it provides a 
reduction in price at the time that care is purchased, it may have the 
concomitant effect of artificially increasing the demand for care 
[Feldstein, 1979]. The price is also increased as there is no incentive to 
'shop around' for the best bargain. 
The impact of excessive use of health care by an individual on insurance 
premiums is spread over the group as a whole. A vicious circle of more 
insurance claims leading to higher costs and higher costs requiring more 
insurance develops [Reisman, 1993]. This hypothesis is supported by 
Evans' [1984] comparison of US and Canadian health care spending 
trends from 1960 to 1982. From 1960 to 1971, funding methods were 
insurance-based for both countries and there was a comparable increase 
in health care spending from 5% to 7.5% of GDP [Evans, 1984]. The 
introduction of national public insurance coverage in Canada in 1971 
initiated a period where health care costs did not rise as a proportion of 
GDP for ten years. During this period, health care in the USA was still 
funded by third party insurance and spending rose to 10.5% of the 
GDP. 
The mechanism of insurance-funded health care leading to an increase in 
health care costs is particularly relevant in the area of high technology 
medicine. New techniques that are not demonstrably effective are more 
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likely to be taken up by hospitals funded by third party insurance than 
by those who are publicly reimbursed. However ineffective they are, 
they contribute to filling beds and inflating bill receipts [Reisman, 19931. 
However, with the prediction in 1987 that the USA would be devoting 
15% of GDP to health care by the year 2000, the issue of rationing 
health care is becoming more prominent [Aaron, 19911. Aaron suggests 
that the elimination of health care interventions that produce 'little or no 
benefit' would immediately result in a reduction in spending of 30%. 
It has been suggested that there is over-provision or inefficient provision 
of health care and intensive care in the USA. Equally it has been 
suggested that there is under-provision in the UK [Metcalfe et a/, 19951. 
However, the provision of health care in the UK is likely to contain as 
many structural and cultural barriers to efficient allocation of resources 
as the USA [Reisman, 19931. The UK NHS is financed primarily from 
general taxation revenue and has a system of primary care provided by 
general practitioners (GPs) who effectively ration hospital-based 
services. The NHS and Community Care Act (1990) separated provision 
of health care from funding [Osborne et a/, 1994]. Health authorities 
and fundholding GPs now purchase health care from the NHS or the 
private sector. In the UK, the clinician is the gatekeeper to health care, 
rather than the patient, as in the USA. In the UK, the agency 
relationship that exists between clinician and patient is different from 
the USA in that the clinician exhibits more autonomy. The clinician 
procures health care on behalf of the patient, taking on the responsibility 
of decisions regarding intervention. Issues implicit within clinical 
decision making that could compromise economic efficiency include 
decisions based on imperfect information; considerations of equity; 
pressure from the patient and fear of litigation [McGuire et a/, 19881. 
However, this agency relationship is also affected by the 
purchaser/provider split that now exists, as clinicians are under pressure 
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from both to produce cost effective health care [Ham, 19921. The 
introduction of competition and associated cost consciousness to the 
NHS has profound implications for costly high technology specialities 
like intensive care medicine. 
A natural consequence of international comparison, whether valid or 
not, is concern that ICU provision in the UK is inadequate [Metcalfe et 
al, 1995]. A King's Fund panel formed to investigate the level of 
provision of intensive care medicine in the UK concluded that there was 
not enough evidence on effectiveness or cost effectiveness of ICUs in 
the UK to answer any questions about optimal levels of provision [King's 
Fund Panel, 1989]. Metcalfe et a/ [1995] examined the provision of 
intensive care in England. They report wide variations in ICU provision 
around the country, wide ranges in occupancy rates and patient refusal 
rates'. On average, 6.7% (range 0 to 47%) of requests for admission 
to ICUs are refused. 70% of these refusals are because of lack of beds 
or nursing staff. Refusal rates are often used to imply that there is 
insufficient ICU provision in Britain. This is misleading because there is 
little evidence to confirm whether patients who are accepted onto ICUs 
are appropriate candidates for intensive care. 
It is not possible, on the basis of the evidence examined, to make 
definitive statements about whether the USA or UK have achieved 
allocative efficiency in intensive care medicine. No evidence has been 
found that indicates differences in patient outcome between the UK and 
the USA. This may indicate either that there is no difference and the 
extra resources used in the USA do not generate better health 
outcomes, or simply that appropriate comparative studies have not been 
1 Patient refusal rates are recorded by most ICUs. When an admission to an ICU is 
refused, for whatever reason, the patient must be transferred to another ICU or 
maintained on a lower dependency unit until an ICU bed becomes free. 
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carried out. The barriers to efficient allocation of resources to intensive 
care in the US are patient autonomy; high litigation levels leading to 
defensive medicine; the perverse incentives associated with third party 
insurance; and lack of effectiveness or cost effectiveness evidence. The 
barriers in the UK are the gatekeepers to ICUs (non-ICU clinicians) not 
being exposed to the true cost; clinician autonomy; until recently the 
inability to provide cost figures for intensive care; and the lack of 
evidence for effectiveness and cost effectiveness. In both systems, the 
consumers of intensive care, patients and clinicians, are not exposed to 
the true economic cost due to the funding mechanisms within their 
health care systems, and they make their decisions based on imperfect 
information. So, although the health care systems in the UK and US 
have resulted in highly disparate levels of intensive care provision, the 
barriers to allocative efficiency are similar. 
2.3 TECHNICAL EFFICIENCY IN INTENSIVE CARE 
Technical efficiency arises from the optimal combination of inputs and 
resource use to produce the maximum output [McGuire et al, 1988]. 
McGuire et a/ suggest that, given a fixed level of input, it can be 
achieved in four ways: 
1. increasing output at a given level of resource use; 
2. maintaining output at the same level whilst decreasing 
resource use; 
3. increasing resource use and output, increasing output at a 
higher rate and 
4. decreasing resource use and output, decreasing resource use at 
a higher rate. 
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Technical efficiency of intensive care exists, for a given level of service 
provision, when the maximum net benefit is derived from the resources 
available for use [Friedman, 19841. Intensive care is a collection of 
technologies and interventions. To assess the technical efficiency of 
intensive care, it is necessary to know how efficient are the individual 
technologies, to allow optimal combinations. The input, process and 
outcome of intensive care and their relationship with technical efficiency 
are addressed in the following three sections. 
2.4 INPUT: THE PATIENTS 
For intensive care medicine to be effective, it should only be used for 
those patients who will benefit. Failure to exclude patients for whom 
intensive care medicine is either unnecessary or unsuccessful wastes 
resources and obscures the benefit of effective therapies. An estimated 
95,000 patients were admitted to 257 UK ICUs in 1992 [Metcalfe et al, 
1995]. With a patient population of this size, in such a costly speciality, 
it is essential that only appropriate patients are admitted. Admission 
guidelines for ICUs were defined by the US National Institute of Health 
Consensus Conference [Ayers et al, 19831: 
1. patients with acute, reversible disease for whom the probability of 
survival is low without ICU but high with it; 
2. patients whose probability of survival is low without ICU care and 
uncertain with such care and 
3. patients admitted to an ICU because they are at risk of becoming 
critically ill so to prevent serious complications or respond 
promptly to any complications that might occur. 
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Patients for whom intensive care is not considered appropriate are those 
admitted for monitoring that could be carried out equally well elsewhere, 
in a less costly environment, and those that are so severely ill that they 
will die with or without intensive care intervention [Miranda et a/, 1990]. 
Distinguishing between appropriate and inappropriate patients requires 
characterisation of the intensive care population. The characteristics 
most commonly used are 'severity of illness', diagnosis and age. 
Severity of illness measurement is used as a routine method of patient 
characterisation because patients are admitted to intensive care as a 
consequence of the severity of their condition, rather than the diagnosis. 
The most widely used and extensively validated severity of illness 
measure is the Acute Physiology and Chronic Health Evaluation 
(APACHE) II score developed by Knaus et a/ [1985], which has recently 
been validated for use in the UK [Rowan et a/, 19931. It combines a 
measure of previous health status with the current acute health state. 
APACHE II was designed to indicate severity of illness of groups of 
patients to enable comparison between units and between patient 
groups in clinical trials. The prognosis attached to severity of illness 
indicators for different diagnoses has been derived. The overall correct 
classification rate of hospital survival for APACHE II is 86%, precluding 
its use for individual patient prognosis [Knaus et al, 19851. It does, 
however, allow stratification of patients and provides a standard 
parameter which allows comparison between ICUs. 
Diagnosis and age are also used to characterise patient groups. 
Diagnostic categorisation of ICU patients is complex because most have 
multiple diagnoses. Precise diagnostic categorisation of patients can 
lead to many diagnostic groups containing small numbers of patients. 
Also, lack of continuity in diagnostic categories makes comparison 
between units or studies difficult [Miranda et a/, 19901. Therefore, it is 
rarely relied upon alone to characterise an ICU population. Age is often 
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used in description, but rarely as a barrier to ICU admission. As the age 
of the population increases, the age of people requiring intensive care is 
rising. Nicholas et a/ [1987] reported that 24.1 % of their French ICU 
population was over 65 and 7.9% was over 75. Increased mortality is 
found in older age groups but this increase is lost once severity of illness 
and previous health status are controlled (Nicholas et al [1987], Wu et a/ 
[1990], Pesau et a/ (1992]). The argument that elderly people do not 
benefit from intensive care is therefore not supported by empirical 
evidence, but the effect on life-years or quality-adjusted life years gained 
may have implications for economic evaluation. 
Other characteristics such as surgical category, race or smoking status 
provide useful information when comparing intensive care populations. 
Patient characteristics may have a significant impact on the resource 
use of an ICU due to their effect on the process of care. Differences in 
resource use and patient outcome between ICUs are more 
comprehendible when differences in patient populations are known 
[Knaus et al, 1985]. Comparison of effectiveness and cost 
effectiveness studies from different centres can be validated or 
precluded by information on types of patient populations used. 
2.5 PROCESS: THE COST OF INTENSIVE CARE 
The process of intensive care medicine utilises a range of technologies, 
specialised staff and vast quantities of consumables. For the purposes 
of economic analysis it is necessary to have information on the resource 
use associated with that process and costs associated with that 
resource use. Costs should have the following characteristics 
[Drummond et al, 1987]: 
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1. They should comprise all relevant resource use associated with 
interventions, on an individual patient or 'bottom-up' basis. 
2. They should reflect the true economic cost of that service. 
3. They should have explicit sources, components and methods of 
collection or derivation. Whether the short or long run is being 
considered should be stated and justified. Explicit handling of fixed, 
semi-fixed and variable costs is necessary. Any uncertainties 
surrounding methods should be explicitly stated and tested for 
importance using sensitivity analysis. 
4. The perspective of the study should be stated. This affects whether 
intensive care, hospital, health sector or indirect costs are included, and 
should be explicitly stated. 
A review of the literature [1976 to 1994] provided twenty-two studies 
on the cost of intensive care, one unpublished study [Gyldmark, 1993] 
and one report [South Australia Health Commission, 1994]. Results 
from these studies are summarised in Table 2.2. Costs per ICU patient 
reported in the studies vary widely, due to technological development 
over time and variations in patient groups, unit characteristics and 
clinical practice. Also, methodological variation in costing intensive care 
increases apparent variation in costs, but does not reflect actual 
resource use differences. This section assesses to what extent the 
methods used by the studies vary and whether they meet the 
methodological guidelines described above. 
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2.5.1 Top-Down Versus Bottom-Up Costs 
The two ways of collecting costs are either 'top-down' or 'bottom-up'. 
Top-down studies use the total budget to produce average costs per bed 
day. ICU costs per patient have been reported by four studies using this 
method (see Table 2.2). This method assumes that all patients have 
similar diagnoses, severity of illness, treatment and constant therapeutic 
intensity throughout the stay. The main limitation of this method is that 
the inter-patient variation in resource use due to interventions or severity 
of illness is not detected, so that the costs are not sensitive enough to 
be useful in an economic evaluation. Most costing studies examined 
reported their costs as 'bottom-up' costs or charges. Bottom-up costs 
are patient-specific, so reflect interpatient variation. However, eleven 
studies did not separate ICU costs from total hospital costs, severely 
limiting the usefulness of their data. 
2.5.2 Use of True Economic Cost 
True economic cost takes into account all the cost associated with an 
intervention, not just acquisition market prices. Whilst empirical 
determination of true economic cost is complex, cost data needs to 
reflect true economic cost as closely as possible. In a nondistorted 
market prices provide an approximation of the value placed upon a 
resource. In a distorted market environment like a health service, 
estimation of true costs is not straightforward as normal price 
mechanisms are rarely present. Thirteen of the studies examined in this 
review are from the USA and all use hospital charges. The reason for 
this is that they are already collected as part of the hospital billing 
system, so are easily accessible. In the USA, hospitals are reimbursed 
by private insurers on the basis of a fixed price per unit for each type of 
service provided [Evans, 19841. Such charges often depart substantially 
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from actual costs of production. This is because hospitals cross- 
subsidise losses on some services with profits on others, while running 
an overall surplus on operations to finance new growth [Feldstein, 
19811. These charges do not reflect the true economic cost of the 
service, although they have an obvious operational function, so should 
not be used in economic evaluation. 
In the British NHS, prices for all health care services are now necessary 
for contracting. Market prices are available for components of the 
services, such as salaries, drugs and equipment costs and these will 
generally provide good approximations to true cost. However, prices 
charged by hospital departments for their services have often been 
criticised for bearing little resemblance to the true cost of the service 
[Drummond et a/, 1987]. Due to the introduction of an explicit 
purchaser/provider split in the UK NHS in 1990, providers have to attach 
costs to services, many of which have never been explicitly costed 
previously. To standardise methods used to attach prices to hospital 
services, 'Costing for Contracting' recommendations were published by 
the NHSME in 1993 [Reeves, 1993]. The National Steering Group on 
Costing [Reeves, 1993] made the following recommendations on 
costing methods: 
1. prices should be based on actual costs; 
2. costs should be established on a 'full cost of treatment' basis 
(that is, including all relevant variable, semi-fixed and fixed costs); 
3. there should be no planned cross-subsidisation between 
specialities, procedures and contracts and 
4. the proportion of costs allocated as 'overheads' should be 
minimised to improve precision of costs. 
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Implementation of these guidelines should improve the quality and 
reliability of costs reported by centres. It should also make comparison 
between centres more valid. 
The final requirement when considering true economic cost is a 
consideration of adjustment of costs for differential timing [Drummond 
et a/, 1987]. Although comparisons in an economic analysis take place 
at one point in time, costs are not usually incurred at one point. 
Therefore, future costs should be reduced or discounted to reflect the 
fact that costs incurred or saved in the future are not considered to 
weigh so heavily as costs incurred in the present. This is due to the 
existence of time preference, whereby individuals prefer to have their 
resources now so that they can benefit from them. Discount rates, if 
used, need to be explicitly quoted. They can be government 
recommended rates (6% in the UK) or be consistent with current 
practice (such as 5% as used in the New England Journal of Medicine). 
2.5.3 Source and Components of Cost Parameters 
It is necessary to define which cost parameter is being considered in an 
economic evaluation. The total cost of intensive care, for a given unit 
of time, is the whole cost of producing a particular quantity of output 
from intensive care in that time period. In intensive care, that output is 
the patients treated and the quantity of output is the patient throughput, 
or activity of the unit. In the short run, total cost is made up of fixed 
and variable costs. Fixed costs do not vary with the quantity of output 
in the short run. In fact, the short run is defined as the time over which 
fixed costs do not vary [Lipsey, 19831. These costs have either been 
incurred at the beginning of the short run period so are 'sunk costs', or 
they are incurred independently of activity levels. In both cases they are 
unaffected by activity. Short run variable costs do vary with activity. 
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The short run total cost of an intensive care patient includes both fixed 
and variable costs. However, admitting another patient to the ICU 
increases the total variable cost to the ICU, but has no effect on the 
fixed cost. Therefore, the variable cost of that extra patient is the short 
run marginal cost to the ICU of treating one more patient. 
In the long run, there are no fixed costs. This period of time is long 
enough for the inputs of all factors of production to be varied [Lipsey, 
19831. In the long run, the ICU can make the decision to change its 
activity level. This will lead to changes in the short run fixed costs to 
accommodate this change. Therefore, in the long run, short run fixed 
costs can be considered as variable costs. So, the long run marginal 
cost of treating one more patient on the ICU includes the short term 
fixed cost of that patient. Therefore, the short run total cost of a 
patient is equivalent to the long run marginal cost of that patient. 
In economic evaluation it is necessary to define whether the impact of 
the intervention is being examined via marginal or average costs in the 
short or long run. If an intervention has a significant impact on the 
length of ICU stay of patients, this changes the activity of the unit in 
the long run. It may be considered necessary to alter the capacity of 
the ICU to accommodate this change in activity. This incurs changes in 
the levels at which fixed costs are set for the next short run period. To 
give an indication of the change in levels of costs required, it is 
necessary to examine the incremental effect of the intervention on short 
run fixed costs. The short run total cost, equivalent to the long run 
marginal cost, provides this information. Consequently, this is the cost 
parameter more useful for policy makers. So, costs in intensive care 
should contain both these fixed and variable components. These are 
described in detail below. An intermediate category, semi-fixed costs, is 
also described. 
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2.5.3.1 Fixed Costs 
In the short run, fixed costs are those incurred whether patients are 
treated or not. They consist of ICU-specific fixed costs such as 
maintenance of equipment. Other fixed costs are hospital overheads 
that are costs not only to the ICU, but to the hospital. 
The two major components of ICU and hospital fixed costs are capital 
costs and overhead costs. Capital costs occur when major capital 
assets such as ventilators or defibrillators are purchased. The two 
components of capital costs are opportunity costs of capital assets (that 
is, the lost opportunity to invest the sum in another venture) and the 
depreciation over time of the asset itself [Drummond et a/, 1987]. 
Capital expenditure is annuitised to reflect opportunity cost of the 
investment and depreciation of the asset. This annual sum is calculated 
by dividing capital expense by an annuity factor based on life 
expectancy and the discount rate. The life expectancy of an asset often 
does not equate to its physical life, being more dependent upon 
technological change. Other fixed costs are land opportunity costs and 
support services. ICU overhead costs are those incurred by support 
services and include catering, portering and laundry, general, medical 
and nursing administration and the maintenance, cleaning and heating of 
the unit. Most of these costs are shared costs, that is the support 
services allocate their costs to the several departments that use them. 
The NHSME (1993] 'Costing for Contracting' guidelines recommended 
that precision of cost analysis would be 'enhanced' by charging 'a 
greater proportion of their costs directly as opposed to... overheads'. 
There are many methods used for cost allocation. Double counting can 
occur if overhead costs are accounted for twice by different support 
departments. Terminology varies between studies and it is not clear 
which components have been included. Some recent studies have 
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handled this more explicitly. Ridley et a/ [19911 reported a daily fixed 
cost for ICU at £82.29 (10% of total cost per patient), listing all the 
components they include, methods of allocation and source of cost. 
2.5.3.2 Semi-Fixed Costs 
Semi-fixed costs remain unchanged over a range of activity. Given 
sufficient changes in activity, they increase or decrease. The principal 
example is staff costs. If activity increases temporarily, short term 
adjustment can be made by using temporary staff. Long term increase 
or decrease in activity requires adjustment to resource levels determined 
for the next short run period. 
Methods of retrospective allocation of staffing costs to patients range 
from very insensitive, that is, allocation by occupancy to give an 
average cost per day, to very sensitive, by assigning exact nursing time 
to all activities. Methods of nursing staff cost allocation have a 
significant effect on overall patient costs because they often comprise 
half the total cost [Gilbertson et a/, 19911. Use of an overall average 
cost does not reflect that patients on intensive care demand wide 
ranges of intensity of care. The most accurate, but time-consuming, 
way is to time each intervention and assign a nursing cost to it [Slatyer 
et a/, 1986; Crew et a/, 1987]. The two most commonly used workload 
indicators are the Therapeutic Intervention Scoring System (TISS) 
[Cullen et a/, 19741 and the Intensive Care Society (ICS) Dependency 
Scoring System (Appendix 2.1). 
Allocation of costs of staff from other departments, such as radiologists 
or pharmacists, can be done on a cost for time basis. Medical staff time 
is more complex to cost. This is because a patient may be attended by 
many clinicians during the ICU stay and medical treatment is not 
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confined to the bedside. Some studies include medical costs as fixed 
costs [Dick eta!, 1992; Gilbertson et a/, 19911 and some as semi-fixed 
costs [Ridley et a/ 1991,1993]. However, Dick of a/ [ 19921 found no 
correlation between therapeutic intensity and total physician activities, 
so medical staff time could be treated as a fixed cost. 
2.5.3.3 Variable Costs 
Variable costs are incurred from a patient's treatment. This includes 
disposables equipment, diagnostic tests, drugs and blood products, 
ventilation costs and so on. Variable costs increase with treatment 
intensity [Dick et al, 19921. Top-down costing studies cannot detect 
this patient variation. Bottom-up studies, using hospital charges or 
costs report wide variation between patients. Gyldmark [1993] reported 
the source of variable costs, using internal costs for diagnostic tests and 
market prices for drugs and blood products. Drugs and other 
consumables may have prices that vary between hospital due to the 
influence of buying groups, contractual agreements, quantity discounts 
and competitive bidding [Bootman et al, 19911. If generalisability is 
important, it may be preferable to use standard prices. Methods used in 
assigning costs to services such as pathology or radiology can 
significantly affect end prices and should always be explicitly stated. 
2.5.4 Perspective of Costing Study 
It is necessary to state the perspective of the study as this determines 
which costs are included. If the cost to intensive care of treating a 
patient is the cost parameter under investigation, variable and semi fixed 
costs incurred on the ICU should be included. Intensive care and 
hospital overheads may or may not be included, depending on the 
50 
purpose of the costing exercise. If the cost to the hospital of treating 
an ICU patient is being examined, additional costs to the hospital must 
be taken into account. If the costs to the health sector of treating an 
ICU patient are derived, additional costs incurred in primary care need to 
be included. The only study reporting inclusion of direct costs to the 
health sector beyond hospital costs is Loes et a! [19871. These 
consisted of daily hotel costs of nursing homes, cost of home nursing, 
physiotherapy and medical consultations needed. Costs to the public 
sector included domestic help and disability pension payments. 
More controversial and methodologically complex is the inclusion of 
indirect costs. Indirect costs can be more narrowly defined as the value 
of productive time lost due to morbidity and mortality [Drummond et a/, 
1987]. The value of productive time lost may originate from time out of 
work or housekeeping; time spent going to health care providers; time 
spent caring for the patient by relatives or paid carers; time forgone 
from leisure and other non-market activities [Hodgeson, 1994]. Time 
out of work tends to be the only indirect cost that can be reliably 
calculated from data. The use of production gains can, however, tacitly 
place a higher value on services catering for employable people rather 
than the elderly or children. There are many methodological difficulties 
associated with indirect costs so they are often not included. Hodgeson 
[1994] suggests that cost effectiveness ratios are usually higher without 
them. Empirical study has shown that indirect costs play an important 
role if health care programs produce health effects in the short term, if 
short term absence from work is significant and the target population is 
mostly employed [Koopmanschap et a/ 1994]. Therefore they may have 
a significant impact on intensive care costs. Pure cost effectiveness 
analysis would not include indirect costs because a benefit expressed in 
monetary terms introduces elements of cost benefit analysis. 
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Related to indirect costs are unrelated downstream medical costs 
[Hodgeson, 19941. When medical intervention increases life 
expectancy, costs are incurred in the added years for illness and disease 
unrelated to the intervention. Downstream costs should be included 
when the perspective is that of the health care provider. Exclusion 
understates the full economic costs of an intervention. No published 
studies of ICU were found that reported indirect or downstream medical 
costs. 
2.5.5 Predictors of Resource Use 
This section examines the published evidence for predictors of resource 
use. Most costing studies report that a few patients account for 
disproportionately high levels of resource use. Shiell [1989] reported 
10% of patients accounting for 45% of costs. Predictors of resource 
use identify those patients that are likely to be resource intensive. They 
can also be used as proxies for individual patient costing in economic 
evaluation. Predictors that have been investigated in the literature are 
diagnosis, age, severity of illness, therapeutic intensity and length of 
stay. 
Diagnosis has been investigated for impact on resource use. Studies 
report ranges of costs for different diagnostic groups but comparison 
between studies is limited by inconsistent definitions. The assumed 
relationship of diagnosis with resource use is used in the reimbursement 
of hospitals in the USA. Patients are categorised by the system of 
diagnostic related groups (DRGs). These contain conditions regarded as 
sufficiently similar to be treated in the same way, and thus consume 
similar amounts of resources. They are thus considered to be 
isoresource groups. However, their use in intensive care is limited as 
they are insensitive to the impact on resource use of severity of illness. 
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Kreis et a/ [1983] reported that only 31 % of hospital charges were 
reimbursed by DRG payment for trauma patients. Bekes et al [ 1988] 
reviewed the 151 most severely ill patients admitted to their ICU, 
finding that expenses per patient were $24098 higher than the DRG 
reimbursement. SA Health Commission [1994] reported that Australian 
DRGs accounted for only 26.8% of resource use variation. They all 
concluded that DRGs could not stratify severity of illness sufficiently 
specifically to reflect extra resources required to treat the most severely 
ill patients. 
Age has also been investigated for impact on resource use. Fedullo et a/ 
[19831, Nicholas et a/ [1987] and Thoner et a/ [1987] reported no 
increase in cost per patient with age. However, hospital mortality 
increased with age, so the cost per survivor increased significantly with 
age from US$26600 in patients under twenty to US$77900 in patients 
over seventy [Thoner et al, 1987]. 
Severity of illness could be expected to have an effect on resource use. 
Prior to the introduction of APACHE II, studies reported that non- 
survivors were more costly to treat than survivors [Cullen et a/, 1976; 
Detsky et al, 19861. Civetta et al [1990] reported that APACHE II 
scores did not predict resource use for individual patients or for the 
whole unit. Prognostic uncertainty is reported as an indicator for high 
resource use by Detsky et al [1986] and Rapaport et al [1990]. The 
highest resource use is by patients who are predicted to die but live, or 
are predicted to live but die. 
Measures of intervention intensity have been examined for their impact 
on resource use. The relationship of TISS to resource use has been 
examined. In the TISS system, therapeutic interventions are scored 
according to intensity of involvement. The points acquired per patient 
per 24 hours are an indicator of the amount of nursing and medical care 
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that patient has received. Total TISS scores are reported by many 
authors to explain resource use [Cullen et a/, 1976; Wagner et a/, 1983; 
Slatyer et al, 19861. Malstarr et al [1992] found that predicted versus 
actual charge per TISS point were very similar (US$48 vs US$54). 
2.6 OUTPUT: THE OUTCOME OF INTENSIVE CARE MEDICINE 
Quantification of changes in health outcomes attributable to intensive 
care is essential to measure effectiveness and efficiency. This section 
outlines which outcome measures are required for economic evaluation. 
It then examines the published evidence to assess what outcome 
measures have been investigated. 
The mode of outcome measure defines the type of economic evaluation 
employed [Drummond et a/, 19871. Cost benefit analysis quantifies 
outcomes in monetary terms. It requires the explicit evaluation of non- 
financial benefits and burdens in monetary terms. This is simpler for 
some measures such as loss of earnings, payment for help and cost to 
the health service of treatment. More difficult is attaching monetary 
values to disability, distress, uncertainty or threat to life. Cost 
effectiveness analysis is often used in preference to cost benefit 
analysis. This allows one health outcome parameter to remain in 
nonmonetary terms, such as mortality or life years gained. The cost 
expended to attain one unit of this outcome is the cost effectiveness 
ratio. Cost utility analysis is used where multiple measures of outcome 
are merged into one utility measure [McGuire et a/, 1988). Cost utility 
analysis requires combination of mortality with morbidity measures into 
a single utility measure. This section, therefore, examines whether valid 
morbidity and mortality measures have been investigated for use in cost 
effectiveness analysis. Evidence on utility changes due to intensive care 
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is examined. Whether cost utility analysis in intensive care with current 
available evidence is possible is explored. 
2.6.1 Outcome Measures: Mortality 
This section examines the range of mortality measures that are used in 
intensive care medicine and their applicability to economic evaluations. 
Mortality is not generally considered to be a useful outcome measure for 
health care interventions due to its dichotomous nature and low 
frequency. However, in intensive care the principal short term aim is to 
avert death in order to treat a reversible but life-threatening condition. 
Therefore, deaths occur more frequently and have more validity as an 
outcome measure than they might have in other therapeutic areas. 
Because of this, mortality rates are often used as intensive care 
performance indicators, especially in the USA [Knaus et a/, 19851. 
However, mortality has been demonstrated to be much more closely 
linked to admission severity of acute illness and chronic health states 
than to organisational factors [Knaus et a/, 1985; Zaren et al, 19881. 
There are different ways of expressing mortality. Unit mortality is least 
useful as patients frequently die in the hospital after ICU discharge, or 
are discharged from intensive care to die more privately on a ward. 
Hospital mortality is a more useful short term mortality outcome 
measure but does not reflect what effect intensive care has on the life 
expectancy of patients. Critical illness continues to shorten life 
expectancy for a considerable period after discharge, especially in older 
patients [Dragsted et a/, 1986; Ridley at a/, 19911. Ridley et a/ [19941 
reported that the risk of dying in the first year after discharge was 3.4 
times higher than the general population. It was not until the fourth 
year that mortality risk returned to that of the general population. 
Currently there are no studies that follow a cohort of intensive care 
patients for the full course of their lives. It is not known what impact 
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intensive care has on life expectancy. Also, technologies change so 
rapidly in intensive care that this information would not be very useful 
by the time it was known. The incremental impact of intensive care on 
mortality or life expectancy will probably never be derived empirically as 
this would require an RCT of admission to intensive care. 
Examination of the evidence demonstrates that most costing studies 
quote cost per ICU or hospital survivor as their outcome measure. 
Using standard life tables, some have calculated life expectancies and 
quote a cost per life year gained [Thoner et a/, 1987]. The latter 
method is more economically robust than the former. However, valid 
economic evaluations must take into consideration the continuing effect 
that intensive care has on survival, as much as present evidence allows. 
2.6.2 Outcome Measures: Morbidity and Quality of Life 
This section examines the importance of using morbidity measures and 
quality of life tools in the assessment of intensive care outcome. The 
importance of using these measures as outcome measures, rather than 
just mortality or life expectancy, is stressed. A model expressing the 
impact of intensive care on quality of life is proposed. The issues 
around assessing a rapidly changing quality of life are examined and 
instruments appropriate for use in intensive care patients are explored. 
It discusses the problems associated with morbidity and quality of life 
measurement in this group of patients. The evidence available is 
reviewed. Finally, suggestions for priorities in future investigation in this 
area are proposed. 
There is a consensus that intensive care outcomes must be evaluated in 
terms of quality of life (QoL), rather than just quantity [PAEEC, 1994]. 
Petros et a/ [1995] have called for morbidity measures to replace 
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mortality as the primary ICU outcome measure. This is due to the 
inadequacy of mortality as an outcome measure. Proof of significant 
reduction in mortality as a result of interventions carried out in intensive 
care is often virtually unobtainable as the large homogeneous patient 
groups required are rarely available. Very large reductions in ICU- 
acquired infection rates due to prophylactic intervention [SDD Trialists' 
Meta-Analysis, 1993] have no demonstrable effect on mortality. 
Without information on impact on morbidity, it is more difficult to 
defend the introduction of this type of intervention. 
There are many methodological problems associated with the 
assessment of morbidity and QoL in intensive care patients. Similarly to 
mortality measurement, the incremental effect of intensive care on 
morbidity is unlikely to be empirically determined. The incremental 
effects of different technologies within intensive care can be more easily 
assessed. Secondly, as intensive care is a rescue therapy, its aim is to 
return the patient to the same QoL after ICU discharge, so that there is 
as little decrease in QoL as possible. This means that QoL before and 
after the intensive care episode are required. Thirdly, in the assessment 
of a rescue therapy like intensive care, there is the issue of when to 
measure QoL, as it is likely to be highly labile immediately post-ICU 
admission. 
To better describe the change in QoL over time from ICU admission, it 
can be depicted graphically. Figure 2.1 proposes a model that charts 
the course of an individual's QoL and the impact that an ICU admission 
has on it. AB is the chronic QoL prior to ICU admission. BC is the point 
at which a precipitating event occurs, resulting in ICU admission. CD is 
the QoL of the patient whilst on ICU. This assumes that QoL whilst on 
ICU is significantly decreased whilst on ICU due to the decreased level 
of consciousness, pain, fear and loss of autonomy associated with the 
ICU stay. DE is the recovery period of the patient, from ICU discharge, 
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through hospital discharge. E is the point at which the individual returns 
to a chronic QoL. This model does not assume that post-ICU QoL is 
equivalent to pre-ICU QoL (AB). FG marks the deterioration of QoL that 
occurs in the terminal stage of life. G is the point at which the 
individual dies. Premature death may occur at any point from B. 
Figure 2.1 Hypothetical Model of Impact of Intensive Care on Quality of 
Life 
A 
. 
Time 
S 
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This model demonstrates the fluctuating nature of the QoL of an 
intensive care patient. This affects the type of QoL measurement tool 
that can be used. Health related QoL tools should be reliable and valid, 
and the appropriate tool should be used for the situation. Apart from 
methodological soundness and empirical validity, the following criteria 
have been recommended by Buxton et a/ [1985] for a subjective health 
measure used to assess the impact of a high technology medical 
intervention. 
1. sensitive to a wide range of health states, and appropriate to patients 
both before and after intervention; 
2. the process of assessment acceptable to patients and any questions 
easily and unambiguously understood and 
3. for purposes of comparison the measure should have been used, or 
should be likely to be used, in studies of other relevant groups. 
Also, a QoL measure should be universally applicable to all intensive 
care patients, correlate QoL with medium and long term survival and be 
applicable after discharge to enable evaluation of interventions [PAEEC, 
19941. Disease-specific QoL tools are not generally appropriate because 
intensive care covers many conditions. 
2.6.3 Quality of Life After Intensive Care-The Evidence 
This section briefly reports to what extent the QoL of intensive care 
patients has been researched and whether the methods used fit the 
recommendations listed above. Sixteen QoL studies in intensive care 
were found and are summarised in Appendix 2.3. Most earlier studies 
used a range of unvalidated tools. Later studies have used validated 
measures such as the Spitzer QL index [Slatyer et al, 1986], Safar 
overall performance indicators [Loes et a/, 19871 and the Nottingham 
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Health Profile [Shiell, 1989]. None of the tools used were validated for 
use in intensive care patients, apart from Patrick's perceived QoL score 
[Patrick et a/, 1988]. The scope of health-related QoL measured ranges 
from purely functional measures which do not assess emotional or 
psychological domains at all [Cullen et a/, 1976; Mundt et a/ 1988] to 
studies that have tried to cover all health-related domains of QoL 
[Patrick et a/, 1988; Ridley et a/, 19911. 
Studies examining QoL prior to and after ICU report that, for most 
patients, QoL does not deteriorate significantly. Those patients in which 
there is deterioration are usually younger, previously fully employed 
patients with good previous health status who undergo trauma of some 
kind [Ridley et a/, 1991 ]. Studies examining the impact of intensive 
care by comparing population data report worse QoL for ex-intensive 
care patients [Patrick et al, 1988; Shiell, 1989). The importance of 
subjective measures is reflected by Patrick's QoL study. The patients' 
perceived quality of life was higher than the Sickness Impact Score and 
the General Well Being Score indicated. Patients who have undergone 
intensive care may rationalise their experience [Patrick et a/, 1988]. If 
perceived QoL is not highly correlated with other measures of health 
outcome, then traditional measures of mortality and functional status 
are not sufficient for evaluating the benefits of intensive care. 
Most studies measured QoL at a point in time after ICU admission so 
rate of recovery of QoL could not be assessed. Published evidence 
provides information on changes in chronic QoL only. QoL whilst on 
ICU, length of time to recovery and impact on life expectancy have not 
been investigated. 
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2.6.4 The Utility of Intensive Care 
Quality of life measurement of intensive care patients does not allow 
cost utility analysis to be carried out unless the QoL measurements can 
be converted into utility measurements. This section discusses the 
issue of utility and its relevance to intensive care patients and economic 
evaluation of intensive care. 
Utility measurement allows integration of mortality and morbidity 
effects, provision of preferences for both hypothetical and actual 
situations and incorporation of time and risk preferences of individuals 
[Drummond et a/, 19871. Utility can be directly measured using rating 
scales, 'standard gamble' and 'time-trade-off' techniques. Attaching 
relative weights or values to components of utility measures is 
methodologically complex. Reliable measures require labour-intensive 
interviews and utility measures for the same health state vary 
considerably across individuals [Feeny et at, 19891. Alternatively, QoL 
measures can be converted to utility measures. This is not 
straightforward as they do not always correlate with one another 
[Tsevat et al, 19901. 
In intensive care, decisions must be made about when to measure 
utilities and whose should be measured. Preferences expressed in a 
calm moment as a hypothetical issue are often different from those 
expressed in the urgency and confusion of a critical illness [Tsevat et al, 
1990]. It can be difficult to make judgements about outcomes one has 
not experienced, especially concerning an alien and frightening 
experience such as intensive care. If preferences for outcomes are 
dramatically different ex post (preferences after experiencing intensive 
care) from ex ante (preferences before experiencing intensive care), then 
a choice about which preferences are appropriate must be made. Due 
to the potential instability of preference judgements over time, work has 
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concentrated on the changes to QoL that occur after intensive care. 
Also, prospective utility or QoL assessment is complicated by the 
inability of the patients to participate because they are too ill, or 
unconscious. Is it appropriate in this situation to use a surrogate 
decision maker such as a relative or doctor? 
The most extensively empirically researched utility measure is quality 
adjusted life years (QALYs). QALYs adjust the number of years of life 
gained by the utility value (on a scale of 0 to 1) of the resulting level of 
health status [Drummond et a/, 19871. A comprehensive discussion of 
the methodological issues surrounding QALYs is beyond the scope of 
this review. However, four main concerns about QALYs are raised by 
Buxton [ 19921. 
The first concern is that there is no consensus on the appropriateness of 
descriptive systems for health-related QoL. A multidimensional 
instrument is required that anchors health states into a scale from 0 to 1 
(dead to full health). The first system by Rosser and Kind valued 29 
health state combinations [Kind et a/, 1982], but is now generally 
recognised to be inadequate in its ability to reflect all the main 
dimensions of health related QoL [Buxton, 1992]. Measures like the 
Nottingham Health Profile and the Sickness Impact Score have too many 
health states to realistically allow valuation. 'Euroqol' [The Euroqol 
Group, 1990] is a multiattribute scaling technique under development, 
where dimensions are hierarchically structured to reduce the extent of 
the valuation procedure. This measure is still being validated, but may 
prove to be applicable to ICU patients. 
The second concern is that of validity and reliability of the process of 
valuation. Evidence suggests that different techniques give different 
answers and the same techniques can give different answers at different 
times [Gafni, 19911. 
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The third concern is the relationship of health state valuations to their 
duration, sequence or profile. This is particularly relevant where short 
health state durations, such as intensive care, are followed by long term 
health states. The utility attached to temporary health states is very 
difficult to measure because, if a future is added to the scenario, the 
preference value measured is actually that of a much broader scenario 
than the one which is claimed to be measured. If no future is added, 
the individual will assume a future so answers will not reflect only the 
preference towards the health state described [Gafni, 19911. 
The fourth concern is whether risk and time preference are handled 
explicitly or implicitly by the valuation. If these factors are handled 
implicitly by the individual, answers may reflect an unquantifiable degree 
of risk and time preference. Time preference is handled explicitly by the 
use of discounting. Future health benefits tend to be discounted at the 
same rate as future costs, although there is debate about whether this is 
appropriate [Coyle et a/, 1992]. 
For these reasons QALYs should be regarded with caution, but not 
dismissed until there is a 'better' practical alternative. 
2.6.5 Evidence for Utility Measurement in Intensive Care 
This section reports on the evidence associated with utility in intensive 
care. Very few ICU studies have used QoL tools appropriate for 
conversion to utilities. Ridley et a/ [19911 have reported converting their 
quality of life measurements to Rosser and Kind disability categories. 
They have not taken this any further, although it would be possible to 
convert this data to QALYs. There have been two studies on integration 
of quantity with quality of life changes due to ICU admission [Williams, 
1986; Kerridge et a/, 19951. Using data from an ICU study by Cullen et 
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a/ [1984], Williams derived an estimate for QALYs gained by ICU 
admission, reporting three QALYs gained per critically ill admission. 
Kerridge et a/ [1995] derived a Rosser index QoL value for each survivor 
from a questionnaire. Life years gained (LYGs) was derived via the 
assumption that survivors at follow up had a life expectancy of 90% of 
age-specific life expectancy and a stable future QoL. The combination 
of LYGs and the Rosser index was used to derive QALYs. The 
discounted QALYs achieved ranged from 11.4 for asthma patients to 
2.7 for pulmonary oedema patients. The discount rate used was 5%. 
2.7 EFFICIENCY OF TECHNOLOGIES WITHIN INTENSIVE CARE 
It has been demonstrated by this review that the technical efficiency of 
technologies within intensive care must be assessed. This section 
discusses this issue. It is necessary to have criteria with which to 
assess the quality of available evidence. The quality of studies that 
should be aimed for is outlined with a consideration of a hierarchical 
grading of evidence. The evidence for clinical effectiveness and 
technical efficiency in intensive care technologies is demonstrated to be 
lacking. Those studies available are assessed for the quality of their 
clinical and economic evidence. The limitations of only carrying out 
economic evaluations attached to RCTs is discussed. Alternative 
methodologies for economic evaluation are suggested. 
2.7.1 The Quality of Clinical and Economic Evaluation 
Cost effectiveness analysis can only be as good as the economic and 
clinical evidence that is used. Also, clinical and economic evaluations 
have resource implications of their own. Therefore it is essential that 
evaluations are designed as rigorously as possible so they produce the 
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'best' quality of evidence. It is possible to assess the quality of data 
available by examination of the design of a study. Eddy (19911 has 
proposed a system for assessing quality of evidence (see Table 2.3). 
Table 2.3 Grade of Evidence [Eddy, 19911. 
Evidence obtained from at least one properly randomised controlled trial 
II-1 Evidence obtained from well designed controlled trials without 
randomisation 
11-2 Evidence obtained from well-designed cohort or case-control analytic 
studies, preferably from more than one centre or research group 
11-3 Evidence obtained from multiple time series with or without the 
intervention. Dramatic results in uncontrolled experiments could also be 
regarded as this type of evidence 
III Opinion of respected authorities, based on clinical experience, descriptive 
studies, or reports of expert committees 
Randomised controlled trials (RCTs) are the most useful design for 
determining the effects of an intervention on outcome. There is most 
control over confounding factors and a high degree of internal validity. 
However, excessive control of design can decrease applicability of study 
results to other settings (external validity). A rigorously carried out 
meta-analysis of RCTs is not included in this system, but would be 
considered to be a higher grade than one RCT alone due to the higher 
degree of external validity. Non-randomised controlled trials (quasi- 
experiments), Grade II-1, in which groups are selected by convenience, 
rather than random allocation, are subject to increased threat of bias to 
internal validity, especially patient-selection bias. The studies are carried 
out in more realistic settings which increases external validity and 
confounding factors can be controlled for by statistical methods. Below 
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this are observational studies (Grade 11-2) where the use of an 
intervention is not manipulated by the researcher. Reality is observed 
and outcomes are interpreted. Cohort studies are more vulnerable to 
patient bias and confounding than RCTs, but have increased external 
validity. Other observational methods are cross-sectional surveys and 
case control studies (Grade 11-3). Clinical series and professional opinion 
are least rigorous in design (Grade III). Whilst useful, this system 
concentrates only on design categories, not actual designs. A well 
designed large cohort study could be more meaningful than a small 
badly designed RCT. 
Unfortunately, the quality of economic evaluations is more often 
decreased by the quality of the economic evidence, rather than the 
clinical evidence. The quality of economic evidence is affected by two 
main factors. The first is the costing methodology used, as discussed in 
section 2.6. The second factor is whether the evidence has been 
deterministically or stochastically obtained. Stochastic evidence is that 
collected from a random sample. The variables concerned have an 
observed mean and variance, that is, the uncertainty around point 
estimates can be quantified. Deterministic evidence consists of point 
estimates derived from expert opinion or assumptions. The variance, or 
uncertainty, of such data cannot be quantified. Both clinical and 
economic evidence can be deterministic or stochastic in origin. Ideally, 
an economic evaluation should use stochastic clinical and economic 
evidence. Data can be considered to be more robust if they are 
retrieved from a Grade I study, an RCT, as they are randomly obtained. 
This means that the data have internal validity and are stochastic, so 
statistical inference can be drawn, and uncertainty around point 
estimates is known. Economic evidence is much more likely to be 
deterministic in origin than clinical evidence, due to the more established 
methods used in clinical effectiveness studies [O'Brien et al, 1994]. 
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Therefore, economic evaluations frequently contain a mixture of the two 
types of data. O'Brien et al 119941 put forward three scenarios: 
1. Deterministic analysis where cost and effect variables are analyzed 
as point estimates due to limited, unsampled data. Deterministic point 
estimates of cost effectiveness so derived are subject to sensitivity 
analysis to explore the impact of uncertainty. 
2. Partially stochastic analysis where effectiveness is estimated from 
clinical trials, expressed as a mean effect size with an associated 
variance, but analysis of costs is deterministic because data are non- 
sampled. This method is common in decision-analytic models of 
economic analysis. It is not appropriate to quote 95% confidence 
intervals around any cost effectiveness ratios. 
3. Wholly stochastic analysis where both costs and effects are 
determined from data sampled from the same patients in a study, either 
RCT or observational. In this situation, formal statistical tests can be 
performed on observed differences in costs and effects. Sensitivity 
analysis may still be useful for assessing external validity of findings. 
2.7.2 Efficiency of Technologies Within Intensive Care: The Evidence 
This section examines the published evidence of efficiency of 
technologies used within intensive care. The quantity and quality of 
evidence is reported, using the hierarchical grading of evidence outlined 
in section 2.7.1. Virtually no effectiveness studies of technologies other 
than drugs have been found. Intensive care medicine often uses 
efficacy data from the operating theatre or ward scenario. 
67 
A literature search covering 1984 to 1995 found six economic analyses 
of intensive care interventions. Four of these concerned drugs, three of 
which related to the anti-endotoxin, HA-1A. Five economic analyses 
were found of drugs that could be used in an intensive care setting. 
Table 2.4 provides a summary of these eleven economic evaluations. 
An assessment of the source and grade [Eddy, 19911 of clinical and 
economic evidence is reported. The study designs are categorised as 
stochastic, partially stochastic or deterministic, and the type of 
economic evaluation is assessed from outcome measures reported. 
The majority of the studies are partially stochastic cost minimisation 
studies of drugs, mostly antibiotics. Although clinical data is frequently 
Grade I RCT data, economic data is mostly deterministic and derived 
from expert opinion (Grade III data). Where the studies are reported as 
cost effectiveness analyses, their outcomes are usually intermediate 
measures such as infection rate changes [Jacobs et al, 19871. The 
quality of the economic data is poor due to use of charges instead of 
costs, or use of drug acquisition costs only, with no handling of 
resource use related to administration, monitoring or maintenance of 
side effects. There are also many therapeutic areas that have not been 
evaluated at all. Recent evaluations of drugs have concentrated on high 
profile, very expensive drugs such as HA-1 A monoclonal antibody 
[Schulman et a/, 1991; Barriere et a/, 1992; Chalfin et a/, 19931. Other 
'expensive' drugs such as inotropes, sedatives and plasma expanders 
have not been investigated so far. Resource intensive technologies 
include pulmonary artery catheters, haemodiafiltration and increasingly 
sophisticated ventilation techniques. These have had little clinical 
evaluation and less economic evaluation. 
The reasons for using RCTs to assess effectiveness in intensive care 
have been discussed in section 2.7.1. There are, however, many 
barriers to RCTs in intensive care, real and perceived. Due to the critical 
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nature of intensive care, it is sometimes difficult to obtain ethical 
approval or patient consent. If RCTs are done, the patient groups tend 
to be either homogeneous but too small for statistical inference, or large 
but too heterogeneous to be of use. Many unevaluated technologies in 
intensive care are so firmly rooted in routine practice that there would 
be a lot of resistance to evaluating them through an RCT. However, 
there are drawbacks to using economic evidence from RCTs. It reflects 
the practice within the trial only, such that the practice patterns may 
not reflect actual clinical practice, reducing external validity. Also, there 
is likely to be resource use associated with running the trial, such as 
extra monitoring tests, that need to be identified. Finally, RCTs measure 
efficacy in a rigorously selected patient group, rather than effectiveness 
in clinical practice. The resource use associated with using the same 
intervention in practice in a less rigorously selected population is likely 
to be different from the trial environment [Drummond et al, 19911. The 
gold standard for economic evaluation is often considered to be 
attachment to an RCT. In intensive care, this may mean that economic 
evaluation of some interventions would never be done. Calling for good 
effectiveness data, Sheldon et a/ [1995] dismiss economic evaluation in 
technologies where 'evidence for effectiveness is so lacking that issues 
of cost effectiveness are irrelevant'. Issues of cost effectiveness in 
resource intensive areas such as intensive care are never irrelevant. 
They are simply more difficult to resolve due to lack of good 
effectiveness data. Sheldon et at [19951 also state that 'economists are 
too ready to carry out economic analysis on the basis of inadequate 
evidence about effectiveness'. In areas such as intensive care, there is 
very little adequate evidence, so the data available must be utilised, with 
explicit discussion of any shortcomings. For the economic evaluation of 
intensive care to progress, alternative methods of evaluation to RCTs 
are needed, or there may be no economic evaluation at all. 
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2.8 IMPLICATIONS FOR ECONOMIC EVALUATION IN INTENSIVE CARE 
Given the scarcity of resources, the high cost of intensive care and the 
doubts surrounding benefit, economic evaluation of intensive care 
medicine is becoming more of an imperative. This review has examined 
the economics of intensive care medicine and identified the issues that 
require most attention and empirical investigation. 
The objectives of intensive care medicine have been defined in terms of 
both clinical effectiveness and economic efficiency in section 2.2. The 
importance of both allocative and technical efficiency is demonstrated. 
In section 2.3, a comparison of UK and US intensive care provision 
shows that the provision of a service within a health care system is 
strongly affected by the framework of that system. This needs to be 
considered when comparing UK intensive care provision with that from 
other countries. This review cannot make definitive conclusions about 
the allocative efficiency of intensive care due to lack of evidence either 
way. This is, in part, due to the lack of evidence about technical 
efficiency in intensive care and competing interventions. The need for 
information about the technical efficiency of intensive care is also 
demonstrated in section 2.4. The ICU patient population is large and 
diverse. It is essential that only patients likely to benefit are admitted to 
ICU. In section 2.5, the problems associated with identifying these 
patients is discussed. The cost of the intensive care process has been 
examined in some detail in section 2.6. The discrepancies between 
what is required for economic evaluation and what is available from 
published evidence are clearly shown. This discrepancy extends 
through all aspects of costing methodology. The major problems with 
cost evidence reported are the widespread use of charges instead of 
costs and the lack of explicit reporting of sources and components of 
costs. Theoretical and empirical problems associated with assessment 
of the impact of intensive care have been identified in section 2.7. 
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Again, there is a discrepancy between what is required and what is 
available. Information on impact of intensive care is confined to short 
term mortality. However, its impact on long term mortality and quality 
of life needs to be known for economic evaluation. A model for the 
impact of intensive care on quality of life has been proposed. This 
provides a useful point of reference when examining the specific areas 
where evidence for quality of life is required. The utility of intensive 
care has been the subject of only two studies. The measurement of 
utility is required for cost utility analysis, but is subject to many 
methodological complexities. It is difficult to attach utility values to a 
transient state, such as being on intensive care. There are also 
questions about when is most appropriate to obtain those values, or 
from whom. So, in conclusion, assessment of technical efficiency of 
intensive care is precluded by the lack of evidence on economic cost 
and outcomes. 
This review also demonstrates that the technical efficiency of intensive 
care is inextricably bound up with that of its constituent technologies. 
Section 2.8 examines the technical efficiency of these technologies. 
The quality of evidence required for economic evaluation is outlined, 
using a published hierarchical grading system. This is used to assess 
the few studies found. There is clearly insufficient effectiveness and 
efficiency evidence about most therapeutic areas within intensive care. 
Reasons for this are suggested, such as difficulties associated with 
doing RCTs causing the lack of effectiveness evidence. The lack of 
efficiency evidence stems partly from this, and partly from barriers, real 
and perceived, to obtaining true economic cost. It proposes that, rather 
than using these issues as a barrier to empirical analysis, alternative 
methods for economic evaluation need to be developed. 
Explicit consideration of resource use and consequences of high 
technology health care interventions is becoming an unavoidable stage 
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in the decision-making process because it is essential for decision 
makers to be able to justify their deployment. Cost effectiveness 
decisions should not be taken on an individual patient basis, but when 
unit policies are being formulated. This is particularly relevant in 
sensitive areas, like intensive care, where making cost effectiveness 
decisions on an individual patient basis would be perceived to be 
insensitive. The role of economic evaluation is to aid the decision 
making process, not to replace it. However, these decisions need to be 
based on accurate, reliable and generalisable effectiveness and cost 
effectiveness evidence. This review has demonstrated that intensive 
care is not able to accurately account for its resource use or measure its 
impact on health outcomes. This is equally true of technologies used 
within intensive care. This review proposes that both effectiveness and 
efficiency evidence are urgently required to better inform policy-makers 
about the net benefit of intensive care. 
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Chapter 3: The Clinical and Economic Impact of Prevention of 
ICU-Acquired Pneumonia with SDD 
3.1 INTRODUCTION 
This chapter specifically examines the clinical and economic impact of 
using selective decontamination of the digestive tract (SDD) to prevent 
ICU-acquired pneumonia. The first half of this review examines the 
clinical and economic implications of ICU-acquired pneumonia, a form of 
nosocomial infection. A nosocomial infection is one that is not present 
or incubating on time of admission to hospital. Section 3.2 describes 
the pathogenesis, diagnosis and epidemiology of ICU-acquired 
pneumonia. For health care providers, costs of ICU-acquired pneumonia 
derive from its diagnosis and treatment, the prolonging of hospitalization 
and handling of any long term morbidity. Section 3.3 describes the 
economic impact of ICU-acquired pneumonia, using published evidence. 
Nosocomial pneumonia is considered the leading cause of, or contributor 
to death, from nosocomial infection [Gross, 19801. In addition to raised 
mortality, nosocomial pneumonia may have effects on short and long 
term morbidity. Section 3.4, therefore, presents the available evidence 
to support this. 
The clinical and economic consequences of ICU-acquired pneumonia has 
prompted many recommendations for infection control [Haley et a/, 
1985; Daschner et al, 1985]. One of the more recent is SDD. SDD is 
very resource intensive, and its impact on patient outcome is equivocal. 
To date, no economic evaluation of SDD has been carried out. The 
second part of this review examines the evidence for the impact that 
SDD has on ICU-acquired pneumonia. Section 3.5 outlines the 
theoretical basis of SDD and evidence for efficacy is presented in 
section 3.6. The large body of efficacy data has given rise to many 
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reviews. The added information gained from these is assessed in 
section 3.7. The economic implications of SDD are examined in section 
3.8, and the quality of published economic evidence is discussed. The 
implications of the evidence covered by this review for the economic 
evaluation of SDD are discussed in section 3.9. 
3.2 CLINICAL ISSUES IN ICU-ACQUIRED PNEUMONIA 
3.2.1 Pathogenesis of Nosocomial and ICU-Acquired Pneumonia 
Pneumonias are defined by their causative organism and the origin of 
the organism (nosocomial or community-acquired). Exogenous 
infections are caused by organisms from outside the patient, such as a 
pneumonia caused by Pseudomonas aeruginosa from a contaminated 
humidifier. Endogenous infections are caused by bacteria living in the 
patient. The commonest causative organisms of nosocomial pneumonia 
are endogenous aerobic gram-negative bacilli (Escherichia co/i, K/ebsie//a 
sp., Proteus sp., Enterobacter sp., Pseudomonas sp., [Craven et al, 
1992]). These bacteria inhabit the oropharynx, stomach and distal 
intestinal system. The principal mechanisms responsible for introduction 
of infection into the lungs are use of respiratory therapy or antibiotics, 
presence of endotracheal and nasogastric tubes, and cross infection. 
Development of pneumonia is dependent on the virulence and numbers 
of these bacteria aspirated into the lung and the ability of the host 
defences to protect against infection. 
3.2.2 Diagnosis of ICU-Acquired Pneumonia 
On suspicion of ICU-acquired pneumonia in the critically ill patient, it is 
essential to rapidly identify presence of infection and select appropriate 
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antibiotic therapy. Due to unavoidable delays in obtaining 
microbiological cultures, conventional criteria for diagnosis use the 
clinical signs of new or progressing pulmonary infiltrates, fever, 
leukocytosis and purulent tracheal secretions. The degree of precision 
of diagnosis of nosocomial pneumonia in general is the poorest of all 
major infections. Meers et al [ 19811 reported that in only 25% cases 
was a positive culture recorded. Up to 75% of pneumonias are clinically 
diagnosed in the absence of positive cultures, more than for any other 
infection [Meers et a/, 19811. Even when positive microbiological 
cultures are obtained, the results have to be used with caution. It is 
extremely difficult to obtain sputum or tracheal aspirate samples that are 
not contaminated by gastric fluids on extraction. So, most patients with 
fever and pulmonary infiltrates tend to be treated according to clinical 
diagnosis and cultures of tracheal aspirates. 
3.2.3 The Epidemiology of Nosocomial and ICU-Acquired Pneumonia 
Patients in hospital are recognised to be at higher risk of infection than 
their counterparts in the general population. Nosocomial infection rates 
vary widely, depending upon the presence of risk factors and the 
efficacy of local infection control programs [Haley, 1986]. 
Epidemiological evidence from the UK reports a 19.1 % infection 
prevalence rate in hospitals, half (9.2%) being nosocomial [Meers et a/, 
1981 ]. The incidence of nosocomial infection is higher on ICUs than in 
the rest of the hospital. Patients admitted to ICUs represent 5 to 10% 
of all hospital patients in the UK, but they can account for 25% of 
nosocomial infections [Trilla, 1994]. The most common nosocomial 
infections among ICU patients are pneumonia (65%), urinary tract 
infection (17%) and bacteraemia (12%) [Vincent et al, 1995]. Reported 
ICU-acquired pneumonia prevalence rates vary widely in the literature, 
ranging from 15.5% [Daschner et al, 1985] to 60% [Kerver et al, 
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1987]. ICU-acquired pneumonia is considered the most significant 
infection on ICUs not only because of its high prevalence but also 
because of the morbidity and mortality this implies, and subsequent 
impact on resource use. 
Factors increasing the likelihood of ICU-acquired pneumonia have been 
investigated. Joshi et al [19921 reported that ICU admissions have a 
base risk of 1 in 40 (2.5%) of developing ICU-acquired pneumonia. 
When certain factors are present, this risk increases as illustrated in 
Table 3.1. Most commonly reported significant patient-derived factors 
are existence of chronic obstructive airways disease, thoracoabdominal 
surgery and depressed consciousness. Significant unit-derived factors 
are most commonly reported are ventilation status, prior use of 
antibiotics and bronchoscopy [Vincent et al, 19951. 
Table 3.1 Absolute Risk Factors for ICU-Acquired Pneumonia (Joshi et 
a/, 1992). 
Risk factor Odds Ratio 95% Cl Absolute 
for risk/% 
acquiring 
pneumonia 
Ultimately fatal 2.79 0.90-8.61' 7 
disease 
Rapidly fatal disease 3.89 0.92-16.40' 9 
Thoracoabdominal 4.34 1.43-13.14' 11 
surgery 
Nasogastric tube 6.48 2.12-19.820 16 
Recent 2.95 1.02.8.52' 7 
bronchoscopy 
f p<0.05; = p<0.01; 0 p<0.001 
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3.3 THE COST OF ICU-ACQUIRED PNEUMONIA 
It has been estimated that nosocomial infections in England increase 
length of hospital stay by 4 days [DHSS/PHLS Hospital Infection Control 
Working Group, June 19861. Using a 5% infection rate for acute 
hospitals, the authors calculated a total cost of £111 m to the NHS in 
1986, with 950,000 lost bed days. US studies have calculated that the 
annual cost of diagnosing and treating nosocomial pneumonia is 1.1 
billion dollars a year [Wenzel, 19891. Between one third and one half of 
all cases of nosocomial pneumonia occur on the ICU and about half of 
these are ventilated patients [Leu et a/, 1989). Changes in resource use 
due to ICU-acquired pneumonia arise from the impact on length of ICU 
and hospital stay and any increase in treatment intensity. This section 
examines the evidence available for both sources of increased resource 
use. 
3.3.1 Increased Length of Stay 
Length of stay is the most commonly used measure of resource use 
attributable to nosocomial infection. A variety of methods have been 
used to determine length of stay associated with nosocomial infection 
and pneumonia. The method used can affect the resulting estimates 
and also the confidence with which those estimates can be used in an 
economic evaluation. The most robust method is multivariate analysis 
of differences between lengths of stay between infected and uninfected 
groups. This enables control of confounding variables. However, the 
most commonly used method is matched pairs cohort analysis. Here, 
confounding variables are accounted for by matching similar infected 
and uninfected patients. Another method is to use clinicians' judgement 
to assess any increased length of stay due to infection. 
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Table 3.2 summarises the studies that have examined the impact of 
ICU-acquired pneumonia on length of ICU stay. Molina of a/ [1993] 
used multiple regression to isolate the increase in length of ICU stay. 
They report the most conservative estimate of increased length of stay. 
All other studies used the matched pairs cohort method. Matching 
characteristics were age, surgery prior to admission and length of 
exposure to risk of infection. Molina et a/ [1993] and Fagon of a/ 
[1993] controlled for severity of illness. The use of matched pairs leads 
to the exclusion of patients that cannot be matched. Kappstein of a/ 
[ 1992] reports that these tend to be older, 'sicker' and ventilated for 
longer. The matched pairs method is likely to produce estimates that 
are much larger than the regression analysis method. This is most likely 
to be due to incomplete matching of patients. This leads to 
confounding factors that have not been sufficiently matched, such as 
chronic health states or severity of illness, exaggerating length of stay 
differences. These results suggest that ICU-acquired pneumonia would 
increase ICU length of stay in a British ICU. None of the studies 
examined is British, so only the direction of the change in length of stay, 
rather than the actual magnitude, can be applied to the British situation. 
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Table 3.2 Published Estimates of Increases in Length of ICU Stay 
Attributable to ICU-Acquired Pneumonia 
Author Patient Method Mean length of stay/days 
group (sd) 
Infected Uninfected 
Craig 1984 All ICU 54 matched pairs of 12.0 (3.8) 4.3 (1.7)' 
(US) admissions survivors 
Kappstein Ventilated 34 matched pairs of Difference: 10.13 (21.5) 
1992 > 24 hrs survivors NST 
(Germany) 
Fagon 1993 Ventilated 48 matched pairs 34 21 
(France) > 72 hours 22 matched pairs of 
survivors 41 22 ' 
Molina 1993 ICU stay 1.88 matched pairs 17.2 (12.6) 6.8 (4.2) 
(Spain) >48 hours 
2.220 patients in 14.2 9.9 
regression analysis 
f p<0.05 
NST: no significance test done 
Length of stay is used both as a measure of resource use and as a 
measure of morbidity. However, lengths of stay are affected by factors 
other than infection. There are interhospital variations in process of 
care, physician or hospital-related characteristics that will have an 
impact, as well as the socioeconomic status of the patient and presence 
or absence of social support systems. 
3.3.2 Other Resource Use Associated with ICU-Acquired Pneumonia 
Treatment intensity may be expected to change due to ICU-acquired 
pneumonia. This can include extra treatment, staff time, respiratory 
support and use of diagnostic services. To capture resource use 
82 
changes attributable to ICU-acquired pneumonia, it is necessary to 
collect all resource use data for a group of infected and uninfected ICU 
admissions in an observational study. Analytical methods can then be 
used to identify differences in resource use attributable to infection. 
This data is rarely routinely recorded, requiring commitment of resources 
to a study. 
Very few studies were found that investigated increases in resource use 
due to ICU-acquired pneumonia. SDD trials report increased use of 
antibiotics in patients who acquire pneumonia. This is discussed in 
more detail in Chapter Four. Other drugs, disposables and disinfectants 
used as a consequence of ICU infections have been reported in a Belgian 
study by de Clerq [ 19831. This study is also reported in more depth in 
Chapter Four. Coello et a/ [19931 reported significantly higher utilization 
of microbiology (p<0.0001), haematology (p<0.001), chemical 
pathology (p<0.001) and radiology (p<0.007) in infected hospital 
patients in a British district general hospital. No published evidence to 
this effect was found in ICU-acquired pneumonia. No other evidence 
has been found on the impact of ICU-acquired pneumonia on ICU 
resource use in Britain. 
3.4 THE CONSEQUENCES OF ICU"ACQUIRED INFECTION AND 
PNEUMONIA 
The ideal endpoint for economic assessment of a clinical intervention is 
an overall measure of benefit to the patient which takes account of all 
effects of treatment, whether adverse or beneficial, on the long term 
morbidity and mortality of the patient. 
The overall impact of an intensive care admission on the QoL of an 
individual has been discussed in Chapter Two. Figure 2.1 charted the 
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proposed course of an ICU admission's QoL. If an individual on ICU 
acquires a pneumonia, this QoL profile may be affected. The first issue 
is that pneumonia may increase the risk of mortality whilst on ICU or in 
hospital, thus losing all subsequent QoL. In Figure 3.1, line ABCHIJK 
depicts the QoL profile of an individual who acquires pneumonia whilst 
on ICU. This can be compared with line ABCDEFG which depicts the 
QoL of a patient who does not acquire pneumonia. If the patient 
survives the episode, their ICU length of stay (CH) may be lengthened, 
increasing the period of time in a poor QoL state. Hospital length of 
stay may be increased and the length of time to full recovery may be 
increased (HI), as the patient has to recover from pneumonia as well as 
their original problem. The long lasting effects of the pneumonia may 
leave long term effects, so that the individual is never able to attain their 
pre-ICU QoL (IJ). There may also be an adverse effect on life 
expectancy, so the individual dies earlier (JK). The impact of ICU 
pneumonia on QoL is therefore represented by the area bound by lines 
ABCDEFG and ABCHIJK in Figure 3.1. To estimate this difference, 
evidence on the impact of ICU-acquired pneumonia on the recovery 
period, post-ICU QoL and life expectancy is required. 
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Figure 3.1 Hypothetical Model of Impact of ICU and ICU-Acquired 
Pneumonia on Quality of Life 
A 
BEF 
TO 
O 
CDH 
KG 
Time 
f 
ABCDEFG: ICU patient who does not acquire pneumonia whilst on ICU 
ABCHIJK: ICU patient who does acquire pneumonia whilst on ICU 
I 
The remainder of this section examines what evidence is available on 
the impact of ICU-acquired pneumonia on morbidity and mortality. 
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3.4.1 Evidence for Morbidity Associated with ICU-Acquired Infection 
and Pneumonia 
No evidence was found on the impact of nosocomial infection or 
pneumonia on patient morbidity, physical or psychological, short or long 
term. Davey et al [19911 note that most studies use surrogate 
variables, such as length of stay, as outcome measures, implicitly 
assuming that control of these proxy measures will result in benefit to 
the patient. Epidemiological studies use increased length of stay as a 
proxy variable for morbidity, even though patients who are most 
severely ill could die earlier [Leu et a/, 19891. 
3.4.2 Evidence for Mortality Associated with ICU-Acquired Infection 
and Pneumonia 
Nosocomial infection is the leading cause of death in the US after heart 
disease, cancer and stroke [White, 1993]. 55.1 % deaths from 
nosocomial infection in the US in 1988 were attributed to nosocomial 
pneumonia, whereas nosocomial pneumonia constitutes only 10.5% of 
all nosocomial infections. This disproportionate share of mortality 
implies that pneumonia is the most lethal nosocomial infection [Haley et 
a/, 19851. The most recent hospital infection prevalence study in the 
UK does not report any mortality parameters [Meers et al, 19811. 
Stevens [1974] report hospital mortality rates of 50% in ICU patients 
who have nosocomial pneumonia, and 3.5% in patients who do not. 
Nosocomial pneumonia rates and hospital mortality from nosocomial 
pneumonia are highest in ventilated ICU patients. Craven et a/ [ 19921 
report a crude mortality of 25% in non-infected ventilated patients and 
55% in infected patients. A French matched cohort study by Fagon et 
a/ [ 19931 reports a crude mortality of 54.2% in patients with 
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pneumonia, compared with 27.1 % in patients without. The authors 
infer from this that pneumonia-attributable mortality is 27.1 %. 
However, it is wrong to assume that the difference between infected 
and uninfected mortality rates is all attributable to infection. This is 
because infection in ICU is considered to be, partly, a consequence of 
critical illness. Severely ill patients are more likely to develop 
nosocomial pneumonia and more likely to die from their underlying 
condition. Infection may or may not be a contributory factor. Logistic 
regression analysis by Craven et a/ [19861 identified factors which 
independently influence mortality. ICU-acquired pneumonia was a 
significant risk factor for mortality in individual analysis (p =0.02) but in 
multiple regression analysis it did not reach significance. The most 
recent meta-analysis of trials of SOD [19931 is the only study to 
demonstrate an independently significant link between ICU-acquired 
pneumonia in ICU and mortality (p = 0.003). 
No published evidence was found on the impact of ICU-acquired 
pneumonia on long term mortality. 
3.5 THE THEORETICAL BASIS OF SDD 
This review has suggested, so far, that ICU-acquired pneumonia may 
have serious clinical and economic consequences, many of which have 
not been adequately quantified. However, reduction of ICU-acquired 
pneumonia incidence is widely considered to be a desirable aim. 
Conventional infection control measures in ICUs are aimed primarily at 
stemming cross infections. SDD, in contrast, aims to stem self- 
infection, by avoiding gastric and oropharyngeal bacterial overgrowth. 
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In SDD, non-absorbable antibiotics are employed to eliminate the gram 
negative aerobic bacilli (GNAB) and yeasts in the gut that cause most 
nosocomial infections. ICU-acquired pneumonias are prevented by 
decreasing the probability of inhaling infected stomach contents. 
Eradication of GNABs in the lower gut decreases the amounts of GNAB- 
derived endotoxins that are absorbed into the bloodstream and lead to 
sepsis. Tobramycin or gentamicin is used, being active against GNABs, 
also having some activity against gram positive Staphylococcus aureus. 
Polymixin B or polymixin E (colistin) is used for its broad activity against 
GNAB. Amphotericin or nystatin is used to prevent fungal growth. The 
decontamination is selective because the normally predominant 
anaerobic bacteria in the lower gut are preserved to prevent overgrowth 
of resistant bacteria. ICU SDD therapy regimes consist of enteral 
preparations of these antibiotics as a paste applied locally to the 
oropharyngeal mucosa and a suspension given orally. For the first three 
to four days, intravenous cefotaxime is used to cover the initial period 
when SDD is only partially established. Drug prophylaxis is 
accompanied by intensive microbiological surveillance. This determines 
the degree of infection present on ICU admission, the efficacy of SDD in 
reducing ICU acquired infection rates and the emergence of resistant 
bacterial strains [Stoutenbeek et a/, 1984]. 
3.6 EFFICACY OF SDD: A DISCUSSION OF THE EVIDENCE 
SDD for critically ill patients was first propounded by Dutch researchers 
Stoutenbeek et al in 1984. They reported decreases in pneumonias, 
urinary tract infections, septicaemia and wound infections in ventilated 
patients expected to require more than five days of intensive care. A 
literature search was carried out from 1982 to 1994. Initial sources 
were Medline and Index Medicus. Unpublished work detailed in the 
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SDD-Trialists' Meta-analysis [1993] was obtained from the co-ordinator, 
R. van Saene. This search produced 37 clinical trials, four meta- 
analyses, 10 review articles, 25 letters and four editorials. Appendix 
3.1 summarises year of publication, country of origin, design of study 
and type of SDD used. Of the 37 trials covered by this review, 24 are 
randomised controlled trials. The remaining trials are historically 
controlled, have consecutive control and/or contemporaneous control 
groups. With this method other infection control practices are more 
likely to be affected during the periods of consecutive control as the 
staff may change their practice. 
3.6.1 The SDD Regimen 
This section summarises the SDD regimens reported in the literature. 
The regimen consists of prophylactic drugs and microbiological 
surveillance. Variation in the regimen can stem from use of different 
drugs, length of treatment and intensity of surveillance. The regimens 
used are detailed in Appendix 3.1.25 trials used the recommended 
regimen of polymixin E, tobramycin and amphotericin (PTA). Some trials 
substitute alternatives because of supply difficulties. These alternatives 
are not expected to have an effect on overall efficacy. An alternative 
used that would be expected to have an effect on efficacy is 
erythromycin [De Champs et al, 19931. 
22 trials used intravenous therapy, 17 using cefotaxime, the remainder 
using ceftazidime, ceftriaxone, cephradine, cefuroxime, ofloxacin and 
trimethoprim. 17 trials used SDD for the entire length of ICU stay. 
Surveillance was reported as carried out on admission and then two to 
three times a week. Most common cultures taken were oropharyngeal, 
rectal, sputum, urine and gastric aspirate. 
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3.6.2 The Patients 
The studies range in size from 24 patients [Fox et at, 1991 ] to 502 
[Nardi et a/, 1993]. The total number of patients investigated in the 37 
trials is 5302. All studies outlined patient inclusion criteria clearly 
(Appendix 3.2). Most studies used SDD in patients considered to be 
'high risk' from ICU-acquired pneumonia, that is, ventilated surgical 
patients anticipated to have a long ICU stay. Studies reported their 
patient groups consisting of 0 to 80% medical patients. A variety of 
surgical groups (vascular, cardiac, abdominal and neurosurgery) are 
reported, as well as trauma patients. However, the definitions of these 
groups and reasons for admission for these patients are not uniform 
between trials, limiting comparison. 
Appendix 3.3 details the ages and severity of illness of the patients. 
Apart from the paediatric study [Zobel et al, 19911, studies reported 
mean ages of between 45 and 60. Ten studies did not report the 
severity of illness of their patients. Of those that did, fifteen used 
APACHE II. Use of a range of severity of illness scores makes direct 
comparison between studies more complex. Mean APACHE II scores 
range from 7 [Martinez-Pelluz et al, 1993] to 23.4 [Aerdts, 1989]. 
Aerdts [1989] and Blair et a/ [19911 stratified their randomisation by 
APACHE II score to investigate whether SOD was more effective for a 
particular APACHE II score band. 
3.6.3 Clinical Outcome Measures in SDD Trials 
Ideal outcome measures would include a measure of the incremental 
effect of SDD on the morbidity and mortality of the patient. However, 
the only outcome measures reported are reductions in infection rates 
and ICU mortality. 
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3.6.3.1 Reduction in Pneumonia Rates 
The primary clinical effectiveness measure used is the reduction in 
infection rate and pneumonia rates. Appendix 3.4 details reductions in 
infection rates and their statistical significance. SDD is shown to reduce 
total infection rates on ICU, reducing bloodstream infections and 
pneumonias. The largest component of this reduction is the reduction in 
pneumonia rate and is the measure uniformly reported by trials. In all 
studies except Brun-Buisson et al [ 1989], Hammond et al [ 1990], Fox et 
a/ [1991 ] and Gastinne et a/ [1992] pneumonia rates are significantly 
decreased from approximately 40 to 50% in controls to 10 to 20% in 
SDD-treated patients. Stoutenbeek et a/ [1992] attributed the lack of 
efficacy by Brun-Buisson to a lower dose of polymixin E. The authors 
themselves attribute the lack of efficacy partly to the high proportion of 
medical patients (79%). Hammond et a/ [1990] and Gastinne et a/ 
[1992] also had a very high proportion of medical patients (62% and 
72% respectively). Fox et a/ [19911 may not have produced a 
significant decrease due to the small size of the trial (27 patients). 
Researchers attempted to identify patient groups in which SDD was 
most effective. Appendix 3.5 details subgroup analysis of pneumonia 
rate reduction. Godard et al [1990] investigated pneumonia rate 
decreases in trauma, surgical and medical patients, finding no significant 
difference. Blair et a/ [19911 reported a significant decrease in numbers 
of infected patients in the APACHE II score band 10-19 (p =0.03). 
Hammond et a/ [ 19921 also reported a significant decrease in number of 
infected patients in the APACHE II score band 17-23 (p<0.01), but no 
significant decrease in trauma patients. Verhaegen [ 19921 found no 
significant decreases in different APACHE II score bands. 
No morbidity measures were reported by any study. Proxy measures 
were length of ICU stay (discussed in section 3.8) and length of 
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intubation. Fifteen studies reported length of stay, thirteen reporting no 
decrease (Appendix 3.5). A significant decrease from 20 to 17 days 
was reported by Garcia et al [19931 (p<0.007) and from 13 to 9.3 days 
reported by Suter et al [19931 (p =0.044). 
3.6.3.2 Mortality Effects of SDD 
Appendix 3.6 details the mortality reduction reported by the studies. All 
studies apart from Nardi et al [1993] reported ICU mortality. Five 
studies reported hospital mortality. Only three studies demonstrated a 
significant decrease in mortality. Rocha's study [1992] contained 79% 
trauma patients, all of whom were ventilated and had ICU lengths of 
stay of more than 5 days. Ulrich et al [1989] included 70% trauma and 
surgical patients all with ICU stays of more than 5 days. Fox et a/ 
[ 19911 only used long stay cardiac surgery patients. However, other 
studies with a high proportion of high risk patients [Blair et a/, 1991; 
Pugin et al, 1991; Korinek et al, 1993; and Verhaegen, 19921 did not 
demonstrate a mortality reduction. The lack of mortality reduction could 
be that patients on ICU die with pneumonia, rather than from it. This is 
likely to be true especially in medical patients. Alternatively, the studies 
were too small to detect mortality differences. 
Six studies carried out sub group analysis to identify patient groups 
whose mortality may have been affected by SDD. Ledingham et a/ 
[1988) and Palomar et a/ [19911 reported significant mortality decreases 
in trauma patients, but Winter et al [1992) found no difference. Godard 
et al [1990) reported a significant decrease in patients with ICU stays of 
more than 7 days, but Blair et a/ [1991], Winter et a/ (1992) and 
Ledingham et a/ [1988) found no difference. Godard et a/ (1990) also 
found a reduction in patients with SAPS scores of 0 to 10. Blair of a/ 
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[19911 found a reduction in patients with APACHE II scores 10 to 19, 
whereas Jacobs et al [ 19921 found no reduction in this subgroup. 
3.6.3.3 Unwanted Consequences of SDD: Emergence of Bacterial 
Resistance 
The antibiotics used in SDD selectively eradicate GNABs, which could 
lead to superinfection with resistant strains of GNAB, and MRSA which 
is not specifically targeted as much as GNABs. The retention of normal 
anaerobic gut flora is intended to prevent overgrowth of these 
pathogens. Most of the studies examined the emergence of resistance 
in their study groups. Significant problems have not been reported. 
There have been studies examining this problem specifically. 
Stoutenbeek et al [1987] reported no increase in resistance during 30 
months of SDD use. The lack of emergence of resistance is due to the 
high concentrations of the topical agents used. The high doses 
eliminate even those organisms that are partially resistant. 
3.7 META-ANALYSIS OF SDD TRIALS 
The large number of trials and equivocal evidence surrounding SDD's 
effect on mortality has given rise to four meta-analyses. Table 3.3 
summarises these analyses. All studies used RCTs only. The low 
number of studies in the recent analysis by Kollef [1994] is because 
they used only English language articles accessed via Medline. This 
gives the analysis a twofold publication bias. This is the only study that 
quotes absolute risk, which is more useful than odds ratios (relative risk) 
for economic evaluations that use decision analysis. The two most 
reliable meta-analyses carried out are those by the SDD Trialists' Group 
[ 19931 and Heyland et a/ [ 19941. The former is the least susceptible to 
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publication bias as four unpublished trials have been included. Methods 
used by Heyland et al [1994] are the most rigorous. They carried out a 
criterion-based systematic review to assess the method quality of the 
studies. The studies were given a score according to quality of method 
(randomisation, blinding and use of placebo), patient selection and 
population description, reproducible description of methods, outcome 
measures and diagnostic criteria. However, some scores were 
subjective and there was 'modest agreement between assessors' which 
limited the strength of inference. The drawback of this meta-analysis 
was the exclusion of some studies (Palomar, Cerra and Kerver) because 
the original papers did not distinguish between the number of infected 
patients and number of infections. The SDD Trialists overcame this by 
contacting original authors. 
Table 3.3 Summary of Published Meta-Analyses 
Study No. RCTs Relative Odds Relative Odds Ratios 
(patients) in Ratios for for mortality with 
analysis pneumonia with SDD (95% Cl) 
SOD (95% Cl) 
Vandenbroucke- 11 (1489) 0.12 (0.15-0.29) 0.90 (0.40-1.53) 
Grauls et al 
[1991] 
SDD Trialists 22 (4142) 0.37 (0.31-0.43) 0.90 (0.79-1.04) 
Collaborative 
Group [ 1993] 
Kollef [1994] 16 (2270) Absolute risk Absolute risk 
Control: 21.9% Control: 26.2% 
SDD: 7.4%" SDD: 24.3% ns 
Heyland et al 20 (3395) 0.46 (0.39-0.56) 0.87 (0.79-0.97) 
[1994] 
rr p<0.0001 
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All meta-analyses reported a very significant reduction in pneumonia 
rates when SDD is used. A review by Loirat et al [ 19921 suggests that 
SDD should be directed at a previously healthy ICU population with 
acute moderate to severe disease and a good prognosis provided 
infectious complications can be avoided, such as trauma and burns 
patients. The meta-analyses were not able to carry out subgroup 
analyses to identify target patient groups due to the inconsistency of 
diagnosis definitions between studies. 
Mortality odds ratios imply that SDD has a marginal effect on mortality. 
SDD only affects mortality through its reduction of pneumonia rates. 
Section 3.4 has discussed the difficulties in attributing mortality to 
pneumonia. The meta-analysis by the SDD Trialists group suggests that 
a trial of 2000 patients would be required to demonstrate a significant 
mortality reduction of 10%. The meta-analyses show an overall 
decrease in mortality of 10%. As the meta-analyses include more 
patients, this estimate does not change, but its confidence intervals 
become narrower. 
3.8 ECONOMIC IMPACT OF SDD 
Changes in resource use due to SDD arise from its implementation and 
its impact on pneumonia rates. This in turn has an effect on length of 
ICU and hospital stay and any increase in treatment intensity. This 
section examines the evidence reported by SDD trials for incremental 
resource use changes associated with SDD implementation and its 
effect on pneumonia rates. 
Appendix 3.7 summarises resource use information available from the 
literature. Five trials do not report any resource use information at all, 
16 trials only recording ICU length of stay. In writing to the authors of 
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the studies only one was able to provide any information at all on the 
sources of their costs (personal communication, Dr. L. Rocha, 1993). 
SDD is a resource intensive intervention, using costly antibiotics in 
preparations that have to be made in the hospital. It is time consuming 
to prepare and administer. Microbiological surveillance in the trials is 
also intensive. Only seven trials quote SDD regimen costs, in varying 
detail. Winter et a/ [19921, Korinek et a/ [1993] and Suter et a/ [1993] 
did not report the source of costs or the year from which the costs were 
derived. Gastinne et al [1992] obtained their drug costs from their 
pharmacy department, but did not detail the components of costs 
reported. 
Impact of SDD on resource use associated with pneumonia was largely 
confined to impact on length of ICU stay. Length of stay was reported 
by thirty studies. Mean lengths of stay were usually over ten days, 
reflecting the severity of illness of the patients included in the studies. 
No significant difference was reported between treatment and control 
lengths of stay for most studies. Verhaegen [1992] reported a 
reduction in length of stay for the treatment group receiving ofloxacin 
(p = 0.012), but no reduction for the group receiving PTA. Verhaegen 
[1992] also reported that once infection is established, SDD has no 
independent effect on length of stay (see Chapter Four). Suter et a/ 
[1993] reported a reduction from 18.5 days to 12.7 days when PTA 
was used. Impact of pneumonia on treatment intensity was largely 
confined to measurement of therapeutic antibiotics. Rocha et al [ 19921 
provided the most detailed cost breakdown of all the SDD trials. They 
used 'real costs' for staffing, pharmacy and 'sanitary material' and 
hospital charges for diagnostic procedures, administration, nutrition and 
other services (personal communication, Dr. L. Rocha, 1993). Unlike 
the other studies, they also related costs to outcomes to derive cost 
effectiveness ratios. Cost per survivor was reported to be lower in SDD 
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treated patients (see Appendix 3.7). This suggests that SDD was more 
effective at a lower cost, so is considered a dominant therapy. 
The many reviews and editorials devoted to SDD have used its high cost 
as a reason for recommending against its use [Atkinson et al, 19931. 
Reviewers sympathetic to SOD recommend that cost effectiveness 
studies are needed to justify its use [Boom et al, 1992; Reidy et al, 
19901. SOD trialists have examined the cost effectiveness of SDD. 
Aerdts [ 19891 and Verhaegen [ 19921 devoted thesis chapters to 'cost 
effectiveness analysis'. Neither author reported sources or breakdowns 
of costs. Also, the costs reported were not related to clinical outcome 
in any way. 
Two reviews have examined the cost implications of SDD. The original 
developers of SDD derived a value for cost per survivor (Miranda et a/ 
[1983]) of $22326. The methods used to obtain these costs were not 
reported. A more recent review of the economics of SDD in ICU 
patients [Markowsky et al, 1994] summarised the cost figures reported 
by SDD trialists, but did not attempt to draw any economic conclusions 
from the primary research. 
3.9 CONCLUSIONS OF THIS REVIEW AND IMPLICATIONS FOR 
ECONOMIC EVALUATION OF SDD 
This review has demonstrated that ICU-acquired pneumonia is 
considered to be the nosocomial infection with the most profound effect 
on resource use and patient outcome. The relationship of ICU-acquired 
pneumonia with mortality is complex and has not been clearly 
quantified. The situation where patients with pneumonia ultimately die 
of their underlying condition, rather than the infection, complicates this 
relationship. It may be that impact of ICU-acquired pneumonia on the 
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morbidity of survivors is a more appropriate outcome measure. Adverse 
morbidity associated with development of ICU-acquired pneumonia has 
not been quantified, although it could be implied from the increased 
length of ICU stay of infected patients. Due to the relative shortage of 
ICU beds in this country, an important organisational consequence is 
that of beds being filled by patients with ICU-acquired pneumonia. This 
means that other patients requiring intensive care are not receiving this 
care, increasing their risk of adverse outcomes. It is therefore desirable 
to reduce ICU-acquired pneumonia to reduce possible morbidity and 
mortality of the infected patient and also that of other potential ICU 
patients. 
The economic impact of ICU-acquired pneumonia has not been fully 
quantified, but the increase in intensity of intervention due to infections 
has significant resource implications. The nature of this resource use 
has not been sufficiently reported so far. The most appropriate method 
to determine whether increase in therapeutic intensity due to infection 
exists is to collect bottom-up resource use data and attach costs to that 
resource use. This method is resource intensive itself and the 
incremental benefit of carrying out such a study should be considered. 
This review has examined the clinical and economic evidence associated 
with SDD. The existence of 37 clinical trials of an intervention, 24 of 
which were well designed RCTs, is unusual in the ICU setting. These 
trials represent a large commitment of resources to an intervention that 
does not attract universal support. SDD unequivocally reduces ICU- 
acquired pneumonia rates but has an equivocal effect on mortality. This 
review has demonstrated how difficult it would be to show an 
independently significant effect on short term mortality. Although 
nearly all the studies report significant decreases in pneumonia rates, 
authors and commentators voice their concern about the lack of 
reduction of mortality, the possible emergence of resistance and the 
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high cost of implementing the SDD regimen. Despite the lack of 
economic evidence from trials, reviewers argue against the use of SDD 
on the basis that it is not cost-effective [Loirat et al, 1992; Reidy et al, 
19921. However, no economic analysis has been carried out. 
On the basis of the available evidence, this review is not able to derive 
any conclusions on the cost effectiveness of SDD. The relevant 
economic issue is whether it is more cost effective to treat ICU-acquired 
pneumonia as it occurs, or to reduce its rate with SDD. It may be that 
SDD reduces total cost as well as improving patient outcomes, in which 
case it becomes dominant. It may be that it improves patient outcomes 
at an increased cost. In this case, incremental cost/outcome ratios need 
to be derived. This has not, so far, been satisfactorily addressed. 
Economic evaluation of SDD needs to take into account the resource 
use and outcome effects of ICU-acquired pneumonia, and then examine 
the effect SDD has on them. It is suggested that conclusions on the 
cost effectiveness of SDD cannot be made until there has been a formal 
consideration of costs and benefits. 
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Chapter 4: A Secondary Economic Evaluation of SDD 
4.1 INTRODUCTION 
Chapter Three has suggested that there is a need for the economic 
evaluation of SDD to improve the information upon which policy decisions 
are made about SOD implementation. However, to date there has been no 
economic evaluation of SDD and it is not known how cost effective it is. 
The discussion in Chapter Two has outlined reasons why economic 
evaluations of technologies used within intensive care are not frequently 
undertaken. 
There are two main ways to carry out economic evaluations. Prospective 
economic studies provide primary economic data where empirical data is 
collected as part of an RCT or observational study. However, prospective 
studies are themselves resource intensive. They can only be recommended 
if it is considered that a prospective study could provide information that 
will improve decision-making. Assessment of whether a prospective study 
is warranted is done by carrying out an economic evaluation using 
secondary sources of data, primarily published clinical and economic 
evidence. Published data are retrieved, usually from multiple sources, and 
used to derive cost/outcome ratios for the intervention. This information 
is already available so does not have the same resource implications as 
primary data. Modelling in economic evaluation can be used either as a 
first or last resort. As a first resort, it is used to indicate whether primary 
economic analysis is warranted and which specific areas of evidence are 
required to improve the robustness of any conclusions made. As a last 
resort, it is used when a primary economic analysis is not feasible. Also, if 
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the published evidence is considered sufficient, it may be possible to carry 
out an economic evaluation without recourse to a primary study. 
This chapter describes a secondary economic analysis of SDD. Section 4.2 
outlines the specific aims and objectives. Section 4.3 describes the 
methods used in the analysis. Section 4.4 reports on the use of these 
methods in the economic analysis of SDD. The results of this economic 
evaluation are discussed in section 4.5 and the implications for future 
economic analysis of SDD are examined in section 4.6. 
4.2 AIMS AND OBJECTIVES OF ECONOMIC EVALUATION 
The aim of the secondary economic analysis of SDD is to derive 
conclusions regarding the cost effectiveness of SDD using published clinical 
and economic evidence. 
The specific objectives of this economic analysis are: 
1. To use the available clinical and economic literature to assess the 
conditions, if any, under which SDD can be demonstrated to be cost 
effective. 
2. To determine whether conclusions can be drawn on cost effectiveness 
of SDD on the evidence available and identify areas where more evidence is 
needed. 
3. To comment upon the appropriateness of applying secondary economic 
analysis methods to answer questions of cost effectiveness in intensive 
care medicine in general and in SDD in particular. 
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4.3 METHODS OF ECONOMIC EVALUATION 
This section describes the methods used in economic evaluation. The aim 
of economic analysis of an intervention is to determine whether, under 
specified conditions, it is cost effective. Economic evaluation can be 
considered to consist of four stages. The first stage is the derivation of the 
research question. In this thesis, decision analysis is used to define the 
research question and express the intervention as a decision-analytic 
pathway [Weinstein, 19801. The second stage is to obtain economic and 
clinical evidence to apply to the decision-analytic model. In primary 
economic evaluation the data comes from primary sources. This is either a 
prospective study attached to an RCT or an observational study. In 
secondary economic evaluation, the sources of data are published 
evidence. Systematic review of economic and clinical data is used to find 
and assess information to combine with the decision-analytic model. The 
third stage is the combination of clinical and economic parameters within 
the decision model framework to derive cost/outcome ratios. This involves 
the analysis of the incremental effect of an intervention on overall resource 
use and patient outcome, compared with alternatives. In the fourth stage, 
the robustness of these ratios is examined using sensitivity analysis to 
determine how much variation in which parameters has most effect on 
conclusions drawn. These methods are used in the secondary economic 
analysis of SDD reported in this chapter. The specific methods used in the 
four stages are presented in the next four sections. 
4.3.1 Derivation of Research Question 
In this thesis, the framework of decision analysis is used to derive the 
research question. Decision-analytic models provide a clear and intuitive 
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framework within which an economic question can be developed 
[Weinstein, 1980]. The ideal decision-analytic model is that which most 
closely resembles real life situations without being prohibitively complex. 
The use of decision analysis enables the research question to be identified 
and bound within a set of explicit conditions. This requires that the 
intervention and any alternatives are described in terms of inputs, process 
and outputs. The perspective or viewpoint of the analysis is defined at this 
point. Evaluations may assume the viewpoint of a single provider, the 
NHS, the patient or society. The perspective affects which costs are 
included and at which points within the intervention process the evaluation 
begins and ends. 
The input to the process is the patient group appropriate for the 
intervention. The intervention process begins with the decision of whether 
the patient is appropriate for treatment or not. The next stage is to 
describe all alternative treatments under consideration. A 'no treatment' 
option should be included if appropriate. In all alternatives, all stages of 
the intervention process need to be stated, including lengths of operating 
time, drug regimes used including doses and lengths of treatment, and any 
investigational or diagnostic tests routinely required. 
The stages at which treatments may be altered or discontinued need to be 
known, as does under which criteria these occur and what, if any, 
alternative treatment is implemented. Probabilistic events expressed as 
chance nodes define the intervention process. The degree of exclusivity of 
the alternatives may vary. The complication rates of each alternative and 
their maintenance are required to assess their full economic impact. 
The final component of the decision-analytic pathway is patient outcome. 
An ideal outcome measure provides a measure of the impact of the 
103 
treatment on quantity and quality of life. In practice, intermediate 
outcomes are often used as multiattribute outcome measures are 
methodologically complex and time-consuming to collect. The clinical 
effectiveness measure used determines the type of economic evaluation. If 
two alternatives are equally effective, they need only be differentiated by 
their economic impact, giving rise to cost minimisation analysis. The use 
of a linear, unidirectional measure of outcome to compare effectiveness, 
such as life years gained, gives rise to cost effectiveness analysis. When 
multi-attribute measures of outcome are used, which combine measures of 
impact in both quantity and quality of life to produce measures of utility, 
the evaluation is a cost utility analysis. Where benefits are expressed in 
monetary terms, the evaluation is a cost benefit analysis. 
Once the components of the research question have been identified, they 
are structured in a logical and temporal sequence. This involves defining 
the clinical starting point, from which the sequence of events is described. 
The time horizon of the decision-analytic model is defined, as well as 
measures of patient outcome and the time at which the treatment ceases 
to have any more effect on outcome. 
4.3.2 Acquisition of Economic and Clinical Evidence 
The second stage in an economic evaluation is to obtain clinical and 
economic evidence required to fill the decision-analytic model. In 
secondary economic analysis the source is published research. It is 
essential that the most robust evidence is used. The quality of evidence 
was discussed in Chapter Two. Robust evidence can be considered to 
consist of data that have been collected using rigorously designed 
methods, as discussed in Chapter Two, section 2.7.1. From Eddy's grades 
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of evidence, the most robust source is held to be RCTs. Secondary data 
are preferably obtained from RCTs. However, in therapeutic areas such as 
intensive care, the quantity and quality of economic data available are 
usually far from satisfactory. Therefore, it is necessary to utilise all 
possible sources of data and then assess which data are appropriate for 
use in an economic analysis. 
When there is much clinical or economic evidence, it is necessary to select 
the most robust data by literature review. Traditional reviews can be 
subject to the idiosyncratic impressions of the individual reviewer. 
Systematic review and critical appraisal of published evidence using simple 
guidelines provide an objective assessment of the research less prone to 
reviewer bias. Mulrow et a/ [1994] list the following justifications for 
systematic review: 
1. When there are many studies on an intervention it allows 
synthesis of large quantities of information into 'palatable pieces for 
digestion'. 
2. Integration of critical pieces of information provides estimates of 
variables and outcomes for use in economic evaluation and decision 
analysis. 
3. It is usually quicker and less costly than embarking on a new 
study. It can shorten the time between medical research discoveries 
and clinical implementation of effective strategies. 
4. Establishment of generalisability provides an interpretative 
context not available in any one study. 
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5. There is assessment of consistency of relationships and whether 
effects are in the same direction and of the same magnitude. 
6. Explanation of inconsistencies and conflicts in data is possible. 
7. There is often increased statistical power. This is particularly 
relevant to relatively low event rates or when small effects are being 
measured. 
8. Increased precision of risk or effect size by narrowing of 
confidence intervals around point estimates. 
One major objective of systematic review is to combine individual study 
results into pooled point estimates (with confidence ranges) of effect size. 
Meta-analysis is the formal approach to combining evidence from multiple 
sources to calculate point estimates and confidence intervals for 
parameters of interest. Meta-analysis weights reported evidence according 
to the number of subjects and variance of results of each study. 
Confidence intervals indicate the precision of the result obtained [Patel, 
19881. The studies should contain robust data and it must be certain that 
they are all measuring the same effect of the same intervention in the same 
subject group. To achieve these two aims, it is necessary to have explicit 
inclusion criteria. The quality of evidence available is the primary concern. 
Most weight should be given to studies that are least subject to bias and 
error, that is RCTs [Light et a/, 19841. Publication bias occurs when 
researchers and publishers are more inclined to publish studies with 
positive results than with negative or inconclusive results. It is possible to 
determine how many unpublished observations would be required to 
influence the significance of a meta-analysis finding. This issue is at least 
made explicit by meta-analysis. Meta-analysis gives more weight to larger 
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studies, so the impact of smaller studies is given an appropriate weight. 
Another problem with comparing studies is the concern of whether 
treatment groups in different studies are the same in fact as well as in 
name. This is often difficult to determine from a published report. A 
related problem can be whether control groups are comparable to treatment 
groups, which is why RCT-derived data is preferably used. It is also 
essential that studies use the same units of analysis. The review should 
only compare those studies that use the same measures of outcome and 
quote confidence intervals and statistical tests. 
The ideal situation exists where all clinical and economic evidence relating 
to an intervention are collected from the same robustly designed RCTs. 
Unfortunately, this situation is unlikely to occur, at the present time, in 
intensive care medicine, and in many other therapeutic areas. Therefore, it 
is necessary to use alternative sources of data. These sources may include 
less rigorously designed studies such as are described in Chapter Two. 
Case-control studies, observational studies, routinely collected data, or that 
collected from 'expert panels' are common alternative sources. RCT data 
are preferred because they are stochastic and control for bias. Precision, or 
lack of it can be quantified, and it is possible to draw statistical inference 
from the sample to the population from which the data are drawn. Data 
not drawn from random sampling, that is, deterministic data, do not allow 
this type of analysis. This issue is more relevant in the acquisition of 
economic data. The use of this type of data usually decreases the 
precision of point estimates. Sensitivity ranges have to employed, instead 
of statistical ranges. These are less satisfactory because of their 
subjectivity. 
Apart from the quality of the data available, it is necessary to be able to 
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account for all effects on the patient and all changes in resource use. 
Therefore the final outcome of the patient should be assessed, not just 
intermediate outcomes. All resource use associated with an intervention 
should be identified and costed, as discussed in Chapter Two. 
The ability of the model to identify specific areas where there is a lack of 
data is important. This information should direct priorities for further 
research. 
4.3.3 Derivation of Incremental Cost/Outcome Ratios 
The third stage in economic evaluation is to combine the clinical and 
economic evidence with the decision-analytic model. Clinical probabilities 
and resource use along each pathway are combined to derive the 
probabilistic cost for each pathway. The first stage is to build a base case. 
This combines the clinical outcome point estimates with the economic cost 
associated with each stage of the model. If one of the alternatives is more 
effective and less costly, it is termed the dominant therapy. When one 
alternative is more effective but requires more resources, the cost required 
to achieve each extra unit of outcome is calculated. If the outcome 
measure is single and unidirectional, this provides an incremental cost 
effectiveness ratio. The lower the value, the more cost effective the 
alternative. In cost utility analysis, the cost/outcome ratio should provide a 
measure of the cost to obtain one more unit of multiattribute outcome, 
such as QALYs. When this outcome measure is not available, the outcome 
measures used must be justified. If outcome measures used are only 
intermediate outputs, such as number of cases detected or decrease in 
infection rate, this must be stated. 
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4.3.4 Sensitivity Analysis: Indications for Use and Standard Methods 
The fourth stage of economic evaluation is the assessment of the 
robustness of the cost/outcome ratios derived. In this situation, robustness 
refers to the sensitivity of cost/outcome ratios to uncertainties in the data 
or alternative methods of analysis. If the conclusions about cost 
effectiveness do not change when these parameters are varied, the 
conclusions can be considered to be robust. The robustness of conclusions 
is examined using sensitivity analysis. Sensitivity analysis has many 
functions when used within an economic analysis. Uncertainty in 
underlying assumptions, including analytical methods, weakens an analysis. 
The use of sensitivity analysis goes some way to quantifying the degree of 
uncertainty existing in an economic evaluation. It may also increase the 
level of uncertainty by identifying uncertainty not previously examined. 
The use of sensitivity analysis identifies areas where more research is 
required to increase robustness. Sensitivity analysis can improve the 
generalisability of a study. It is particularly useful when applying ranges to 
point estimates derived from deterministic data. As discussed earlier, 
clinical evidence is much more likely than economic evidence to be 
available as stochastic data. Economic evidence, if available at all, is often 
reported as deterministic data. Uncertainty surrounding the available 
resource use data is often very significant due to inadequacy of the point 
estimates. It is necessary to assess the impact of variation of these 
estimates. The variation examined should reflect realistic ranges of the 
point estimate. Studies which provide a source or explanation for the 
ranges used are likely to be of more use to decision makers than studies 
which employ an arbitrary range in their sensitivity analysis. 
There is more than one way of conducting a sensitivity analysis [Briggs et 
al, 1994]. 'Simple' sensitivity analysis varies one or more parameters 
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across a plausible range. In 'one-way' analysis, each uncertain component 
is varied individually, to establish the separate effect of each on the results 
of the analysis. This may be sufficient if each of the uncertain components 
is independent of the others. 'Multi-way' simple sensitivity analysis varies 
two or more components at the same time. However, it becomes 
progressively more difficult to present the results of multi-way analyses the 
greater the number of components that are varied. A form of this is 
'scenario analysis' which explores the implications of alternative 'states of 
the world', each of which affects a number of parameters in an evaluation. 
'Threshold analysis' is concerned with identifying the critical value of 
parameters above or below which the conclusions of the study will change. 
Threshold analysis is useful in cost effectiveness analysis in defining points 
at which the therapy under investigation becomes dominant. Another 
method is 'analysis of extremes'. This involves comparing a base case 
scenario with the most pessimistic and most optimistic scenarios. 
4.4 SECONDARY ECONOMIC EVALUATION OF SDD 
This section reports the secondary economic evaluation of SDD. It 
investigates whether SDD can be demonstrated to be cost effective 
compared with appropriate alternatives. Using the methods described in 
section 4.3, the research question is defined through the design of a 
decision-analytic model. Clinical and economic sources of evidence are 
identified to provide data to apply to the model. Cost/outcome ratios are 
derived and their robustness is examined using sensitivity analysis. 
110 
4.4.1 Definition of Research Question 
This section defines the research question and proposes a decision-analytic 
model to provide a framework within which to answer that research 
question. The clinical aim of SDD is to decrease the incidence of ICU- 
acquired pneumonia, as defined in Chapter Two, and its associated 
morbidity and mortality. The actual category of pneumonia affected is late- 
onset Gram-negative pneumonia only. The economic aim is that this 
should be carried out as efficiently as possible, that is, maximizing output 
for a given level of input. The research question in this analysis asks 
whether SDD can be shown to be cost effective. To address this question 
in a systematic way, it is necessary to examine the process of the 
intervention and represent it as a decision-analytic model. The input and 
the process of the intervention, its associated resource use and outcome 
need to be identified. 
4.4.1.1 Input to the Intervention 
The input to the intervention is the patient group considered appropriate for 
SDD therapy are those ICU admissions considered most at risk from ICU- 
acquired pneumonia. Therefore, the target patient group is ventilated ICU 
admissions, as discussed in Chapter Three. 
4.4.1.2 Process of the Intervention 
The next stage is to describe the process of the intervention of SDD. From 
the literature review reported in Chapter Three, SDD is known to consist of 
topical application of antibiotics (polymixin E, tobramycin and amphotericin: 
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'PTA') to the buccal mucosa and gastrointestinal tract in combination with 
an intravenous broad spectrum antibiotic (cefotaxime). Intensive 
microbiological monitoring is employed to assess the infective state of the 
patient and to monitor the emergence of resistant bacterial strains. The 
SDD treatment regimen is either implemented totally, or not at all. There is 
no intermediate alternative. The alternative to SDD is not to treat, and 
treat pneumonias as they occur. SDD is either used for the whole of the 
ICU stay or just whilst the patient is ventilated. The patient either receives 
SDD from the beginning of the ICU stay or does not receive it at all. The 
patient will not receive SDD once they return to a normal ward. SDD 
would not be initiated in the middle of the ICU stay. The occurrence of 
ICU-acquired pneumonia in patients who do and do not receive SDD will 
lead to therapeutic interventions which are not expected to differ between 
SDD-treated and non SDD-treated patients. It is necessary to identify the 
resource use associated with each stage of the intervention process and 
attach unit costs to that resource use. This economic evaluation aims to 
assess the long term impact of implementation of SDD. Therefore, the 
costs should include all fixed and variable components, as recommended in 
Chapter Two. This provides a total cost for the patient, which can be 
equated to their long run marginal cost. 
The first category of economic measures required are the impact of the 
SDD regimen. The second category arises from the impact of SDD on ICU- 
acquired pneumonia rates. Chapter Three has identified that ICU-acquired 
pneumonia has a significant impact on resource use. This impact occurs 
mainly through the increase in length of ICU stay due to an episode. There 
is also some evidence that treatment intensity is increased. If SDD affects 
ICU-acquired pneumonia incidence, it therefore affects resource use due to 
that pneumonia. 
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4.4.1.3 Outcome of the Intervention 
The type of cost/outcome ratios derived depends upon the outcome 
measures used. The effect on clinical outcome of SDD is considered to be 
its effect on patient morbidity and mortality through its effect on ICU- 
acquired pneumonia incidence. If SDD is not shown to change patient 
outcomes, but resource use only, then it becomes a cost minimisation 
analysis. If there is a difference in patient outcome arising from the use of 
SDD, cost/benefit or cost/outcome analyses are used. Ideal patient 
outcome measures combine the impact of SDD on quality and quantity of 
patients' lives. 
Once the components of the research question have been identified, they 
are structured into a logical and temporal sequence in a decision-analytic 
model. The model developed for the implementation of SDD in ventilated 
ICU admissions is shown in Figure 4.1. The first step is to define the 
starting point of the model, which in this case is the point of admission to 
ICU. The second step is to select a time horizon, that is, the point at 
which final outcomes are measured. The ideal time horizon includes the 
whole life span of the patient so that all possible effects of the intervention 
can be examined. Probabilistic events and events arising as a result of 
clinical decisions need to be distinguished from one another. The only 
decision involved in this intervention is whether to administer SDD to this 
group of patients, or not. All subsequent consequences are probabilistic. 
When a ventilated patient is admitted to ICU, he has a known risk of 
contracting ICU-acquired pneumonia. ICU mortality, hospital mortality or 
life expectancy may be affected by an episode of ICU-acquired pneumonia. 
SDD changes the probability of developing ICU-acquired pneumonia and, 
thus, any associated change in risk of mortality. This defines the chance 
nodes of the decision-analytic model. 
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Figure 4.1 Decision Tree for Use of SDD in Ventilated ICU Admissions 
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Only when the combined information of clinical probabilities, outcomes and 
economic cost are known can the decision-analytic model be used to 
examine the cost effectiveness of SDD. The clinical and economic 
evidence required for the decision-analytic model can be summarised into 
five categories: 
1. The probability that the patient will contract ICU-acquired pneumonia 
with or without SDD; 
2. The impact of ICU-acquired pneumonia and SDD on the short and long 
term mortality of the patient; 
3. The impact of ICU-acquired pneumonia and SDD on the short and long 
term morbidity of the patient; 
4. The impact of ICU acquired pneumonia and SDD on the resource use 
associated with the patient; 
5. The unit costs associated with resource use. 
The acquisition of clinical and economic evidence for these five categories 
is described in the next section. 
4.4.2 Acquisition of Clinical Evidence 
This section describes acquisition of information required by the decision 
analytic model by examination of the available clinical literature. The 
clinical evidence required for the decision-analytic model consist of the first 
three categories in the previous section. The ideal sources of these 
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categories of data are RCTs of SDD. The extent to which the evidence 
required can be extracted from these sources is examined. Alternative 
sources of evidence are used if necessary. The limitations of data drawn 
from these alternative sources is discussed. Any steps necessary to 
transform the data into a form where they can be used in the decision- 
analytic model for economic evaluation are reported. A summary of the 
clinical data obtained for use in the secondary economic evaluation is 
provided at the end of this section. 
4.4.2.1 Derivation of Clinical Probabilities from Trials of SDD 
This section examines the evidence on the effectiveness of SDD available 
in SDD trials. A literature search on SDD was carried out from 1982 to 
1994. SDD in ICU patients was first designed in 1983 and reported in 
1984 [Stoutenbeek et a/, 1984]. The initial sources used were Medline 
and Index Medicus. The original designers of SDD were contacted for 
information on any unpublished trials. Any unpublished work detailed in 
the SDD-Trialists' Meta-Analysis [1993] was obtained from the co- 
ordinator, R. van Saene. This search produced 37 clinical trials of SDD, 
four meta-analyses, ten review articles, 25 letters and four editorials. One 
review of the economic implications of SDD was found, but no formal 
economic evaluation. The volume of clinical literature required that it be 
systematically reviewed to extract the 'best' quality evidence to be used. 
Inclusion criteria were designed, as discussed in section 4.2. The 
systematic review of the SDD literature was carried out using the following 
inclusion criteria: 
1. Only randomized clinical trials (RCTs) were used, to decrease internal 
bias. If the test centre changed from using no SDD to SDD, in the case of 
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historic and consecutive controls, there may be associated implicit changes 
in other infection control practices as nursing and medical staff are likely to 
change their normal practice. This also happens in RCTs but to a lesser 
extent, and temporal changes in infection control practices, such as 
improved handwashing should be equal between the trial and control 
groups. Blinded trials are the ideal, but realistically have been difficult to 
achieve in SDD. 
2. Only trials with explicit patient inclusion and infection diagnosis criteria 
were used. 
3. No trials with components in the SDD regime significantly different from 
the standard PTA regimen were included, to ensure comparable antibiotic 
effectiveness. 
4. No trials with ICU patient groups considered significantly different from 
a representative adult population were included. It was considered that 
their underlying pathologies would have had a significant confounding 
effect on infection rates, length of stay, and mortality. 
5. Only measures that were reported in more than one study were used. 
6. Any trials that duplicated data from earlier trials were excluded. 
It would have been ideal to use only British studies because the clinical 
practice variation will be decreased. However, there were only seven 
British studies, only three of which are RCTs. Excluding use of foreign 
study data would have prevented use of a lot of data. 
Appendix 4.1 shows which trials were excluded and for what reasons. 
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Most trials were excluded on the basis of one exclusion criterion, usually 
because the study was not an RCT. 
It was expected that trials with more medical patients would have a wider 
range of lengths of ICU stay and also have higher mortality, due to 
increased influence of underlying pathology. SDD is considered to be more 
appropriate and more effective in surgical or trauma patients with no 
underlying pathology, who are nevertheless very prone to infection. To 
test this hypothesis, two successively more selective sub-groups of trials 
were derived: 
1. 'Mixed ICU' Model. - 
In the first subgroup only trials with less than 50% medical patients were 
included. This subgroup has 18 trials, covering 2828 patients. 
2. 'Surgery/Trauma' Mode% 
The most selective subgroup included only trials with 21 % or fewer 
medical patients to produce a model with clinical measures derived mostly 
from surgical or trauma patients. This subgroup had 10 trials, covering 
2020 patients. 
Appendix 4.2 outlines which trials were included in each group. A model 
containing only surgery or trauma patients was investigated. Few trials 
reported effect sizes exclusively for trauma or surgical patients. Definitions 
of trauma and surgical categories varied significantly between studies. To 
develop a model of surgery or trauma patients only would require access to 
the primary trial data. 
Patient group size, effect sizes and effect size variance were obtained from 
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each of the included trials. The data were then pooled, using fixed effect 
method meta-analysis. This was carried out for each of the three groups of 
trials. The specific statistical methods used to derive weighted means and 
confidence intervals are outlined in Appendix 4.3. 
4.4.2.2 Results of Systematic Review and Meta-Analysis 
The above criteria were applied to the 37 trials available for systematic 
review. 24 trials remained for use in data extraction. Appendix 4.2 details 
the 24 trials that were included for meta-analysis. The 24 trials covered 
3693 patients. The only clinical effectiveness parameters measured by 
these trials are reductions in pneumonia rates and ICU mortality. No 
evidence was reported on the impact of SDD on long term mortality, or any 
morbidity measures. Alternative sources had to be used, and are reported 
in the next section. 
All the trials included were RCTs so it can be assumed that the data from 
them are robust. However, the presence of publication bias is 
demonstrated by the plot of effect size against sample size in Figure 4.2. 
This shows that the larger effect size is reported by small studies. When 
the data from these trials are pooled, the contribution from each trial is 
weighted by its size and reported variance. This means that the larger 
studies with smaller variances would have the greatest impact on pooled 
effect size, minimizing the effect of publication bias. 
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Figure 4.2 Plot of Study Sample Size Against Pneumonia Rate Reduction 
by SDD to Assess Publication Bias 
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The pooling of these trials provided weighted effect sizes for impact of 
SDD on ICU-acquired pneumonia rates and ICU mortality. These pooled 
values were derived for each of the three specified groups of trials. The 
clinical evidence obtained from the published literature, as appropriate for 
the three defined subsets of trials is summarized in Tables 4.1 and 4.3. 
The distribution of patient populations in each of the models is reported in 
Table 4.1. Weighted point estimates and confidence intervals for 
pneumonia rate decrease are reported in Table 4.2 and ICU mortality 
decrease are reported in Table 4.3. 
Table 4.1 Patient Populations of Clinical Trials Groups 
Parameter All trials Mixed ICU model Surgery/trauma model 
No. trials 24 18 10 
No. patients 3693 2828 2020 
% Surgical' 38.2 45.2 50.0 
(16.1-60.3) (18.4-72.0) (15.5-84.5) 
% Medical 31.8 20.5 12.2 
(11.9-51.7) (0.6-40.6) (0-21.0) 
% Trauma 35.1 38.0 41.4 
(11.8-58.4) (11.9-64.9) (7.1-75.7) 
' Weighted means (ranges in parentheses) 
Table 4.1 demonstrates the variation in patient population between the 
models. The large confidence intervals indicate the wide variation between 
individual trials. The two most common patient groups included in trials for 
each of the three models were ventilated patients with a length of stay of 
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two or more days and ventilated patients with a length of stay of five or 
more days. Apart from the differences in the proportion of surgical to 
medical patients, patient inclusion criteria and SDD regimes reported for 
each of the three models do not differ significantly. 
Effect size of SDD measured as ICU-acquired pneumonia rate reduction is 
reported in Table 4.2. The narrow 95% confidence intervals indicate 
consistency of SDD's efficacy in reducing pneumonia rates. The lack of 
significant differences detected between the successively more selective 
trial groups may indicate that SDD is not more effective in surgical and 
trauma patients. Alternatively, the patient groups in each trial are so 
heterogeneous that it effectively obscures any significant difference 
between trials. Also, the trials have been carried out in different countries 
with different clinical practice, so diagnostic definitions may also vary. 
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Table 4.2 Effect of SDD on Pneumonia Rates of Trials Groups 
Parameter All trials Mixed ICU model Surgery/trauma 
weighted means weighted means model 
weighted means 
Base pneumonia 29.4 30.2 28.8 
rate/%' (1394, (1008, (918, 
8.5-50.3%) 5.7-34.7%) 0-59.7%) 
SDD-treated 13.8 12.7 15.1 
pneumonia rate/%' (1394, (1008, (918, 
0-35.5%) 0-38.8%) 0-43.2%) 
Effect size/%' 15.6 17.5 13.7 
(2788, (2016, (1836, 
12.7-18.5 %)3 14.2-20.8%) 6.9-20.5%) 
' Numbers in parentheses are total numbers of patients included in derivation of weighted 
mean, ranges. 
2 Numbers in parentheses are total numbers of patients included in derivation of weighted 
mean, 95% confidence intervals. 
3 Equivalent to a mean reduction in pneumonia rate of 53% (95% Cl: 43 to 63% 
reduction). 
Table 4.3 reports the effect of SDD on ICU mortality in the three trials 
groups. Most trials report a small, non-significant reduction in mortality. 
This is reflected in the small reductions in pooled mean mortality rates from 
control to treatment. The derived effect sizes are small and their 
confidence intervals indicate that they are not significant. 
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Table 4.3 Effect of SDD on ICU Mortality Rates of Trials Groups 
Parameter All trials Mixed ICU model Surgery/trauma 
weighted means weighted means model 
weighted means 
Base mortality 29.6 28.1 25.5 
rate/%' (1811, (1409, (1013, 
0-51.6%) 0-53.2%) 0-57.7%) 
SDD-treated 26.5 25.0 24.3 
mortality (1811, (1409, (1013, 
rate/%' 0-48.0%) 0-49.4%) 0-55.9%) 
Effect size/%2 3.1 3.1 1.2 
(3622, (2828, (2026, 
-9.9-16.1 %)3 -3.1-9.3%) -3.1-5.5%) 
' Numbers in parentheses are total numbers of patients included in derivation of weighted 
mean, range. 
Numbers in parentheses are total numbers of patients included in derivation of weighted 
mean, 95% confidence interval. Negative values in 95% Cl indicate studies who reported 
an increase in mortality in SDD-treated groups. 
3 Equivalent to a reduction in mortality of 10% (range: -34 to 54%). 
As this analysis has failed to show significant differences between the 
three models, the values from the 'All ICU' model are used in the economic 
analysis. 
Also, SDD is not reported to increase outbreaks of resistant bacteria. No 
other complication rates have been reported by SDD studies. For the 
purposes of the decision-analytic model, it is assumed, therefore, that there 
are no complications associated with SDD. 
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4.4.2.3 Use of Alternative Sources for Clinical Evidence 
The decision-analytic model requires evidence on the life expectancy and 
QoL of post-ICU patients and the impact of ICU-acquired pneumonia on this 
life expectancy and QoL. Neither has been reported in the SDD trials 
found. It was necessary, therefore, to utilise alternative data sources for 
this evidence. This section reports the evidence found on life expectancy 
and QoL of ICU patients and the incremental effect of ICU-acquired 
pneumonia. 
Research into the long term survival of ICU patients is usually limited to 
reporting one or two year mortality. The most long term recent study is 
that reported by Ridley et a/ [1994]. They reported that the life expectancy 
of post-ICU patients is adversely affected for up to four years after ICU 
discharge. In the absence of any other data, most studies have used age- 
specific life expectancies can be obtained from reference tables. However, 
the assumption underlying the use of these data is that post-ICU patients 
have the same mortality as the general population. In their calculation of 
QALYs, Kerridge et al [19951 assume that ICU admission does have an 
effect on life expectancy. They assign 90% of age-specific life expectancy 
to ICU survivors. There is no published evidence on the incremental impact 
of ICU-acquired pneumonia on life-expectancy. 
The decision-analytic model also requires evidence on the effect ICU 
admission has on QoL. This involves the measurement of QoL prior to ICU 
admission, QoL whilst on ICU, the length of time taken to return to a 
chronic QoL state and how much this state differs from QoL prior to ICU 
admission. The impact of ICU-acquired pneumonia and SDD on this QoL 
progression is also required. The impact of ICU on QoL was discussed in 
Chapter Two. No evidence has been found on QoL whilst on ICU, or time 
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taken to recover to a chronic QoL. Review of QoL literature has not 
revealed any studies addressing the impact of ICU-acquired pneumonia on 
QoL. 
Consequently, there has been very little work on integration of quantity 
with QoL changes due to ICU admission. The only recent work is by 
Kerridge et a/ [1995] as discussed in Chapter Two. Discounted incremental 
QALYs achieved due to ICU admission is reported by diagnostic group and 
by APACHE II score range. These are summarised in Table 4.5. There is 
no published evidence that examines the impact of ICU-acquired pneumonia 
on QALYs gained. 
Table 4.4 QALYs Gained per ICU Admission by APACHE II Score [Kerridge 
et a/ 19951 
APACHE II Score QALYs achieved' 
0-4 15.2 
5-9 9.9 
10-14 8.8 
15-19 6.3 
20-24 5.1 
25-29 3.6 
30-34 0.8 
35+ 1.2 
' Discounted at 5% 
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4.4.2.4 Use of Reported Clinical Evidence in Secondary Economic 
Evaluation of SDD 
This section examines the clinical evidence reported above for use in the 
secondary economic analysis of SDD. The areas examined are impact of 
SDD on ICU-acquired pneumonia rate, short and long term mortality, and 
short and long term morbidity. The robustness of the evidence is 
examined. Areas of uncertainty are emphasised and recommended for 
sensitivity analysis. Ranges for sensitivity analysis are derived from the 
evidence and their selection justified. The data are assessed to see 
whether they are in a form that can be applied to the decision-analytic 
model. If not, methods for altering their form are reported. 
4.4.2.4.1 Impact of SDD on ICU-Acquired Pneumonia 
For economic analysis, it is necessary to know the probability of acquiring 
ICU-acquired pneumonia, with or without SDD. The probability of a 
ventilated patient on an ICU acquiring pneumonia when SOD is not used is 
derived from the pooled value in Table 4.2 for the ICU-acquired pneumonia 
rate in control groups. 29.4% patients acquire pneumonia, giving a 
probability of 0.294. The reciprocal probability of remaining uninfected is 
0.706. When SDD is used, 13.8% patients acquire pneumonia, giving a 
probability of 0.138. The reciprocal probability of remaining uninfected is 
0.862. The reduction in pneumonia rates is 53% (95% Cl 43 to 63%) in 
this model. Ranges for sensitivity analysis are required for reduction in 
pneumonia rates by SDD. SDD trials quote pneumonia rate reductions of 
less than 10% to 80%, although the 95% confidence intervals around the 
mean are much narrower. The cost/outcome ratios may be expected to be 
affected by variations in the effectiveness of SDD. To test for the impact 
127 
of variation of effect, the 95% confidence intervals for effectiveness (43 to 
63%) are used as the sensitivity ranges. The extremes of 10 to 80% are 
also examined to test for the effect of larger variations. 
Ranges for sensitivity analysis are also required for base pneumonia rates. 
SOD trials quote widely differing base pneumonia rates. If the base 
pneumonia rate is low, this necessarily reduces the impact of SDD, as 
fewer episodes of ICU-acquired pneumonia will be prevented. This can be 
expected to affect the cost/outcome ratios of SDD. The majority of 
reported pneumonia incidence rates lie between 10% and 50%. This range 
is used to examine the impact of variation of the base pneumonia rate on 
the effectiveness of SDD. 
4.4.2.4.2 Impact of SDD on Short Term Mortality 
For the purposes of economic evaluation, it is necessary to quantify the 
impact of SDD on mortality. It is also necessary to quantify the uncertainty 
around that impact. The probability of short term mortality of patients with 
or without ICU-acquired pneumonia is required for economic analysis. ICU 
mortality is the only short term mortality parameter reported by the SDD 
trials. Probability of live discharge with and without infection are required. 
In the absence of other evidence, it is assumed that the mortality risk from 
pneumonia is the same, once it has been contracted, for SDD and non-SDD 
treated patients. From examination of published evidence discussed in 
Chapter Three, it is likely that the mortality of patients who have an 
episode of ICU-acquired pneumonia is higher than those who do not. The 
SDD Trialists' Meta-Analysis [1993] demonstrates a significant independent 
link between ICU-acquired pneumonia and mortality (p =0.003). However, 
the clinical trials of SDD report only mortality for SDD-treated and non-SDD 
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treated groups, not differentiating between infected and uninfected 
patients. The merged weighted mean value for SDD and non SDD treated 
patients is 26.7% and 29.5% respectively. These values do not reflect the 
probabilities for mortality of infected and uninfected patients. 
There are three possible ways to derive probabilities for mortality. The first 
method would be to use the SDD trials and the derived meta-analysis odds 
ratio of 0.9. However, no base mortalities are quoted, only relative risk, 
which are not applicable to decision analysis. The second method is to use 
data from epidemiological studies of ICU-acquired pneumonia and attach 
their mortalities to the decision tree. The studies by Kappstein et a/ 
[19921, Fagon et a/ [1993] and Craven et a/ [1986] split their patients into 
infected and uninfected patients. However, sicker patients are intrinsically 
more susceptible to ICU-acquired pneumonia and often die as a 
consequence of their underlying disease. The infected group is intrinsically 
sicker and its mortality cannot be simply compared with the uninfected 
group. Multiple regression analysis is the most appropriate method for 
comparison and has not identified ICU-acquired pneumonia as an 
independent predictor for mortality, except in the SDD Trialists' Meta- 
Analysis [1993]. Epidemiological studies and SDD trials have failed to 
demonstrate significant changes in mortality due to pneumonia or SDD due 
to inappropriate groups for comparison and insufficient patients. 
The third method for determining mortality probabilities is to use simple 
algebra to synthesise them from the data already extracted from the trial 
data. The proportions of infected and uninfected patients are known in the 
SDD and non-SDD treated patient groups where the group mortality is 
known. Therefore, it is possible to derive the mortalities of the infected 
and uninfected patients. This method is detailed in Appendix 4.5. Infected 
ICU mortality is calculated to be 42.3% and the uninfected mortality is 
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24.2%. These mortality rates can be applied to the decision-analytic 
model. Due to the derived nature of the values, sensitivity analysis is 
required to assess the impact of smaller or zero mortality increases due to 
ICU-acquired pneumonia. 
4.4.2.4.3 Impact of SDD on Long Term Mortality 
The SDD trials do not report the effect of SDD on long term mortality. No 
evidence on the long term mortality of ICU patients was found. Therefore, 
for the purposes of this analysis, the assumption made by Kerridge et al 
[19951 that the age-specific life-expectancy of ICU patients returns to 90% 
of the normal population is used. This assumption is used in this analysis 
to assess incremental cost per life year gained. Any calculations also make 
the assumption, in the absence of evidence to the contrary, that ICU- 
acquired pneumonia has no effect on long term mortality. 
The majority of SDD studies report a mean age of about sixty years old, 
which would give a life expectancy of 19.2 years life expectancy [CSO 
Annual Abstract, 19911. Assigning 90% of these years to ICU survivors is 
used to provide an estimate of 17.3 life years gained by ICU survivors in 
the model. The accuracy of this point estimate is not known because it 
was not derived from the population to which it is being applied. As it is a 
deterministic estimate, its precision is also unknown, that is, the 
uncertainty surrounding it is not quantified. This necessarily makes 
selection of ranges for sensitivity analysis ranges arbitrary. To assess the 
impact of the variation of life years gained on the cost per LYG ratio, the 
life years gained by an ICU survivor are varied from 50% of the base value 
(8.7 LYGs) to 150% of the base value (26.0 LYGs). These ranges reflect 
that SDD has been administered to adults of a wide age range (15 to 90). 
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4.4.2.4.4 Impact of SDD on Quality of Life and Utility 
The SDD trials do not report the effect of SDD on QoL and utility. No 
evidence on the impact of ICU-acquired pneumonia was found. The only 
work found is that by Kerridge et al [19951 who report QALYs gained by 
ICU survivors. For this analysis it is assumed that SDD and ICU-acquired 
pneumonia affect QALYs gained via their effect on ICU mortality only. The 
base value for discounted QALYs (dQALYs, 5% discount rate), taken from 
the Kerridge values, is 6.3 per ICU survivor, as this relates to the mean 
APACHE scores of the majority of the SDD trials. The authors derived this 
value from 11.9 LYGs. The numbers of LYGs was estimated by an expert 
panel. The ranges for sensitivity analysis are 0.8 to 9.9 dQALYs gained 
(derived from 1.6 to 20.5 LYGs), to include patients with higher and lower 
APACHE scores. 
It would be inappropriate to directly compare the LYGs from British life 
expectancy statistics with the dQALYs derived from Australian research 
data. However, it can be seen that fewer LYGs are attributed to ICU 
patients by Kerridge than by using the assumption of a life expectancy 
90% of normal for an ICU patient. This suggests that research similar to 
that by Kerridge et a/ [1995] is needed to inform economic evaluation. 
Table 4.5 summarises the clinical parameters required for the secondary 
economic evaluation of SDD. The values derived from the literature are 
listed, with their ranges for sensitivity analysis. 
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Table 4.5 Summary of Clinical Parameters, Their Associated Values and 
Ranges for Sensitivity Analysis 
Clinical No SDD SDD Incremental Ranges for 
Parameter Effect Size Sensitivity 
due to SDD Analysis 
ICU-acquired 29.4' 13.8 5342 95% Cl: 43-634 
pneumonia Extremes: 10- 
rate/% 804 
ICU 29.6 26.5 9.54 0- 201 
Mortality/% 
Life 17.3 17.3 0 8.7-26.04 
Expectancy per 
ICU 
survivor/LYGs 
dQALYs per 6.3 6.3 0 0.8-9.9 4 
ICU survivor3 
' Base ICU-acquired pneumonia rate also varied from 10% to 50% 
2l Indicates that there is a decrease in the parameter 
I Discount rate 5% 
4 Sensitivity analysis ranges are used to vary the parameters for both SDD and non-SDD 
patients. 
4.4.3 Acquisition of Economic Evidence 
This section examines the evidence on the incremental economic cost 
associated with the implementation of SDD. The two categories of 
economic evidence are the resource use associated with SDD 
implementation and treatment of ICU-acquired pneumonia, and the unit 
costs of that resource use. As stated above, the ideal sources for these 
two categories of economic data are RCTs of SDD. In the event that these 
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trials do not provide enough information, the use of alternative sources is 
reported. A summary of the economic data obtained for use in the 
secondary economic evaluation is provided at the end of this section. 
4.4.3.1 Resource Use and Unit Costs Associated with SDD 
Implementation 
The resource use and unit costs associated with the SDD regimen has 
three components. These are the drug treatment, the microbiological 
surveillance and the maintenance of side effects of SDD. The SDD trials 
were examined for economic data in these three areas. 
4.4.3.1.1 Resource Use and Unit Cost Associated with SDD 
Pharmaceutical Regimen 
Resource use associated with the SDD regimen was reported by all studies. 
Review of the trials revealed that 23 studies used the original PTA regimen 
reported by Stoutenbeek et a/ [19841. Minor variations include using oral 
gel instead of paste and gentamicin instead of tobramycin. Variations are 
detailed in Appendix 4.6 and 4.7. Nineteen trials used SDD for the whole 
of the patient's stay on ICU. Thirteen trials used it only whilst the patient 
was ventilated. Fourteen trials reported using intravenous therapy. Ten 
used cefotaxime, as recommended by Stoutenbeek et al [19841. Appendix 
4.8 outlines the range of cefotaxime doses reported. Other trials have 
used ceftriaxone, ceftazidime, trimethoprim or ofloxacin. 
The common resource use reported was PTA liquid and paste (or gel) used 
four times a day for the whole ICU stay, and cefotaxime 1g four times a 
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day for four days, intravenously. 
However, 28 trials out of the 36 originally examined do not report any unit 
costs of SDD regimens. The costs reported by eight trials are reported in 
Chapter Three. The quality of cost data is varied. Winter of a/ [19921, 
Korinek et al [19931 and Suter et al [19931 did not report the source of the 
costs or the year from which the costs were derived. Gastinne et al [ 19921 
obtained drug costs from their pharmacy department, but did not state 
what specific costs constituted the final figures used. 
Most authors reported acquisition costs of drugs only, not including labour 
costs of preparing or administering the drugs. Also, the costs were all 
reported by foreign studies. Therefore the costs of SDD were obtained 
from British sources. Two British centres using SDD provided preparation 
and overhead costs (pharmacy departments, personal communications). 
The Bristol Royal Infirmary reports overall cost of PTA gel per tube as 
£9.30 (1994). This lasts 4 days so the cost per day is £2.33. 
Southampton General Hospital reports overall cost of PGA paste per tube 
as £4.53 (1994) so the cost per day is £1.13. The components of the 
nasogastric preparation and the intravenous cefotaxime are available 
commercially. The costs per day of treatment are derived from drug 
acquisition costs and pharmacy overhead costs, reported in Table 4.6. An 
estimated daily cost of SDD therapy is £19.95 per day when the paste is 
used and £21.15 when the gel is used. As the most common cefotaxime 
regimen is 1g qds for four days, the total cost of the course is £92.56. 
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Table 4.6 Estimated Unit Costs of SDD Regimen Components' 
DRUG Quantity & strength Cost per Dose per Cost per 
of preparation unit/£ day day/£2 
AMPHOTERICIN 12ml (100mg/5m1) 2.31 500mg qds 4.43 
COLISTIN 80ml (0.25mu/5ml) 3.98 2mu qds 2.29 
TOBRAMYCIN 80mg/2ml vial for 2.63 80mg qds 12.10 
injection 
GENTAMICIN 80mg/2ml vial for 1.59 80mg qds 7.31 
injection 
CEFOTAXIME 1g vial for injection 4.95 1g qds 23.14 
& 10ml WFI 0.08 
CEFOTAXIME 2g vial for injection 9.90 2g tds 34.74 
& 20ml WFI 0.17 
[Prices from British National Formulary, September 19941 
' See abbreviations list 
2 Pharmacy overhead: 15% of acquisition cost added (Buxton et a/ [19851). 
4.4.3.1.2 Resource Use and Unit Cost of Microbiological Surveillance of 
SDD 
The reasons for intense microbiological surveillance when SDD is used are 
discussed in Chapter Three. The most common microbiological surveillance 
policy reported in the SDD trials is oropharyngeal, rectal, urine, tracheal 
aspirate and gastric aspirate samples on admission to ICU; and then 
oropharyngeal, rectal, tracheal aspirate and gastric aspirate samples twice a 
week (see Appendix 4.10). 
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However, this intensive type of surveillance results from clinical trial 
protocols. It would not be expected for this intensity of microbiological 
surveillance to be common clinical practice. The surveillance in the trials is 
intended to determine which patients become disinfected, the types of 
infections and to monitor the emergence of resistant bacterial strains. In 
clinical practice microbiological cultures are usually only employed when 
presence of infection is suspected. The implementation of SDD in a 
practice setting would demand more environmental monitoring to assess 
emergence of resistant bacteria. Therefore there should be some regular 
surveillance, but not as much as is demanded by clinical trial protocols. 
This provides the possibility for a range of microbiological surveillance 
scenarios. This can be simplified into three resource use models, a method 
used by Buxton et al, [1992]: 
1. Resource sparing (minimum regimen possible): Only culture 
tracheal aspirate swabs when respiratory infection is suspected. 
2. Resource moderate (minimum regimen required to adequately 
monitor SDD): Oropharyngeal and rectal swabs on admission, then 
twice a week. 
3. Resource intensive (most common regimen reported in trials): 
Oropharyngeal, rectal, gastric aspirate and urine cultures on 
admission, then oropharyngeal, rectal and gastric aspirate cultures 
twice a week. 
Although some SDD studies report charges of microbiological tests, none 
are British. Again, it was considered appropriate to use current British unit 
costs. British costs obtained and detailed in Appendix 4.11 are used in the 
analysis. The costs of these three models are reported in Table 4.7. 
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Table 4.7 Estimated Costs of Microbiological Surveillance 
Model Cost on admission/£ Cost during stay/£ 
Resource sparing 0 8.82 on suspicion of 
pneumonia 
Resource moderate 17.09 17.09 every 3rd day 
Resource intensive 30.32 25.91 every 3rd day 
4.4.3.1.3 Cost Associated With the Maintenance of Side Effects Arising 
From SDD 
No side effects have been reported in the SDD trials. Emergence of 
resistant bacterial strains has not been reported. Therefore, in the absence 
of evidence to the contrary, it is assumed that there are no costs 
associated with the maintenance of side effects arising from SDD. 
The SDD regimen selected for use in the economic evaluation is 
summarised in the table below. This is referred to as the 'resource 
moderate' regimen. To assess the effect of more or less intensive SDD 
regimes on cost/outcome ratios, a 'resource sparing' and a 'resource 
intensive' model are also summarised in the table. The resource sparing 
regimen uses daily PTA, the lowest level of microbiological surveillance and 
no cefotaxime. The resource intensive regimen uses the highest level of 
microbiological surveillance, cefotaxime and daily PTA. The impact of 
these models is examined in the sensitivity analysis. 
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Table 4.8 Summary of SDD Regimens Proposed for Use in Economic 
Evaluation 
Component of Regimen Resource Resource Resource 
Sparing Moderate Intensive 
Regimen Regimen Regimen 
Cost of PTA gel and liquid 21.15 21.15 21.15 
per day/£ 
Cost of Cefotaxime 1g iv - 92.56 92.56 
qds for 4 days/£ 
Cost of microbiological 0 17.09 30.32 
surveillance on admission/£ 
Cost of microbiological 8.821 17.09 25.91 
surveillance twice a week/£ 
' On suspicion of pneumonia only 
4.4.3.2 Resource Use and Unit Costs Associated With ICU-Acquired 
Pneumonia 
Resource use resulting from ICU-acquired pneumonia can be divided into 
two parts. The first is the resultant increase in stay on the ICU and 
increase of overall hospital stay. The second is the increase in treatment 
resulting from infection. The unit costs associated with this resource use 
that are required are costs per day on an ICU and the unit costs of 
resources associated with treating ICU-acquired pneumonia. 
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4.4.3.2.1 Evidence for Increased Length of ICU Stay due to ICU-Acquired 
Pneumonia 
The review in Chapter Three has suggested that ICU-acquired pneumonia 
increases length of ICU stay. 14 SDD trials report lengths of ICU stay for 
SDD-treated and non-SDD-treated patients. Only one reports a reduction in 
length of ICU stay between SDD-treated and non-SDD treated groups 
(Suter et a/ [1993]: 18.5 to 12.7 days, p=0.023). Other trials report no 
significant reduction in length of ICU stay. Data from the trials that 
reported length of ICU stay in each of the three original subgroups of trials 
were used to derive pooled estimates for length of ICU stay in SDD and 
non-SDD treated patients. Table 4.9 reports this analysis. The weighted 
means are 18.03 days (sd = 9.85) for non-SDD treated and 17.51 days 
(sd = 10.62), calculated from 1309 patients. This length of stay is higher 
than the average ICU stay for all ICU patients, because these patients are 
the more severely ill portion of the ICU population. It can be seen that 
there is a small and non-statistically significant effect size. 
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Table 4.9 Effect of SDD on Length of ICU Stay of Trials Groups 
Length of ICU stay All trials Mixed ICU model Surgery/trauma 
(days) weighted means' weighted means' model 
weighted means' 
Base length of ICU 18.03 18.57 18.75 
stay (1266, (1004, (793, 
8.13-27.93) 6.67-30.47) 4.25-33.25) 
SDD-treated 17.51 18.00 18.81 
length of ICU stay (1266, (1004, (793, 
6.91-28.11) 5.40-30.60) 3.01-34.61) 
Effect size2 0.52 0.57 0.06 
(2532, (2008, (1586, 
-0.68-1.72) -0.83.1.97) -1.54-1.66) 
' Numbers in parentheses are total numbers of patients included in derivation of weighted 
mean, 95% confidence interval. 
2 Negative values in 95% Cl indicate that there are studies reporting an increase in length 
of stay in SDD-treated groups. 
This lack of a significant difference between SOD and non-SDD treated 
groups may be due to the grouping together of infected and uninfected 
patients in the control and treatment groups. The impact of grouping the 
patients together in this way is illustrated by examination of results 
reported by Verhaegen et a/ [19921. They are the only SDD researchers to 
separate length of stay of infected patients from that of uninfected 
patients. The table below demonstrates that the change in length of stay 
from SDD-treated to placebo-treated patients is insignificant. However, 
when the two groups are divided according to presence or absence of 
pneumonia, there is a significant increase in length of ICU stay in both SDD 
and placebo-treated patients who acquire pneumonia. 
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Table 4.10 Impact of Pneumonia and SDD on ICU Length of Stay 
[Verhaegen et al, 1992] 
Length of stay Placebo group 
Mean (SD)/days 
SDD treated group 
Mean (SD)/days 
Patients without pneumonia 10.6' (5.8) 12.42 (8.8) 
Patients with pneumonia 27.9' (18.6) 33.62 (20.1) 
Increase due to pneumonia 17.3 21.2 
All patients 18.93 (16.0) 22.43 (18.5) 
' Comparison between infected and uninfected group: p<0.0001 
Z Comparison between infected and uninfected group: p<0.0001 
3 Comparison between placebo and SDD-treated group: no significance shown. 
This study reports an increase in the order of 20 days between infected 
and uninfected patients. The increase is so large because it is not adjusted 
for other factors affecting length of ICU stay, as discussed in Chapter 
Three, section 3.3.1. There are a variety of methods for estimating 
increased length of ICU stay associated with ICU-acquired pneumonia, as 
discussed in Chapter Three. Epidemiological studies and SOD trials have 
failed to demonstrate significant changes in length of stay due to 
pneumonia or SDD due to inappropriate groups for comparison and 
insufficient patients. In order to obtain a base value for increase in length 
of stay from pneumonia, a value has been synthesized from the SDD trial 
literature in the same way as mortality (Appendix 4.4). The derived ICU 
length of stay is 20.2 days in patients who contract ICU-acquired 
pneumonia. ICU length of stay is 17.1 days in those who do not. The 
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derived pneumonia-attributable length of stay is 3.1 days. Due to the 
derived nature of this value, it is necessary to carry out sensitivity analysis. 
The ranges for sensitivity analysis need to reflect real ranges of increase in 
length of ICU stay due to ICU-acquired pneumonia. Chapter Three reports 
published increases of zero to nineteen days. Four of the five published 
estimates are ten days or below, so ten days is selected as the upper limit. 
If there is considered to be an increase in length of ICU stay due to ICU- 
acquired pneumonia, there will be an associated increase in the cost of the 
patient. It is therefore necessary to know the cost of keeping a patient on 
ICU for a day. The only British cost per ICU day reported in an SDD study 
was by Jacobs et al [1992]. They report a day on ICU costing £1181 in 
the UK. However, there is no breakdown of this cost, indication of patient 
population from which it was derived, or the year of the costs. Therefore, 
it was necessary to use alternative sources for costs. Estimates of 'top- 
down' or 'bottom-up' costs of one day's stay on ICU are often difficult to 
obtain because intensive care costs are included in surgery or anaesthetics 
department costs. Ridley et a/ [19911 carried out an individual patient 
'bottom-up' costing study on intensive care, as discussed in Chapter Two. 
The mean cost of a British ventilated patient in 1989 was reported as £726 
(95% Cl: £656-795). Inflating to 1994/95 prices using the Health Services 
Prices Index gives a mean value of £886 (95% Cl: £849-970). 
Sensitivity analysis of the effect of smaller costs per day (as would be 
expected at a district general hospital) and larger costs per day (as would 
be expected at a teaching hospital) is undertaken. In the absence of more 
reliable evidence, a cost per ICU day at a DGH was suggested to be about 
£800. A day on a teaching hospital ICU was suggested to be £1000 
[personal communication, finance department, Charing Cross Hospital, 
19941. These two values were used as high and low estimates of cost per 
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day. However, there is a wide variation in cost per ICU day within a single 
ICU, as illustrated in Chapter Two. The impact of this was examined by 
setting the sensitivity ranges at £500 and £1500. 
4.4.3.2.2 Evidence for Increased Therapeutic Activity Associated with 
ICU-Acquired Pneumonia 
An episode of ICU-acquired pneumonia may be expected to lead to 
increased resource use and thus incur increased costs. Resource use 
arising from extra therapeutic intervention may include antibiotics, X-rays, 
physiotherapy, microbiological surveillance and prolonged ventilation. Very 
little information on treatment of ICU-acquired pneumonia was found in 
SDD trials. The two areas investigated most were the number of 
therapeutic antibiotic days and microbiological surveillance. 
Therapeutic Antibiotics and Other Drugs 
11 SDD trials report antibiotics used to treat infections. A significant drop 
was reported from control to SDD-treated groups, expressed as number of 
antibiotic days. Details of which agents were used were not given. Total 
costs only are reported, rather than levels of resource use and associated 
unit costs. Korinek (France, 1993) reported a mean cost per patient of 
US$556(sd = 506) in control patients and US$469 (sd = 413) in SDD 
treated patients (US$, 1989). Gastinne (France, 1992) reported a mean 
cost per patient of US$158 (sd = 691) in control patients and US$53 
(sd = 202) in SDD treated patients (US$, 1992). Rocha (Spain, 1989) 
reported a mean cost per infected patient of 119660 Pta (Pta, 1989, Oct 
1994: E1 =203.99Pta, inflating to 1994,119660 Pta = £748.66). No 
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significance tests were reported. The two French authors do not 
differentiate between infected and uninfected patients. The Spanish study 
does. However, none of these trials is British, so the data have limited 
applicability to a British setting. Also, the costs reported are just the 
acquisition cost. Antibiotics have a variable amount of associated costs 
from disposables, serum level monitoring requirements and management of 
side effects. In the absence of any other data, the antibiotic costs reported 
by Rocha et al [1989] are used. 
Other drugs, disposables and disinfectants used as a consequence of ICU 
infections have been reported in a Belgian study by de Clerq [ 19831. The 
sources are not quoted and no significance tests are reported. The 
infection-attributed increase in costs of laboratory material, sterile 
disposables and disinfectants is 891.1 BFr at 1983 prices. Inflating to 
1994 (Oct 1994: £1 =50.2BFr), this equates to £17.75. Infection- 
attributed costs of other drugs and infusion fluids are quoted as 969BFr per 
day, which is equivalent to £33.01 per day [19941. These costs were the 
only published information available. 
Pneumonia-Attributable Investigations 
Increased pathology and radiology testing may be expected as a result of 
pneumonia. However, little relevant work has been carried out in the UK. 
No SDD trials report relevant information. Coello et a/ [1993) carried out a 
matched cohort study of hospital acquired infection in surgical patients in a 
DGH. They report significantly higher utilization of microbiology 
(p<0.0001), haematology (p<0.001), chemical pathology (p<0.001) and 
radiology (p<0.007) in infected hospital patients. No evidence to this 
effect was found in ICU-acquired pneumonia. In the absence of any other 
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information, the increases in numbers of tests and costs of tests reported 
by Coello et al [ 19931 can be used as conservative estimates. The 
increased cost in microbiology is £18.80 (1994: £19.74), radiology is 
£8.00 (1994: £8.40), haematology is £18.10 (1994: £19.01) and 
chemistry is £12.10 (1994: £12.71). 
The combination of cost data on antibiotics used to treat pneumonia 
(E748.7 [Rocha et a/, 1993]), pneumonia-attributable investigations (E59.9 
[Coello et a/, 1993], other drugs attributable to pneumonia (£666.8 We 
Clerq et a/, 1983]) and pneumonia-attributable equipment (£17.8 We Clerq 
et al, 19831) gives a cost of £1493 to treat an episode of ICU-acquired 
pneumonia. It is known that this estimate is not very accurate. However, 
the degree of uncertainty is unknown, making selection of sensitivity 
analysis ranges more difficult. Arbitrary ranges of 50% (E750) to 150% 
(E2250) have been selected to enable investigation of the impact of 
variation of this area of cost on the cost/outcome ratios. 
4.4.3.3 Summary of Costs of Patients for Base Case Scenario 
Table 4.11 summarises the resource use and cost evidence reported in this 
section. The two main categories of cost are those from SDD 
implementation and from ICU-acquired pneumonia treatment. The point 
estimates for the cost categories are reported, as well as their ranges for 
sensitivity analysis. 
The decision-analytic model requires costs for infected and uninfected 
patients, in the event of either having or not having SDD. These four costs 
are derived from the economic evidence listed. The cost of a ventilated 
patient who does not contract an ICU-acquired pneumonia is derived from 
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the published cost per ICU day and the derived length of ICU stay for an 
uninfected patient, to give the value of £15151. This cost is then adjusted 
in the event of an episode of pneumonia by adding the cost of extra days 
on ICU and the treatment cost associated with pneumonia, to give a value 
of £19390. If SDD is used, the costs associated with SDD are added to 
these costs to give £15717 for an uninfected patient and £20036 for an 
infected patient. 
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Table 4.11 Summary of Costs of Patients for Economic Evaluation of SDD 
Cost component Cost per infected 
patient/£ 
Cost per 
uninfected 
patient/E 
Length of ICU stay (days)' 20.2 17.1 
Cost per day on ICU [Ridley, 1991 ]2 886.0 886.0 
Antibiotics to treat pneumonia [Rocha, 
1989]' 
748.7 0 
Pneumonia attributable investigations 
[Coello, 19931 
59.9 0 
Other drugs attributable to pneumonia [de 
Clerq, 19831 
666.8 0 
Pneumonia-attributable equipment [de 
Clerq, 1983] 
17.8 0 
Total cost per non-SDD ICU patient 19390 15151 
Cost of drugs associated with SDD regime` 519.8 454.2 
Cost of microbiological investigation 
associated with SOD 
126.2 111.8 
Total cost per ICU patient on SDD 20036 15717 
' Increase in length of ICU stay: 3.1 days: varied from 0 to 10 days. 
2 Cost per day varied from £500 to £1500. 
3 Total cost of pneumonia treatment: £1493; varied from £750 to £2250. 
SDD regimen more and less resource intensive in sensitivity analysis 
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4.4.4 Derivation of Cost/Outcome Ratios for SDD 
The third stage of the economic evaluation is to derive costloutcome ratios 
for SDD compared with its alternatives. This is done by attaching clinical 
probabilities and economic cost data to the decision analytic model to 
derive incremental cost/outcome ratios. A 'base case' model is produced 
first using point estimates derived from extracted clinical and economic 
data. 
Firstly, clinical probabilities were attached to the decision-analytic model, 
from Table 4.5, as shown in Figure 4.3. This was to allow overall path 
probabilities to be calculated. Clinical probabilities were attached to each 
part of Tree A. 
Figure 4.3 Decision-Analytic Model of SDD, Including Clinical Probabilities 
Ventilated ICU 
Live ICU discharge 
Pneumonia 0.577 
0.138 Dead ICU discharge 
Given SDD 0.423 
Live ICU discharge 
No pneumonia 0.758 
0.862 Dead ICU discharge 
0.242 
Live ICU discharge 
given SDD 0.423 
Uve ICU discharge 
0 
Pneumonia 0.577 
0.294 Dead ICU discharge 
No pneumonia 0.758 
0.706 Dead ICU discharne 
" 0.242 
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However, clinical probabilities could not be attached to Tree B which 
considers the long term effects of SDD and pneumonia on life expectancy. 
because there was no available evidence on the effect of pneumonia or 
SOD on life expectancy and quality of life. This tree was collapsed into a 
single outcome that assumes that ICU survivors acquire 17.3 LYGs and 6.3 
dQALYs whether they acquire pneumonia or are given SDD or not. The 
economic data was also attached to the decision-analytic model, as 
summarised in Table 4.11. The cost associated with each pathway is then 
added to each pathway. No costs were available beyond ICU discharge. 
This restricts the perspective of the analysis to that of the ICU. 
The treatment and control arms of Tree A can be interpreted in the 
following way. A ventilated patient is admitted to ICU with a probability of 
0.294 of contracting ICU-acquired pneumonia. If he contracts pneumonia 
he costs the ICU £19390 and has a 42.3% risk of death on the ICU. If he 
does not contract pneumonia, he costs the ICU £15151 and has a 24.2% 
risk of death on the ICU. In either situation, if he survives ICU, he gains 
17.3 life years and 6.3 dQALYs. The branch of the model where SDD is 
administered is interpreted in the same way. It is necessary to combine the 
costs and outcomes of the pathways within the model in such a way as to 
elucidate the incremental cost and outcome differences between SDD and 
the control. This was done by applying a theoretical cohort of 2000 
ventilated ICU patients to the model. One thousand were modelled to 
receive SDD and one thousand entered the control arm. Without the use of 
SDD, 294 patients contracted pneumonia and 295 died on ICU, at a total 
cost of £1.640x10'. The 705 survivors gained 12196.5 life years and 
4441.5 dQALYs in total. Of the 1000 patients treated with SDD from ICU 
admission, 138 contracted pneumonia and 267 died on ICU at a cost of 
£1.631x107. The 733 survivors gained 12680.9 life years and 4617.9 
dQALYs in total. The overall incremental decrease in cost associated with 
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the patients who receive SDD is £0.09x107. This decrease in cost is 
associated with 156 fewer episodes of pneumonia, 28 fewer ICU deaths, 
an additional 484 life years gained and 176 added dQALYs. As the clinical 
outcomes are improved by SDD at a lower cost, SDD is the dominant 
therapy. This analysis is reported in Table 4.12. 
The results of this economic evaluation suggest that SOD is a dominant 
therapy, which, in turn, suggests that SOD should be implemented in ICUs 
to improve patient outcomes at a decreased cost to the unit. However, the 
process of acquisition of clinical and economic evidence reported in 
sections 4.4.2 and 4.4.3 has uncovered many areas where there is a lack 
of good, or any, data. The reduction in pneumonia rates has narrow 
confidence intervals. However, some clinical parameters, such as quality 
of life and life expectancy are based on poor quality data. Most economic 
parameters are based on deterministic point estimates of poor quality. 
These data either have wide ranges of variation, such as increase in length 
of ICU stay by pneumonia, or the degree of uncertainty is not known at all, 
such as cost of pneumonia treatment. The use of data with a high level of 
attached uncertainty necessarily introduces uncertainty into cost/outcome 
ratios. It is possible that variation in these parameters may significantly 
affect cost/outcome ratios. 
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4.4.5 Sensitivity Analysis of the Economic Analysis of SDD 
The conclusion that SDD is a dominant therapy relates only to the 
conditions defined in the base case detailed in section 4.4.4. Cost 
effectiveness and cost utility measures calculated for SDD have 
necessarily proceeded by making assumptions about the clinical and 
economic evidence. It is necessary to test the sensitivity of this 
dominance to these assumptions. This section tests the sensitivity of 
the conclusions derived to the data used. This is done by varying the 
clinical and economic parameters to see how sensitive the conclusions 
are to these variations. The extent to which the conclusions can be 
changed by varying parameters gives an indication of the robustness of 
these conclusions. The ranges of the variation of the parameters are 
used as outlined in the previous section. The parameters examined are 
variation in SDD effectiveness in reducing pneumonia rates; base 
pneumonia rates; pneumonia-attributable mortality; cost of different 
SDD regimens; increased length of ICU stay due to pneumonia; cost per 
ICU day and costs associated with pneumonia treatment. 
4.4.5.1 Effect of Changing Decrease in Pneumonia Rate by SDD 
The reduction in pneumonia rate by SDD ultimately effects all other 
outcomes, mortality, LYGs and QALYs, so it is an influential variable. 
The reduction in ICU-acquired pneumonia rate by SDD is 53% (95% Cl: 
43 to 63%). The narrow confidence interval indicates the high level of 
precision of the estimate. The sensitivity analysis examines the 
variation of cost/outcome ratios within these ranges. However, reported 
efficacies of SDD range from 10 to 80%, so the effect of this amount of 
variation is also examined. Table 4.13 summarises the effect that these 
variations in reduction in pneumonia rate have on cost per pneumonia 
avoided, cost per death averted, cost per LYG and cost per dQALY 
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gained. 
Figure 4.4 illustrates the impact of changing the decrease in pneumonia 
rate, in stages from 10% to 80%. The base case (B) where there is 
53% reduction and the low (L) and high (H) limits of the 95% 
confidence intervals are marked on the graph. Cost/outcome ratios 
become smaller as the effectiveness increases. Cost per death averted 
shows the largest variation. SDD becomes dominant for all ratios above 
42% reduction in pneumonia rate. The pneumonia reduction rate has a 
large effect on cost/outcome ratios between the extreme ranges. 
However, the cost/outcome ratios do not vary dramatically within the 
95% confidence intervals. 
Negative cost/outcome ratios imply that SDD is the dominant therapy. 
It is important to note that, in this sensitivity analysis and all subsequent 
reported by this thesis, that the values of these cost/outcome ratios are 
meaningless in terms of decision-making. They illustrate only that the 
therapy remains dominant for a wide range of SOD effectiveness values. 
The conclusion that SDD is dominant does not change, that is, it is 
robust, unless the effectiveness of SDD is assumed to drop below 42%. 
In this situation, improved outcomes (reduced infections and so on) are 
achieved at a higher cost. When this is the case, it is appropriate to 
quote cost/outcome ratios. 
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Table 4.13 Effect of Variation of Reduction in Pneumonia Rate by SDD 
on Cost/Outcome Measures 
Reduction in 
pneumonia rate by 
SDD/% 
Cost per 
pneumonia 
avoided/£ 
Cost per 
ICU death 
averted/C 
Cost per 
LYG/£ 
Cost per 
dQALY 
gained/£ 
10% (lower limit) 15913 88586 5130 14109 
43% (lower 95% CO 338 1761 109 381 
53% (base value) -577 -3214 -186 -511 
63% (upper 95% CI) -1147 -5976 -370 -1017 
80% (upper limit) -1822 -9475 -587 -1615 
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Figure 4.4 Graph to Show Variation of Cost/Outcome Ratios with 
Variation in Pneumonia Rate Reduction by SDD 
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L: Low estimate for decrease in pneumonia rate (43%) 
B: Base estimate for decrease in pneumonia rate (53%) 
H: High estimate for decrease in pneumonia rate (63%) 
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4.4.5.2 Effect of Changing Base Pneumonia Rate 
The ICU-acquired pneumonia rate of the control arm was varied to see 
to what extent variation in local incidence rates would affect 
cost/outcome ratios. The base pneumonia rate was varied from 10% to 
50%. This reflects the range of pneumonia rates reported in ICUs, as 
discussed in Chapter Three. Figure 4.5 illustrates the variation of 
pneumonia rate reduction by SDD with base pneumonia rates. It can be 
seen that the higher the base pneumonia rate is, the more cost effective 
SDD is shown to become at each level of effectiveness of SDD. The 
lower the base pneumonia rate, the larger the reduction in that rate 
required to achieve low cost/outcome ratios. SDD becomes the 
dominant therapy at lower levels of effectiveness the higher the base 
pneumonia rate. This pattern was the same when this analysis was 
applied to the other cost/outcome ratios. Therefore, the base 
pneumonia rate of any particular ICU will affect the opportunity that 
SDD has to be cost effective. The conclusion that SDD is a dominant 
therapy is very dependent upon this parameter. Therefore, uncertainty 
around it greatly decreases the robustness of the conclusions. 
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Figure 4.5 Graph to Show Variation of Cost per Pneumonia Avoided 
with Reduction in Pneumonia Rate for a Range of Base Pneumonia Rates 
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B: Base estimate for decrease in pneumonia rate (53%) 
H: High estimate for decrease in pneumonia rate (63%) 
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4.4.5.3 Effect of Changing Mortality Effects of Pneumonia 
The use of derived mortalities for infected and uninfected mortality, 
rather than values taken directly from research decrease the confidence 
with which the values can be used. The base case model uses a 
reduction of 9.5% mortality in the SOD group. This sensitivity analysis 
examines the impact of an increase or decrease in this mortality 
reduction. The number of deaths averted by SDD (and thus life years 
and dQALYs gained) is dependent upon the reduction in pneumonia rate. 
The change in resource use due to the implementation of SOD is not 
affected. SDD is dominant, so any deaths averted occur in conjunction 
with a reduction in cost. It is not appropriate, therefore, to quote 
cost/outcome ratios. Instead, the effect on numbers of deaths averted, 
number of LYGs and dQALYs gained if the mortality of the group is 
assumed to be reduced by 0 to 20% if SDD is used is examined. If 
mortality is not reduced by SOD there will be no deaths averted and no 
associated LYGs or QALYs gained. If the mortality is reduced by 20%, 
there will be 59 deaths averted, 1020.7 LYGs and 371.7 dQALYs 
gained. At either extreme, the resource use saving will still be £90000. 
Therefore, the conclusion that SDD is dominant is not affected by 
variations in the reduction of mortality. So, the conclusions are robust 
with respect to this parameter. 
The second area of uncertainty here is the precision of the estimates for 
LYGs and dQALYs. The values for LYGs and dQALYs are very tentative 
due to their sources. The significant uncertainty surrounding these 
values is reflected in their wide, and largely arbitrary, ranges for 
sensitivity analysis. The sensitivity ranges selected for LYGs and 
dQALYs gained from Table 4.5 are used to derive ranges for these 
outcome measures. The results of this analysis are reported in Table 
4.14. The values for LYGs and dQALYs gained by ICU survivors in this 
model are very tentative and rely entirely upon the decrease in mortality. 
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However, the conclusion that SDD is dominant is not affected by 
variations in the numbers of life years or QALYs gained. So, the 
conclusions are robust with respect to these parameters, even though 
there is much uncertainty associated with them. 
Table 4.14 Effect of Variation of LYGs and dQALYs Gained by ICU 
Survivors 
Outcome parameter Units of outcome gained 
per 1000 patients 
Sensitivity 
Analysis Range 
ICU deaths averted 28 - 
Life years gained 484 244-728 
dQALYs gained 176 22-277 
4.4.5.4 Effect of SDD Regimen 
Variation in the resource use associated with the SDD regimen itself 
may have an impact on cost/outcome ratios. Table 4.15 summarises 
the effect of using the three regimens outlined in the previous section. 
It can be seen that SOD remains the dominant therapy for all three 
alternatives. Therefore, the conclusion that SDD is dominant is robust 
with respect to this parameter. 
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Table 4.15 Effect of Intensity of SDD Regimen on Cost/Outcome Ratios 
SOD Regimen Cost per 
pneumonia 
avoided/£ 
Cost per 
ICU death 
averted/£ 
Cost per 
LYG/£ 
Cost per 
dQALY 
gained/£ 
Resource sparing -2145 -11952 -691 -1902 
Resource moderate -577 -3214 -186 -511 
Resource intensive -218 -1217 -70 -194 
4.4.5.5 Effect of Increase In Length of ICU Stay by Pneumonia 
The difference in length of stay between infected and uninfected 
patients was derived as 3.1 days in section 4.4.3. An increase of 0 to 
10 days is employed as the range in the sensitivity analysis. Table 4.16 
summarises the effect of this variation on the cost/outcome ratios. It 
can be seen that there is very large effect on the ratios when this 
parameter is varied. This is illustrated in Figure 4.6 where the variation 
in cost per pneumonia avoided only is examined. SDD therapy remains 
the dominant therapy if the increase in length of ICU stay is assumed to 
be at least 2.7 days. 
The conclusion that SDD is a dominant therapy is very dependent upon 
this parameter. Therefore, uncertainty around it greatly decreases the 
robustness of the conclusions. 
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Table 4.16 Effect of Variation of Length of Stay Increase Due to 
Pneumonia on Cost Outcome Measures 
t Length ICU stay due 
to pneumonia/days 
Cost per 
pneumonia 
avoided/£ 
Cost per 
ICU death 
averted/£ 
Cost per 
LYG/£ 
Cost per 
dQALY 
gained/£ 
0 (lower limit) 2470 13761 796 2187 
3.1 (base value) -577 -3214 -186 -511 
10 (upper limit) -7176 -39979 -2313 -2048 
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Figure 4.6 Graph to Show Variation of Cost per Pneumonia Avoided 
where Length of Stay Increase in the Presence of Pneumonia is Varied 
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4.4.5.6 Effect of Cost per ICU Day 
The base case cost/outcome ratios are calculated using a cost per ICU 
day of £886. A high and low mean daily ICU cost was considered to be 
£1000 and £800, respectively. Table 4.17 lists the cost/outcome ratios 
derived from using these three values. To better reflect the range of 
reported daily costs, extreme ranges of £500 and £1500 were used. 
This is illustrated in Figure 4.7, using cost per pneumonia avoided only. 
It can be seen that the higher the daily ICU cost, the more cost effective 
SDD is shown to be. SDD remains the dominant therapy if the cost per 
ICU day is greater than £700. 
The conclusion that SDD is a dominant therapy is dependent upon cost 
per ICU day. Therefore, uncertainty around it decreases the robustness 
of the conclusions. 
Table 4.17 Effect of Variation of Cost per ICU Day on Cost/Outcome 
Ratios 
Cost per ICU day/£ Cost per 
pneumonia 
avoided/£ 
Cost per 
ICU death 
averted/£ 
Cost per 
LYG/£ 
Cost per 
dQALY 
gained/£ 
800 (lower limit) 274 1577 88 243 
886 (base value) -577 -3214 -186 -511 
1000 (upper limit) -894 -4981 -288 -792 
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Figure 4.7 Graph to Show Variation of Cost per Pneumonia Avoided 
where Cost per ICU Day is Varied 
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4.4.5.7 Effect of Variation in Treatment Intensity of Pneumonia 
The base case cost/outcome ratios are calculated using a cost of £1493 
to treat an episode of ICU-acquired pneumonia. Arbitrary ranges for the 
cost of treatment were selected as £750 to £2250, respectively. Table 
4.18 lists the cost/outcome ratios derived from using these ranges. 
This is illustrated in Figure 4.8, using cost per pneumonia avoided only. 
It can be seen that the higher the cost of treating pneumonia, the more 
cost effective SDD is shown to be. SDD becomes the dominant therapy 
if the cost of treating pneumonia is greater than £900. 
The conclusion that SDD is a dominant therapy is dependent upon the 
cost of treating an episode of pneumonia. Therefore, uncertainty around 
it decreases the robustness of the conclusions. 
Table 4.18 Effect of Variation of Cost of Pneumonia Treatment on 
Cost/Outcome Ratios 
Cost per ICU day/£ Cost per 
pneumonia 
avoided/£ 
Cost per 
ICU death 
averted/£ 
Cost per 
LYG/£ 
Cost per 
dQALY 
gained/£ 
£750 (lower limit) 155 863 50 136 
£1493 (base value) -577 -3214 -186 -511 
£2250 (upper limit) -1353 -7536 436 -1198 
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Figure 4.8 Graph to Show Variation of Cost per Pneumonia Avoided 
where Cost of Pneumonia Treatment is Varied 
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4.4.5.8 Translating Theoretical Results into Practice 
This economic evaluation has suggested that, given the conditions 
stated, the implementation of SDD in a British ICU reduces the incidence 
of ICU-acquired pneumonia, at a lower cost. The use of SDD in 1000 
theoretical ventilated ICU admissions would result in cost savings of 
£900,000. This cost saving is due to the prevention of 156 episodes of 
ICU-acquired pneumonia. 3.1 days extra stay on ICU are therefore 
avoided per episode. This means that 483.6 patient days are made 
available, equivalent to 1.32 ICU beds per year. This section examines 
to what extent these theoretical cost savings can be translated into 
practice. 
In practice, British ICUs have a smaller annual patient admission rate, 
mostly between 200 and 400 patients per year [Metcalfe et a/, 19951. 
Furthermore, not all these patients would be expected to be eligible for 
SDD. 57% ICU admissions in the UK are ventilated [Metcalfe et a/, 
19951. Therefore, the number of eligible patients on an ICU would be 
more likely to be between 120 and 240. This translates into making 
available 58 to 116 bed days per year, on a typical ICU. This is 
alternatively expressed as 0.16 to 0.32 ICU beds made available per 
year. However, this may not be realised in practice, for a variety of 
local organisational reasons. 
There are two general theoretical scenarios into which SDD is 
introduced, the first being an ICU operating at higher than optimal 
occupancy levels, reflected by a high patient admissions refusal rate. 
The second scenario is SDD being introduced into an ICU operating at a 
lower than optimal occupancy rate, reflected by a zero patient 
admissions refusal rate and consistently empty beds. The impact of 
SDD on occupancy, patient turnover and patient refusal rates is different 
in the two scenarios, described below. 
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4.4.5.8.1 High Occupancy Unit 
Shorter lengths of ICU stay in a subset of patients means those patients 
leave the ICU earlier than they would have done without SDD. As this 
is a high occupancy unit, this means that more patients can be 
admitted. Therefore, the patient refusal rate may drop, the overall 
occupancy will remain the same as before and there will be a higher 
patient turnover. This increase in patient turnover at a constant level of 
occupancy will affect the resource use of the ICU. 
From the point of view of the ICU, SDD could have an overall effect on 
fixed, semi-fixed and variable costs. If the bed/days made available by 
SDD are immediately filled, as suggested above, the occupancy of the 
unit is not decreased. So, the ICU is required to run at the same 
occupancy level as before. Therefore, there are no implications for 
reducing fixed costs at the beginning of the next short run. Semi-fixed 
costs, that is nursing costs, are also not 'saved' in practice, as they will 
be directed to the extra admissions. Nursing costs may actually be 
increased by the demands of a higher rate of admission and discharge. 
Variable costs saved by the shorter length of ICU stay will also not be 
saved in practice as they will be absorbed by the extra admissions. 
Therefore, the actual cost savings due to SDD may not be very high at 
all. Also, there is the added cost of SDD implementation. Therefore, 
the introduction of SDD could theoretically increase the patient turnover 
of the ICU, with an increase in variable cost. 
However, from the perspective of the refused admissions, the 
opportunity cost associated with refusal would be avoided. This is 
discussed in more detail in Chapter Eight. 
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4.4.5.8.2 Low Occupancy Unit 
Shorter lengths of ICU stay in a subset of patients means those patients 
leave the ICU earlier than they would have done without SDD. As this 
is a low occupancy unit, this means that it is likely that no more 
patients will be admitted. This leads to the same patient turnover and a 
decreased occupancy. 
This decrease in occupancy at a constant patient turnover would affect 
costs. In the short run, fixed costs are not affected by occupancy. 
Therefore, in reality, these costs are not saved. Medical and nursing 
costs may also not be saved in reality. In the event of low occupancy, 
nurses and medical staff are deployed to work on other wards, although 
a minimum level of staffing has to be maintained on the ICU to be ready 
for new admissions. The variable costs associated with these unused 
patient days would be saved. Extra variable costs would be incurred 
from the implementation of SDD. So in reality, some variable costs 
could be saved, but the SDD costs, staff and fixed costs would still be 
incurred. 
This shows that local information on unit size, bed occupancy, patient 
turnover and refusal rates are needed to assess realisable cost savings. 
This issue is handled quantitatively in the economic evaluation in 
Chapter Eight. 
4.5 DISCUSSION OF RESULTS OF SECONDARY ECONOMIC 
EVALUATION 
The main objective of this study was to use the clinical and economic 
literature to assess the conditions, if any, under which SDD can be 
demonstrated to be cost effective. The second objective was to assess 
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whether the methods used were able to generate robust conclusions, or 
whether further investigation was required. 
Section 4.4.1 described the derivation of the research question and the 
associated decision-analytic model. The model was straightforward 
with one clinical decision node and four subsequent probabilistic nodes. 
The process of the SDD intervention was precisely defined. The patient 
group modelled to receive SDD were ventilated ICU admissions. The 
alternative to SDD was no treatment. The clinical probabilities and 
categories of resource use associated with each section of the treatment 
pathway were identified. Desired outcome measures incorporating long 
term morbidity and mortality were defined. 
The next stage was to attach clinical and economic evidence to the 
decision-analytic model to enable derivation of incremental cost/outcome 
ratios. Section 4.4.2 outlined the acquisition of clinical data required by 
the model. The parameters required were effectiveness of SDD in 
reducing pneumonia rates, and its effect on short and long term 
morbidity and mortality. SDD trials were the initial source, 37 clinical 
trials being retrieved and then reviewed systematically. Using meta- 
analysis, pneumonia and ICU mortality reduction rates were obtained. 
This method was very successful for deriving a mean value for reduction 
in pneumonia rate of 53% with narrow confidence intervals. However, 
mortality was not reported by the SDD trials in such a way that the data 
could be used in the decision-analytic model. This necessitated further 
processing of the data. It could not be unequivocally concluded that 
SDD reduces ICU mortality, but the results of the meta-analysis suggest 
that there is a relationship. Published meta-analyses discussed in 
Chapter Three suggest that there is a relationship, although 
epidemiological studies of the effect of ICU-acquired pneumonia on 
mortality were not able to indicate an independent relationship. No 
evidence was available from the trials regarding the impact of SDD or 
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ICU-acquired pneumonia on quantity and quality of life. Alternative 
sources were examined. This did not provide any information about the 
impact of ICU-acquired pneumonia on short and long term morbidity and 
mortality. The evidence for LYGs was taken from age-specific life 
expectancy tables, rather than being derived from an ICU population. 
The evidence for QALYs (discounted) was taken from a study of ICU 
patients. It was not possible for either dataset to differentiate between 
patients who do or do not acquire pneumonia. 
Section 4.4.3 described the acquisition of economic evidence, which 
consisted of resource use and associated unit costs. The categories 
required were the resource use and costs associated with SDD 
implementation and those associated with the treatment of ICU-acquired 
pneumonia. The SDD trials provided very little evidence, apart from 
some reporting of costs of SDD regimens. However, the source and 
components of these costs were not known and they were mostly from 
foreign studies. Alternative sources were investigated for economic 
information. The SDD regimens reported by the trials were costed for 
use in this country using British costs of drugs and microbiological tests. 
Costs associated with the treatment of ICU-acquired pneumonia were 
inadequately characterised. These costs divide into the increase in 
length of ICU stay, the increase in treatment intensity whilst on ICU, 
and subsequent effects on resource use on the ward. The literature 
reported varying increase in length of ICU stay due to pneumonia. The 
increase in length of stay was derived from the fourteen SDD trials that 
reported length of stay. Costs attributable to pneumonia treatment 
were derived from a variety of sources. This category of economic data 
was the least satisfactorily quantified by published evidence. No 
evidence was found on the resource use of the patient once they have 
left ICU. 
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Using the clinical and economic evidence available, an incremental 
economic analysis of SDD was carried out in section 4.4.4. The 
outcome measures used were pneumonias avoided, ICU deaths avoided, 
LYGs and dQALYs gained. Within the assumptions of the base case, 
SDD was less costly and more effective, that is, dominant. 
The clinical and economic evidence was demonstrated to be 
unsatisfactory in many areas. The lack of robustness in the evidence is 
reflected by the wide ranges recommended for use in the sensitivity 
analysis. If the conclusion that SDD is dominant is changed by varying 
these underlying parameters, then the conclusions are not robust. To 
assess the sensitivity of the conclusions to variations in different clinical 
and economic parameters, a sensitivity analysis was carried out in 
section 4.4.5. This sensitivity analysis showed that SDD remained 
dominant through most degrees of variation for most parameters. The 
parameters that reversed the conclusion that SDD was dominant, when 
varied sufficiently, were effectiveness of SDD, base pneumonia rates, 
increase in length of ICU stay by pneumonia, cost per ICU day and costs 
associated with treating pneumonia. 
SDD lost dominance if its effectiveness was assumed to drop below a 
42% decrease in pneumonia rates. The effectiveness of SDD has 
narrow confidence intervals (43 to 63%), so, in practice, this variation 
would probably not be realised. SDD also lost dominance if the base 
pneumonia rate was reduced. Chapter Three has illustrated the ranges 
in base ICU-acquired pneumonia rates. The implication of this sensitivity 
analysis is that the conclusions from this economic evaluation cannot be 
generalised to a particular unit, unless their base pneumonia rate is 
known. 
The sensitivity analysis also demonstrated the effect of varying the 
economic parameters. The uncertainty around the increase in length of 
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ICU stay due to pneumonia and the costs associated with treating an 
episode of pneumonia was reflected in the wide ranges employed for 
sensitivity analysis. The more costly it was to treat an episode of 
pneumonia in terms of increased length of stay and increased intensity 
of treatment, the more likely SDD was to be dominant. SDD lost 
dominance if the increase in length of ICU stay was assumed to be less 
than 2.7 days. It also lost dominance if the cost associated with 
treating pneumonia was assumed to be less than £900. 
The most precisely known resource use and associated unit costs were 
those of the SDD regimen. The sensitivity analysis showed that SDD 
remained dominant for all three regimens. 
This analysis also identified the lack of long term outcome measures for 
intensive care patients. The hypothetical QoL model described in 
Chapter Three illustrated the areas where quality of life measurement is 
required. No work was found that examined the impact of ICU on long 
term quality of life or life expectancy. More specifically, no work was 
found that described the impact of iatrogenic events like ICU-acquired 
pneumonia on post-ICU recovery time, chronic health states and life 
expectancy. This type of investigation is essential to assess the impact 
of intervention on patient outcomes. There are no QoL tools designed 
for intensive care patients and no studies were found that used QoL 
tools to assess the impact of an intervention. In this analysis, the 
uncertainty around the LYGs and dQALYs gained did not affect the 
robustness of the conclusion that SDD was dominant. However, the 
estimates for LYGs and dQALYs gained were subject to wide variation, 
reflecting the uncertainty around the point estimates. Until research into 
the ultimate impact of ICU on quantity and quality of life is available, 
cost/LYG and cost/QALY ratios can only be very tentative. 
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4.6 CONCLUSIONS AND IMPLICATIONS FOR FURTHER ECONOMIC 
EVALUATION 
This study has provided a framework for the economic evaluation of 
SDD. The secondary economic evaluation of SDD reported in this 
chapter has shown that SDD can be demonstrated to be economically 
dominant, given specified conditions. It has also shown that this 
conclusion is robust through wide ranges of the underlying clinical and 
economic parameters. 
The sensitivity analysis showed that, although variations in 
effectiveness of SDD could reduce the robustness of the conclusions, 
this does not occur because the degree of uncertainty around 
effectiveness is known. However, variations in base pneumonia rate 
and the economic cost of an episode of pneumonia could also reduce 
the robustness of the conclusions, and do, as the degree of uncertainty 
around them is not known. 
To improve the robustness of the conclusions, it is necessary to 
quantify the uncertainty around base pneumonia rates and the economic 
costs of treating a pneumonia episode. It is also necessary to obtain 
information on current practice patterns of SOD so that the assertion 
that the regimen used does not affect the robustness of conclusions can 
be confirmed with relevant practice information. The final 
recommendation from this evaluation is that evidence on the impact of 
ICU admission and ICU-acquired pneumonia on the morbidity and 
mortality of patients is also required. This is, unfortunately, outside the 
time scale of this project. 
The epidemiological and economic evidence can be obtained in two 
ways. The first is to design an RCT of SDD that is powerful enough to 
detect differences in resource use and long term outcome attributable to 
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SDD. This provides a great deal of internal validity. However, the use 
of a clinical trial protocol decreases the external validity of the resource 
use data collected within it. RCTs essentially measure practice before 
the routine introduction of prophylaxis. Predictions of cost savings from 
a trial may not accurately reflect cost savings in clinical practice. 
Assessment of the difference in practice between clinical trials and 
clinical practice is necessary to make any economic evaluation 
generalisable. Therefore, some modelling would have to be carried out 
anyway. The second approach, therefore, is to pursue the decision- 
analytic model methodology used in the economic evaluation reported in 
this chapter. It is suggested that the availability of improved 
epidemiological and economic evidence will improve the robustness of 
the conclusions derived from this method without having to resort to an 
RCT. 
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Chapter 5: National Survey of Current Practice of SDD 
5.1 INTRODUCTION 
To carry out an economic evaluation of SDD in practice, it is necessary to 
have information about clinical practice, as it is probable that there will be 
significant deviations from the trial environment. Local circumstances have 
a bearing on efficiency. There is no published survey of patterns of SDD in 
clinical practice. This chapter reports the results of a national survey of the 
clinical practice of SDD in Britain. 
Using a postal questionnaire, this survey reports on total numbers of 
centres, numbers and types of patients that receive SDD. SDD 
implementation and related practices in infection prevention such as stress 
ulcer prophylaxis policies, pneumonia diagnostic techniques and current 
antibiotic treatment of ICU-acquired pneumonia are investigated to build a 
more detailed picture of resource use in this area. The results provide an 
overview of the current state of dissemination of the therapy. Reasons for 
use or non-use of SDD are examined. 
5.2 OBJECTIVES OF SURVEY 
The aim of this survey was to determine current practice patterns relating 
to SDD. 
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The specific objectives were to determine: 
1. which centres are using SDD in which patient groups; 
2. the uniformity, or otherwise, of types of SDD treatments being used; 
3. the prevailing opinions of clinicians regarding the efficacy of SDD and 
4. which centres might be usefully contacted to obtain information about 
acquisition, compounding and administration costs of a range of SDD 
regimens. 
Objectives 1 and 3 were addressed via a postal questionnaire to ICU 
clinicians. Objectives 2 and 4 were addressed via a postal questionnaire to 
ICU pharmacists. 
5.3 METHODS 
5.3.1 Study Design 
As the primary objective of the study was to find out where and how SDD 
was being used, a postal questionnaire was the most appropriate survey 
method. 
The questionnaire design was dictated by the need for a high return rate. 
This was required to provide the most accurate picture of clinical practice. 
Structured questions were employed to increase ease and speed of 
answering and to aid analysis. No assumption of knowledge of SDD was 
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made (Appendices 5.1 & 5.2). 
The questionnaires and covering letters were designed with advice from a 
sociologist, two ICU clinicians, the microbiologist who designed SDD, Dr H. 
van Saene, and two ICU pharmacists. 
Mostly factual information was to be obtained from the two questionnaires. 
This consisted of information on unit size and patient type; SOD 
implementation details and information on management of ICU-acquired 
pneumonia. Other information obtained from the questionnaire was 
concerned with clinicians' opinions about SDD. Number of patients treated 
per annum was omitted from the questionnaire and had to be ascertained 
by telephone. 
The questionnaire was sent to all specified units in England, Wales and 
Scotland (273 ICUs). 
5.3.2 Pilot Study 
ICUs in Wales were identified from the Directory of Emergency and Special 
Care Units 1993 from the categories 'adult/paediatric intensive care unit' 
and 'intensive/coronary care unit'. A questionnaire was sent to ICU 
clinicians and ICU pharmacists at each hospital in the survey. Two 
postings were done. Telephone follow up was used to clarify points of 
detail. In the event of no response from a hospital at all, clinicians and 
pharmacists were followed up by telephone. The questionnaires were 
piloted in Wales in September and October 1993 (18 ICUs). Two postings 
of the questionnaire were employed, four weeks apart. The response rate 
after the first posting was 36.8% for clinicians and 72.2% for pharmacists. 
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For the second posting, the same questionnaire was sent to all non- 
respondents. After the second posting the clinician response rate was 
68% and the pharmacist response rate was 94% (see Tables 5.1 and 
5.2). The questionnaires were revised slightly to request more information 
from pharmacists and less from clinicians to improve clinician response 
rate. The questions on ulcer prophylaxis and antibiotic prophylaxis were 
transferred from the clinicians' to the pharmacists' questionnaire. 
Questions on status of responder were discarded from both questionnaires. 
The format of the questions was not altered, enabling the results from the 
pilot study to be used in the final analysis. 
5.3.3 Main Study 
ICUs in England and Scotland were identified from the Directory of 
Emergency and Special Care Units 1993 from the categories 
'adult/paediatric intensive care unit' and 'intensive/coronary care unit'. The 
main study commenced in November 1993.255 ICUs were included in the 
survey. The second posting was sent in December 1993. The same 
questionnaire was sent to all non-respondents. All centres that reported 
using SDD, via clinician, pharmacist or both were followed up in January 
1994 by telephone for a variety of purposes. The number of patients 
treated with SDD in the previous year was obtained. Details of SDD 
regimens were clarified in a number of cases. Cost of SDD regimens was 
obtained from three centres. 
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5.4 RESULTS 
5.4.1 Response Rate of Study 
In the pilot study, 18 questionnaires were sent to clinicians and 
pharmacists. The clinician response rate was 68%, the pharmacist 
response rate was 94%, and one centre reported that there was no ICU 
present. 
In the main study, a total of 255 questionnaires were sent to clinicians and 
pharmacists in England and Scotland (see Table 5.1). The clinician 
response rate was 69.8% and the pharmacist response rate was 82.8%. 
Eleven ICUs responded as having no ICU at the time of posting so were 
excluded from the analysis. 
Table 5.1 Response Rate of Study 
Questionnaires 
I F-Clinicians 
Pharmacists 
No. pilots sent 18 18 
No. pilots returned 12 17 
No. main study sent 255 255 
No returned (1st & 2nd posting) 
Total sent (pilot & main study) 
178 (133+45) 
273 
211 (134 + 77) 
273 
Total returned (pilot & main study) 190 228 
'No ICU present' reported 12 12 
Final response rate (pilot study 
included, 'No ICU' excluded) 
178/261 
(68.2%) 
216/261 
(82.8%) 
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This resulted in a response rate from the 261 ICUs of England, Scotland 
and Wales of 68.2% (clinicians) and 82.8% (pharmacists). 57.9% ICUs 
returned responses from both clinicians and pharmacists. 10.3% ICUs 
responded via clinician only and 24.9% responded via pharmacist only. 
6.5% centres did not respond via clinician or pharmacist. 
All results discussed below include results of both the Welsh pilot study 
and the subsequent study in England and Scotland, unless stated 
otherwise. 
5.4.3 Unit Characteristics 
Mean reported annual ICU admissions was 371 (sd: 209, range: 70-1200). 
Mean annual ICU surgical admissions was 205 (sd: 135, range: 0-900). 
Mean annual ICU admissions staying for more than 3 days was 148 (sd: 
81, range: 22-488). The National ICU audit carried out by the Royal 
College of Anaesthetists in 1992/3 for 254 ICUs in the United Kingdom 
reports that 43.3% patients stay on ICU for longer than 48 hours. This 
survey reports that 39.9% patients stay for longer than 3 days. 
A comparison of unit characteristics for those ICUs using and not using 
SOD is reported in Table 5.2. 
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Table 5.2 Comparison of Characteristics of SDD Non-using and SDD-using 
ICUs 
Unit Characteristics Non SDD Users SDD Users 
Admissions p. a. 367 (210) 435' (190) 
Mean (sd) 
Surgical admissions 201 (135) 271' (135) 
p. a. Mean (sd) 
Admissions >3 days 146 (80) 181 (81) ns 
p. a. Mean (sd) 
p<0.05 (x2 test) 
5.4.4 Extent of SDD Use 
Clinicians or pharmacists from 16 centres reported using SDD. Centres 
using SDD and the regimens used is reported in Appendix 5.3. Twelve 
centres used the standard PTA SDD regimen as recommended by 
Stoutenbeek et a/ [1984]. This regimen consisted of an oral gel or paste 
(tobramycin 2%, amphotericin 2%, colistin 2%) and oral liquid (tobramycin 
80mg, amphotericin 500mg, colistin 100mg) four times a day. 
Two centres use gentamicin instead of tobramycin. One centre uses the 
liquid only. The two liver transplant centres use neomycin instead of 
tobramycin or gentamicin. This is the standard antibiotic used in liver 
transplant patients. Nine centres use SDD in ventilated patients and six 
centres use it in trauma patients. Adjunctive intravenous antibiotics are 
used by ten centres, nine of those using cefotaxime. According to the 
survey, the overall number of patients treated with SDD annually in 
England, Wales and Scotland is 530. 
182 
5.4.5 Cost of SDD Regimen 
The constituents of the liquid and the intravenous antibiotics are available 
commercially, so costs will depend on local arrangements. The gel and 
paste are made by hospital pharmacy manufacturing units and sold to other 
hospitals. Two centres provided details of costs of making SDD paste or 
gel. None were able to give full breakdowns of cost, due to confidentiality, 
but provided costs per day of treatment that were reported to include drug 
acquisition costs and an element of manufacturing overheads. The paste 
and gel was reported to cost £1.30 and £4.50 per day, respectively. 
5.4.6 Dynamics of SDD Use in Clinical Practice 
The current ICU users of SDD reported the length of time that they have 
been using it. Figure 5.1 shows the trend in SDD use in ICUs in Britain 
from 1988 to 1993. In summary, of 44 ICUs in Britain that have 
implemented SDD over the last 5 years, 66% of centres have stopped 
using it. 
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Figure 5.1 Trends in SDD Use in ICUs In Britain (1988-1993) 
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5.4.7 Infection Control Related Practices 
Clinicians at 16 ICUs reported using protected specimen brush technique to 
diagnose pneumonia. Most of these qualified their use of this diagnostic 
method as 'rare'. Stress ulcer prophylaxis at most ICUs consists of 
ranitidine and sucralfate as first line treatments (58.8% and 52.6%). Many 
" centres reported using sucralfate as first line and only using ranitidine if 
nasogastric access was not possible. There was no significant difference 
between SDD users and non-SDD users. 
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Pharmacists from 211 ICUs reported the first, second and third line 
antibiotic regimens used on their unit to treat a suspected Gram negative 
infection before sensitivities are available. Pharmacists from seven ICUs 
reported no protocol. Pharmacists from 188 centres reported second line 
antibiotics and 147 centres reported third line antibiotics. Gentamicin is 
used most frequently, both alone and in combination at all three levels. It 
is most commonly used alone (65 reports) and in combination with 
piperacillin (20 reports), added to cefuroxime (15 reports), ceftazidime (13 
reports) and ampicillin (11 reports). Apart from gentamicin, the most 
common first line antibiotic is cefotaxime (54/211 reports). The most 
commonly reported second line antibiotic is ceftazidime (42/188 reports). 
The most commonly reported third line antibiotic is ciprofloxacin (42/147 
reports). 
Clinicians from 72% of ICUs report monitoring infection rates (119 non- 
SDD users, 9 SOD users). Clinicians from 79% of ICUs report record 
severity of illness (130 non-SDD-users, 10 SDD users). This compares with 
122/256 (47.7%) centres reporting APACHE II scoring in the ICU Audit 
1992/3. Five SDD users record SDD costs. 
5.4.8 Clinicians' Opinions and Beliefs about SDD 
This section examines the opinions and beliefs of ICU clinicians concerning 
SDD. 
5.4.8.1 Clinicians' Opinions about SDD 
Clinicians were asked to state whether they agreed with a range of 
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statements concerning the clinical efficacy of SDD. The results for ICU 
SDD-users (n = 11) and non-SDD users (n = 167) are summarised in Table 
5.3. The only significant difference between the two groups was an 
increased belief by SDD users in the ability of SDD to reduce respiratory 
infection rate (p =0.013). Most of both groups did not believe that SOD 
decreased mortality or length of stay, increased emergence of antibiotic 
resistant strains of bacteria or adherence to infection control policies. 
Table 5.3 ICU Clinicians' Opinions Regarding the Clinical Efficacy of SDD 
SDD efficacy parameters believed by 
clinicians 
SOD Users 
n =11 
Non-SDD 
users n= 167 
L Respiratory infections 9 72t 
i ICU length of stay 2 11 
fr Mortality 2 16 
t Antibiotic resistance 1 33 
t Infection control policy adherence 3 27 
tp=0.013 (Xltest) 
5.4.8.2 Clinicians' Reasons for Not Using SDD 
Out of 167 non-SDD using clinicians, the most frequently reported reasons 
for not using SDD were lack of evidence for clinical efficacy (138 reports), 
financial and time constraints (46 and 49 reports), microbiological 
resistance (31 reports), pharmacy and nursing resistance, inappropriate 
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patients and not knowing about SDD (5 reports for each reason). 
5.4.8.3 Clinicians' Knowledge About SDD 
A postal questionnaire does not allow an in depth assessment of a 
clinician's knowledge base in SDD, upon which he bases his opinions. 
Awareness of the recent meta-analysis of 22 RCTs of SDD published in the 
British Medical Journal [ 1993] was used as proxy measure of clinicians' 
awareness of SDD and an indirect measure of their knowledge base. All 
clinicians using SDD reported reading the article, compared with 62.3% 
non-SDD users (X= 6.4232, p=0.011). 
5.4.8.4 Comparison of Clinicians' Awareness of SDD with Their Beliefs 
About its Clinical Efficacy 
The beliefs of non-SDD users about SDD's clinical efficacy were examined 
in relationship to their 'awareness' of SDD (Table 5.4). 
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Table 5.4 ICU Clinicians (Non SDD Users) Opinions Regarding the Clinical 
Efficacy of SDD and the Relationship with Awareness of SDD 
SDD efficacy parameters believed by 
clinicians 
Clinicians who had 
read SDD meta- 
analysis (n =104) 
Clinicians who had 
not read SDD meta- 
analysis (n = 63) 
4 Respiratory infections 53 190 
4 ICU length of stay 7 4 
1 Mortality 12 4 
t Antibiotic resistance 22 11 
t Infection control policy adherence 21 6' 
Op <0.001 
'p = 0.07 
The results reported in Table 5.4 indicate that those clinicians who reported 
reading the SDD meta-analysis published in the British Medical Journal in 
1993 have a more accurate knowledge of the areas of efficacy of SDD. 
5.5 DISCUSSION OF RESULTS 
This survey was sent to ICU clinicians and pharmacists to obtain 
information on current practice patterns of SDD. There was a high 
response rate, such that, of 261 ICUs, the SDD practice was known for 
93.5%. Six clinician questionnaires were accidentally returned twice from 
the same centre, at least one month apart. This was due to overlap of the 
first and second postings. Five of the six questionnaires had been 
completed both times by the same clinician. The responses were virtually 
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identical from the first and second postings. This overall consistency 
between the first and second responses from these six centres suggests 
that the questionnaire was reliable. 
This survey demonstrates that SDD is not being used in many centres 
around the country, and generally, a small number of patients at each 
centre receive the treatment (530 patients annually from 74,600 ICU 
admissions reported). Appropriate patient groups are being targeted, such 
as trauma and burns patients or those expected to be ventilated for more 
than 48 hours. These patients are those considered at high risk of 
nosocomial pneumonia and are most likely to benefit from SDD. Of the 44 
ICUs reporting use of SDD, 66% have stopped using it. 
ICUs that use SDD tend to have more annual admissions than non-SDD 
users, and a high proportion of these are surgical patients. The standard 
SDD regimens is most commonly used, 9 of the 16 centres using 
intravenous cefotaxime. Variations in regimens are mostly pragmatic in 
origin. The oral gel is more acceptable to the patient, but is more costly. 
The pastes and gels are not available commercially so are made by 
pharmacy manufacturing units who sell them to other hospitals. This 
resource use information, with the information on stress ulcer prophylaxis, 
pneumonia diagnosis and antibiotic treatment is necessary for economic 
evaluation of SDD in practice. 
The other information obtained from this survey provides some insight into 
why SDD is not widely used in Britain. Measures of efficacy of SDD 
concentrate on decreases in pneumonias, mortality, length of stay, 
emergence of resistant bacteria and changes in infection control practices, 
with varying quality of evidence for each. SDD reduces incidence of 
pneumonias by 63% according to the recent meta-analysis of 22 RCTs 
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[SDD Trialists' Meta-Analysis, 1993]. There is no conclusive evidence that 
it reduces mortality or length of stay. There is no evidence that SDD 
increases the risk of emergence of resistant strains of bacteria 
[Stoutenbeek et al, 19871 or that SDD increases awareness of infection 
control in general. SDD users and non-users believed that SDD decreased 
pneumonias, and neither group tended to believe that it decreased mortality 
or length of stay, increased resistance or adherence to infection control 
policies. In summary, this means that the clinicians were largely basing 
their opinions of SDD on published evidence. A higher proportion of SDD 
users believed that SDD reduced pneumonias. This implies that clinicians 
are basing their opinions on clinical data available. However, the most 
commonly reported reason for not using SOD was lack of evidence of 
clinical efficacy. This may be due to lack of knowledge, or to a lack of 
confidence in the clinical data available. However, it is incongruent with 
this scepticism that the majority of technologies are used in the ICU setting 
without any effectiveness data at all. 
A proxy variable for awareness or knowledge of SDD was employed by 
asking clinicians whether they recalled reading the SDD Trialists' meta- 
analysis in the British Medical Journal in 1993. Those who had not read 
the article were significantly less likely to believe that SDD reduced 
pneumonia incidence. 
Clinicians may believe that SDD reduces pneumonia in the patient groups 
studied, but not in their own patients. Ten clinicians in the survey qualified 
their responses by stating that they did not believe that SDD would work in 
'their patient population'. They also perceive it as a costly intervention, 
27.5% responders reporting financial constraints as a reason for not using 
SDD. 
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5.6 CONCLUSIONS AND IMPLICATIONS FOR ECONOMIC EVALUATION 
OF SDD 
The main aim of this survey was to provide resource use and unit cost 
information on SDD upon which to base an economic evaluation of SDD in 
practice. The information obtained includes number and type of patients, 
treatment schedules and some associated infection control practices. The 
numbers of patients reported as receiving SDD per year are probably 
estimates. They provide information on the order of numbers of patients 
receiving SDD each year. This allows the assessment of the current overall 
economic impact of SDD. 
Economic evaluation of SDD in practice in a British ICU setting should 
therefore examine the use of the standard PTA regimen with cefotaxime in 
ventilated adult ICU admissions. This will provide an economic model that 
most closely mirrors current SDD practice patterns. 
The secondary aim of the survey was to assess clinicians' opinions about 
SDD. If they are not using SDD because it is considered too costly, then 
an economic evaluation will affect their decision whether to use it or not. 
However, if they do not believe it is clinically effective, an economic 
evaluation is likely to have little impact on decision-making. 
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Chapter 6: Prospective Patient Cost and Outcome Study in 
Two British ICUs 
6.1 INTRODUCTION 
The secondary economic evaluation reported in Chapter Four identified a 
lack of evidence on the economic impact of ICU-acquired pneumonia and 
SDD implementation. This chapter describes a prospective observational 
study carried out at two British ICUs to obtain data on the economic 
impact of ICU-acquired pneumonia in two different practice settings, a 
London teaching hospital (LTH) and a district general hospital (DGH). 
Economic impact of ICU-acquired pneumonia, from the perspective of the 
ICU, can be determined by examining the difference in total patient costs 
attributable to an episode of pneumonia. Total patient cost is a function of 
length of stay and cost per patient day. Therefore, the cost parameters 
quantified by this study are total cost, length of ICU stay and cost per 
patient day. 
Chapter Four also suggested that local factors including patient 
characteristics, ICU-acquired pneumonia rates and unit occupancy would 
affect the cost effectiveness of SDD. This study therefore provides data 
for these three categories. 
The specific aims and objectives of the study are outlined in section 6.2. 
Section 6.3 describes the study design required to obtain data that fulfil 
these aims and objectives. Methods used for collecting resource use data 
and attaching costs to this information are outlined. The results of the 
study are reported in section 6.4. This section considers the proportion of 
192 
patients at each centre that would be appropriate for SDD therapy if it 
were implemented. These subgroups are examined separately to determine 
their admission characteristics, infection status, resource use and outcome. 
Finally, Section 6.5 discusses the study with reference to the strength of 
methods used, problems common to both centres and problems specific to 
each centre. The confidence with which the data collected can be used is 
discussed. 
6.2 AIMS AND OBJECTIVES OF STUDY 
The aim of this study was to identify and quantify the resource use 
associated with ICU-acquired pneumonia in a British ICU practice setting. 
This can be broken down into five specific objectives: 
1. to obtain well-defined patient information on admission to ICU to allow 
characterisation of the populations studied; 
2. to obtain bottom-up prospective resource use data and unit costs of 
that resource use to provide precise information on defined cost parameters 
(total cost, length of ICU stay and cost per patient day); 
3. to obtain information on infection rates, using explicitly defined 
diagnosis criteria, to provide incidence rates for ICU-acquired pneumonia; 
4. to obtain information on short and longer term outcomes of the 
populations studied and 
5. to identify a patient group at the study centres that would have been 
suitable for SDD, if it were implemented at either centre. 
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6.3 STUDY DESIGN 
This section describes the study designed to achieve the five objectives 
listed above. The four main areas of data required were patient admission 
characteristics, bottom-up resource use and associated costs, infection 
incidence rates and patient outcomes. The methods used, therefore, were 
designed to obtain these four groups of data. This section describes what 
information is required in each of these categories of data, why it is 
required and how it was collected. These data requirements dictate the 
remaining elements of the study design. These are the patient group size, 
patient inclusion criteria and selection of centres, also outlined in this 
section. Finally, the preliminary fieldwork and pilot study required to 
develop the methods used in the full study are reported. 
6.3.1 Patient Admission Characteristics 
Patient characteristics are required for four reasons. The first is to enable 
description of the study group in terms of severity of illness, diagnosis, 
age, chronic health, ventilation and infection status on admission, and type 
of surgery. The second is to assess the study group in terms of its 
generalisability to other ICU populations. For this reason, it is essential to 
use standard measurements of severity of illness and accepted diagnosis 
definitions. The third reason is to identify which patients in the study 
groups would be appropriate candidates for SDD therapy. This is required 
for the economic analysis in Chapter Eight. The fourth reason is that 
patient characteristics may have an impact on resource use. These 
characteristics need to be controlled for when assessing the impact of ICU- 
acquired pneumonia on resource use. 
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Therefore, the details collected for each patient on admission were those 
considered necessary to characterise the patient population and identify 
presence of risk factors for increased resource use. The parameters 
recorded are listed in Appendix 6.1a. Standard severity of illness scores 
(APACHE II) and diagnosis categories (APACHE II diagnosis categories 
[Knaus et al, 1985]) were used. Patients who would theoretically be 
considered suitable for SDD therapy are those ventilated on admission to 
the ICU, as discussed in Chapter Four. Therefore, the patient 
characteristics of this group are reported separately. 
6.3.2 Cost Parameters and Resource Use Data 
The second category of data required is the resource use associated with 
each patient and the cost associated with that resource use. This is 
required to quantify cost per patient and cost per patient day, required for 
use in the economic analysis of SDD. Total costs contain fixed, semi-fixed 
and variable components. As discussed in Chapter Two, total patient cost 
equates to the long run marginal cost of that patient. This is required to 
assess the long term impact of an intervention on ICU activity and 
capacity. 
To be able to detect pneumonia-related changes in costs, patient-specific 
'bottom-up' resource use data is necessary. Collection of this type of 
resource use data is labour intensive due to the evolving nature of hospital 
data retrieval systems in the UK. Therefore it is desirable to minimise this 
data collection by concentrating on resource use that is known to be 
affected, in this case by ICU-acquired pneumonia. However, it is not easy 
to assess which elements of resource use will be important at the outset, 
and which will not. Some resource use related to an infection like 
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pneumonia may be obvious, such as the use of antibiotics and microbiology 
tests. Other areas of change may not be so obvious, such as changes in 
artificial ventilation requirements or physiotherapy. Therefore, in this 
study, all identifiable resource use associated with a patient's ICU stay was 
recorded. The types of resource use collected are listed in Appendix 6.1b. 
Once the resource use for each patient is known, costs need to attached to 
that resource use. The costs obtained should reflect the true economic 
cost of that service as closely as possible. Therefore, it was necessary 
that the source and components of those costs were known. If the full 
cost of a service was not known, then it was necessary to derive that cost 
prospectively. An example is the full cost of a drug dose including 
pharmacy department overheads and administration costs as well as the 
drug acquisition costs. It was necessary to be aware of all components of 
costs such that double-counting of costs was avoided, such as support 
department overheads. Table 6.1 summarises the source of fixed, semi- 
fixed and variable costs. The next sections describe the methods used for 
recording and costing fixed, semi-fixed and variable resource use. 
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Table 6.1 Sources of Fixed, Nursing (Semi-Fixed) and Intervention 
(Variable) Costs 
Cost Category Source of Costs 
1. Fixed cost per patient/hour 
Estates, portering, electricity and lighting, 
Finance department 
laundry, cleaning, security, personnel, 
clinical engineering, management, finance, 
medical records, medical staff costs 
2. Nursing staff costs Finance department 
3. Intervention costs 
Chemical pathology tests 
Chemical pathology department 
Haematology and blood products Haematology department 
acquisition costs 
administration disposables costs 
Contracts/supplies' 
Interventions, ventilation, dialysis Contracts/supplies disposables costs 
drug costs 
See 'drugs and nutrition' 
Microbiology tests Microbiology department 
Drugs and nutrition 
drug acquisition costs 
Pharmacy department 
administration disposables costs 
Contracts/supplies 
pharmacy department overheads 
Finance department 
Physiotherapy treatment Physiotherapy department 
Radiology tests Radiology department 
Specialist beds Intensive care contracts 
'Intensive care contracts/supplies/central sterile supplies department 
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6.3.2.1 Fixed Costs 
These are the costs that were incurred independently of ICU activity. They 
are costs of ICU to the estates department, electricity, security, laundry, 
cleaners, porters, catering, personnel, finance, management and clinical 
engineering. Fixed costs were obtained from the finance department of 
each hospital. The methods used to allocate the costs incurred from these 
departments were necessary to avoid double counting. They were 
allocated to each patient on the basis of a fixed cost per patient day. 
6.3.2.2 Semi-Fixed Costs 
In this study, semi-fixed costs referred to ICU nursing costs. The number 
of nurses and their grade on each shift was recorded. The cost to the 
hospital of employing each grade per hour was obtained. This allowed cost 
per shift to be calculated. Nursing cost per dependency point was used at 
LTH, as reported by Ridley et a/ [ 19911. Dependency scores were not 
recorded at DGH so nursing costs were allocated by occupancy, not 
adjusted for dependency. Ridley et a/ 119911 also allocate medical staff 
costs on the basis of dependency scores, assuming that increased nursing 
dependence leads to increased clinician dependence. However, research by 
Dick et al [1992] demonstrates no significant relationship between nursing 
dependence and clinician dependence of ICU patients. This study therefore 
allocated medical staff costs as a fixed amount per patient day. 
6.3.2.3 Variable Costs 
Patient-specific resource use data were collected daily on an immediately 
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retrospective basis. The parameters recorded are listed in Appendix 6.1 b. 
Interventions, such as intubation, and patient monitoring, such as ECG 
recording, were recorded at or soon after the time of occurrence. Resource 
use associated with those interventions and monitoring were obtained 
separately by observational study and interview. The associated cost of 
this resource use was obtained from relevant support and accounting 
departments. 
6.3.3 Infection Status 
SDD only reduces the incidence of a subset of ICU-acquired pneumonias, 
that is Gram-negative late-onset pneumonia. There is no evidence to 
suggest that management of different types of ICU-acquired pneumonias 
differs other than in the selection of antibiotics. Therefore, it is reasonable 
to assume that the resource use associated with Gram-negative late-onset 
pneumonia does not differ from ICU-acquired pneumonia in general. All 
episodes of ICU-acquired pneumonia experienced by patients were 
recorded. As other infections may also incur additional resource use, they 
were recorded. The patient's infective status was recorded from the 
patient's medical notes and from the microbiology department's records. 
Infections may be present on admission to ICU, or may be incurred during 
the patient's stay. During the ICU stay, infective episodes were recorded. 
Infections were categorized by site and type of organism. Site categories 
were abdomen, axilla, blood, central nervous system (CNS), groin, lines, 
lung, nasogastric aspirate, skin, stool, throat, vagina, urine and wound. 
Types of organism were Gram positive bacterial, Gram negative bacterial, 
anaerobic bacterial, fungal, viral and mixed. Major infections were classed 
as those originating in the abdomen, blood, CNS and lungs [Shulkin of a/, 
1993]. Other sites were classed as minor. Major infection episodes 
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treated without a positive microbiological culture ever being obtained were 
treated 'blindly', so were classed as 'blind' infections. Infection was 
defined as being present on ICU admission ('Pre-ICU'), becoming present in 
the first 48 hours of the ICU stay ('early onset') or becoming present after 
the first 48 hours of the ICU stay ('late onset'). Gram-negative late-onset 
pneumonia is the infection prevented by SDD. The incidence of Gram- 
negative late-onset pneumonia rates for patients hypothetically suitable for 
SDD (ventilated admissions) is required for the primary economic analysis. 
Interview with ICU directors from both centres provided details of diagnosis 
of ICU-acquired pneumonia. At DGH, pneumonia was diagnosed by the 
clinical criteria of radiological changes or history of aspiration. At LTH, 
other clinical signs used were purulent sputum, deterioration in blood gases 
and temperature changes. Antibiotics were initiated before microbiological 
confirmation at both centres. 
6.3.4 Patient Outcome 
The impact of pneumonia on patient outcome ideally requires measurement 
of short and long term morbidity and mortality. Due to time constraints 
and the lack of QoL tools validated for use in this area, this study restricted 
itself to measuring outcome in terms of ICU, hospital and six month 
mortality. The least useful outcome measure is ICU mortality because 
moribund patients are often discharged to die privately on a ward. Hospital 
mortality is more useful, but does not reflect those patients who are 
discharged home or to a nursing home to die. The most useful short term 
mortality measure collected by this study was, therefore, six month 
mortality. Patients surviving beyond this time were much more likely to 
have recovered from the effects of their ICU stay. However, Ridley et a/ 
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[ 19941 have reported that mortality does not return to that of the normal 
population for up to four years after discharge. Unfortunately, this length 
of follow-up was beyond the scope of this study. 
The patient's destination on leaving the ICU and hospital was recorded. 
This required telephone follow up at other hospitals in some cases. Six 
month mortality was recorded from hospital records, contacting the 
patient's GP or use of OPCS records. 
The patient groups are examined in the analysis in Chapter Seven to assess 
whether factors such as which ICU a patient is admitted to, or ICU- 
acquired pneumonia, have an impact on mortality. 
6.3.5 Patient Group Size 
The principal statistical analysis method used in this study to identify 
resource use due to ICU-acquired pneumonia is linear regression analysis. 
This analysis technique demands that there are more observations than 
independent variables in the final linear regression model and that the 
difference between the two is as large as possible [Kennedy, 19931. 
However, the determination of a specific sample size is not straightforward 
due to the nature of the linear regression model not being known prior to 
the analysis. The largest sample size possible within the experimental time 
frame should, therefore, be obtained. 
6.3.6 Patient Inclusion Criteria 
This section lists the criteria for selecting patients to include in the resource 
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use study. The selection criteria were used to exclude any patients that 
would not be considered to be 'true' intensive care patients. All 
consecutive adult ICU admissions (age 15 and above to allow collection of 
APACHE II scores) with lengths of stay of more than eight hours were 
included. A population of predominantly surgical patients was required, to 
provide a patient group hypothetically appropriate for SDD therapy. 
Lengths of stay of less than eight hours indicated patients not appropriate 
for ICU admission due to them being too well or their critical condition 
being irretrievable. Patients admitted because the CCU or HDU were full 
were excluded. 
6.3.7 Selection of Centres 
This section justifies the centres selected for the study. It was expected 
that ICUs in teaching hospitals and district general hospitals would have 
differing resource use patterns. Studies are often carried out in large 
teaching hospitals. It is not always clear that it is appropriate to generalize 
results from this setting to a district general hospital. To examine this 
potential difference, the study was carried out at two centres, LTH and 
DGH, with similar patient populations. The centres were selected by the 
following criteria: 
1. appropriate patient population (adult, mostly surgical); 
2. average or above average annual patient turnover (over 300 admissions 
[ICU Audit, 1992/931); 
3. relative ease of resource use data retrieval; 
4. ethical committee and ICU director approval and 
5. geographical convenience to enable three visits a week to each centre. 
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Both centres selected took trauma, post-general and vascular surgery 
patients. LTH also took neurosurgery patients. Centres using SOD were 
not used. This allowed easier isolation of resource use associated with 
ICU-acquired pneumonia, without the confounding effects of SDD on 
infection rates. 
6.3.8 Preliminary Fieldwork and Pilot Study 
The pilot study was carried out after preliminary fieldwork. This involved 
visiting the ICUs to identify what data could be collected routinely and from 
which sources. All support departments at each centre were visited to 
determine the most reliable data sources. In January 1994, a two week 
pilot study was carried out at both centres. The aims of this study were 
to: 
1. determine that all required patient characteristic and resource use 
variables could be collected from both sites as planned and 
2. determine which were the most reliable information sources. 
The pilot study indicated that more data would be available from LTH. 
More detailed patient characteristics data were available due to the routine 
use of a patients admission database. This included daily collection of 
APACHE II scores, TISS scores and recording of interventions. APACHE II 
score on admission and daily TISS scores were available from DGH. All 
patient characteristic and resource use variables considered essential could 
be collected from both centres. Almost without exception, the most 
reliable source of variable resource use was the records of the clinical 
support service. A higher retrieval of resource use from LTH was expected 
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due to the higher degree of computerisation of clinical support records. 
Drugs, nutrition and blood products use were recorded from bedside charts. 
Interventions, line and drain changes were recorded from notes and from 
the attending nurse. At LTH, physiotherapy time was recorded as the 
quantity of 15 minute treatment sessions for each day. This was not 
carried out at DGH, the physiotherapist recording a visit on the patient's 
chart only. 
6.3.9 The Full Study 
The study was passed by the Ethics Committees at both hospitals. Each 
required that the patients included in the study give their signed consent. 
Patient recruitment for the full study was carried out at both centres from 
1st February 1994 to 30th November 1994. Data collection was 
continued until all recruited patients had been discharged from the ICUs. 
6.4 RESULTS 
This section reports the results of the resource use study. The results of 
this study are divided into three sections: 
1. patient admission, infection and outcome characteristics; 
2. costs associated with resource use obtained from each centre and 
3. patient resource use characteristics. 
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6.4.1 Patient Population Characteristics 
This section summarizes the patient admission, infection and outcome 
characteristics for the study groups obtained from the two centres. 
At LTH, 237 admissions were recorded for 224 patients. There were 212 
eligible first admissions. In accordance with the study inclusion criteria, 12 
admissions were excluded as the patients were on ICU for less than 8 
hours. Thirteen admissions were readmissions. At DGH, 189 admissions 
were recorded for 170 patients. There were 137 eligible first admissions. 
In accordance with the study inclusion criteria, 52 admissions were 
rejected (19 readmissions (10 for haemodialysis sessions), 24 less than 8 
hours long, 6 CCU overflow patients and 2 patients younger than 15 years 
old). 
6.4.1.1 Patient Admission Characteristics 
No patient refused to be entered into the study. Table 6.2 summarises 
characteristics of eligible first admissions at both centres. The populations 
are similar in their age, sex and severity of illness distribution. Mean 
patient age and APACHE II score are similar to those reported by other 
British ICUs [Shiell, 1989; Ridley et a/, 1993]. Both centres have a 
predominantly surgical population, although the proportion of surgical 
patients is higher at LTH. Table 6.3 illustrates the similar profile of surgical 
specialities at the two centres. The difference worthy of note is that LTH 
ICU takes neurosurgery patients because the hospital is a tertiary referral 
centre. LTH is also a tertiary referral centre for oncology, reflected in the 
higher proportion of admissions with active cancer. There were many 
reasons for admission recorded by the clinicians at the two centres. The 
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largest groups at both centres were 'post peripheral vascular surgery' (21 % 
at DGH; 16.5% at LTH), 'post neurosurgery' at LTH (12.3%) and 
'respiratory insufficiency post-op' (17.4% at DGH, 9.0% at LTH). All 
recorded categories are detailed in Appendix 6.2. The patients at the two 
centres have similar types of previous medical history, levels of infections 
on admission, cardiopulmonary resuscitation prior to admission and 
subsequent readmissions to ICU. LTH has a substantially higher unit and 
hospital mortality than DGH. Reasons for this are examined in Chapter 
Seven. The mean ICU and hospital mortalities reported by Metcalfe et a/ 
(1995] for 257 British ICUs were 18% (range: 4 to 41 %) and 26% (range 
10 to 50%) respectively. The mortalities reported here fall within these 
ranges. A major proportion of admissions to both centres were ventilated. 
These patients are those hypothetically suitable for SDD therapy. These 
patient groups are examined separately in section 6.5.6. 
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Table 6.2 Summary of Eligible Patient Characteristics (First admission only) 
Patient characteristic DGH In a 137) LTH (n-212) 
Age' 61.1; 16.4; 15-91; 62.8 59.3; 18.3; 15-90; 63.1 
Sex (% male) 60.6 56.6 
APACHE II' 15.0; 7.7; 0-40; 14.02 14.7; 7.0; 3-44; 143 
% Surgical 63.5 76.4 
% Elective 32.8 34.9 
% reported PMH 67.4 54.7 
% Active cancer 10.9 27.8 
% Infected admissions 26.3 24.1 
% CPR before ICU 8.8 8.0 
% admitted ventilated 65.0 80.7 
% ventilated on ICU 67.9 86.8 
% dialysed 7.3 11.3 
% with a PA catheter 30.7 33.0 
% Readmitted 6.1 6.5 
% ICU mortality 13.1 24.5 
% Hospital mortality 28.5 36.7 
%6 month mortality 35.94 45.65 
' Mean, sd, range, median 
2n =130 as there are 7 missing values; 3n= 207 as there are 5 missing values 
n= 131 as there are 6 missing values; 5 n=206 as there are 6 missing values 
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Table 6.3 Distribution of Surgical Admissions 
Type of Surgery DGH (%) LTH (%) 
No surgery (medical) 50 (36.5)' 50 (23.6)2 
General surgery 36 (26.1) 49 (23.1) 
Vascular surgery 35 (25.4) 43 (20.3) 
Neurosurgery 0 (0) 38 (17.9) 
Trauma surgery 2 (1.5) 10 (4.7) 
Other surgery 14 (10.1)' 22 (10.4)` 
' Cardiology, general medicine, geriatrics, nephrology, neurology and paediatrics. 
2 Cardiology, general medicine, geriatrics, haematology, nephrology, neurology, oncology 
and rheumatology. 
I Gynaecology, orthopaedics, plastic surgery and urology. 
` ENT, orthopaedics, plastic surgery and urology. 
6.4.1.2 Infection Status of Patients 
The infection status of patients was recorded on admission to ICU and 
monitored throughout the ICU stay. This provided the incidence rate of 
serious infections and specifically pneumonia. These were divided into 
'Pre-ICU', early onset and late onset infection rates. Tables 6.4a and 6.4b 
detail the incidence of serious infections and pneumonias that occurred on 
the two ICUs. Not all infections and pneumonias were confirmed by a 
microbiological culture, but were treated on the basis of clinical criteria. 
Infections that were treated in this way are termed 'blindly treated'. The 
incidence of infections including these blindly treated infections are 
included in the tables in parentheses. 'Pre-ICU' infections were those that 
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had been diagnosed and where treatment had been initiated prior to ICU 
admission. Early and late-onset infections are diagnosed and treated after 
ICU admission. Identification of resource use associated with ICU-acquired 
pneumonia examines the two latter groups together. 
Table 6.4a Incidence (Number of Episodes per Patient) of Serious Infection 
and Pneumonia Episodes in Eligible First Admissions at LTH (n = 212) 
Infection category Pre-ICU' Early onset2 Late onset2 
Serious infection' 0.24 (0.24) 0.14 (0.21) 0.70 (0.76) 
Pneumonia 0.09 (0.09) 0.07 (0.14) 0.42 (0.48)' 
Includes pneumonia, CNS, abdominal sepsis and bloodstream infection. 
2 Infections with and without positive microbiological culture in parentheses 
3 102 episodes of late-onset pneumonia in 65 patients (63% are Gram-negative, so the 
incidence of Gram-negative late-onset pneumonia is 0.30 episodes per ICU admission). 
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Table 6.4b Incidence (Number of Episodes per Patient) of Serious Infection 
and Pneumonia Episodes in Eligible First Admissions at DGH (n =137) 
Infection category Pre-ICU2 Early onset2 Late onset2 
Serious infection' 0.27 (0.27) 0.14 (0.26) 0.11 (0.16) 
Pneumonia 0.18 (0.18) 0.06 (0.18) 0.09 (0.15)' 
1 Includes pneumonia, CNS, abdominal sepsis and bloodstream infection. 
2 Infections with and without positive microbiological culture in parenthesis 
20 episodes late-onset pneumonia in 18 patients. (60% are Gram-negative, so the 
incidence of Gram-negative late-onset pneumonia is 0.09 episodes per ICU admission). 
The overall ICU-acquired serious infection and pneumonia rates recorded at 
the two centres are very different, 97% and 62% respectively at LTH 
compared with 42% and 33% respectively at DGH. These infection rates, 
reflect the range of incidence rates discussed in Chapter Three. A recent 
epidemiological study of ICU-acquired pneumonia in British ICUs confirms 
that, while the incidences observed here are very different, they merely 
reflect the wide range reported around the country [Vincent et a/, 19951. 
The high proportion of ICU-acquired serious infection that is pneumonia 
observed here is reflected in the published evidence reported in Chapter 
Three. The higher incidences of ICU-acquired pneumonias on large surgical 
ICUs was also reported by George et a/ [19931. 
The ICU-acquired and Gram-negative late-onset pneumonia rates for 
ventilated patients are reported separately in section 6.5.6. 
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6.4.2 Summary of Costs Associated with Resource Use Obtained from 
each Centre 
This section reports the sources and components of costs associated with 
resource use obtained from each of the study centres. Fixed, semi-fixed 
and variable costs are reported. 
6.4.2.1 Fixed Costs 
The fixed costs allocated to the ICU at each study centre are reported in 
this section. Departmental overheads were allocated using locally designed 
allocation models. Local allocation of overheads is detailed in Table 6.5. 
At both centres, intensive care was categorized as a clinical support 
service. Therefore, other clinical support services were not allocated to 
ICU as all clinical support services were allocated directly to clinical 
directorates. A range of allocation methods were used, such as the 
allocation of costs on the basis of floor area, bed days, staff time and 
workload. 
This study apportioned fixed costs to individual patients according to their 
length of stay on the ICU, to the nearest half hour. The fixed cost per 
patient day was derived for both centres using total fixed costs for the year 
and total patient days during that time period. At LTH, total patient days 
on ICU for 1994/95 was 1830. This gives a fixed cost per patient day of 
£129.1. At DGH, total patient days for 1994/95 were derived from the 
dataset as 1100 per annum, giving a fixed cost per patient day of £182.6. 
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Table 6.5 Department overhead costs and methods (1994/5 budget) 
Department DGH cost LTH cost Method of allocation 
p. a. /£ p. a. /£ 
Estates 20656 21191 Floor area 
Portering and waste 4140 5224 
Security 760 970 
Catering 4849 - 
Sewing room 2049 - 
Cleaning 29600 37466 hours/week 
CSSD' 7747 24207 Issues 
Supplies department 29782 38869 Pro rata to cost of 
Issues 
Telecommunications 8512 14093 Workload 
Personnel 9979 - WTE's2: 58.2 
Occupational health - 3679 
Staff dental - 255 
Human resources 5270 4890 
Nursing education 37075 0 
Finance 15873 29328 
Executive services and 24611 5319 Pro rata to other 
senior management overheads 
Pathology 0 0 Overheads in request 
Imaging services 0 0 costs 
Physiotherapy 0 0 
Pharmacy (non drugs) (80000)3 (86955)' 6.27% of workload 
Clinical engineering 50777 6.51 % of workload 
TOTAL departmental 200903 236268 
overhead allocation: 
' Central Sterile Supplies Department 
I Whole time equivalents 
I Not included in this total, added to drugs pro rata 
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6.4.2.2 Nursing and Medical Staff Costs 
This section reports the allocation of medical and nursing staff costs to 
patients at the two centres. To do this, it was necessary to determine 
total nursing and medical costs for each unit and allocate costs 
appropriately to each patient. Total nursing cost per shift was obtained by 
recording the number and grades of permanent and temporary nursing staff 
present for each shift from the nursing duty rota. The cost to the hospital 
of employing each nursing grade for a shift was obtained from finance 
departments. Costs of temporary nursing staff were obtained from the 
Clinical Nurse Leader, derived from the 1994/95 financial year. Costs 
included the nurse's wage, inner or outer London allowances and hospital 
employer contributions. The grades of nurse ranged from 'D' to W. The 
cost for the midscale of each grade was used. Shifts were costed 
according to the number of hours they lasted and whether they occurred 
on weekdays, weekends or bank holidays. Appendix 6.3 summarises costs 
per shift for each grade at both centres. Total nursing cost per shift was 
then derived. The simplest allocation method is the use of ICU occupancy 
to derive nursing cost per patient day (see Table 6.6). 
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Table 6.6 Summary Statistics of Nursing Cost per Patient Day (calculated 
from data from 271 days) 
Cost per patient day/£ DGH LTH 
Mean 332.4 307.0 
Standard deviation 148.5 65.9 
Median 246.64 287.8 
Range 
11 
151.6-939.9 201.1-743.0 
1 
Nursing costs per shift varied quite widely, due to usual staffing problems 
such as people calling in sick and not being able to employ bank or agency 
staff. Senior staff were sometimes all on the same shift to enable 
management meetings to be carried out. These variations were due to 
factors other than the patient occupancy. To eliminate their effect on 
individual patient costs, mean nursing costs per patient day were used. 
Table 6.6 shows that the two centres had similar nursing costs per patient 
day. The increased variation at DGH is a function of the smaller ICU size. 
A unit change in patient occupancy has a larger proportional effect on cost 
per patient day in a smaller ICU. The occupancy of staffed beds at LTH 
and DGH for the study period was 93.5% (range 88.4% to 97.7%) and 
69% (range not reported) respectively. The mean monthly patient refusal 
rate at LTH was 44% (range 26% to 65%) (see Chapter Two for 
definitions of patient refusal rates). This meant that for every 100 
admission requests, 44 were refused. This may have included one patient 
being refused more than once. Refusal rates were not recorded at DGH. 
At LTH, routine recording of ICS dependency scores enabled allocation of 
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nursing costs by patient dependency. To derive the nursing cost 
associated with each patient per shift, the total nursing cost per shift was 
allocated to patients according to nursing dependency (Appendix 2.2). 
This is the method reported by Ridley et a/ [19911. The sum of individual 
patient dependency scores was the total shift dependency score. Nursing 
cost per dependency point for each shift was calculated (see Table 6.7). 
Mean cost per dependency point for early, late and night shifts were used. 
This allowed the daily nursing cost for each patient to be derived, 
depending on their nursing dependency scores. 
Table 6.7 Summary Statistics of Nursing Cost per Dependency Point for 
Early, Late and Night Shifts at LTH (calculated from data from 341 days) 
Parameter Early Shift Late shift Night Shift 
Mean cost per 
dependency point 
67.83 62.94 92.46 
Standard deviation 18.77 15.92 22.23 
Median 64.77 60.17 87.92 
Range 36.02-148.06 33.36-126.16 52.98-185.38 
Although nursing costs were allocated at LTH using the ICS dependency 
scoring system, the correlation between patient nursing costs and length of 
ICU stay was 0.991. This indicates that nursing costs were virtually 
behaving as a fixed cost. 
Details of medical staffing levels on the ICU were obtained from Clinical 
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Directors. Medical staff costs were obtained from finance departments 
(see Appendix 6.4). Total medical costs were derived for each contra and 
allocated to each patient according to their length of stay on the ICU. 
Medical costs per patient day were £132 at LTH and £124 at DGH. 
6.4.2.3 Variable Costs 
The resource use associated with each patient was recorded as described 
in section 6.3.2. Acquisition of costs attached to each area of resource 
use is described in this section. The areas of resource use costed were 
pathology, radiology, drugs and nutrition, monitoring and interventions 
whilst on the ICU. 
6.4.2.3.1 Pathology Tests (Chemical pathology, haematology, 
microbiology) 
At both centres, pathology departments provided components and sources 
of costs. This involved annuitised and discounted fixed costs being 
combined with variable and staff costs to combine an overall cost for the 
financial year 1994/95. Costs of blood products provided included the 
acquisition cost only. Costs of 48 chemical pathology, 17 haematology 
(and 4 blood products) and 29 microbiology tests were obtained from LTH 
and 30 chemical pathology, 9 haematology (and 4 blood products) and 23 
microbiology tests were obtained from DGH. 
6.4.2.3.2 Radiology Tests 
Radiology departments provide a range of imaging services from 'X-rays' of 
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all parts of the body, to ultrasound examinations of internal organs, 
computerised tomography (CT) scans of the head and spine, magnetic 
resonance imaging (MRI) scans of the head and body. Due to their 
immobile and unstable condition, ICU patients are not able to be 
transported to the department so the radiology department uses portable 
machines to provide X-rays and ultrasound scans on the ICU. The 
radiology department also provided the sources and components of the 
costs of their tests. This involved annuitised and discounted fixed costs 
being combined with variable and staff costs to combine an overall cost for 
the financial year 1994/95. Costs of 38 radiology investigations were 
obtained for LTH and 12 for DGH. 
6.4.2.3.3 Drugs and Nutrition 
The pharmacy department provides drugs and nutritional products to ICU at 
both centres. Only acquisition costs of products were available from the 
pharmacy department. It was necessary to construct costs of doses by 
including the acquisition cost of the drug with a pharmacy overhead cost 
and costs of disposables required to prepare the drug for administration. 
Pharmacy annual running costs excluding drugs costs were obtained from 
the finance department. The pharmacy overhead cost per individually 
dispensed item was derived as £1.10 at LTH and £1.48 for DGH. Details 
of intravenous fluids and disposables required to prepare the drug for 
administration were obtained from hospital policies, observation and 
interview with nursing and pharmacy staff. Appendix 6.5 details the 
derivation of the overhead cost and provides illustrations of drug cost 
breakdowns. Costs for 200 drugs (antibiotics, cardiac drugs, respiratory 
drugs, sedatives, plasma expanders and miscellaneous other drugs) and 
nutrition products were constructed in this way for both centres. 
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6.4.2.3.4 Monitoring and Interventions on ICU 
Information regarding resource use associated with respiratory therapy, 
physiotherapy, line and drain insertion and maintenance, use of special 
beds, renal replacement, patient monitoring and other interventions such as 
post mortem care was obtained by observation and interview. Costs 
associated with resource use were obtained from the NHS supplies 
catalogue, supplies department, central sterile supplies department, 
physiotherapy department and individual contract arrangements. All costs 
were obtained for the financial year 1994/95 and included V. A. T. 
Appendix 6.6 details the interventions for which resource use details were 
obtained, sources of costs and illustrations of cost construction for 
interventions. 
These costs were attached to the resource use recorded for each patient, 
to derive total patient costs and cost per patient day. 
6.4.3 Individual Patient Resource Use and Costs 
This section reports the values for the cost parameters previously outlined 
in section 6.2.1 for the patient groups at each centre. The mean, median 
and 95% confidence intervals for total costs, total variable costs, length of 
ICU stay, total cost per patient day and variable cost per patient day are 
reported. The constituents of total costs are reported. The frequency 
distribution of the cost parameters is reported and the relationship between 
total costs and length of ICU stay is demonstrated. 
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6.4.3.1 Summary of Results for All Eligible First Admissions 
The mean total cost, variable cost, total cost and variable cost per patient 
day and length of ICU stay of eligible first admissions is reported in Table 
6.8. LTH has a higher mean cost per patient and a much higher variable 
cost per patient than DGH. The mean length of ICU stay is similar for the 
two centres. This results in the cost per patient day and variable cost per 
patient day being higher at LTH than at DGH. The mean total cost per 
patient day at LTH derived in this study correlates closely with the top- 
down patient day cost supplied by the LTH finance department for the 
financial year 1994/95 of £1100. This information was not available at 
DGH. At both centres, the distribution of total cost, variable cost per 
patient and length of stay is heavily skewed by high cost outliers, as 
indicated by the differences between median and mean. This non-normal 
distribution of these parameters is illustrated in Figures 6.1 and 6.2. 
Variable cost per patient showed a similar distribution to total cost per 
patient as illustrated in Figure 6.1. Cost per patient day is much more 
normally distributed, suggesting a relatively constant treatment intensity 
between patients. This is illustrated in Figure 6.3. Variable cost per 
patient day shows a similar distribution. The plots in Figures 6.1 and 6.2 
suggest that total patient costs are highly correlated with length of ICU 
stay. At LTH, total costs and variable costs per patient are highly 
correlated with ICU length of stay (Spearman p =0.983,0.946 
respectively). This close relationship is illustrated by the scatter plots in 
Figure 6.4. The linear fit to the observed data shows a very close 
relationship, even at the longer lengths of ICU stay. At DGH, total costs 
and variable costs per patient were less closely correlated with ICU length 
of stay (p=0.551,0.543 respectively). This lower level of correlation is 
illustrated by the scatter plots and linear fit in Figure 6.5. The reasons for 
this difference in relationship are discussed in section 6.5.3. 
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Table 6.8 Cost per Patient, Length of ICU Stay and Cost per Patient/day 
of All Eligible First Admissions 
Cost parameter: Mean DGH/£ LTH/£ 
(95% Cl of mean, 
range, median) 
Total cost per patient 5204.9 7288.2 
(3820.9-6588.9, (5766.8-8809.6, 
332.3-59288.4, 316.2-82053.7, 
1836.7) 2746.3) 
Variable cost per patient 1729.6 3304.5 
(1173.5-2285.7, (2602.5-4006.5, 
49.8-28144.6, 101.1-39017.2, 
532.5) 1276.9) 
Length of ICU stay 5.36 6.83 
(4.03-6.69, (5.44-8.22, 
0.33-48.73, 0.44-66.45, 
2.04) 2.80) 
Total cost per patient 945.6 1099.2 
day' (911.8-979.4, (1050.2-1148.2, 
681.6-1728.7, 643.2-3021.6, 
888.0) 1003.2) 
Variable cost per patient 307.2 520.8 
day' (273.4-341.0, (475.7-565.9, 
42.48-1089.6, 157.0-2170.6, 
248.2) 430.8) 
'Costs per patient hour were calculated, and then converted to a cost per patient day. 
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Figure 6.1 Frequency Distribution of Total ICU Patient Cost (Eligible First 
Admissions at LTH and DGH) 
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Figure 6.2 Frequency Distribution of ICU Patient Length of ICU Stay 
(Eligible First Admissions at L TH and D GH) 
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Figure 6.3 Frequency Distribution of ICU Patient Cost per Patient Day 
(Eligible First Admissions at L TH and DGH) 
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Figure 6.4 Relationship of Total Patient Cost with Length of ICU Stay 
(Eligible First Admissions at L TH) 
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Figure 6.5 Relationship of Total Patient Cost with Length of ICU Stay 
(Eligible First Admissions at D GH) 
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The components of total patient costs is reported in Table 6.9. The 
increased total patient cost at LTH is due to an increased nursing, medical 
and variable cost. Most areas of variable cost are higher at LTH. The five 
principal areas of variable cost that appear to contribute to higher costs at 
LTH are use of blood products and drugs, radiology, physiotherapy and the 
use of special beds. Reasons for this are discussed in section 6.5.3. 
Table 6.9 Components of Total Patient Costs (Eligible First Admissions) 
Cost component Cost at DGH/£ (%) Cost at LTH/£ (%) 
Fixed overheads 993.1 (19.1) 880.7 (12.1) 
Staff: 
Nursing 1807.5 (34.7) 2202.6 (30.2) 
Medical 674.7 (13.0) 900.5 (12.4) 
Variable Total 1729.6 (33.2) 3304.5 (45.3) 
Blood products 426.6 (8.2) 991.9 (13.6) 
Drugs 459.6 (8.8) 626.2 (8.9) 
Radiology 72.5 (1.4) 453.2 (6.2) 
Physiotherapy 179.3 (3.4) 309.2 (4.2) 
Respiratory therapy 160.6 (3.1) 158.0 (2.2) 
Haematology 69.7 (1.3) 141.1 (1.9) 
Special beds 0 (0) 129.1 (1.8) 
Renal therapy 89.8 (1.7) 133.5 (1.8) 
Microbiology 41.5 (0.8) 98.4 (1.4) 
Chemical pathology 65.9 (1.3) 100.4 (1.4) 
Lines 54.0 (1.0) 84.7 (1.2) 
Monitoring 17.4 (0.3) 34.8 (0.5) 
Nutrition 88.6 (1.7) 20.2 (0.3) 
Drains 2.1 (0.1) 20.6 (0.3) 
Other events 1.9 (0.1) 3.0 (0.0) 
Total 5204.9 7288.2 
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6.4.3.2 Epidemiological and Economic Parameters of Patients Suitable for 
SDD at the Two Centres 
This section summarises the epidemiological and economic cost parameters 
of the patient groups hypothetically considered suitable for SOD at both 
centres. In the economic analysis of SDD, ventilated admissions from the 
two study centres are the hypothetical target patient groups. This 
constitutes 80.7% LTH ICU admissions and 60.5% DGH ICU admissions. 
The parameters required for this group for use in economic analysis of SOD 
are ICU-acquired pneumonia and late-onset Gram-negative pneumonia 
rates, ICU, hospital and six-month mortality; length of ICU stay; total cost; 
total variable cost; total cost per patient day; and variable cost per patient 
day. Table 6.10 outlines these parameters. At both centres, ventilated 
admissions are observed to have a longer ICU stay, higher cost, higher 
pneumonia rate and higher mortality than the general ICU population. This 
may be attributable to their ventilation status, or more likely to factors 
leading them to be ventilated. 
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Table 6.10 Ventilated Patient Characteristics (First Admission Only) 
Patient characteristic DGH (n-89) LTH (n=171) 
Mean Age (range) 62.6 59.9 
(18.0-90.8) (15.2-89,2) 
ICU length of stay' 6.44 7.18 
(4.54-8.34, (5.55-8.81, 
0.33-48.73) 0.44-66.45) 
Hospital length of stay' 21.9 36.2 
(17.1-26.7,0.4-126.0) (29.1-43.3,1-271) 
Episodes of ICU acquired 0.22 0.64 
pneumonia per patient' (0.10-0.34,0-2.00) (0.50-0.78,0-5.00) 
Episodes of Gram negative 0.13 0.32 
late onset pneumonia per (0.06-0.20, (0.23-0.41, 
patient' 0-2.00) 0-3.00) 
Total cost per patient/£' 6792 7715 
(4810-8774, (5942-9488, 
344-59288)2 349-82054)' 
Total variable cost/£' 2337 3510 
(1921-2753, (2688-4332, 
117-28145)4 105-39018)6 
Total cost per patient day/£' 965.8 1122.7 
(924.8-1006.8, (1067.3-1178.2, 
758.4-1728.7) 683.5-3021.4) 
Variable cost per patient 362.4 489.6 
day/£' (321.4-403.4, (437.5-541.7, 
119.3-1092.0) 159.8-2327.5) 
% ICU mortality 18.0 26.9 
% Hospital mortality 38.2 41.6 
%6 month mortality 40.7 50.3 
' Mean, 95% Cl of mean, range; I Total cost for this group: £604488 
3 Total cost for this group: £1319214; "Total variable cost for this group: £207993 
Total variable cost for this group: £600210 
6.5 DISCUSSION OF STUDY RESULTS 
The primary objective of this study was to obtain a dataset for use in a 
primary economic analysis. This dataset has four components: patient 
characteristics, patient costs, infection rates and patient outcomes. This 
discussion examines to what extent this was achieved by this study, 
limitations in the methods used and the confidence with which these 
results can be used in a primary economic analysis. 
6.5.1 Overall Study Design 
The two centres selected for the study provided epidemiological and 
economic information for two different ICU environments. The study 
design was the same for both centres, with a few small methodological 
changes, discussed below. Patient consent was not a problem at either 
centre. However, the patient group at DGH was much smaller than 
anticipated due to a sharp reduction in surgery during the summer of 1994. 
This may have an impact on the conclusions that can be derived from this 
smaller dataset. 
6.5.2 Patient Characteristics 
The patient population was characterised at both study centres. This 
information was required to identify a hypothetical group at both centres 
appropriate for SDD therapy. This was carried out by collecting 
information on the patients' previous and current health status, the primary 
reason for admission to ICU and other patient-specific information 
considered relevant. The limitations to the data collected arose mainly 
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from omissions from the patients' medical histories. APACHE scoring at 
LTH was done by the same senior clinician through the research period, 
whereas at DGH, it was carried out by a range of junior and senior 
clinicians. This may have had an impact on the precision of the scores 
obtained. When compared with published evidence, the patient 
populations at the two centres reflect that of British adult mixed 
(surgical/medical) ICUs. This means that any conclusions drawn from this 
population are more likely to be generalizable to other district general and 
large teaching hospitals. 
6.5.3 Resource Use and Cost Data 
Individual patient costs were derived by recording individual patient 
resource use and attaching costs to those data. Fixed costs were allocated 
on a cost per patient day basis. Both centres were able to provide 
information on ICU and hospital overheads and their allocation methods. 
There were some differences in the components of the fixed costs at the 
two centres, but they are still comparable, although the costs supplied by 
the two centres had to be taken at 'face value'. The fixed cost per patient 
day was lower at LTH. This is possibly a reflection of a larger ICU with 
more patients leading to economies of scale. Medical costs were higher at 
LTH, possibly due to the dedicated nature of medical staffing. 
Nursing costs were lower and fluctuated less per patient day through the 
study period at LTH (Table 6.6). This indicates closer tailoring of nursing 
requirements to patient occupancy than at DGH. The use of ICS 
dependency scoring at LTH allowed more accurate allocation of nursing 
costs to patients on the basis of their nursing dependency. However, this 
scoring system is relatively crude and subjective, and does not provide 
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greatly enhanced information. This is illustrated by the fact that nursing 
costs at LTH tended to behave as fixed costs. 
Variable patient costs were obtained by recording all interventions and 
monitoring undergone by the patient during their ICU stay, and attaching 
costs to that resource use. Recording of resource use was much more 
straightforward at LTH as most interventions and monitoring had 
computerized records. At DGH, written reports inserted into the patient 
notes had to be relied upon. It was expected that the retrieval of variable 
resource use would be decreased because of this. Attaching costs to 
resource use was relatively straightforward at both centres. All clinical 
support departments were willing to provide current costs for their 
services, with details of sources and components. As far as could be 
determined, pathology and radiology departments at both centres used very 
similar costing methods. Centre-specific information on resource use 
associated with interventions, such as intubation, was obtained by 
observation and interview. Most ICU procedures required very similar 
levels of resources for interventions at the two centres. The acquisition 
costs of resources used also did not differ greatly because the two centres 
used the same NHS supplies division. This demonstrates that the 
difference in variable costs between the two centres was due to 
differences in treatment intensity, rather than variation in costs. 
Both centres had a similar distribution of total patient and variable patient 
cost. At both centres, the distribution of costs was highly skewed, with 
some very high cost outliers. This distribution was also observed in the 
length of stay. At both centres, length of ICU stay correlated strongly with 
patient costs. The correlation was stronger at LTH. The lower correlation 
of length of ICU stay with total cost and variable cost at DGH can be 
attributed to two reasons. The first is that the methods used failed to pick 
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up all variable costs incurred by the patients, as suggested above. The 
second is that the ICU is less resource intensive than LTH. If there is less 
routine monitoring and intervention on a daily basis, then overall variable 
costs will be lower. Also, rather than carrying out interventions and 
monitoring on an anticipatory basis, it is suggested that DGH is more 
reactive in its approach. This would lead to bursts of high resource use 
consumption rather than a continuous high level. Chapter Seven examines 
whether the lack of correlation between length of ICU stay and variable 
cost at DGH is due to this, or to flaws in the data collected. A higher 
mean variable cost per patient reported at LTH and a very high correlation 
between length of stay and cost suggests that there is a higher level of 
routine monitoring and intervention. 
Examination of the differences in components of variable costs between 
the two centres shows that they are increased in most areas at LTH, 
indicating a higher level of intervention in general. This difference between 
a district general hospital and a London teaching hospital could be 
expected. The five principal areas of increased variable cost are blood 
products, drugs, special beds, radiology and physiotherapy. Increased use 
of blood products may be attributable to cultural practice differences or the 
larger proportions of trauma and general surgery carried out at LTH. The 
increased drug use probably reflects overall increased therapeutic intensity, 
but may also be affected by the large amounts of sedatives and 
anaesthetics used in neurosurgical patients. The use of special beds is 
probably partly cultural, but also due to the high numbers of neurosurgery 
patients at LTH. The presence of a CT scanner at LTH, combined with the 
neurosurgical intake, is likely to account for the increased radiology costs. 
Increased physiotherapy costs may be due to increased levels of treatment 
or more reliable methods of recording. Reasons for variation in costs are 
examined statistically in Chapter Seven. The problems associated with 
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collecting these variable costs at DGH, combined with the smaller patient 
group, is expected to affect the analysis of factors causing variation in 
these costs. 
6.5.4 Infection Rates 
Infection rates were collected at both centres to obtain information on ICU- 
acquired pneumonia and Gram-negative late-onset pneumonia rates. The 
rates reported from the two centres are very different. The much higher 
rate at LTH may be due to many factors. The environment of a large 
surgical ICU is reported to increase infection rates [George of a/, 19931. 
Also, there may be less stringent infection control procedures at LTH, 
leading to more cross-infection. An alternative explanation is the increased 
microbiological monitoring and chest X-rays at LTH leading to more 
pneumonias being detected or suspected. Pneumonias suspected on the 
basis of clinical criteria are included in the reported infection rates and 
associated analysis because pneumonia is difficult to diagnose using 
microbiological cultures, as discussed in Chapter Three. Therefore, the 
pneumonia rate at LTH may possibly be artificially high due to over- 
diagnosis and that at DGH may be artificially low, due to under-diagnosis. 
The cost attributable to ICU-acquired pneumonia is investigated in Chapter 
Seven. 
At both centres, over half of microbiologically confirmed late-onset 
pneumonias are Gram-negative. This is the infection rate that would 
theoretically be reduced by the use of SDD, so is essential for the 
economic analysis in Chapter Eight. The large difference in this pneumonia 
rate is expected to significantly affect the overall impact of SDD. 
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6.5.5 Patient Outcomes 
The only patient outcomes recorded by this study are ICU, hospital and six 
month mortality. No information has been obtained on morbidity or long 
term mortality, due to time restrictions. As discussed in section 6.3.4, six 
month mortality is the most useful short term mortality measure. The 
reasons for the higher mortality at LTH, and whether this can be attributed 
to the higher ICU-acquired pneumonia rate, is examined in Chapter Seven. 
6.5.6 Patients Suitable for SDD Therapy 
The final objective of this study was to identify a patient group at both 
centres that would have been suitable for SDD, if it were implemented at 
either centre. Published evidence reviewed in Chapter Three suggests 
ventilated ICU admissions are those most likely to benefit from SDD. 
Therefore, the ventilated admissions to LTH and DGH were quantified and 
characterised in terms of defined cost parameters, infection rates and 
outcomes. A group of only 89 patients was identified at DGH, compared 
with 171 at LTH. These patient groups are examined in Chapter Seven to 
assess the impact of pneumonia on resource use and six month mortality. 
They are then used in Chapter Eight as two groups of patients modelled to 
receive SDD. 
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6.6 CONCLUSIONS 
The aim of this study was to provide improved economic evidence for the 
impact of ICU-acquired pneumonia. The cost data obtained are bottom-up, 
current and practice-based. The sources and components of the costs are 
explicitly outlined. The discussion above has shown that the resource use 
and cost collection methods used were as robust as possible. Given the 
limitations described in the discussion, the costs reported for the patients 
in this study approximate as closely to their true economic cost (to the 
intensive care unit) as methodological limitations allow. The stochastic 
nature of the data means that statistical analysis can be applied to it to 
identify the resource use attributable to ICU-acquired pneumonia, rather 
than 'matched pairs' as discussed in Chapter Three. Therefore, it is 
concluded that these data fulfil the recommendations outlined in Chapter 
Two. 
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Chapter 7: Identifying Cost Associated with ICU-Acquired 
Pneumonia 
7.1 INTRODUCTION 
Chapter Six has described a prospective study to collect primary economic 
and epidemiological data on two British ICUs. This chapter describes the 
analysis of these two datasets to determine the cost and mortality 
attributable to ICU-acquired pneumonia. The analysis reported in this 
chapter investigates whether any of the variation in cost observed in this 
study can be attributed to pneumonia. Variable costs are the cost 
components that would be expected to vary with pneumonia incidence. 
Length of ICU stay was shown in Chapter Six to be closely correlated with 
total variable cost, especially at LTH. Therefore, knowledge of the factors 
that cause increase in length of ICU stay ultimately provides information on 
variation in cost. Investigation of variable cost per patient day allows 
investigation of factors affecting treatment intensity. So, the three cost 
parameters investigated are total patient variable cost, length of ICU stay 
and variable cost per patient day. Section 7.2 outlines the specific 
objectives of the analysis. Section 7.3 provides the theoretical background 
for the statistical method used. Analysis of the two datasets is reported. 
The factors affecting the three cost parameters are reported, including the 
impact of ICU-acquired pneumonia. The subgroups of ventilated 
admissions at each centre and the impact of ICU-acquired pneumonia on 
cost in these patients is examined separately. The derivation of increased 
length of ICU stay and variable cost per patient day attributable to 
pneumonia is also described. Section 7.4 reports a logit regression analysis 
to determine whether ICU-acquired pneumonia can explain the difference in 
236 
mortality between the two centres. The reasons for selection of the 
method and its theoretical basis are outlined. The impact of ICU-acquired 
pneumonia on ventilated admissions is examined. Whether the centre has 
an independent effect on six month mortality is also examined. Finally, 
section 7.5 summarises the results of the analyses and discusses their 
application in the economic analysis of SDD. 
7.2 AIMS AND OBJECTIVES OF ANALYSIS 
The aim of this analysis is to identify changes in defined cost parameters 
attributable to ICU-acquired pneumonia both in the general ICU population 
and in ventilated admissions at DGH and LTH. The specific objectives are 
to: 
1. determine what factors affect total variable cost, length of ICU stay and 
variable cost per patient day at both centres; 
2. determine whether ICU-acquired pneumonia affects these cost 
parameters, and to what extent, at both centres; 
3. derive the increased length of ICU stay and variable cost per patient day 
attributable to pneumonia; 
4. determine what factors affect six month mortality at both centre and 
5. determine whether the higher ICU-acquired pneumonia rate at LTH 
contributes to the higher six month mortality at LTH. 
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7.3 STATISTICAL ANALYSIS TO IDENTIFY COST DUE TO PNEUMONIA 
This section describes the statistical analysis to identify cost due to ICU- 
acquired pneumonia at the two centres. The theoretical basis of the 
statistical method selected is outlined. The application of this method to 
the two datasets is reported. Factors associated with total variable cost, 
length of ICU stay and variable cost per patient day are elucidated. The 
extent to which ICU-acquired pneumonia affects these three parameters is 
investigated. The models derived are then applied to the ventilated 
patients subgroups. The impact of ICU-acquired pneumonia on the three 
cost parameters in these patients is elucidated. Finally, the evidence 
derived from this analysis necessary for economic analysis is summarised. 
7.3.1 Selection of Analysis Method 
This section discusses the selection of the analysis method. Changes in 
cost parameters due to ICU-acquired pneumonia are under investigation. 
Other factors (covariates) influencing cost parameters must be identified 
and controlled for. Covariates selected are those previously reported in the 
literature to be significant, including patient admission characteristics and 
events occurring on ICU. To characterise the association of covariates 
with one another and with cost parameters, it is necessary to statistically 
adjust the estimated effects of each covariate for different associations 
with, and distributions of, the other covariates using linear multiple 
regression. Covariates remaining significant in a multiple regression model 
are considered independently related to cost, controlling for all other 
covariates. 
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7.3.2 Summary of Linear Regression Analysis Method Used 
Multiple linear regression allows identification of the impact of one 
independent variable on a continuous dependent variable, whilst controlling 
for the effects of other variables (covariates). This produces a linear 
regression model, containing all significant independent covariates. This 
section outlines the analysis methods used to derive regression models for 
the cost parameters listed above. 
The cost parameters are expected to be influenced by several independent 
factors, in the relationship defined in equation 7.1, where y represents the 
cost parameter. 
y= Qo + ß1x1 + Q2x2 + ... +ßx, [7.1; Sandy, 19901 
In this analysis, ordinary least squares (OLS) linear regression is used to 
identify the intercept Qo, estimates of the parameters (coefficients) ß,, 
, ß2... ß; of independent covariates x,, x2.... x,, and the error or variation 
associated with the estimators. Independent and dependent variables may 
be transformed to improve relationships, such as log transformation. Log 
transformation may be appropriate because of the skewed nature of the 
dependent variable (y). Multicollinearity exists where there is a relationship 
between independent variables and is often present in observational data. 
If it exists, the coefficients and explanatory power of the model stay the 
same, but the variances are increased. This is because there is not enough 
independent variation in the variable to calculate with confidence the effect 
it has on the dependent variable [Kennedy, 19931. This decreases the 
power of hypothesis testing. 
Multicollinearity can be identified using correlation coefficients (p). P, 
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however, only identifies two dimensional interaction. Variance inflation 
factors, VIF,, are derived from the inverse of the correlation matrix and are 
given by (1-R2, )''. A high VIF indicates an R2, near unity and hence 
suggests collinearity. As a 'rule of thumb', a VIF, > 10 indicates harmful 
collinearity [Studenmund, 19921. Multicollinearity can be handled by 
grouping interacting covariates to form composite variables. An example is 
'infection on admission' and 'neurosurgical patient' becoming 
'neurosurgical patient infected on admission'. 
To assess the goodness of fit of the model, the sample coefficient of 
multiple determination, R2 is used. The 'adjusted' R2, ßi2, adjusts for the 
number of covariates used in the regression model. A2 of one indicates a 
perfect fit. An A2 of 0.69 is interpreted such that 69% of variation in the 
data is explained by the model. 
The robustness of the model is decreased by the presence of observations 
that have a disturbing influence on the estimates. Detection of outliers 
(points unusually far from the regression line or bulk of the data) is 
necessary to check for measurement error. Outliers are not always 
influential, so it is also necessary to test for individual observation 
influence. 
An assumption of the OLS procedure is that the error term has a constant 
variance, that is, it is homoskedastic. Violation of this assumption is 
common in cross-sectional models. The presence of heteroskedasticity 
does not change the estimators, just their variance, usually by decreasing it 
and thus making the model appear more robust than it really is 
[Studenmund, 1992]. It is necessary to test for heteroskedasticity of the 
final model. This analysis uses the White test [Studenmund, 19921. This 
test derives a test statistic with a Chi-squared () distribution. If this 
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statistic is larger than the critical value for the degrees of freedom 
associated with the model, then the null hypothesis is rejected (XI, 
p<0.05) and the conclusion is that the model is heteroskedastic. 
7.3.3 Linear Regression Analysis of LTH Dataset 
This section outlines the linear regression analysis carried out on the LTH 
dataset to identify independent predictors of the three cost parameters. 
Firstly, the covariates listed in Tables 7.1 a and 7.1 b were investigated 
individually to assess their unadjusted effect on the three cost parameters. 
Table 7.1 a reports patient admission characteristics that may affect the 
three cost parameters. Table 7.1b reports recorded events occurring on 
ICU that may have an impact on the three cost parameters. Three 
covariates recorded are proxies for organ failure: requirement of dialysis on 
ICU indicates acute renal failure; requirement of ventilation whilst on ICU 
indicates acute respiratory failure; requirement of invasive cardiac 
monitoring by a pulmonary artery catheter (P. A. catheter) indicates acute 
cardiac failure. 
From the initial analysis summarised in Tables 7.1 a and 7.1 b it can be seen 
that some covariates exert their effect on total variable cost through the 
length of ICU stay (such as surgical categories). Some covariates exert 
their effect on cost per patient day (such as APACHE score). Other 
covariates have an effect on both length of ICU stay and on treatment 
intensity, such as dialysis on the ICU. ICU-acquired pneumonia increases 
total variable cost per patient by increasing length of ICU stay and variable 
cost per patient day (Table 7.1 b). This reported effect is not adjusted by 
the effects of other covariates. Serious infections acquired on ICU have a 
marginally significant effect on variable cost. 
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Many of the covariates2 significantly affect one another, as shown in Table 
7.1 b. Many of them are related to the occurrence of pneumonia. For 
example, the number of days ventilated correlates closely with number of 
days with a pneumonia (p=0.794, p=0.0001). Number of days PA 
catheterised correlates closely with number of days with a pneumonia 
(p=0.606, p =0.0001). Number of days dialysed correlates with number 
of days with a pneumonia (p=0.501, p=0.0001). This demonstrates the 
necessity for controlling for these confounding effects by the use of 
multiple regression techniques, reported in the next three sections. 
2Covariate Abbreviations and Definitions 
CANCER: Active cancer present at the start of this hospital episode 
ELECT: Planned admission to ICU following planned hospital admission/surgery 
CPR: Cardiopulmonary resuscitation leading to this ICU admission 
CHRONIC: Presence of serious chronic health condition (as defined in APACHE II 
score) 
CARDIAC: Presence of serious chronic cardiac condition (as defined in APACHE II 
score) 
HOSPLOS: Length of hospital stay 
IATRO: Unexpected event, other than CPR, occurring immediately prior to ICU 
admission, such as haemorrhage or fitting. 
ICULOS: Length of ICU stay 
VENT: Ventilated on admission to ICU 
MEDICAL: Has not undergone surgery 
NEURO: Has undergone neurosurgery 
GENERAL: Has undergone general surgery 
TRAUMA: Has undergone multiple surgery for trauma 
VASCULAR: Has undergone vascular surgery 
OTHER: Has undergone atypical surgery (see section 6.2) 
INFECT: Infected on admission to ICU. 
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Table 7.1 a Individual Analysis of Patient Admission Characteristics as 
Predictors of The Three Cost Parameters (LTH) 
Predicting factor p (Total variable 
cost) 
p (Variable cost per 
patient day) 
p (ICU LOS) 
Sex (MALE) ns 0.0161 t ns 
CANCER 0.02184 <0.00005 t ns 
ELECT 0.00044 ns ns 
CPR ns 0.0165 t ns 
IATRO 0.0844 t 0.0055 t ns 
INFECT 0.0004 t ns 0.0063 t 
Age' ns ns ns 
APACHE II' 0.0557 t 0.0010t4 ns 
CHRONIC ns ns ns 
CARDIAC <0.00005 t 0.02774 <0.00005 t 
VENT 0.0098 t ns 0.0539 t 
NEURO2 <0.00005 4 0.0016 4 <0.00005 4 
GENERAL' ns 0.0957 t ns 
VASCULAR2 0.0037 4 0.0101 t 0.0357 4 
TRAUMA2 0.0001 t ns 0.0094 t 
OTHER2 ns 0.0297 4 0.0695 
' Correlation test. All other significance tests: t-test 
2 Significance compared with 'medical' category 
3 p=0.278 (significant, p<0.01) 
`p=0.227 (significant, p<0.01) 
t Cost parameter increases in presence of risk factor 
& Cost parameter decreases in presence of risk factor 
Table 7.1b Individual Analysis of Relationship of Events on ICU with The 
Three Cost Parameters (LTH) 
Predicting factor p (Total 
variable 
cost) 
p (Variable 
cost per 
patient day) 
p (ICULOS) 
Ventilated during ICU stay 0.008 t 0.013 t 0.0095 t' 
Dialysed during ICU stay 0.0001 t 0.0001 t 0.0001 t2 
PA catheter during ICU stay 0.0001 t 0.0002 t 0.0001 t3 
Serious infection during ICU stay 0.1069 t ns ns 
Pneumonia during ICU stay 0.0060 t <0.00005 t 0.0081 t' 
ICU survival 0.00141 <0.00005 4 ns 
'Number of days ventilated correlated closely with ICU length of stay (p=0.934, 
P=0.0001). 
2Number of days dialysed correlated closely with ICU length of stay (p =0.701, 
P=0.0001) 
3Number of days with a pulmonary catheter in situ correlated closely with ICU length of 
stay (p=0.788, p=0.0001) 
`Number of days with a pneumonia correlated closely with ICU length of stay (p = 0.899, 
P=0.0001) 
t Cost parameter increases in presence of risk factor 
4 Cost parameter decreases in presence of risk factor 
7.3.3.1 Linear Regression Analysis of Total Variable Cost per Patient at 
LTH 
This section reports the linear regression analysis of factors affecting total 
variable cost per patient at LTH. OLS regression was used to develop a 
linear regression model, using the methods described in section 7.3.2. 
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Initially, a correlation matrix was derived for all the covariatos in the 
analysis. This detected the extent of two-dimensional interaction between 
the covariates. Marginally significant multicollinearity (n = 212, critical 
p=0.164, p=0.05) was detected between many combinations of 
covariates. Interacting combinations of covariates that produced 
independently significant combinations were OTHER (surgery) and 
IATRO(genic event), and ICU mortality and APACHE. The first combination 
indicates that iatrogenic events, other than CPR, occurring in surgery only 
have a significant effect on total variable cost when the patient has 
undergone atypical surgery. The second combination suggests that 
severity of illness is only associated with an increase in total variable cost 
in patients who do not survive ICU. All the variance inflation factors (VIFs) 
in the final model were less than 1.5. Heteroskedasticity was not a 
problem in the untransformed model (White test; p=0.1412 [Studenmund 
1992]). The intercept and coefficients of independently significant 
covariates are reported in the model derived in Table 7.2. 
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Table 7.2 Regression Model for Explaining Total Variable Cost per Patient 
at LTH 
Source Estimate 
(ß) 
Standard 
error of Q 
T for Ho' P> IT 
Intercept (ß0) -652.2 228.0 -2.861 0.0047 
CHRONIC -415.06 210.7 -1.965 0.0551 
APACHE ICU mortality 
composite 2 
68.2 12.0 5.695 0.0001 
OTHER/IATRO composite 3 409.2 198.0 2.066 0.0401 
ICU length of stay 475.6 10.6 45.002 0.0001 
VASCULAR surgery 1079.7 303.2 3.562 0.0005 
GENERAL surgery 792.3 276.7 2.864 0.0046 
TRAUMA surgery 1406.4 527.1 2.668 0.0083 
' Null Hypothesis: Parameter= 0 
Z Composite = APACHE x ICU mortality 
Composite = Other surgery x latrogenic event 
The A' of the model was 0.911 (F = 301.18, p=0.0001), indicating that 
the model explains 91.1 % of the variation in total variable cost per patient. 
Twelve outliers were identified but when tested for influence, were not 
found to cause significant disturbance in the model. Most explanatory 
power comes from ICU length of stay (p=0.948). This model suggests 
that the presence of chronic illness decreases the total variable cost of the 
patient. Admissions from vascular, general and trauma surgery increase 
variable cost significantly over medical patients. Neurosurgery patients do 
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not have a significantly larger total variable cost than medical patients, 
once the other factors in the model are taken into account, so are lost from 
the model. If the patient is dialysed on ICU, there is a significant impact on 
total variable cost. However, there was significant correlation between 
dialysis occurring on ICU with length of ICU stay (p=0.41). This 
interaction significantly increases the error estimates of coefficients for 
both covariates. This implies that dialysis on ICU increases length of ICU 
stay and increases the intensity of treatment whilst on ICU, as 
demonstrated in the individual analysis. Because of this joint effect, this 
factor cannot be included in a model that contains length of stay, due to 
the interaction. Removing the dialysis covariate did not greatly affect 
explanatory power. However, the interaction suggests that examination of 
length of ICU stay separately from treatment intensity is necessary to 
control for factors that impact on both components of total variable cost. 
Moreover, ICU-acquired pneumonia and insertion of a PA catheter are not 
shown to have a significant effect on total variable cost. However, they 
have both been shown to individually affect ICU length of stay. This 
analysis demonstrates, therefore, that it is necessary to examine the two 
components of total variable cost separately, that is, build regression 
models for ICU length of stay and variable cost per patient day separately. 
Isolation of the effect of dialysis, pneumonia and PA catheters on length of 
ICU stay and treatment intensity, as well as the other covariates, is 
examined in the next two models. 
If ICU-acquired pneumonia is included in the model derived above, it has a 
marginally significant impact on total variable cost (Q= £432.4,95% Cl = 
£0 - £924.36, p =0.0869). A2 is not affected but the model becomes 
heteroskedastic (White test; p=0.0365). In the individual analysis it is 
suggested that pneumonia exerts its effect on length of ICU stay. 
Therefore the presence of ICU stay in the model effectively controls for the 
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effect of pneumonia, explaining the non-significance of ICU-acquired 
pneumonia in this model. It is possible that a larger dataset would have 
demonstrated a significant effect. ICU-acquired serious infections other 
than pneumonia were not shown to have a significant effect. 
7.3.3.2 Linear Regression Analysis of ICU Length of Stay at LTH 
OLS regression was used to develop a linear regression model to explain 
variations in length of ICU stay. On examination of interaction, the only 
interacting combination of covariates that produced independently 
significant composites was ICU mortality and APACHE. This combination 
implies that, in patients who die on the ICU, the more severely ill they are, 
the shorter their length of ICU stay. All the variance inflation factors (VIFs) 
in the final model were less than 1.5. Heteroskedasticity was a problem in 
the untransformed model (White test; p<0.0001 [Studenmund 19921). 
Log transformation of length of ICU stay was required to render the data 
homoskedastic (White test: p=0.136). The semi-log (log-lin) model 
derived is outlined in Table 7.3. 
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Table 7.3 Regression Model for Explaining Log ICU Length of Stay at LTH 
Source Estimate 
(Al) 
Standard 
error of Q 
T for 
Ho' 
P> ITI 
Intercept (ßo) 0.484 0.082 5.894 0.0001 
APACHE ICU mortality 
composite' 
-0.001 0.0002 -5.216 0.0001 
Dialysed during stay 0.836 0.202 4.133 0.0001 
PA3 catheter during stay 0.441 0.146 3.023 0.0028 
ICU-acquired pneumonia 1.131 0.127 10.323 0.0001 
' Null hypothesis: Parameter= 0 
2 Composite = APACHE2 X ICU mortality (this composite was required to produce the 
highest A2, to ensure that the intercept was significant and to reduce interaction). 
3 PA catheter: pulmonary artery catheter inserted during ICU stay 
A2 of the model was 0.510 (F = 54.65, p =0.0001), indicating that the 
model explains 51.0% of the variation in log length of ICU stay. 
Unexplained variation may be explained by insufficient data, omission of 
explanatory covariates or complex relationships between length of stay and 
covariates not detected by this analysis. The model is interpreted such 
that the coefficients represent the percentage increase in the length of 
stay. Therefore, being dialysed whilst on ICU increases the length of stay 
by 83.6% (95% Cl: 44.1%-123.4%) and the insertion of a PA catheter is 
associated with a 44.1% (95% Cl: 15.5%-72.7%) increase in length of 
ICU stay. Ten outliers were identified but when tested for influence, were 
not found to cause significant disturbance in the semi-log model. 
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Being admitted with pneumonia was not shown to affect ICU length of 
stay. Acquiring a pneumonia whilst on ICU is associated with an 
increased length of ICU stay. In the regression model, an episode of ICU 
acquired pneumonia increases length of ICU stay by 113% (95% Cl: 
88.2%-138.0%). Serious infections other than pneumonia did not retain 
an independent effect on length of ICU stay. 
7.3.3.3 Linear Regression Analysis of Variable Cost per Patient Day at LTH 
OLS regression was used to develop a linear regression model to explain 
variations in variable cost per patient day. On examination of interaction, 
interacting combinations of covariates that produced independently 
significant composites were NEURO and INFECT, OTHER and IATRO, 
VASCULAR and AGE, ICU mortality and APACHE. These combinations can 
be interpreted such that neurosurgical patients admitted with infections; 
atypical surgery patients admitted after iatrogenic events in surgery; older 
vascular surgery patients and severely ill patients who subsequently die 
incur the greater treatment intensity. Whether the patient was dialysed or 
had 
.a 
pulmonary artery catheter were also significantly correlated with one 
another (p=0.450). All the variance inflation factors (VIFs) in the final 
model were less than 2. Heteroskedasticity was not a problem in the 
untransformed model (White test; p=0.7809 (Studenmund 19921). The 
model derived is outlined in Table 7.4. 
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Table 7.4 Regression Model for Explaining Variable Cost per Patient Day at 
LTH 
Source Estimate 
(ßr) 
Standard 
error of 
T for 
Ho' 
P> (T 
Intercept (Q0) 368.9 39.0 9.450 0.0001 
CHRONIC -100.8 42.1 -2.394 0.0176 
APACHE ICU mortality 
composite2 
0.4 0.1 3.981 0.0001 
OTHER/IATRO composite3 89.3 36.0 2.483 0.0139 
Infected neurosurgery 
patient 4 
1059.0 288.3 3.674 0.0003 
VASCULAR/AGE 
composite5 
2.0 0.7 2.616 0.0096 
GENERAL surgery 215.4 50.1 4.297 0.0001 
Dialysed or PA catheter 
during ICU' 
403.6 138.3 2.919 0.0039 
ICU-acquired pneumonia 51.0 24.1 2.119 0.0354 
Null Hypothesis: Parameter =0 
Composite = (APACHE)2 X ICU mortality 
I Composite = Other surgery x iatrogenic event 
` Composite = Neurosurgery x infected on admission 
5 Composite = Vascular surgery x age 
8 Composite = Proportion of ICU stay dialysed or pulmonary artery catheter present 
The ßi2 of the model was only 0.295 (F = 11.78, p=0.0001), indicating 
that the model only explains 29.5% of the variation in variable cost per 
patient day, or treatment intensity. This can be explained by insufficient 
data, omission of explanatory covariates or complex relationships not 
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detected by this analysis. Seven outliers were identified but when tasted 
for influence, were not found to cause significant disturbance in the model. 
Being admitted with pneumonia was not shown to affect cost per patient 
day. ICU-acquired pneumonia increases variable cost per patient day by 
£51.0 (95% Cl: £4.1-£98.2). Other serious infections were not shown to 
have a significant effect. 
7.3.3.4 Summary of Linear Regression Analysis of Cost Parameters at LTH 
In summary, this analysis demonstrates that, in all eligible first admissions 
to LTH ICU, an episode of ICU-acquired pneumonia has an independent 
effect on: 
1. length of ICU stay, increasing it by 113% (95% Cl: 88% - 138%); 
2. treatment intensity, increasing variable cost per patient/day by E51.0 
(95% Cl: £4.1 - £98.2) (10.2% increase from mean). 
7.3.3.5 Linear Regression Analysis of Factors Affecting Cost Parameters in 
Ventilated Patients at LTH ICU 
The models described above were run on ventilated admissions only 
(n =171). The R2 of the models were not at all significantly different. ICU- 
acquired pneumonia increased ICU length of stay by 116% (95% Cl: 
88.0% - 144.0%, p =0.0001). Variable cost per patient day was 
increased by £53.3 (95% Cl: 2.4 - 101.3, p=0.049). Total variable cost 
per patient was marginally significantly increased by £473.6 (95% Cl: 0- 
£1048.5, p=0.10). 
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7.3.4 Derivation of Changes In Cost Parameters Attributable to ICU- 
Acquired Pneumonia at LTH 
For economic analysis, the actual changes in resource use due to an 
episode of ICU-acquired pneumonia in a ventilated patient are required. 
From the regression analysis reported above, it is known that length of ICU 
stay is increased by 116% and variable cost per patient day is increased by 
£53.3. However, it is not known from what value the increase occurs. 
Therefore, the actual length of ICU stay and variable cost per patient day 
for ventilated patients who do and do not experience an episode of ICU- 
acquired pneumonia is not known. This section describes how these 
values can be derived from the information already known. 
It is known that the mean ICU length of stay of ventilated patients is 7.18 
days, the mean variable cost per patient day is £489.6, the incidence of 
ICU-acquired pneumonia is 0.64 episodes per ventilated patient (see Table 
6.10) and an episode increases ICU length of stay by 116% and variable 
cost per patient day by £53.3. From this it is possible to derive lengths of 
stay and variable costs per patient day for infected and uninfected 
patients3. These derived values represent the lengths of ICU stay and 
variable costs per patient day for two theoretical groups of ICU patients. 
The lengths of ICU stay and variable cost per patient day of these two 
groups have been controlled for the effects of the other factors shown to 
be significant by the regression analysis. Therefore, the only difference 
3 0.36(uninfected LOS) + 0.64(infected LOS) = 7.18, where 
infected LOS = 2.16 x uninfected LOS 
0.36(uninfected variable cost per patient/day) + 0.64(infected variable cost per 
patient/day) = £489.6, where infected cost = uninfected cost + £53.3 
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between these two groups (within the limits of this regression analysis) is 
that one group does and one group does not experience an episode of ICU- 
acquired pneumonia. The derived difference represents the difference 
independently attributable to that episode of pneumonia. The derived 
differences are reported in Table 7.5a. 
Table 7.5a also reports total costs. As the length of ICU stay is known, it 
was possible to calculate the fixed costs that are associated with that 
length of stay. The total cost per patient with and without an episode of 
ICU-acquired pneumonia is the cost parameter required for economic 
evaluation of SDD. 
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Table 7.5a Changes in Resource Use Associated with ICU-Acquired 
Pneumonia in Ventilated Patients at LTH 
Resource Use Parameter Cost/C 
Length of stay of uninfected patient/days' 4.1 
Length of stay of patient with ICU-acquired pneumonia/days' 8.9 
Variable cost per patient day for uninfected patients/£' 456.0 
Variable cost per patient day for infected patients' 508.8 
Total variable cost per uninfected patient/£2 1869.6 
Total cost per uninfected patient/£3 4198.8 
Total variable cost per patient with ICU-acquired pneumonia/£' 4528.3 
Total cost per patient with ICU-acquired pneumonia/£3 9584.4 
Increase in total cost due to ICU-acquired pneumonia/£ 5385.6 
' Derived values 
2 Value derived from derived ICU length of stay and variable cost per patient day for 
uninfected ventilated patients 
' Fixed costs (£129.1), nursing costs (mean £307.0) and medical staff costs (E132) 
added back to variable cost to give total cost per ventilated patient 
` Value derived from derived ICU length of stay and variable cost per patient day for 
infected ventilated patients 
The derived total cost for uninfected and infected ventilated patients is 
£4199 and £9584. Confidence intervals cannot be quoted because the 
variable cost per patient day used for infected and uninfected patients is a 
derived value. These derived costs per patient are used in the primary 
economic analysis in Chapter Eight. The ranges of the parameters for 
sensitivity analysis in Chapter Eight are listed in Table 7.5b. 
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Table 7.5b Ranges of Parameters Required for Economic Analysis for the 
LTH Dataset 
Parameter for Use in Economic Analysis Ranges for 
Sensitivity Analysis 
Increase in length of ICU stay due to pneumonia 88%-144% 
derived from linear regression 
Length of stay of uninfected patient/days' 3.7,4.6 
Length of stay of patient with ICU-acquired 8.7,9.2 
pneumonia/days' 
Increase in variable cost per patient/day due to 2.4-101.3 
pneumonia derived from linear regression/£ 
Variable cost per patient/day for uninfected 424.8,488.1 
patients/£Z 
Variable cost per patient/day for infected 490.5,526.1 
patients2 
' Uninfected and infected lengths of stay derived from 88% increase in length of ICU 
stay are 4.6 and 8.7 days respectively. Uninfected and infected lengths of stay derived 
from 144% increase in length of ICU stay are 3.7 and 9.2 days respectively. 
2 Uninfected and infected variable cost derived from £2.4 increase are £488.1 and 
£490.5 respectively. Uninfected and infected variable cost derived from £101.3 increase 
are £424.8 and £526.1 respectively. 
7.3.5 Linear Regression Analysis of DGH Dataset 
This section outlines the linear regression analysis carried out on the DGH 
dataset to identify independent predictors of the three cost parameters. 
Firstly, the covariates listed in Tables 7.6a and 7.6b were investigated 
individually to assess their unadjusted effect on the three cost parameters. 
Table 7.6a reports patient admission characteristics that may affect the 
three cost parameters. Table 7.6b reports recorded events occurring on 
ICU that may have an impact on the three cost parameters. Three 
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covariates recorded are proxies for organ failure (see section 7.3.3). 
From this initial analysis summarised in Tables 7.6a and 7.6b it can be soon 
that, as with the LTH dataset, covariates exert their effect on total variable 
cost through the length of ICU stay or through cost per patient day. Other 
covariates have an effect on both length of ICU stay and on treatment 
intensity. ICU-acquired pneumonia increases total variable cost per patient 
by increasing length of ICU stay. There is no detectable increase in 
variable cost per patient day (Table 7.6b). These effects are not adjusted 
for the effects of other covariates. Serious infections acquired on ICU have 
a significant effect on variable cost through their effect on length of stay. 
As 78.6% of ICU-acquired serious infections at DGH are pneumonias, it is 
likely that this reflects the effect of ICU-acquired pneumonias. 
Many of the covariates significantly affect one another, as illustrated in 
Table 7.6b. Many of them are related to the occurrence of pneumonia. 
For example, the number of days ventilated correlated closely with number 
of days with a pneumonia (p = 0.858, p=0.0001). Number of days PA 
catheterised correlated closely with number of days with a pneumonia 
(p = 0.473, p=0.0001). Number of days dialysed correlated with number 
of days with a pneumonia (p=0.535, p=0.0001). This again 
demonstrates the necessity for controlling for these confounding effects by 
the use of multiple regression techniques, reported in the next three 
sections. 
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Table 7.6a Analysis of Patient Characteristics as Predictors of The Three 
Cost Parameters (DGH) 
Predicting factor p (Total 
variable cost) 
p (Variable cost per 
patient day 
p (ICU LOS) 
Sex (MALE) 0.0107 t ns <0.00005 t 
CANCER ns ns ns 
ELECT < 0.00005 4 ns 0.03244 
CPR 0.0272 t ns ns 
IATRO 0.0380 t ns ns 
INFECT <0.00005 t 0.0202 t 0.0018 t 
Age' ns ns ns 
APACHE II' 0.01053 ns 0.0094 
CHRONIC <0.00005 t ns ns 
CARDIAC <0.0003 4 ns <0.003 4 
VENTILATED <0.00005 t ns <0.00005 t 
READMISSION ns <0.00005 t 0.0333 t 
GENERAL2 0.0048 t ns 0.0007 t 
VASCULAR2 0.0036 4 ns ns 
TRAUMA2 0.0037 4 ns 0.00264 
OTHER' 0.05664 0.0851 0.0001 4 
ICU survivor ns ns 0.0090 4 
' Correlation test. All other significance tests: t-test. 
2 Significance compared with 'medical' category 
3 p=0.223 (p<0.01) 
`p=0.228 (p<0.01) 
t Cost parameter increases in presence of risk factor 
4 Cost parameter decreases in presence of risk factor 
Table 7.6b Individual Analysis of Relationship of Events on ICU with the 
Three Cost Parameters (DGH) 
Predicting factor p (Total 
variable cost) 
p (Variable cost 
per patient day) 
p (ICULOS) 
Ventilated during ICU stay <0.00005 t 0.0832 t <0.00005 f' 
Dialysed during ICU stay <0.00005 t 0.018 t <0.00005 t2 
PA catheter during ICU stay <0.00005 t ns <0.00005 t 
Serious infection during ICU stay 0.045 t ns <0.00005 t 
Pneumonia during ICU stay <0.00005 f ns <0.00005 t` 
ICU survival ns ns 0.00904 
'Number of days ventilated correlated closely with ICU length of stay (p=0.667, 
p=0.0001). 
2Number of days dialysed correlated with ICU length of stay (p=0.538, p=0.0001) 
'Number of days with a pulmonary catheter in situ correlated with ICU length of stay 
(p=0.490, p=0.0001) 
"Number of days with a pneumonia correlated closely with ICU length of stay (p = 0.630, 
P=0.0001) 
t Cost parameter increases in presence of risk factor 
L Cost parameter decreases in presence of risk factor 
7.3.5.1 Linear Regression Analysis of Total Variable Cost per Patient at 
DGH 
This section reports the linear regression analysis of factors affecting 
variable cost per patient at DGH. OLS regression was used to develop a 
linear regression model, using the methods described in section 7.3.2. No 
interacting combinations of covariates produced independently significant 
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principal components. The A' of the model was improved if the cubs 
product of ICU length of stay was used. The model derived is outlined in 
Table 7.7. 
Table 7.7 Regression Model for Predicting Total Variable Cost per Patient 
at DGH 
Source Estimate 
(ß) 
Standard 
error of Q 
T for Ho' P> IT 
Intercept (ß0) 1545.5 865.4 1.786 0.0766 
APACHE 85.7 29.1 2.950 0.0038 
Age -30.5 13.5 -2.254 0.0260 
(ICU length of stay)3 0.17 0.02 8.280 0.0001 
VENT 926.4 444.2 2.086 0.0391 
Dialysed whilst on ICU 2005.6 876.9 2.287 0.0239 
' Null Hypothesis: Parameter=0 
The model produced had no VIF values over 1.5, so harmful 
multicollinearity was not present. The 12 was 0.531 (F=25.32, 
p=0.0001), indicating that the model explains 53.1 % of the variation in 
total variable cost per patient. However, this model is significantly 
heteroskedastic (White test: p<0.0005). Obtaining a homoskedastic 
model required the use of fewer covariates to produce the model outlined 
in Table 7.8. 
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Table 7.8 Revised Regression Model for Explaining Total Variable Cost per 
Patient at DGH 
Source Estimate 
(1011) 
Standard 
error of Qý 
T for 
Na' 
P> ITI 
Intercept (Q0) 1147.5 216.6 5.297 0.0001 
(ICU length of stay)3 0.16 0.02 8.119 0.0001 
Dialysed whilst on ICU 2288.3 911.4 2.511 0.0132 
' Null Hypothesis: Parameter =0 
The model produced had no VIF values over 1.5, so harmful 
multicollinearity was not present. The A2 was 0.464 (F = 59.8 1, 
p=0.0001), indicating that the model explains 46.4% of the variation in 
total variable cost per patient. The model has a homoskedastic error 
distribution (White test; p=0.611). Chapter Six discussed the possible 
reasons for the lack of correlation between length of ICU stay and total 
variable cost per patient at DGH. The possible reactive nature of 
therapeutic intervention at DGH leading to a different distribution in variable 
cost is not supported by this linear regression analysis. Whilst therapeutic 
interventions affect variable cost on an individual basis (see Table 7.6b), 
none apart from dialysis retain independent significance in the regression 
model. This suggests that there may be flaws in the collection of resource 
use data relating to variable cost. 
When ICU-acquired pneumonia was added to the regression model, it 
tended towards significance but did not reach it (p =0.15). 
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7.3.5.2 Linear Regression Analysis of ICU Length of Stay at DGH 
OLS regression was used to develop a linear regression model to explain 
variations in length of ICU stay. Marginally significant multicollinoarity 
(n=137, critical p=0.220, p=0.05) was detected between many 
combinations of covariates, such as AGE and APACHE. ICU mortality and 
APACHE score were the only interacting covariates to produce 
independently significant composites. As at LTH, patients that die on ICU 
have a shorter length of ICU stay the more severely ill they are. Obtaining 
a homoskedastic model required log transformation of length of stay to 
produce the semi-log (log-lin) model outlined in Table 7.9. 
Table 7.9 Regression Model for Explaining Log ICU Length of Stay at DGH 
Source Estimate 
(911) 
Standard 
error of Q 
T for 
Ho' 
P> IT 
Intercept (ß0) -0.562 0.231 -2.435 0.0163 
APACHE 0.039 0.011 3.573 0.0005 
ICU mortality -0.589 0.234 -2.516 0.0131 
Male patient 0.592 0.165 3.589 0.0005 
Ventilated on admission 0.387 0.167 2.325 0.0217 
ICU-acquired pneumonia 1.090 0.146 7.485 0.0001 
' Null hypothesis: Parameter=0 
The semi-log model produced had no VIF values over 1.5, so harmful 
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multicollinearity was not present. The A' was 0.456 (F = 22.58, 
p =0.0001), indicating that the model explains 45.6% of the variation in 
log length of ICU stay. The model is interpreted such that the estimates of 
the coefficients represent the percentage increase in the length of stay. 
Therefore, being ventilated on admission to ICU increases the length of 
stay by 38.7%. Six outliers were identified but did not cause significant 
disturbance in the model. 
Being admitted with pneumonia was not shown to affect ICU length of 
stay. ICU-acquired pneumonia increases length of ICU stay by 109% (95% 
Cl: 80.4% - 137.6%). Neither pneumonia covariates significantly 
interacted with other covariates. ICU-acquired serious infections had no 
significant effect once ICU-acquired pneumonia was controlled for. 
7.3.5.2 Linear Regression Analysis on Variable Cost per Patient Day at 
DGH 
OLS regression was used to develop a linear regression model to explain 
variations in variable cost per patient day. No interacting combinations of 
covariates produced significant composites. The regression model derived 
is outlined in Table 7.10. 
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Table 7.10 Regression Model for Explaining Variable Cost per Patient Day 
at DGH 
Source Estimate 
(Q) 
Standard 
error of fl,, 
T for 
Ho' 
P> ITI 
Intercept (ß0) 264.2 21.1 12.603 0.0001 
IATRO 143.1 48.4 2.958 0.0037 
PA catheter whilst on ICU 68.2 36.3 1.881 0.0622 
' Null Hypothesis: Parameter=0 
The regression model reported in Table 7.10 was the only model that had a 
significant intercept, had a homoskedastic error distribution (White test; 
p=0.1095) and individually significant covariate estimators. The model 
produced had no VIF values over 1.5, so harmful multicollinearity was not 
present. The A2 was only 0.070 (F = 6.19, p=0.0027), indicating that the 
model only explains 7.0% of the variation in log variable cost per patient 
day, or treatment intensity. This may be explained by insufficient data, 
omission of explanatory covariates or complex relationships not detected 
by this analysis. It is likely that this lack of explanatory power is due to 
flaws in the collection of resource use data relating to variable cost. 
Being admitted with pneumonia was not shown to affect cost per patient 
day. ICU-acquired pneumonia did not independently affect variable cost 
per patient day. Other ICU-acquired serious infections were also not 
shown to have a significant effect. 
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7.3.5.3 Summary of Linear Regression Analysis of Cost Parameters at 
DGH 
In summary, this analysis demonstrates that, in all eligible first admissions 
to DGH ICU, an episode of ICU-acquired pneumonia has: 
1. an independent effect on length of ICU stay at DGH, increasing it by 
109%; 
2. no independent effect on treatment intensity, showing no increase in 
variable cost per patient day; 
3. no independent effect on total variable cost over and above that due to 
increase in length of ICU stay. 
7.3.5.4 Linear Regression Analysis of Factors Affecting Cost Parameters in 
Ventilated Patients at DGH ICU 
The models described above were run on ventilated admissions only 
(n=89). The A2 of the models were not significantly different from the 
models derived from the entire ICU population. ICU-acquired pneumonia 
increased ICU length of stay in ventilated admissions by 111 % (95% Cl: 
78.3% - 143.7%, p=0.0001). Total variable cost and variable cost per 
patient/day were not affected by ICU-acquired pneumonia. 
7.3.6 Derivation of Resource Use Changes Attributable to ICU-Acquired 
Pneumonia at DGH 
For economic analysis, the actual changes in resource use due to an 
episode of ICU-acquired pneumonia are required. From the regression 
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analysis above, it is known that the mean ICU length of stay of ventilated 
patients is 6.44 days, the incidence of ICU-acquired pneumonia is 0.22 
episodes per ventilated patient and an episode increases ICU length of stay 
by 111 %. However, as with the LTH dataset, it is not known from what 
value the increase occurs. Again, the actual length of ICU stay and 
variable cost per patient day for ventilated patients who do and do not 
experience an episode of ICU-acquired pneumonia is not known. In this 
section, these values are derived from the information already known, 
using the same methods as reported in section 7.3.4. 
It is known that the mean ICU length of stay of ventilated patients is 6.44 
days, the incidence of ICU-acquired pneumonia is 0.22 episodes per 
ventilated patient (Table 7.10) and an episode increases ICU length of stay 
by 111 %. With this information, it is possible to derive hypothetical 
lengths of stay for infected and uninfected patients4. As for the LTH 
dataset, these values represent the lengths of ICU stay for two theoretical 
groups of ICU patients. The lengths of ICU stay and variable cost per 
patient/day of these two groups have been controlled for the effects of the 
factors shown to be significant by the regression analysis. Therefore, the 
only difference between these two groups (within the limits of this 
regression analysis) is that one group does and one group does not 
experience an episode of ICU-acquired pneumonia. The derived difference 
represents the difference independently attributable to that episode of 
pneumonia. The derived differences are reported in Table 7.11 a. 
Table 7.11 a also reports total costs. As the length of ICU stay is known, it 
was possible to calculate the fixed costs that are associated with that 
` 0.78(uninfected LOS) + 0.22(infected LOS) = 6.44, where infected LOS = 2.11 x 
uninfected LOS 
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length of stay. The total cost per patient with and without an episode of 
ICU-acquired pneumonia is the cost parameter required for economic 
evaluation of SDD. 
The derived costs for uninfected and infected ventilated patients are 
reported in Table 7.11 a to be £5207 and £10915 respectively. Confidence 
intervals are quoted in the table because the variable cost per patient day is 
the actual value obtained from the data, not a derived value as at LTH. 
The values derived here are used in the primary economic analysis in 
Chapter Eight. In the sensitivity analysis, all the parameters are varied to 
assess the impact of their variation. The ranges of the parameters are 
listed in Table 7.11 b. The ranges of variable costs per day are combined 
with the ranges of lengths of ICU stay, and their associated fixed costs, to 
provide a range of costs for sensitivity analysis. 
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Table 7.1 la Changes in Resource Use Associated with ICU-Acquired 
Pneumonia in Ventilated Patients at DGH 
Resource Use Parameter Value 
Length of stay of uninfected patient/days' 5.2 
Length of stay of patient with ICU-acquired 10.9 
pneumonia/days' 
Variable cost per patient day' for Infected and 362.4 
uninfected patients (95% Cl) (4.8-720.0) 
Total variable cost per uninfected patient/£3 (95% CO 1884 
(24-3744) 
Total cost per uninfected patient/£ (95% CI)` 5207 
(3347-7067) 
Total variable cost per patient with ICU-acquired 3950 
pneumonia/£6 (95% CO (52-7848) 
Total cost per patient with ICU-acquired pneumonia/£ 10915 
(95% CO' (7017-14813) 
Increase in variable cost due to ICU-acquired 5708 
pneumonia/C 
' Derived values 
2 Mean, 95% Cl 
3 Value derived from derived ICU length of stay for uninfected ventilated patient, mean 
variable cost per patient day for ventilated admissions. Upper and lower ranges derived 
from 95% Cl of variable cost per patient day. 
Fixed costs (£182.6), nursing costs (mean £332.4) and medical staff costs (£124) 
added back to variable cost to give total cost per patient 
6 Value derived from derived ICU length of stay for infected ventilated patient and mean 
variable cost per patient day for ventilated admissions. Upper and lower ranges derived 
from 95% Cl of variable cost per patient day. 
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Table 7.11b Ranges of Parameters Required for Economic Analysis for the 
DGH Dataset 
Parameter for Use in Economic Analysis Ranges for 
Sensitivity Analysis 
Increase in length of ICU stay due to pneumonia 78-144% 
derived from linear regression 
Length of stay of uninfected patient/days' 4.9,5.5 
Length of stay of patient with ICU-acquired 9.8,11.9 
pneumonia/days' 
Increase in variable cost per patient day due to 0 
pneumonia derived from linear regression/£ 
Variable cost per patient day for uninfected and 362.4 
infected patients/£2 (95% CI of mean) (119.3-1089.6) 
' Uninfected and infected lengths of stay derived from 78% Increase in length of ICU 
stay are 5.5 and 9.8 days respectively. Uninfected and infected lengths of stay derived 
from 144% increase in length of ICU stay are 4.9 and 11.9 days respectively. 
2 Uninfected and infected variable costs are the same, so the mean variable cost per 
patient day is used. The ranges used for sensitivity analysis are 95% confidence intervals 
of the mean. 
7.4 STATISTICAL ANALYSIS TO IDENTIFY MORTALITY DUE TO 
PNEUMONIA 
The six month mortality rates at LTH and DGH are 50.3% and 40.7%, 
respectively. The ICU-acquired pneumonia rates at LTH and DGH are 65% 
and 28%, respectively. This section describes the statistical analysis to 
examine whether the higher ICU-acquired pneumonia rate at LTH explains 
the higher six month mortality at LTH. This is done by identifying whether 
mortality can be attributed to ICU-acquired pneumonia at the two centres. 
From published evidence, it is not expected to detect a difference in 
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mortality due to ICU-acquired pneumonia (see Chapter Three, section 
3.4.2), unless there is a large attributable mortality. This is duo to a small 
patient population and the presence of many confounding factors. Factors 
contributing to the difference in mortality between the two centres is 
examined. Firstly, the selection of the most appropriate method for 
identification of mortality attributable to ICU-acquired pneumonia is 
discussed. Six month mortality is the most 'useful' short term mortality 
parameter, so is the parameter investigated in this analysis. The theoretical 
basis of the statistical method selected is outlined. The application of this 
analysis technique to the two datasets is reported. Factors associated with 
mortality are elucidated. The extent to which ICU-acquired pneumonia 
affects mortality is investigated. The models derived are applied to the 
ventilated patients subgroups. This allows assessment of the impact of 
ICU-acquired pneumonia on mortality in these patients. 
7.4.1 Selection of Research Method 
The aim of this analysis is to identify and quantify the effect of ICU- 
acquired pneumonia on patient six-month mortality, in all eligible ICU 
admissions and ventilated eligible ICU admissions. Identification and 
quantification of the effect of ICU-acquired pneumonia on mortality requires 
that other factors influencing mortality must be identified and controlled 
for. Eligible first admissions to each ICU were analysed to assess which 
factors affected six month outcome. Covariates selected were those 
previously reported in the literature to be significant. To characterise the 
association of covariates with one another and with mortality, it is 
necessary to statistically adjust the estimated effects of each covariate for 
different associations with, and distributions of, the other covariates 
[Hosmer et a/, 19891. The technique used when the dependent variable is 
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dichotomous is logit regression. The theoretical basis of this technique is 
outlined in the next section. Logit regression is used to identify 
independent predictors of six month mortality, to assess the impact of ICU- 
acquired pneumonia. 
7.4.2 Summary of Logit Regression Analysis Method Used 
The goal of logit regression is to find the best-fitting model, with a priori 
logic, to describe the relationship between a dichotomous dependent 
variable and a set of independent variables (covariates) [Hosmer et a/, 
19891. Logit regression follows the same general principles as linear 
regression, differing primarily in the choice of the parametric model and 
assumptions. The model uses the logistic distribution, where the curve is 
'S'-shaped. The specific form of this model is: 
n(x) = ego+, el" (7.2) [Hosmer et al, 19891 
1 +eg0+P'x 
where (x) represents the conditional mean of the dependent variable (Y) 
given x. The logit transformation of this expression gives the following: 
g(x) = In n(x) (7.3) 
1-n(x) 
= Qo+ß1x (7.4) 
Equation 7.4 gives the expression central to logit regression modelling, for 
a logit model with one independent variable. 
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Where there is more than one independent variable, the expression 
becomes: 
g(x) = Qo+Q, a+ßzb.... ßrj (7.5) 
where (x) represents the conditional mean of Y given a, b.... j. 
7.4.2.1 Fitting the Logfit Regression Model 
To fit the logit regression model in equation 7.5 to a set of data requires 
estimation of Qo, Q1, Q2.... A,, the unknown parameters. The general method 
of estimation in logit regression that equates to the least squares function 
under the linear regression model is called maximum likelihood. The 
maximum likelihood function expresses the probability of the observed data 
as a function of the unknown parameters. Estimators of these parameters 
are those which maximize this function. 
After estimating the coefficients, the covariates included in the model are 
assessed for significance (whether they are significantly related to the 
outcome variable). The estimate of the coefficient can be insignificant for 
two reasons: firstly the covariate has no effect on the outcome variable, or 
secondly, the dataset is too small, resulting in large error intervals 
incorporating zero. The estimate of the coefficient, ß1, represents the 
change in the logit for a change of one unit in the independent variable, x 
[Hosmer et a/, 1989]. Where independent variables are dichotomous, ß1 is 
the log odds ratio. The odds ratio (4)) indicates how much more likely it is 
for the outcome to be present among those observations where x=1, than 
among those where x=0. 
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The odds ratio is derived from the estimate of the coefficient as expressed 
in equation 7.6. 
= eO1 (7.6) 
Where x is a continuous variable, the odds ratio is derived in the same 
way. In this situation the odds ratio indicates, for a unit increase in x, how 
much more likely it is for the outcome to be present. 
It is necessary to test whether the covariates included in the model are, in 
fact, independently related to the dependent variable (Kennedy, 19921. To 
test the significance of a covariate, the log likelihood of the logit model 
containing the covariate (full model) is compared with the log likelihood of 
the model not containing it (reduced model), using a likelihood ratio test. If 
the p-value of this likelihood ratio test is more than 0.05 (according to 
assigned level of significance), then the reduced model is as good as the 
full model, and there is no advantage to including the covariate in the 
model. 
When interaction between covariates is present, the association between 
one covariate and the dependent variable is modified by the level of 
another covariate [Hosmer et a/, 1989]. Two-dimensional interaction can 
be assessed simply, prior to building the model, by producing a correlation 
table of the covariates [Kennedy, 1992]. The smaller the sample, the 
larger the correlation coefficient needs to be to indicate significant 
correlation. If the correlation between covariates exceeds the critical value 
for that population, there is interaction, which must be explicitly handled. 
It is necessary to measure how effective the model is in describing the 
outcome variable. Complete assessment of the fitted model involves both 
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the calculation of summary measures of the difference in observed and 
predicted values and the individual components of these measures. A 
likelihood ratio test is used to measure the extent to which the restricted 
model fits the unrestricted model (that is, a model containing all possible 
covariates) [Hosmer et a/, 1989). However, unlike the R2 value in linear 
regression, the aim is not simply to increase the 'p' value to as near unity 
as possible [Kennedy, 19921. The predictive power of a logit model is 
assessed by running the model on a dataset other than the one from which 
it was derived. This method is frequently used in models built to predict 
survival. The following parameters can be derived from the data [Chang of 
a/, 1988]: 
Specificity (correct prediction of survival/%) 
= PredAAlive x100 
(PredAAlive + PredDAlive) 
False positive rate = (1-specificity)xlOO 
Sensitivity (correct prediction of death/%) 
= PredDDead x100 
(PredDDead + PredADead) 
Overall correct prediction rate/% 
= (PredAAlive + PredDDead) x100 
Total patients 
Predictive value positive/% = PredDDead x100 
Total predicted to die 
Predictive value negative/% = PredAAlive x100 
Total predicted to live 
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where: 
PredAAlive = Predicted to live and lived 
PredADead = Predicted to live but died 
PredDAlive = Predicted to die but lived 
PredDDead = Predicted to die and died. 
If the model is run on the parent dataset (that is, the one from which it 
was derived), the parameters above can be derived to provide information 
on how well the model fits the data. 
In summary, the aim in logit regression should be to derive a model that 
has the following characteristics: 
1. the components of the model should exhibit individual significance 
(p <0.05); 
2. correlation between covariates should be minimised (p<criticalp); 
3. the model should not be significantly different from the unrestricted 
model (likelihood ratio test: p>0.05); 
4. the model should be assessed to make sure it has a priori logic. 
7.4.3 Logit Regression Analysis of Factors Affecting Six Month Mortality 
at LTH and DGH 
This section outlines the logit regression analysis carried out on the LTH 
and DGH datasets to identify independent predictors of the six-month 
mortality. Firstly, the covariates listed in Tables 7.12a and 7.12b were 
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investigated individually to assess their unadjusted effect on six-month 
mortality. Table 7.1 2a reports patient admission characteristics that may 
affect six-month mortality. Table 7.12b reports recorded events occurring 
on ICU that may have an impact on six-month mortality. Three covariates 
recorded are proxies for organ failure (see section 7.3.3). 
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Table 7.12a Patient Admission Factors Associated with Six Month 
Mortality at DGH (n =131) and LTH (n = 206) 
Predicting factor p (DGH) p (LTH) 
Sex ns ns 
CANCER ns ns 
ELECT 0.0014 <0.00005 4 
CPR <0.0005 t <0.00005 t 
Age' ns ns 
APACHE II' ns 0.0022 t 
CHRONIC 0.055 t ns 
CARDIAC 0.052t ns 
IATRO 0.062 t ns 
VENT ns 0.007 t 
NEURO2 - 0.062 t 
GENERAL2 ns ns 
VASCULAR2 0.012t 0.0324 
TRAUMA2 ns ns 
OTH ER2 0.024 4 ns 
INFECT 0.031 tJ 0.029 t 
' t-test. All other significance tests: X; ns: p 'a 0.10 
significance with respect to the remaining surgical category 'medical'. 
t Mortality increases in presence of risk factor 
4 Mortality decreases in presence of risk factor 
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Table 7.12b Events on ICU and Cost Parameters Associated with Six 
Month Mortality at DGH and LTH 
Source p (DGH) p (LTH) 
ICU length of stay 0.0551 ns 
Ventilated whilst on ICU 0.021 t 0.006 t 
Dialysed whilst on ICU ns 0.002 t 
PA catheter whilst on ICU ns 0.005 t 
Pneumonia whilst on ICU 0.095 t ns 
ICU-acquired serious 
infection 
0.100t ns 
Total hospital stay 0.016 <0.000054 
Variable patient cost/£ ns ns 
Variable patient day cost/£ ns <0.00005 t 
t Mortality increases in presence of risk factor 
4 Mortality decreases in presence of risk factor 
From this initial analysis, it can be seen that some covariates appear to 
affect mortality at both centres, such as CPR prior to ICU admission or 
elective admissions. Other covariates have an impact at only one centre, 
such as APACHE scoring or presence of a cardiac condition. APACHE II 
has been validated for use in the UK as a severity of illness measure. The 
lack of a relationship demonstrated between it and mortality at DGH 
suggests measurement inaccuracies. ICU-acquired pneumonia has a 
marginally significant effect on mortality at DGH and none at all at LTH, 
when other factors have not been controlled for. Multiple logit regression 
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is necessary to examine whether this lack of relationship remains when the 
other factors are taken into account. 
Logit regression models were derived for ICU, hospital and six month 
mortality at each centre. This was carried out to examine whether 
different factors were significant at different times, and whether ICU- 
acquired mortality was significant at different times. Only the models for 
six month mortality are reported in this chapter. This is because this is the 
most useful short term outcome measure, and the models for ICU and 
hospital mortality do not differ greatly from the models for six month 
mortality. The models derived for ICU and hospital mortality are 
summarised in Appendix 7.1. One model is described in detail to illustrate 
the analysis method. 
7.4.3.1 Logit Regression Analysis of Six Month Mortality at LTH 
This section outlines the logit regression analysis carried out on the LTH 
dataset to identify independent predictors of six-month mortality, using the 
methods described in section 7.4.2. The regression model derived is 
summarised in Table 7.13. 
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Table 7.13 Logit Regression on Factors Explaining Six Month Mortality at 
LTH 
Source Estimate 
(ß) 
Standard 
error of Q 
DF x2 4) P 
Intercept 1ß01 -4.270 0.970 1 19.36 0.01 <0.00005 
PA catheter on ICU 0.436 0.198 1 4.87 1.55 0.0273 
Hospital LOS 6-11 
days' 
-1.684 0.612 1 7.58 0.19 0.0059 
Hospital LOS > 11 
days 
-2.158 0.545 1 15.70 0.12 0.0001 
Presence of cancer 0.729 0.214 1 11.63 2.07 0.0006 
APACHE 112 16-18 0.594 0.276 1 4.61 1.81 0.0317 
APACHE II 19-20 0.777 0.285 1 7.45 2.17 0.0063 
APACHE II 21-26 1.626 0.559 1 8.45 5.08 0.0036 
APACHE II 27-44 1.811 0.565 1 10.26 6.12 0.0014 
Likelihood ratio - - 28 16.87 - 0.95104 
' Continuous variables converted to categories to reduce number of populations, 
categories compared with hospital LOS of less than 6 days. 
2 Continuous variables converted to categories to reduce number of populations, 
categories compared with APACHE II score 0-15. 
I Log odds ratio 
4 p>0.05; therefore the restricted model is not significantly different from the unrestricted 
model 
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The model summarised in Table 7.13 shows that six month mortality of 
ICU patients at LTH is independently affected by insertion of a PA catheter 
whilst on ICU (indicating acute cardiac failure); their length of hospital stay; 
the presence of active cancer on admission and their acute severity of 
illness (APACHE II score). These factors all have a statistically significant 
(p<0.05) independent effect on mortality. Their effect is quantified by the 
odds ratio, 4), derived from the estimate of the coefficient, ß, for each 
covariate. The risk of death at six months is increased by a factor of 1.55 
if a PA catheter is inserted during the ICU stay. Compared with a hospital 
length of stay of less than six days, the risk of death decreases to 0.19 for 
a length of stay of 6 to 11 days, and decreases further to 0.12 for a length 
of hospital stay of more than 11 days. The presence of active cancer on 
ICU admission increases the six month risk of death by a factor of 2.07. 
Assuming that risk of death for patients with APACHE II scores less than 
sixteen is one, the higher APACHE score categories have increasingly 
higher risks of death as the score increases. 
The model was run on the parent dataset to assess 'goodness-of-fit'. The 
results of this are summarised in Table 7.14. The predictive power of the 
model is not reported as this can only be determined by running the model 
on datasets other than that used to derive the model. 
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Table 7.14 Fit of Logit Model (Explanation of LTH 6 Month Mortality) to 
Parent Dataset 
Model Parameter Results of running logit on 
parent dataset (%)' 
Sensitivity 100.0 
Specificity 99.1 
False positive rate 0.92 
Overall correct prediction rate 99.5 
' If the model predicted that the patient had a 50% or greater chance of death at six 
months, this was taken to be a prediction of death. 
2 One patient predicted to die within 6 months of discharge, who lived. 
ICU-acquired infections and pneumonias did not retain independent 
significance in logit regression. Mortality attributable to ICU-acquired 
pneumonia cannot therefore be assumed. When the logit models were run 
on a dataset only including ventilated patients, ICU-acquired pneumonia 
was still not independently significant. 
7.4.3.2 Logit Regression Analysis of Six Month Mortality at DGH 
This section outlines the logit regression analysis carried out on the DGH 
dataset to identify independent predictors of six-month mortality, using the 
methods described in section 7.4.2. The regression model derived is 
summarized in Table 7.15. 
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Table 7.15 Logit Regression on Factors Explaining Six Month Mortality at 
DGH 
Source Estimate 
(ß) 
Standard 
error of 
DF X2 W P 
Intercept (ß0) 0.667 0.339 1 3.87 1.95 0.0491 
ELECT -0.664 0.246 1 7.26 0.51 0.0070 
APACHE II score > 18' 0.535 0.221 1 5.85 1.71 0.0156 
Hospital LOS >7 days' -0.718 0.273 1 6.92 0.49 0.0085 
Age > 50yrs 3 0.739 0.289 1 6.56 2.09 0.0104 
Likelihood ratio - - 7 4.83 - 0.6809 
' Continuous variables converted to categories: category compared with APACHE 0-18 
2 Continuous variables converted to categories: category compared with LOS 0-7 days 
3 Continuous variables converted to categories: category compared with age up to 50 yrs. 
The model summarised in Table 7.15 shows that six month mortality of 
ICU patients at DGH is independently affected by age; their length of 
hospital stay; whether they are an elective admission or not and their acute 
severity of illness (APACHE II score). Their effect is quantified by the 
odds ratio, 4P, derived from the estimate of the coefficient, ßn, for each 
covariate. The risk of death at six months has an odds ratio of 0.51 if the 
patient is an elective admission. Compared with a hospital length of stay 
of less than eight days, the risk of death decreases to 0.49 for a length of 
stay of eight or more days. Patients with ages greater than 50 years on 
ICU admission have a six month risk of death that is 2.09 that of patients 
50 years old or younger. Assuming that risk of death for patients with 
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APACHE II scores less than nineteen is one, the higher APACHE II score 
category has a 1.71 times higher risk of death. The use of dichotomous 
categorization in this model for APACHE scoring and length of hospital stay 
is attributable to the smaller patient group at DGH. In the case of APACHE 
II scores, it is also due to the probable lack of accuracy with which the 
scores have been collected. 
The model was run on the parent dataset to assess 'goodness-of-fit'. The 
results of this are summarised in Table 7.16. 
Table 7.16 Fit of Logit Model (Explanation of DGH Six Month Mortality) to 
Parent Dataset 
Model Parameter Results of running logit on 
parent dataset 
Sensitivity 100.0 
Specificity 97.6 
False positive rate 2.42 
Overall correct prediction rate 98.5 
1 If the model predicted that the patient had a 50% or greater chance of death at six 
months, this was taken to be a prediction of death. 
2 Two patients who were predicted to die within six months of discharge, lived. 
ICU-acquired infections and pneumonias did not retain independent 
significance in logit regression. Mortality attributable to ICU-acquired 
pneumonia cannot therefore be assumed. When the logit models were run 
on a dataset only including ventilated patients, ICU-acquired pneumonia 
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was still not independently significant. 
7.4.3.3 Effect of Centre on Six-Month Mortality 
The datasets from the two centres were combined to assess effects of 
centre on six-month mortality. The logit model derived from the LTH 
dataset was run on the combined dataset. The model is described in 
Appendix 7.2. The centre did not remain significant once centre-specific 
factors such as neurosurgery were controlled for. ICU-acquired pneumonia 
did not demonstrate significance. 
7.5 DISCUSSION OF ANALYSIS FINDINGS 
The principal aim of this analysis was to identify the impact on defined cost 
parameters of ICU-acquired pneumonia at two British ICUs in all ICU 
admissions and in ventilated admissions. The secondary aim was to 
identify whether the higher six month mortality at LTH could be explained 
by the higher ICU-acquired pneumonia rate. The isolation of increases in 
cost and mortality was complicated by the presence of other factors that 
could also have had an effect. This required the use of statistical 
techniques that allowed these other confounding factors to be controlled. 
7.5.1 Analysis of Cost Parameters 
The cost parameters investigated by this analysis were total variable cost, 
length of ICU stay and variable cost per patient day. These parameters 
were continuous dependent variables so linear regression was used to 
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isolate the effect of ICU-acquired pneumonia. The datasets used for this 
analysis were those collected and described in Chapter Six. Linear 
regression models were developed for both centres to explain the variation 
in variable cost, length of ICU stay and variable cost per patient day. 
At LTH, the model derived to explain total variable cost explained 91 . 0% of 
the variation, suggesting a model that fit the data very well. Important 
factors were length of ICU stay, chronic health status, severity of illness of 
non-survivors and surgical speciality. It is unlikely that any important 
explanatory factors have been omitted from this model. At DGH, the 
equivalent model only explained 53.1 % of the variation. This means that 
nearly half the variation in cost has not been explained by the model. It is 
suggested that this is due to incomplete retrieval of variable resource use 
at DGH. The only two factors remaining significant were length of ICU 
stay and dialysis whilst on ICU. Most of the explanatory power of the 
models at both centres is due to the correlation of variable cost with length 
of ICU stay. This correlation is stronger at LTH than at DGH, probably due 
to the improved data collection and also to increased regular treatment 
intensity at LTH. No impact on variable cost by ICU-acquired pneumonia 
was detected in either model. It was suggested that this was due to ICU- 
acquired pneumonia only affecting length of ICU stay, which would have 
been masked by these models. 
Analysis of the datasets at both centres suggests that to better understand 
the factors explaining variation in variable cost, it is necessary to examine 
factors affecting length of ICU stay and variable cost per patient day 
separately. The regression model derived to explain length of ICU stay 
accounted for 51.1% of the variation at LTH and 45.6% at DGH. Models 
with similar ability to explain variation in length of ICU stay at the two 
centres were produced. The similarity must be partly due to the quality of 
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data collected being similar at the two centres, unlike the data on variable 
cost. Variation in length of ICU stay was attributed to dialysis whilst on 
ICU and insertion of a PA catheter whilst on ICU at LTH; sex and 
ventilation status at DGH; severity of illness, dying on the ICU, and 
occurrence of an episode of ICU-acquired pneumonia at both centres. 
Possible reasons why more of the variation was not accounted for are 
suggested organisational factors not measured by this analysis. These may 
include varying pressure for ICU beds determining discharge of some 
patients, availability of a bed on a ward to allow a patient to be discharged, 
ICU staffing levels affecting discharge rates or availability of senior medical 
staff to allow patient discharge. Analysis of both centres demonstrates 
that ICU-acquired pneumonia increases length of ICU stay by 113% in all 
LTH admissions, 116% in ventilated LTH admissions, 109% in all DGH 
admissions and 111 % in ventilated DGH admissions. 95% confidence 
intervals for these values are listed in the model summaries. 
Examination of factors affecting variable cost per patient day produced a 
regression model that was only able to explain 29.5% of the variation at 
LTH and 7.0% at DGH. The variable cost per patient day is a function of 
the total variable cost and length of ICU stay of that patient. Therefore, it 
is reasonable to assume that uncertainty around the factors causing 
variation in length of ICU stay have translated into these models. The low 
explanatory power of the DGH model in particular may be attributable to 
the poor variable cost data. The analysis of the LTH dataset suggests that 
an episode of ICU-acquired pneumonia increases variable cost per patient 
day modestly, by £53.3, in ventilated patients. The analysis of the DGH 
dataset shows no increase. This may be due to the absence of an increase 
or to the poor variable cost data. 
As discussed in section 7.3.4, for economic analysis, the actual changes in 
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resource use due to an episode of ICU-acquired pneumonia in a ventilated 
patient are required. From the regression analyses reported the actual 
length of ICU stay and variable cost per patient day for ventilated patients 
who do and do not experience an episode of ICU-acquired pneumonia was 
not known. Therefore, it was necessary to derive these values for both 
centres. The analysis of the LTH dataset suggests that, in ventilated 
admissions, an episode of ICU-acquired pneumonia increases the length of 
ICU stay by 4.8 days and the total variable cost by £2660 (see Table 7.5 
for ranges). Analysis of the DGH dataset suggests an increase in the 
length of ICU stay of 5.7 days and the total variable cost by £2060 (see 
Table 7.11 for ranges). Combination of this derived variable cost with 
fixed and staff costs associated with the ICU stay provided total costs per 
infected and uninfected patients for both centres. These values are 
required for economic evaluation of SDD. 
The derived estimates of the impact of ICU-acquired pneumonia on length 
of ICU stay can be compared with the published evidence. The studies 
examining this are discussed in Chapter Three, section 3.3.1. Most studies 
used matched pairs to identify length of stay changes, and estimates range 
up to twenty days. Molina at a/ [19931 used the same method as reported 
in this analysis. The length of stay attributable to ICU-acquired pneumonia 
reported by them is 4.3 days, comparable with this study. No studies were 
found that reported the impact of ICU-acquired pneumonia on treatment 
intensity. It is reasonable to suggest that the incidence of pneumonia 
should have an effect on treatment intensity. However, in critically ill 
patients who are already receiving intense treatment, it is difficult to 
identify that incremental effect, especially if the retrieval of variable 
resource use is not reliable. 
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7.5.2 Analysis of Six Month Mortality 
The secondary aim of this analysis was to identify whether the higher 
mortality at LTH could be attributed to ICU-acquired pneumonia. The 
analysis method used was logit regression because mortality is a 
dichotomous dependent variable. The mortality parameter examined was 
six-month mortality, considered to be the most useful short term mortality 
measure collected by this study. At LTH, the factors independently 
associated with mortality were length of hospital stay, severity of illness 
(as measured by APACHE II score), presence of active cancer on admission 
and acute cardiac failure requiring insertion of a PA catheter on ICU. At 
DGH, the factors identified were severity of illness, length of hospital stay, 
age and elective admission. The impact of these factors on mortality was 
expressed as odds ratios. The centre was not significant once the 
neurosurgery patients at LTH had been controlled for. Therefore, the case 
mix at LTH led to the higher mortality rate, rather than the higher incidence 
of ICU-acquired pneumonia. 
Section 3.4.2 in Chapter Three discusses the published evidence for impact 
of ICU-acquired pneumonia on mortality. Studies containing much larger 
groups than the two analysed here were not able to demonstrate an 
independent association, so the inability of this analysis to do so is 
comprehendible. 
7.6 CONCLUSIONS AND IMPLICATIONS FOR ECONOMIC EVALUATION 
The aim of this analysis was to provide economic data for use in an 
economic analysis of SDD. The impact of ICU-acquired pneumonia on cost 
is necessary for this analysis. The data provided by this analysis quantifies 
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the economic impact of ICU-acquired pneumonia, from the ICU perspective. 
The data provided has been derived from datasets obtained from a district 
general hospital and a London teaching hospital. This will enable the 
economic analysis of SDD to be carried out, considering two different ICU 
environments. 
The impact on total patient cost has been divided into the impact on ICU 
length of stay and on treatment intensity. A large increase in length of ICU 
stay has been detected at both centres, comparable with published 
evidence. A small increase in treatment intensity was detected at LTH 
only. Derived costs for infected and uninfected patients have been 
produced by this analysis. These figures are directly applicable to the 
decision-analytic model derived in Chapter Four. There are wide ranges 
around the point estimates from which the derived values are obtained. 
The effect of these on any conclusions drawn in the economic analysis 
must be investigated using sensitivity analysis. 
The original decision-analytic model derived in Chapter Four (Figure 4.1) 
requires evidence on the life expectancy of post-ICU patients and the 
impact of ICU-acquired pneumonia on this life expectancy. Neither has 
been measured beyond six months in this study. Neither centre 
demonstrated an increase in any of the mortality parameters in the 
presence of ICU-acquired pneumonia. Therefore, it may either be assumed 
that the use of SDD to reduce the incidence of ICU-acquired pneumonia 
will have no effect on mortality, or that this study was not large enough to 
pick up the differences that do exist. In the former case, there will be no 
life-years gained as a result of the use of SDD. It is not possible to derive 
an incremental cost per life year gained. As no morbidity measures were 
collected to assess the impact of ICU-acquired pneumonia on quality of life, 
it is not possible to assess the incremental impact of SDD on quality of life. 
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Therefore, it is also not possible to derive incremental costs per QALY 
gained. In the latter case, it is necessary to return to published evidence 
for impact of ICU-acquired pneumonia on mortality. 
In conclusion, the economic evidence reported in this chapter is British, 
current, based as closely on true economic costs as possible and patient- 
specific. This is a significant improvement over the economic evidence 
available for use in the secondary economic analysis of SDD. This 
evidence is expected to further improve the robustness of conclusions from 
Chapter Four. 
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Chapter 8: Economic Evaluation of SDD in Two British 
ICUs 
8.1 INTRODUCTION 
Chapter Four describes an economic evaluation of SDD, using published 
clinical and economic evidence. This economic evaluation concluded 
that SDD was a dominant therapy, as it was shown to improve patient 
outcomes at a reduced overall cost. This conclusion was also shown to 
be very robust, despite the significant uncertainty associated with many 
of the clinical and economic parameters. The parameters that were 
associated with most uncertainty, and could reverse the conclusion that 
SDD was dominant if varied, were base pneumonia rates, increase in 
length of ICU stay associated with pneumonia, cost per ICU day and 
increased therapeutic intensity associated with treating pneumonia. It 
was also suggested that the use of SDD regimens of differing cost 
affects the cost effectiveness of SDD. Empirical work reported in this 
thesis has aimed to reduce the uncertainty associated with these 
parameters. Chapter Five has provided practice information on the use 
of SOD in Britain. Chapters Six and Seven have provided primary 
economic evidence on the economic impact of ICU-acquired pneumonia 
on the cost of an ICU patient in two British ICU settings. The economic 
evaluation in this chapter applies this local economic and epidemiologic 
evidence to the decision-analytic pathway developed in Chapter Four. 
The theoretical cost effectiveness of SDD, if it were to be implemented 
at these two centres, is derived. 
Section 8.2 outlines the aims and objectives of this analysis. The 
research question is defined in section 8.3. Sections 8.4 and 8.5 
summarise the clinical and economic evidence for use in the economic 
analysis. Section 8.6 reports the incremental economic analysis for the 
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two centres. The sensitivity of the conclusions of the economic 
analysis to variation in clinical and economic parameters is considered in 
section 8.7. Section 8.8 investigates whether the use of primary 
stochastic economic data increases the robustness of conclusions, when 
compared with the secondary economic analysis reported in Chapter 
Four. The impact of centre-specific factors, such as occupancy and 
patient turnover rates, on the realisable cost savings from the 
implementation of SDD is examined in section 8.9. Finally section 8.10 
examines the policy implications of this economic evaluation. 
8.2 AIMS AND OBJECTIVES OF ECONOMIC EVALUATION OF SDD 
The aim of this economic evaluation is to generate conclusions about 
the cost effectiveness of SDD if it were introduced into two British 
ICUs, using primary epidemiologic and stochastic economic evidence. 
The specific objectives of this analysis are: 
1. to combine published clinical effectiveness data with primary 
epidemiologic and economic data to assess whether SDD can be 
demonstrated to be cost effective if introduced at either of the two 
centres; 
2. to test the robustness of these conclusions using sensitivity analysis; 
3. to examine whether the additional empirical evidence has increased 
the robustness of conclusions and 
4. to examine what are the realisable clinical and economic implications 
of introducing SDD to the two centres, compared with the theoretical 
implications. 
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8.3 DEFINITION OF RESEARCH QUESTION 
This economic evaluation assesses whether it would be cost effective to 
introduce SDD at two British ICUs. The two centres examined are a 
London teaching hospital (LTH) and a district general hospital (DGH) in 
the same geographical location. These are the two centres from the 
prospective resource use study reported in Chapter Six. The decision- 
analytic model developed in Chapter Four is used in the economic 
analysis of SDD at these two centres. This section describes the 
components of the research question. 
8.3.1 Input to the Intervention 
The input to the process of the intervention is the patient group. 
Literature review of SDD trials showed that the ICU patients most likely 
to receive SDD were ventilated adult admissions. The survey of British 
SDD users (Chapter Five) showed that ICU patients most likely to 
receive SDD were ventilated adult admissions. Therefore, as in Chapter 
Four, the target patient group is ventilated ICU admissions. This 
constitutes 89 patients at OGH and 171 patients at LTH. 
8.3.2 Process of the Intervention 
The intervention modelled to be undertaken at the two centres is the 
same process described in Chapter Four. The decision-based 
component of this process is the implementation of SDD. The 
probabilistic components are the occurrence of ICU-acquired pneumonia 
and short and long term mortality rates. The cost components are the 
implementation of the SOD regimen and maintenance of ICU-acquired 
pneumonia. 
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8.3.3 Output of the Intervention 
The type of cost/outcome ratios derived depends upon the outcome 
measures used. The effect on clinical outcome of SDD is considered to 
be its effect on patient morbidity and mortality through its effect on 
ICU-acquired pneumonia incidence. If SDD is not shown to change 
patient outcomes, but cost only, then it becomes a cost minimisation 
analysis. 
The input, process and outcome for the economic evaluation of SDD at 
LTH and DGH does not differ in principle from that in the economic 
evaluation in Chapter Four. Therefore, the structure of the decision- 
analytic model does not alter other than that the short term mortality 
measure is six month mortality instead of ICU mortality. This model is 
outlined in Figure 8.1. 
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Figure 8.1 Decision-Analytic Model for the Use of SDD on ICU 
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The clinical and economic evidence required for the decision-analytic 
model for each of the two study centres can be summarised into five 
categories: 
1. the probability that the patient will contract ICU-acquired pneumonia 
with or without SDD; 
2. the impact of ICU-acquired pneumonia and SDD on the short and 
long term mortality of the patient; 
3. the impact of ICU-acquired pneumonia and SDD on the short and 
long term morbidity of the patient; 
4. the impact of ICU acquired pneumonia and SDD on the resource use 
associated with the patient and 
5. the unit costs associated with resource use. 
The acquisition of clinical and economic evidence for these five 
categories is described in the next two sections. 
297 
8.4 ACQUISITION OF CLINICAL EVIDENCE 
This section summarises the clinical evidence for use in the decision- 
analytic model. The evidence required is: 
1. impact of SDD on ICU-acquired pneumonia rates at LTH 
and DGH; 
2. short and long term mortality probability with or without 
ICU-acquired pneumonia at LTH and DGH; 
3. impact of SDD and ICU-acquired pneumonia on quality of 
life at LTH and DGH. 
8.4.1 Impact of SDD on ICU-acquired Pneumonia Rates at LTH and 
DGH 
SOD only reduces the ICU-acquired pneumonia rate through its effect on 
Gram-negative late onset pneumonia. The probability of a ventilated ICU 
admission acquiring ICU-acquired pneumonia and Gram-negative late- 
onset pneumonia without the use of SOD was observed for each centre 
in the study reported in Chapter Six. These incidence rates are reported 
in Table 8.1 and are used in the economic evaluation. The 95% 
confidence intervals of the Gram-negative late-onset pneumonia rates 
are used as ranges for base pneumonia rates in the sensitivity analysis. 
The effect of SOD on these ICU-acquired pneumonia rates is derived 
from the systematic review and meta-analysis of published clinical 
evidence in Chapter Four. The meta-analysis reported a 53% reduction 
(95% Cl: 43% to 63%) in late onset Gram-negative pneumonia rate by 
SDD. Table 8.1 summarises the impact this would have on ICU- 
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acquired pneumonia rates and Gram-negative late onset pneumonia ratos 
at the two centres. The probabilities of acquiring any pneumonia on the 
two ICUs are required for the decision-analytic pathways. 
Table 8.1 Impact of SDD on ICU-Acquired Pneumonia Rates at LTH and 
DGH 
Type of Pneumonia Episodes per patient 
(LTH) 
Episodes per patient 
(DGH) 
No SDD SDD No SDD SDD 
Early onset 0.14 0.14 0 0 
Late onset Gram+ve 0.19 0.19 0.11 0.11 
Late onset Gram-ve 0.32' 0.15 0.172 0.08 
Overall ICU-acquired 0.65 0.48 0.28 0.19 
' 95% Cl of mean incidence rate: (0.23-0.41) 
2 95% Cl of mean incidence rate: (0.10-0.24) 
The overall ICU-acquired pneumonia rate would be reduced from 65% to 
48% at LTH and from 28% to 19% at DGH if SDD was introduced, 
assuming that SDD reduced Gram negative late-onset pneumonia by 
53%. These theoretical reductions in pneumonia rate are used in the 
economic evaluation. The 95% confidence intervals (43% to 63%) 
quoted for this reduction are used in the sensitivity analysis to examine 
the effect of variation in SDD effectiveness on cost/outcome ratios. 
Trials have reported pneumonia rate reductions of less than 10% to 
80%. To test for the impact of wider variation of effectiveness, these 
extremes are used as the sensitivity analysis ranges. 
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8.4.2 Impact of SDD on Short Term Mortality 
In the economic evaluation of SDD in Chapter Four, the ICU mortality 
only was known. From the study of the two centres, the ICU, hospital 
and six month mortality is known for ventilated patients (Table 8.2) 
Table 8.2 Summary of Ventilated Patient Mortality at LTH and DGH 
Patient characteristic DGH (n=89) LTH (n-171) 
% ICU mortality 18.0 26.9 
% Hospital mortality 38.2 41.6 
%6 month mortality 40.7 50.3 
However, logit regression analysis in Chapter Seven was not able to 
identify an independent effect of ICU-acquired pneumonia on any of 
these mortality parameters at LTH or DGH. This may be because ICU- 
acquired pneumonia does not have any effect on mortality. 
Alternatively, the patient group may have been too small to pick up any 
significant differences. In the absence of any other evidence it must be 
assumed for the base case economic evaluation that pneumonia does 
not affect mortality at either centre. If the reason for lack of detection 
was just due to group size, then it is necessary to examine the effect of 
an increase in mortality attributable to ICU-acquired pneumonia. 
Sensitivity analysis examines the situation where the mortality of 
patients receiving SDD is reduced through a reduction in pneumonia 
rates. The sensitivity ranges suggested are a lower limit of 0%, as 
observed in the empirical study and a higher limit of 10% (the value for 
mortality reduction by SDD derived by the meta-analysis in Chapter 
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Four). It is assumed, as in Chapter Four, that ICU-acquired pneumonia 
is extremely unlikely to be associated with a docroaso in mortality rates. 
8.4.3 Impact of SDD on Long Term Mortality 
The ideal decision-analytic model (Figure 8.1) requires evidence on the 
life expectancy of post-ICU patients and the impact of ICU-acquired 
pneumonia on this life expectancy. Neither has been measured beyond 
six months in this study. If short term mortality is not assumed to be 
affected by ICU-acquired pneumonia or SDD and there is no evidence on 
the effect on long term mortality, then it is assumed for the base case 
economic evaluation that ICU-acquired pneumonia and SDD do not have 
an impact on long term mortality, so no incremental life years are gained 
by the use of SDD. For the purposes of sensitivity analysis, the effect 
of a 10% decrease in short term mortality is examined. In this situation, 
the theoretical effect on the overall long term mortality, and incremental 
LYGs, of the group is modelled. The same secondary data sources for 
LYGs are used as in the economic analysis in Chapter Four. The 
assumption made by Kerridge et al [19951 that the age-specific life- 
expectancy of ICU patients returns to 90% of the normal population is 
used. This assumption is used in this analysis to assess incremental 
cost per LYG. Any calculations also make the assumption, in the 
absence of evidence to the contrary, that ICU-acquired pneumonia has 
no other effect on long term mortality, as in the analysis in Chapter 
Four. 
The ventilated patient groups at LTH and DGH have mean ages of 59.9 
and 62.2 years, respectively. This would give an age-specific life 
expectancy of 19.2 years life expectancy (CSO Annual Abstract, 1991). 
Assigning 90% of these years to ICU survivors provides an estimate of 
17.3 LYGs by ICU survivors in the model. The accuracy of this point 
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estimate is not known because it was not derived from the population to 
which it is being applied. To assess the impact of the variation of LYGs 
on the cost per LYG ratio, the LYGs by an ICU survivor are varied from 
50% of the base value (8.7 LYGs) to 150% of the base value (26.0 
LYGs), as in the analysis in Chapter Four. 
8.4.4 Impact of SDD on Quality of Life and Utility 
The observational study reported in Chapter Six did not assess the 
effect of ICU-acquired pneumonia on QoL or utility of ICU patients. If 
the assumption is made that ICU-acquired pneumonia has no effect on 
mortality, and there is no evidence on its effect on morbidity, it must be 
assumed, for the base case economic evaluation, that no QoL or utility 
was gained or lost. For the purposes of the sensitivity analysis where 
an effect on mortality is assumed, the theoretical impact on QoL and 
utility is modelled. The same secondary sources are used as in Chapter 
Four. Kerridge et al (19951 reported QALYs gained by ICU survivors. 
The base value for discounted QALYs (dQALYs, 5% discount rate) 
gained, taken from the Kerridge values, is 6.3 per ICU survivor, as this 
relates to the mean APACHE scores of the ventilated patients at the two 
centres. The ranges for sensitivity analysis are 0.8 to 9.9 dQALYs 
gained, to include patients with higher and lower APACHE scores, as in 
the analysis in Chapter Four. 
Tables 8.3a and 8.3b summarise the clinical parameters required for the 
economic evaluation of SDD at LTH and DGH. The values derived from 
the literature and the observational study are listed, with their ranges for 
sensitivity analysis. 
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Table 8.3a Summary of Clinical Parameters, Their Associated Values 
and Ranges for Sensitivity Analysis at LTH 
Clinical No SDD SDD Incremental Ranges for 
Parameter Effect Size Sensitivity 
due to SDD Analysis 
Late-onset 32' 15 53% 12 95 % Cl: 43.63 4 
gram-negative Extremes: 10- 
pneumonia 804 
rate/% 
ICU 26.9 26.9 0 0- 104 
Mortality/% 
6 month 50.3 50.3 0 0- 104 
mortality/% 
Life 17.3 17.3 0 8.7-26.0` 
Expectancy per 
ICU 
survivor/LYGs 
dQALYs per 6.3 6.3 0 0.8- 9.94 
ICU survivor3 
' Base pneumonia rate varied from 23 to 41 % 
21 Indicates that there is a decrease in the parameter 
3 Discount rate 5% 
4 Sensitivity analysis ranges are used to vary these parameters for both SDD and non- 
SDD patients. There is no incremental effect attributable to ICU-acquired pneumonia 
or SDD. 
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Table 8.3b Summary of Clinical Parameters, Their Associated Values 
and Ranges for Sensitivity Analysis at DGH 
Clinical No SDD SDD Incremental Ranges for 
Parameter Effect Size Sensitivity 
due to SDD Analysis 
Late-onset 17' 8 53 42 95% Cl: 43-634 
Gram negative Extremes: 10- 
pneumonia 804 
rate/% 
ICU 18.0 18.0 0 0-104 
Mortality/% 
6 month 40.7 40.7 0 0- 104 
mortality/% 
Life 17.3 17.3 0 8.7-26.0` 
Expectancy per 
ICU 
survivor/LYGs 
dQALYs per 6.3 6.3 0 0.8- 9.94 
ICU survivor3 
' Base pneumonia rate varied from 10% to 24% 
24 Indicates that there is a decrease in the parameter 
3 Discount rate 5% 
Sensitivity analysis ranges are used to vary these parameters for both SDD and non- 
SDD patients. There is no incremental effect attributable to ICU-acquired pneumonia 
or SDD. 
8.5 ACQUISITION OF ECONOMIC EVIDENCE 
This section summarises the economic evidence for use in the decision- 
analytic model. The cost consists of resource use and unit costs 
associated with that resource use. The two categories of resource use 
and unit costs are SDD implementation and treatment of ICU-acquired 
pneumonia. The costs incurred on ICU only are examined in this 
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economic analysis. Summaries of the economic data obtained for use in 
the revised economic evaluation are provided at the end of this section 
for both LTH and DGH. 
8.5.1 Resource Use and Unit Costs Associated with SDD 
Implementation 
The resource use and unit costs associated with the SDD regimen has 
three components. These are the drug treatment, the microbiological 
surveillance and the maintenance of side effects of SDD. 
8.5.1.1 Resource Use Associated with SDD Pharmaceutical Regimen 
The SDD pharmaceutical regimen modelled to be used by each centre in 
the event of implementing SDD is that reported most commonly used by 
British SDD users in the survey reported in Chapter Seven. The 
standard regimen proposed by Stoutenbeek et al [1984) and that used 
by the majority of published SDD studies is used most widely in Britain. 
Polymixin E, tobramycin and amphotericin (PTA) gel and liquid are 
reported to be used four times a day during the ICU stay. The gel is 
bought from a hospital pharmacy manufacturing unit. The constituents 
of the liquid are bought commercially. Intravenous cefotaxime 1g is 
used four times a day for the first three days. For each centre, the 
estimated theoretical costs of the SDD pharmaceutical regimen were 
derived from local drug acquisition, pharmacy overhead and 
administration costs. These costs are summarised in Table 8.4. 
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Table 8.4 Estimated Theoretical Cost of SDD Regimen at LTH and DGH 
Using Local Costs 
Regime constituents Cost at LTH/E Cost at OGH/£ 
PTA Oral gel'-2 2.60 2.70 
PTA Liquid 2: 
Polymixin E 2mu qds 3.98 4.29 
Tobramycin 80mg qds 12.08 19.96 
Amphotericin 500mg qds 5.68 6.32 
Cefotaxime 1g iv qds for 3 days 59.52 57.60 
Acquisition cost from BRI [1994); pharmacy overhead cost added for each centre 
2 Cost per day 
8.5.1.2 Cost of Microbiological Surveillance of SDD 
Expected microbiological surveillance associated with SDD use is 
described in Chapter Four. The resource sparing, resource moderate and 
resource intensive surveillance programmes proposed in that evaluation 
are used in this economic analysis, substituting local costs for individual 
tests. Tables 8.5a and 8.5b summarise the estimated costs of these 
three models. 
Table 8.5a Estimated Costs of Microbiological Surveillance at LTH 
Model Cost on admission/£ Cost during stay/£ 
Resource sparing 0 8.34 on suspicion of 
pneumonia 
Resource moderate 15.30 15.30 every 3rd day 
Resource intensive 27.82 23.64 every 3rd day 
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Table 8.5b Estimated Costs of Microbiological Surveillance at DGH 
Model Cost on admission/C Cost during stay/f 
Resource sparing 0 9.00 on suspicion of 
pneumonia 
Resource moderate 18.00 18.00 every 3rd day 
Resource intensive 37.00 27.00 every 3rd day 
8.5.1.3 Cost Associated with the Maintenance of Side Effects Arising 
from SDD 
As there is no evidence to the contrary, it is assumed that there are no 
complications associated with the use of SDD, including outbreaks of 
antibiotic-resistant bacteria. 
The SDD regimen selected for use in the economic evaluation is 
summarised in Tables 8.6a and 8.6b. This is referred to as the 
'resource moderate' regimen at each centre. To assess the effect of 
more or less intensive SOD regimens on cost/outcome ratios, a 'resource 
sparing' and a 'resource intensive' model are also summarised in the 
table. These models have the same components as those used in the 
economic evaluation in Chapter Four. The resource sparing regimen 
uses daily PTA, the lowest level of microbiological surveillance and no 
cefotaxime. The resource intensive regimen uses the highest level of 
microbiological surveillance, cefotaxime and daily PTA. The impact of 
these models is examined in the sensitivity analysis. 
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Table 8.6a Summary of SDD Regimens Proposed for Use in Economic 
Evaluation at LTH 
Component of Regimen Resource Resource Resource 
Sparing Moderate Intensive 
Regimen Regimen Regimen 
Cost of PTA gel and liquid 24.34 24.34 24.34 
per day/f 
Cost of Cefotaxime 1g iv - 59.52 59.52 
qds for 4 days/£ 
Cost of microbiological 0 15.30 27.82 
surveillance on admission/£ 
Cost of microbiological 8.34' 15.30 23.64 
surveillance twice a week/£ 
' On suspicion of pneumonia only 
Table 8.6b Summary of SDD Regimens Proposed for Use in Economic 
Evaluation at DGH 
Component of Regimen Resource Resource Resource 
Sparing Moderate Intensive 
Regimen Regimen Regimen 
Cost of PTA gel and liquid 33.27 33.27 33.27 
per day/£ 
Cost of Cefotaxime 1g iv - 57.60 57.60 
qds for 4 days/£ 
Cost of microbiological 0 18.00 37.00 
surveillance on admission/£ 
Cost of microbiological 9.00' 18.00 27.00 
surveillance twice a week/£ 
' On suspicion of pneumonia only 
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8.5.2 Resource Use and Unit Costs Associated with ICU-Acquired 
Pneumonia 
Resource use resulting from ICU-acquired pneumonia can be divided into 
two parts. The first is the resultant increase in stay on the ICU and 
increase of overall hospital stay. The second is the increase in 
treatment resulting from pneumonia. The unit costs required are those 
associated with a day's stay on ICU and with treating an episode of 
pneumonia. The prospective study reported in Chapter Six identified 
cost independently associated with ICU-acquired pneumonia in 
ventilated patients at the two centres. Tables 8.7a and 8.7b summarise 
the impact of ICU-acquired pneumonia on cost at LTH and DGH, derived 
from the regression analysis in Chapter Seven. 
Table 8.7a Ranges of Parameters Required for Economic Analysis for 
the LTH Dataset 
Parameter for Use in Economic Base case Ranges for 
Analysis value Sensitivity 
Analysis 
Increase in length of ICU stay due to 116 88-144% 
pneumonia derived from linear 
regression/% 
Length of stay of uninfected 4.1 3.7,4.6 
patient/days' 
Length of stay of patient with ICU- 8.9 8.7,9.2 
acquired pneumonia/days' 
Increase in variable cost per patient 53.3 2.4-101.3 
day due to pneumonia derived from 
linear regression/£ 
' Uninfected and infected lengths of stay derived from 88% increase in length of ICU 
stay are 4.6 and 8.7 days respectively. Uninfected and infected lengths of stay 
derived from 144% increase in length of ICU stay are 3.7 and 9.2 days respectively. 
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Table 8.7b Ranges of Parameters Required for Economic Analysis for 
the DGH Dataset 
Parameter for Use in Economic Base case Ranges for 
Analysis value Sensitivity 
Analysis 
Increase in length of ICU stay due to 111 78-144% 
pneumonia derived from linear 
regression/% 
Length of stay of uninfected 5.2 4.9,5.5 
patient/days' 
Length of stay of patient with ICU- 10.9 9.8,11.9 
acquired pneumonia/days' 
Increase in variable cost per patient 0 02 
day due to pneumonia derived from 
linear regression/£ 
' Uninfected and infected lengths of stay derived from 78% Increase in length of ICU 
stay are 5.5 and 9.8 days respectively. Uninfected and infected lengths of stay 
derived from 144% increase in length of ICU stay are 4.9 and 11.9 days respectively. 
I Mean variable cost per patient day is £362.4.95% Cl: £4.8 to £720.0. 
8.5.3 Summary of Cost of Patients for Economic Evaluation of SDD at 
LTH and DGH 
This section has listed all the economic parameters required for the 
economic evaluation of SDD, with justified ranges for sensitivity 
analysis. For both centres, the cost of treating a ventilated admission, 
whether they suffer an episode of ICU-acquired pneumonia or not, has 
been reported. An estimated theoretical cost of SDD implementation 
has also been reported. The combination of these two categories of 
cost enables a theoretical cost to be derived for treating those patients if 
SDD were implemented. Those derived costs are reported in Table 8.8 
and are used in the base case cost/outcome analysis reported in section 
8.6. Values of the economic parameters are varied according to the 
ranges reported in this section for sensitivity analysis in section 8.7. 
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Table 8.8 Summary of Patient Costs at LTH and DGH for Base Case 
Economic Evaluation of SDD 
Ventilated patient subgroup Cost per patient 
at DGH/£ 
Cost per patient 
at LTH/£ 
No SDD, no ICU acquired pneumonia 5207 4199 
No SDD, ICU acquired pneumonia 10915 9584 
SDD, no ICU acquired pneumonia 5489 4395 
SDD, ICU acquired pneumonia 11421 9921 
8.6 INCREMENTAL ECONOMIC ANALYSIS OF SDD AT LTH AND DGH 
In this section, the incremental costs and outcome changes that would 
occur if SDD were implemented at DGH and LTH were derived. This 
was carried out by attaching the epidemiologic, clinical and economic 
data to the decision analytic model for each centre. A 'base case' 
model was produced using clinical and economic point estimates. 
Firstly, clinical probabilities were attached to the decision-analytic 
model, from Tables 8.3a and b, for each of the two centres, as shown 
in Figures 8.2a and 8.2b. It was still not possible to attach clinical 
probabilities to Tree B because there was no available evidence on the 
effect of pneumonia or SDD on life expectancy from the empirical study. 
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Figure 8.2a: Decision-Analytic Model of SDD, Including Clinical 
Probabilities at LTH 
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Figure 8.2b: Decision-Analytic Model of SDD, Including Clinical 
Probabilities at DGH 
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The economic data was also attached to the decision analytic models, 
as summarised in Table 8.8. Incremental economic analyses wore 
carried out for both centres. They are considered separately below. 
8.6.1 Incremental Economic Analysis at LTH 
At LTH, 171 ventilated patients were admitted to ICU during the study 
period. They had a 65% chance of contracting an episode of ICU- 
acquired pneumonia which included a 32% chance of contracting a 
Gram-negative late onset pneumonia. If infected, they cost the ICU 
£9584 each and had a 50.3% chance of dying in the following six 
months. If they did not contract pneumonia, they cost the ICU £4199 
each and still had a 50.3% chance of dying in the following six months. 
The six month survivors were assumed to have gained 17.3 LYGs and 
6.3 dQALYs each. For the SDD arm of the model, these 171 patients 
were modelled to receive SDD. They therefore would have had a 48% 
chance of contracting ICU-acquired pneumonia, including a 17% chance 
of contracting Gram-negative late onset pneumonia. Infected and 
uninfected patients would have cost the ICU £9921 and £4395, 
respectively. They would have had the same outcomes as the patients 
who do not receive SDD. 
Without the use of SDD, 111 patients contracted pneumonia and 86 
died in the following six months, at a total cost of £1.317x108. The 85 
survivors theoretically gained 1470.5 LYGs and 535.5 dQALYs in total. 
If the 171 patients were treated with SDD from ICU admission, 82 
would have contracted pneumonia and 86 would have died in the 
following six months at a cost of £1.205x108. The 85 survivors gained 
1470.5 LYGs and 535.5 QALYs in total. The overall incremental 
decrease in cost associated with the patients who receive SDD would 
have been £0.11x106. This decrease in cost would have been 
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associated with 29 fewer episodes of pneumonia, no fower ICU deaths, 
or additional LYGs or added dQALYs. The inference is that SDD is the 
dominant therapy. If reduction in pneumonia rate is assumed to an 
intermediate outcome, then there is no change in ultimate patient 
outcome associated with SDD. Therefore this analysis becomes a cost 
minimisation analysis. The therapy is still dominant because the use of 
SDD results in an overall reduction in cost per six month survivor of 
£1307. This analysis is reported in Table 8.9a. 
8.6.1 Incremental Economic Analysis at DGH 
At DGH, 89 ventilated patients were admitted to ICU during the study 
period. They had a 28% chance of contracting an episode of ICU- 
acquired pneumonia which included a 17% chance of contracting a 
Gram-negative late onset pneumonia. If infected, they cost the ICU 
£10915 each and had a 40.7% chance of dying in the following six 
months. If they did not contract pneumonia, they cost the ICU £5207 
each and still had a 40.7% chance of dying in the following six months. 
The six month survivors were assumed to have gained 17.3 LYGs and 
6.3 dQALYs each. For the SDD arm of the model, these 89 patients are 
modelled to receive SDD. They therefore would have had a 19% 
chance of contracting ICU-acquired pneumonia, including an 8% chance 
of contracting Gram-negative late onset pneumonia. Infected and 
uninfected patients would have cost the ICU £11421 and £5489, 
respectively. They would have had the same outcomes as the patients 
who do not receive SDD. 
Without the use of SDD, 25 patients contracted pneumonia and 36 died 
in the following six months, at a total cost of £6.057x106. The 53 
survivors gained a theoretical 916.9 LYGs and 333.9 dQALYs in total. 
If the 89 patients were treated with SDD from ICU admission, 17 would 
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have contracted pneumonia and 36 would have died in the following six 
months at a cost of £5.888x105. The 53 survivors would have gained 
916.9 LYGs and 333.9 dQALYs in total. The overall incremental 
decrease in cost associated with the patients who receive SDD would 
have been £0.17x106, This decrease in cost would have boon 
associated with 8 fewer episodes of pneumonia, no fewer ICU deaths, 
or additional LYGs or added dQALYs. The inference is that SDD is the 
dominant therapy. If a cost minimisation analysis is carried out, the 
therapy is still dominant because the use of SDD would result in an 
overall reduction in cost per six month survivor of E319. This analysis 
is reported in Table 8.9b. 
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8.7 SENSITIVITY ANALYSIS 
The conclusions from the economic analyses that SOD is dominant at 
the two centres only hold for the conditions defined in the base cases. 
It is necessary to test the sensitivity of this dominance at the two 
centres to variation in underlying parameters. The ranges of the 
variation of the parameters are used as outlined in sections 8.4 and 8.5. 
The parameters examined are variation in SOD effectiveness in reducing 
pneumonia rates; base pneumonia rates; pneumonia-attributable 
mortality; cost of different SDD regimens; increased length of ICU stay 
due to pneumonia and costs associated with pneumonia treatment. 
8.7.1 Effect of Changing Decrease in Pneumonia Rate by SDD 
The reduction in ICU-acquired pneumonia rate by SDD is 53% (95% Cl: 
43% to 63%). The sensitivity analysis examines the impact of variation 
of SDD effectiveness on the conclusion that SDD is dominant, at both 
ICUs. However, reported reductions in pneumonia rate by SDD range 
from 10 to 80%, so the effect of this amount of variation is also 
examined. Table 8.10 summarises the effect that these variations in 
reduction in pneumonia rate have on cost per pneumonia avoided and 
cost per six month survivor. Figures 8.3 and 8.4 illustrate the impact on 
cost per pneumonia avoided and cost per six month survivor of changing 
the decrease in pneumonia rate, in stages from 10% to 80%. The base 
case (B) where there is 53% reduction and the low (L) and high (H) 
limits of the 95% confidence intervals are marked on the graph. 
This sensitivity analysis suggests that SDD is dominant at both centres 
within the 95% confidence intervals of effectiveness. Therefore, the 
conclusion that SOD is dominant at LTH and DGH is insensitive to the 
effectiveness of SDD. SDD becomes the dominant therapy at DGH 
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where it reduces pneumonia rates by at least 34%. In comparison, SDD 
becomes the dominant therapy at LTH where it reduces pneumonia rates 
by at least 18%. It is suggested that this difforonco can bo attributed to 
the higher ICU-acquired pneumonia incidence at LTH. The analysis in 
Chapter Four showed that a higher base pneumonia rate increased the 
cost effectiveness of SDD. 
Table 8.10 Effect of Variation of Reduction in Pneumonia Rates by SDD 
on Cost/Outcome Ratios at Both Centres 
Upper and lower limit of sensitivity 
analysis and base value of SDD efficacy 
Incremental cost/C 
Cost per pneumonia avoided DGH LTH 
l 10% pneumonia rate by SDD 14327 3454 
453% pneumonia rate by SDD -2109 -3832 
480% pneumonia rate by SDD -3399 -4404 
J 
Incremental cost per six month survivor 
410% pneumonia rate by SDD 2167 1178 
$ 53% pneumonia rate by SOD -319 -1307 
480% pneumonia rate by SDD -514 -1502 
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Figure 8.3 Graph to Show Effect of Variation of SDD Efficacy on 
Incremental Cost per Pneumonia Avoided at DGH and LTH 
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Figure 8.4 Graph to Show Effect of Variation of SDD Efficacy on 
Incremental Cost per Six Month Survivor at DGH and L TH 
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8.7.2 Effect of Changing Base Pneumonia Rate 
The base ICU-acquired and Gram-negative late onset pneumonia rates 
are known for both centres. It is known from the analysis in Chapter 
Four that this parameter significantly affects the cost effectiveness of 
SDD. The higher the base pneumonia rates are, the more cost effective 
SDD can be. The ICU-acquired and Gram-negative late onset pneumonia 
rates are 65% and 32% at LTH, and 28% and 17% at DGH. These 
observed values were derived empirically and have 95% confidence 
intervals. Therefore, the cost per pneumonia avoided curves in Figure 
8.3 are actually more accurately represented as bands, with the 
boundaries defined by the 95% confidence intervals of the incidence 
rates. This is represented graphically for each centre in Figures 8.5a 
and 8.5b. The bands are narrow at both centres, due to the narrow 
95% confidence intervals around the pneumonia incidences. 
The conclusion that SDD is dominant at LTH is not changed within 
these ranges. However, the conclusion that SOD is dominant at DGH is 
not robust to variation in base pneumonia rates. Figure 8.5b shows that 
at the lower 95% confidence interval where the base pneumonia rate is 
10%, SDD loses dominance. This reinforces the conclusions made in 
Chapter Four that the cost effectiveness of SDD is very sensitive to 
base pneumonia rates. 
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Figure 8.5a Effect of Variation of SDD Efficacy on Incremental Cost per 
Pneumonia Avoided at LTH (including 95% confidence intervals for base 
pneumonia rate) 
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Figure 8.5b Effect of Variation of SDD Efficacy on Incremental Cost per 
Pneumonia Avoided at DGH (including 95% confidence intervals for 
base pneumonia rate) 
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8.7.3 Effect of Changing Mortality Effects of Pneumonia 
The base case models for both centres assumed that ICU-acquired 
pneumonias did not increase mortality. This sensitivity analysis 
examines the impact of an increase in mortality associated with 
pneumonia and the associated reduction in mortality in the SDD-treated 
group. The number of deaths averted by SDD (and thus LYGs and 
dQALYs gained) is entirely dependent upon the magnitude of the 
reduction in pneumonia rate. The change in cost due to the 
implementation of SDD is not affected. SDD is dominant at both 
centres, so any deaths averted occur in conjunction with a reduction in 
cost. If mortality is not reduced by SDD there will be no deaths averted 
and no associated LYGs or QALYs gained at either centre. If the 
mortality were reduced by 10%, there would be 8.5 deaths averted at 
six months after ICU discharge, 147.7 LYGs and 53.8 dQALYs gained 
at LTH. The cost reduction would still be £111131. Similarly, at DGH, 
there would be 3.4 deaths averted at six months after ICU discharge, 
58.5 LYGs and 21.3 dQALYs gained. The cost reduction would still be 
£16905. This sensitivity analysis implies that, in a time period of eleven 
months, at least eight lives could have been saved at LTH and three at 
DGH if SDD were implemented, along with the associated LYGs and 
dQALYs gained. However, this is based on the assumption that, in 
reducing pneumonia rates, SDD also reduces mortality. This has not 
been unequivocally proven, so these results can only be tentatively 
supported. 
The second area of uncertainty here is the precision of the estimates for 
LYGs and dQALYs. The values for LYGs and dQALYs are very tentative 
due to their sources, discussed in Chapter Four. The significant 
uncertainty surrounding these values is reflected in their wide, and 
largely arbitrary, ranges for sensitivity analysis. The sensitivity ranges 
selected for LYGs (8.7 to 26.0) and dQALYs gained (0.8 to 9.9) from 
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Tables 8.3a and 8.3b are used to derive ranges for those outcome 
measures. The results of this analysis are reported in Tablas 8.11 a and 
8.11 b. 
However, the uncertainty around these outcome parameters does not 
change the conclusion that SDD is dominant at both centres, so the 
conclusions are insensitive to the variation arising from this uncertainty. 
Table 8.11 a Effect of the Assumption that SDD Causes a 10% 
Reduction in Six Month Mortality at LTH 
Outcome parameter Units of 
outcome gained 
Sensitivity 
Analysis Range 
Deaths averted at six months 8.5 - 
LYGs 147.7 74.3-222.0 
dQALYs gained 53.8 6.8-84.6 
Table 8.11 b Effect of the Assumption that SDD Causes a 10% 
Reduction in Six Month Mortality at DGH 
Outcome parameter Units of 
outcome gained 
Sensitivity 
Analysis Range 
Deaths averted at six months 3.4 
LYGs 58.5 29.4-87.9 
dQALYs gained 21.3 2.7-33.5 
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8.7.4 Effect of SDD Regimen 
This section examines the impact of varying the components of the SDD 
regimen to make it more or less resource intensive. Table 8.12 
summarises the effect of using the three regimens outlined in section 
8.5.1. This is also depicted graphically in Figures 8.6a and 8.6b. This 
sensitivity analysis suggests that SDD is dominant at both centres 
however resource intensive the SDD regimen. Therefore, the conclusion 
that SDD is dominant at LTH and DGH is insensitive to the cost of the 
SDD regimen. 
Table 8.12 Effect of Variation of SDD Regimen on Cost/Outcome Ratios 
at Both Centres 
Effect of different SDD regimens on cost/outcome 
ratios 
Incremental cost/£ 
Cost per pneumonia avoided DGH LTH 
Resource intensive SDD regimen -1711 -3653 
Resource moderate SDD regimen (base case) -2109 -3832 
Resource sparing SDD regimen -3179 -4428 
Incremental cost per six month survivor 
Resource intensive SDD regimen -259 -1246 
Resource moderate SOD regimen (base case) -319 -1307 
Resource sparing SDD regimen -481 -1511 
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Figure 8.6a Effect of Different SDD Regimens on Incremental Cost per 
Pneumonia Avoided at LTH 
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Figure 8.6b Effect of Different SDD Regimens on Incremental Cost per 
Pneumonia Avoided at DGH 
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8.7.5 Effect of Increase in Length of ICU Stay Attributable to 
Pneumonia 
The base case model for DGH and LTH assumes an increase in length of 
ICU stay due to pneumonia of 111 % and 116%, respectively. These 
values were derived from linear regression and have 95% confidence 
intervals associated with them. This section examines the effect on the 
conclusion that SDD is dominant at both centres if the increase in length 
of stay is varied up to these ranges for each centre. Table 8.13 
summarises the effect of this variation on cost/outcome ratios. It can 
be seen that SDD becomes more cost effective as length of stay 
increase due to pneumonia is increased. This is illustrated in Figure 8.7, 
where the variation in cost per pneumonia avoided only is examined. 
SDD becomes the dominant therapy if the increase in length of ICU stay 
due to pneumonia is at least 20% at LTH, and at least 65% at DGH. 
This sensitivity analysis suggests that SDD is dominant at both centres 
within the 95% confidence intervals of the increase in length of ICU 
stay attributable to ICU-acquired pneumonia. Therefore, the conclusion 
that SDD is dominant at LTH and DGH is insensitive to the variation in 
this parameter. 
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Table 8.13 Effect of Variation of Increase In Length of ICU Stay by 
Pneumonia at Both Centres 
t Length of ICU stay 
by pneumonia 
Cost per 
pneumonia 
avoided/£ 
Cost per six 
month 
survivor/£ 
DGH 
t 78% (Lower limit) -758 -115 
t 111 % (Base value) -2109 -319 
t 144% (Upper limit) -3501 -530 
L TH 
t88% (Lower limit) -3081 -1051 
t 116 (Base value) -3832 -1307 
t 144% (Upper limit) -4467 -1524 
332 
Figure 8.7 Graph to Show Effect of Variation of Incroaso in Length of 
ICU Stay Due to Pneumonia at LTH and DGH 
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8.7.6 Effect of Increased Treatment Intensity 
Increase in treatment intensity due to ICU-acquired pneumonia is only 
reported to occur at LTH. The increase in variable cost per patient day 
derived from the LTH dataset is £53.3 (95% Cl: £2.4-£101.3). Table 
8.14 summarises the effect of this variation on cost per pneumonia 
averted and cost per six month survivor. This sensitivity analysis 
suggests that SDD is dominant within the 95% confidence intervals of 
the increase in variable cost per patient day attributable to ICU-acquired 
pneumonia. Therefore, the conclusion that SDD is dominant at LTH is 
insensitive to the variation in this parameter. This is illustrated in Figure 
8.8, where the variation in cost per pneumonia avoided only is 
examined. 
Table 8.14 Effect of Variation of Increase in Variable Cost per Patient 
Day by ICU-Acquired Pneumonia at LTH 
t Variable cost per 
patient day by 
pneumonia/£ 
Cost per 
pneumonia 
avoided/£ 
Cost per six 
month 
survivor/£ 
t £2.4 (Lower limit) -3538 -1207 
t £53.3 (Base value) -3832 -1307 
t £101.3 (Upper limit) -4114 -1404 
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Figure 8.8 Graph to Show Effect of Variation of Variable Cost per 
Patient Day Due to Pneumonia at LTH 
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8.7.7 Summary of Sensitivity Analysis 
In summary, this sensitivity analysis has suggested that the conclusion 
that SOD is dominant at both centres is robust to variation in underlying 
parameters. The sensitivity analyses carried out are summarised below. 
8.7.7.1 Increases in SDD effectiveness increase the cost effectiveness 
of SDD. The conclusion that SDD is dominant at both centres was not 
affected by variation in this parameter. 
8.7.7.2 Increased base ICU-acquired pneumonia rates lead to increased 
cost effectiveness of SDD. The conclusion that SDD is dominant at LTH 
was not affected by variation in this parameter. At DGH, however, SDD 
lost dominance if this parameter was varied. 
8.7.7.3 The assumption that there is an increase in short term mortality 
due to ICU-acquired pneumonia means that SDD could reduce mortality 
rates and increase LYGs and QALYs gained by ICU patients. Although 
there was much uncertainty around the estimates for LYGs and QALYs 
gained, this did not change the conclusion that SOD was dominant at 
both centres. 
8.7.7.4 More resource intensive versions of the SDD regimen could 
reduce the cost effectiveness of SDD. However, the conclusion that 
SDD is dominant at both centres was not affected by variation in this 
parameter. 
8.7.7.5 The larger the increase in length of ICU stay attributable to 
ICU-acquired pneumonia, the more cost effective SDD could become. 
However, the conclusion that SDD is dominant at both centres was not 
affected by variation in this parameter. 
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8.7.7.6 The more costly it is to treat a patient with pneumonia, the 
more cost effective SDD could become. However, the conclusion that 
SDD is dominant at LTH was not affected by variation in this parameter. 
8.8 AN EXAMINATION OF THE 'ADDED VALUE' OF THE ECONOMIC 
EVALUATION OF SDD AT LTH AND DGH 
This section compares the results obtained from this economic 
evaluation with those obtained from the economic evaluation of SDD in 
Chapter Four. Whether there is 'added value' gained from the addition 
of empirical evidence is examined. Added value can be interpreted as 
an increase in robustness or relevance of conclusions. This may be due 
to a decrease in an area of uncertainty, quantification of an area of 
uncertainty or use of clinical or economic evidence that is more relevant 
to a particular setting. The impact of clinical and economic evidence on 
the robustness of conclusions is investigated. Reasons for differences 
between the conclusions for the two centres are suggested. 
8.8.1 Impact of Improved Clinical Evidence 
The areas of clinical evidence required for economic evaluation of SDD 
are the effectiveness of SDD in reducing ICU-acquired pneumonia rates, 
base ICU-acquired pneumonia rates, and the impact of ICU-acquired 
pneumonia on long term mortality and morbidity. The impact of 
variation of these parameters on conclusions is examined in this section. 
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8.8.1.1 Effect of Information Regarding SDD Effectiveness 
The ability of SDD to reduce ICU-acquired pneumonia rates has been 
shown by both economic evaluations in this thesis to have a vary largo 
impact on SDD's cost/outcome ratios. The large amount of clinical 
evidence available suggests that SDD has a relatively consistent effect 
on reducing ICU-acquired pneumonia rates, in a clinical trial context at 
least. A succession of meta-analyses have produced similar point 
estimates for reduction in pneumonia rates. The point estimate (53%) 
produced by the meta-analysis in Chapter Four has very narrow 
confidence intervals (43% to 63%) indicating that the point estimate is 
precise. Therefore, although variation in effectiveness affects 
cost/outcome ratios significantly, in practice, this variation is not 
expected to occur. However, these point estimates for effectiveness 
are actually point estimates for efficacy of SDD as measured within the 
conditions of an RCT. Effectiveness of SDD is the ability of SDD to 
reduce ICU-acquired pneumonia rates in a practice setting. Due to less 
rigorous patient selection and deviation from recommended practices 
and regimens, the effectiveness of SDD is likely to be lower than its 
efficacy. The two economic evaluations in this thesis use published 
efficacy data. This reliance on secondary clinical data reduces the 
relevance of the economic evaluations to the centres in which they are 
based. 
8.8.1.2 Effect of Local Epidemiological Information on Pneumonia Rates 
The economic evaluation in Chapter Four illustrated that variations in 
local ICU-acquired pneumonia incidence rates have a very largo effect on 
the cost/outcome ratios of SDD. Knowing the local pneumonia rate 
therefore eradicates the possibility of this variation in the economic 
evaluation of SDD at LTH and DGH. The conclusion that SDD is 
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dominant is, therefore, more robust due to this extra information. The 
economic evaluation in Chapter Four suggested that the higher the local 
pneumonia rate, the more cost effective SDD is shown to be. This is 
illustrated in the economic evaluation reported in this chapter. 
8.8.1.3 Effect of Information Regarding Impact of ICU-Acquired 
Pneumonia on Mortality and Morbidity 
Chapter Four suggested that there was a lack of evidence available on 
the effect of SDD on the ultimate outcome of the patient, in terms of 
mortality and morbidity. It is probable that ICU-acquired pneumonia may 
increase mortality in the short term. This assumption is used in the 
economic evaluation in Chapter Four. Values were derived from the 
meta-analysis of SDD trials, so were secondary data, not measured on 
the actual patient group to which they were applied. This, and their 
algebraically derived nature, decreased the robustness of conclusions 
drawn when using them. 
The statistical analysis reported in Chapter Six suggested that there was 
no increase in short term mortality that could be attributed to ICU- 
acquired pneumonia. It was suggested that the lack of effect detected 
was largely due to the insufficient patient group sizes. The impact of an 
increase in mortality due to ICU-acquired pneumonia as derived in 
Chapter Four was examined in the sensitivity analysis for this economic 
evaluation. 
There is no published evidence on the impact of SDD or ICU-acquired 
pneumonia on longer term mortality or morbidity. The lack of evidence 
meant that alternative sources had to be used in the economic 
evaluation in Chapter Four. The resultant cost/outcome ratios were vary 
tentative with very wide and arbitrary ranges. In the economic analysis 
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in this chapter, the same sources for long term mortality and morbidity 
were used as for the economic evaluation in Chapter Four. This 
variation did not affect conclusions about the cost effectiveness of SDD 
in any of the economic evaluations. 
8.8.2 Impact of Improved Economic Evidence 
The areas of economic evidence required for economic evaluation were 
resource use and associated unit costs arising from SOD implementation 
and the maintenance of ICU-acquired pneumonia. This latter category 
can be divided into increased length of ICU stay due to ICU-acquired 
pneumonia, cost associated with one patient day on ICU and increased 
cost associated with increased therapeutic intensity. 
8.8.2.1 Effect of Information on SDD Regimen 
In the secondary economic evaluation in Chapter Four, the most 
common SDD regimen reported in the SDD trials was used and local 
British costs were attached to it. The types of regimens reported were 
relatively uniform. The more resource sparing regimens examined were 
more cost effective. In the revised economic evaluation reported in this 
chapter, the SOD regimens used were based on a survey of SDD use in 
the UK. Costs from the two study centres were attached to these 
regimens. Again, the more resource sparing regimens provided SDD 
with the opportunity to be more cost effective, although the variation 
was not particularly large. However, the dominance of SOD was not 
affected by varying the regimen used. 
In the economic evaluation in this chapter, use of SDD regimens known 
to be used in the UK and costs appropriate to that particular centre 
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increased the relevance of the costs of the SDD regimens. Tho 
dominance of SDD was not affected at either contra by varying tho 
regimen used. 
8.8.2.2 Impact of Information on Increase In ICU Length of Stay by 
ICU-Acquired Pneumonia 
The economic evaluation in Chapter Four suggested that the extent of 
increase in ICU length of stay by ICU-acquired pneumonia had a 
significant impact on the cost effectiveness of SDD. The larger the 
increase, the more cost effective SDD became. The increase in length 
of ICU stay was algebraically derived from the meta-analysis of SDD 
trials. The conclusion that SDD was a dominant therapy was sensitive 
to variation in this parameter, due to the wide ranges employed for 
sensitivity analysis. The economic evaluation in this chapter used 
increases in length of ICU stay statistically derived from empirical data. 
The mean increases had associated 95% confidence intervals, so the 
uncertainty surrounding point estimates was quantified. Variation within 
these ranges did not affect the conclusion that SOD was dominant at 
either centre. The conclusion that SDD is dominant is, therefore, more 
robust due to this extra information. 
8.8.2.3 Effect of Information on Cost per Patient Day 
In the economic evaluation reported in Chapter Four, the cost per day on 
intensive care was derived from a British study and inflated to a current 
year, giving a value of £886 per day. The costs were rigorously 
collected in the study and were British, increasing their relevance. 
However, they were four years old, so this decreased their robustness. 
Using this data, increased cost per day was demonstrated to moderately 
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increase the cost effectiveness of SDD. Largo variations in cost par day 
were necessary to reverse the conclusion that SDD was dominant. The 
economic evaluation reported in this chapter uses costs per ICU day that 
have been empirically determined. This is considered to increase the 
applicability and relevance of the economic evaluation to each contra. 
8.8.2.4 Effect of Information on Costs Associated with Treatment of 
Pneumonia 
The economic evaluation in Chapter Four examined the impact of an 
increase in treatment intensity associated with the treatment of 
pneumonia on cost/outcome ratios. Secondary evidence on this was 
very difficult to find. This meant that multiple sources had to be used, 
most of which were not British and not very current. The final 
estimates achieved were not very precise and wide sensitivity ranges 
had to be used. Sufficient variation in this parameter reversed the 
conclusion that SDD was dominant. 
The empirical study reported in Chapters Six and Seven was able to 
identify an increase in variable cost per day (with 95% confidence 
intervals) at LTH, but not at DGH. Variation within these ranges did not 
affect the conclusion that SDD was dominant. The conclusion that SDD 
is dominant is, therefore, more robust due to this extra information. 
8.9 REALISABLE COST SAVINGS FROM THE IMPLEMENTATION OF 
SDD 
This section examines to what extent the theoretical cost/outcome 
ratios that have been derived in this economic analysis can be translated 
into realisable cost savings at either centre. Local organisational factors 
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that may affect realisable cost savings that arc considorod horo are ICU 
occupancy rates and patient refusal rates. Each contra is considored 
separately. 
8.9.1 Realisable Cost Savings at LTH 
This economic evaluation has suggested that, given the conditions 
stated, the implementation of SDD at LTH reduces the incidence of ICU- 
acquired pneumonia, at a lower cost. The use of SDD in 171 ventilated 
patients, admitted over a period of 11 months, results in theoretical cost 
savings of £11 1131. This would be equivalent to treating 187 
ventilated patients at a saving of £121234 per year. 
In practice, local organisational factors will affect this theoretical cost 
saving. LTH ICU has a mean occupancy of 93.5% (range 88.4 to 
97.7%) and a mean refusal rate of 44% (range 26 to 65%). Total 
admissions for 1994 were 259. This means that a further 220 
admission requests were refused. This refusal rate does not take 
account of early ICU discharges and may include one patient being 
refused more than once. However, these figures suggest that this ICU 
is a high occupancy unit that turns away a significant proportion of 
potential admissions. The reasons for refusal were not recorded. 
According to Metcalfe et a/ (19951,31 % of ICU refused admissions in 
the UK in 1992 were appropriate, that is, the patient was not suitable 
for ICU. The remaining refused admissions were due to the size of the 
unit and lack of nursing staff. If this proportion is assumed to 
approximate to the situation at LTH, this would mean that of the 220 
refused admissions, 68 were turned away appropriately and 152 were 
refused admission due to the ICU being full or not having enough staff. 
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The use of SDD reduces the length of stay of 29 ventilated patients 
who do not contract late-onset Gram-negative pneumonia from 8.9 to 
4.1 days. In the 171 patients studied, this equated to 139 patient days 
being made available by SDD. In one year this would make available 
152 patient days, equivalent to 0.41 ICU beds. If occupancy of these 
beds is 93.5%, this suggests that 142.1 patient days could be 
otherwise utilised. These could, in theory, be filled by erstwhile refused 
admissions. The mean length of ICU stay of ICU patients at LTH in 
general is 6.83 days. This suggests, therefore, that an extra 21 
patients could be treated on the ICU if SOD were implemented. This 
would increase annual admissions to 280 and reduce the mean patient 
refusal rate to 41.5%. 
This increase in patient turnover at a constant level of occupancy will 
affect the resource use of the ICU, as described in Chapter Four. If the 
patient days made available by SDD are immediately filled, as suggested 
above, the occupancy of the unit is not decreased. So, the ICU is 
required to run at the same occupancy level as before. Fixed costs 
cannot be 'saved' in practice, as they are independent of activity. 
Nursing costs are also not 'saved' in practice, as they will be directed to 
the extra admissions. Variable costs saved by the shorter length of ICU 
stay will also not be saved in practice as they will be absorbed by the 
extra admissions. Also, there would be the added cost of SOD 
implementation. This would equate to £53519 per year to treat 187 
ventilated admissions. Therefore, the introduction of SDD could 
theoretically increase the patient turnover of the ICU by 21 patients per 
year at an added cost of £53519. 
However, from the perspective of the refused admissions, the 
opportunity cost associated with refusal would be avoided. Metcalfe of 
a/ [19951 did not find an increase in hospital mortality among refused 
admissions, that could be attributed to their refusal. There is no 
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evidence available on the impact of refusal on long term mortality or 
morbidity. Reduction in the refusal rate reduces costs to the hospital of 
having to find another ICU bed at another hospital for that patient, the 
costs of transporting that patient, and the costs to the second choico 
ICU of caring for that patient. If these costs were quantified and taken 
into account, the cost savings from SDD Implementation could be 
significantly larger. 
8.9.2 Realisable Cost Savings at DGH 
An equivalent consideration of realisable cost savings was made at 
DGH. This economic evaluation has suggested that, given the 
conditions stated, the implementation of SOD at DGH reduces the 
incidence of ICU-acquired pneumonia, at a lower cost. The use of SOD 
in 89 ventilated patients, admitted over a period of 11 months, results 
in theoretical cost savings of £16915. This would be equivalent to 
treating ventilated 97 patients at a saving of £18453 per year. 
Again, local organisational factors will affect this theoretical cost saving. 
DGH ICU had an occupancy of 67.2% in 1994 (range not reported). 
The refusal rate of was not known. Total admissions for 1994 were 
206. On the basis of this low occupancy, it is assumed, for this 
exercise, that any refusals would have been due to the 
inappropriateness of the patients, rather than because the ICU was full. 
The use of SDD reduces the length of stay of eight ventilated patients 
who do not contract late-onset Gram-negative pneumonia from 10.9 to 
5.2 days. In the 89 patients studied, this equated to 45.6 patient days 
being made available by SDD. In one year this would make available 
49.7 patient days, equivalent to 0.14 ICU beds. However, as the ICU is 
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underutilised at the moment, it is unlikely that those patient days will bo 
taken up by other patients. The occupancy of tho unit could 
theoretically decrease from 67.2% to 63.8% 
This decrease in occupancy at a constant patient turnover would affect 
costs. Fixed costs are not affected by occupancy. Therefore, in reality, 
these costs (E9075 per year) are not saved. Medical and nursing costs 
may not be partly saved in reality. In the event of low occupancy, 
nurses and medical staff are deployed to work on other wards. If all 
staff were redeployed, the cost of employing them is still incurred 
(£22683). The variable costs associated with these unused patient 
days would be saved because there would an actual reduction in 
resource use. This would lead to a saving of El 5268. However, it 
would cost £28580 to implement SDD and treat the 97 ventilated 
patients with it. Therefore, the cost savings would have to take this 
into account. So in reality, the variable costs would be saved and the 
SDD costs, staff and fixed costs would still be incurred. This would 
result in an annual increase in cost of £13305. 
8.10 CONCLUSIONS AND IMPLICATIONS FOR POLICY 
The aim of the economic evaluation reported in this chapter was to 
assess whether SDD could be shown to be cost effective if it were 
implemented at two British ICUs. One was located in a London teaching 
hospital and the other in a district general hospital. The secondary 
economic evaluation reported in Chapter Four had recommended that 
improved economic and patient outcome evidence was required. This 
chapter has described an economic evaluation of SDD applying primary 
economic evidence to the decision-analytic model developed in Chapter 
Four. 
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Section 8.4 described the clinical evidence required for this economic 
evaluation. The SDD efficacy and long term mortality and morbidity 
evidence used in Chapter Four was also used hero. Base pneumonia 
rates and six month mortalities were obtained from the study in Chapter 
Six. Section 8.5 described the economic evidence required. Details on 
SDD regimens were obtained from a survey (Chapter Five). Evidence on 
increase in length of ICU stay due to ICU-acquired pneumonia, costs per 
ICU day and costs associated with treating an episode of pneumonia 
were obtained from the study in Chapter Six. The incremental economic 
analysis concluded that SDD improved patient outcomes at a lower 
cost, so was dominant, at both centres (section 8.6). The sensitivity 
analysis in Section 8.7 examined the robustness of this dominance to 
the various clinical and economic parameters used. The conclusion that 
SDD was dominant was robust to variation of underlying parameters. 
Section 8.8 went on to compare this economic evaluation with the 
secondary economic evaluation reported in Chapter Four. Whether the 
use of primary economic evidence fulfilled its objective in improving the 
robustness of conclusions was examined. Improved information was 
available on resource use and unit costs of the SOD regimen; local 
pneumonia incidence rates; increased length of ICU stay due to 
pneumonia; cost per ICU day; and costs associated with treating 
pneumonia. It was concluded that this improved evidence decreased 
uncertainty around parameters. This reduced the levels of variation in 
the sensitivity analysis, such that the conclusion that SDD was a 
dominant therapy was made even more robust than it was in Chapter 
Four. 
The lack of information on the impact of SDD, ICU-acquired pneumonia, 
or admission to ICU in general, had on long term morbidity and mortality 
continued to severely restrict the conclusions that could be made about 
the impact of SDD on ultimate patient outcomes. 
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Section 8.9 assessed to what extent the theoretical cost savings that 
had been derived in this economic evaluation could be translated into 
realisable cost savings at either centre. Patient occupancy rates at the 
two centres were shown to significantly affect realisable cost savings. 
It was suggested that there may actually be an increased cost to the 
ICU if SDD were implemented at LTH or DGH. 
This economic evaluation has provided evidence on the theoretical cost 
effectiveness of SDD if it were to be implemented at these two centres. 
It has suggested that SOD can be shown to be dominant in two types of 
British ICU. The conclusions made at LTH and DGH could possibly be 
generalised to other British teaching hospitals and district general 
hospitals. The decision-analytic model developed was applied 
successfully to both centres, so it is reasonable to assume that it would 
also work in other centres. The published effectiveness data on SDD 
would have the same level of relevance as it does for these two centres. 
The generalisability of the study to other centres is higher than that of 
the secondary economic evaluation in Chapter Four because of the use 
of current economic data from local practice settings. The conclusions 
have been shown to be very robust, even in the face of substantial 
variation of underlying parameters. This implies that the conclusion that 
SDD is dominant could be applied to other ICUs. 
Policy-makers considering implementing SDD have three options. The 
first option is to directly apply the evidence from this economic 
evaluation to their own setting, undertaking no extra work. This could 
occur if the policy-makers believed that the economic, epidomiologic and 
clinical evidence were sufficiently generalisable to their setting. The 
second option is to substitute local pneumonia rates, resource use and 
costs into the decision-analytic pathway developed by this thesis. This 
would occur if decision-makers were happy with the effectiveness data, 
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but felt that local economic and epidemiologic data wore nooded to 
derive conclusions about SDD that were applicablo to their setting. 
The third option would be that used by decision-makers who do not 
believe that the published efficacy evidence on SDD is applicable to their 
situation. In this situation, it would be necessary to set up a study of 
SDD in their ICU to measure its effectiveness and cost implications in 
their practice setting. 
In conclusion, the recommendation from this economic evaluation is that 
SDD implementation on ICUs should be considered again by policy- 
makers, in light of this new evidence. 
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Chapter 9: Conclusions and Recommendations for Future 
Research 
The primary objective of this thesis was to examine whothor SDD could 
be demonstrated to be cost effective, using modelling in economic 
evaluation as an alternative to RCT-linked studies. The secondary 
objective was to examine whether modelling in economic evaluation 
could generally be used in evaluating intensive care interventions, as a 
realistic alternative to RCT-linked evaluations. 
The need for economic evaluation in intensive care and its constituent 
technologies was suggested in Chapter Two. Through a consideration 
of published evidence, the significant economic impact of intensive care 
on the health care systems of industrialised countries was illustrated. 
The annual spending on intensive care in the US was shown to be 
twenty times higher per capita than that in the UK. It was considered 
that the structure of the health care system in general is likely to 
contribute partly to this difference. However, it also reflects the lack of 
consensus about the optimal use of intensive care. Decisions on 
appropriate use of intensive care and its specific therapies are prevented 
by the lack of information available on allocative or technical efficiency 
of intensive care. 
This review suggested that intensive care medicine is unable to 
accurately account for its resource use or measure its impact on health 
outcomes. Reasons for the lack of research into the technical efficiency 
of intensive care and its constituent technologies were discussed. The 
absence of evidence for effectiveness of technologies used in intensive 
care was attributed particularly to the difficulties associated with 
carrying out RCTs in the intensive care environment. Additionally, little 
research has been carried out the effects of intensive care on mortality 
and morbidity, so the long term impact of intensive care is not known. 
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The economic impact of intensive care and its technologies is also not 
known due to the lack of rigorously carried out economic research in 
this area. This review concluded that economic evaluation of 
technologies used in intensive care is needed, but that alternative 
methods of economic evaluation incorporating modelling need to be 
further developed and tested, rather than relying on the attachment of 
economic evaluation to RCTs, with all their problems. 
Chapter Three introduced the specific clinical area investigated by this 
thesis. ICU-acquired pneumonia, an iatrogenic event, was shown to 
have potentially major clinical and economic implications. SDD is a 
resource intensive intervention, used on ICU to prevent ICU-acquired 
pneumonia. Thirty-seven RCTs of SDD have been published, none with 
a formal economic evaluation. Also, no long term outcomes have been 
investigated. It was suggested that further investigation into the 
economic and long term clinical impact of SDD was required. This 
review concluded that a formal assessment of costs and benefits was 
required to inform the debate on the cost effectiveness of SDD. 
Chapters Two and Three suggested that alternative methods of 
economic evaluation were necessary if the economic evaluation of 
technologies in intensive care in general and SDD in particular was to be 
taken forward. Chapter Four, therefore, described a secondary 
economic evaluation of SDD, combining modelling techniques with 
published clinical and economic evidence. The research question was 
defined in terms of a decision-analytic model. 
Application of published evidence to this model uncovered significant 
limitations to the clinical and economic data available. Although there 
was a large quantity of stochastic clinical evidence, it was not always 
presented in such a way as to be of use in the decision-analytic model. 
Also, only intermediate outcome measures were used in SDD trials to 
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assess the clinical effectiveness of SDD. It also showed that the little 
economic evidence available was deterministic, old and from a range of 
non-UK practice settings. The weakness of much of the evidence was 
reflected by the wide ranges recommended for the sensitivity analysis. 
The incremental economic analysis of SDD suggested that SDD was a 
dominant therapy. The subsequent sensitivity analysis showed that this 
conclusion was robust through substantial variation of the underlying 
clinical and economic parameters. The parameters that reversed the 
conclusion that SDD was dominant, when varied sufficiently, were 
effectiveness of SDD, base pneumonia rates, increase in length of ICU 
stay by pneumonia, cost per ICU day and costs associated with treating 
pneumonia. Variations in base pneumonia rate and the economic cost 
of an episode of pneumonia reduced the robustness of the conclusions 
because the degree of uncertainty around them was not known. It was 
concluded from this analysis that improved evidence on long term 
outcomes of patients and the economic impact of ICU-acquired 
pneumonia and SDD was needed to better inform conclusions on cost 
effectiveness. This thesis concentrated on improving the economic 
evidence on the impact of ICU-acquired pneumonia and SDD. 
Investigation into the long term mortality and morbidity of ICU patients 
is urgently required, but could not be investigated within the timescale 
of this thesis. 
A national postal survey was undertaken to provide detailed information 
about the state of SOD implementation in Britain (Chapter Five). This 
survey had a high response rate and showed that SDD was not widely 
used in this country, only 5% of ICUs reporting that they used it. This 
contrasted with the high profile that it has in the medical literature. Its 
use was also shown to be declining. There were two main reasons 
given by ICU clinicians for not using SDD. The first reason was that 
they considered it was too expensive. The second reason was that they 
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did not believe that it decreased mortality. This survey provided 
information on the resource use and unit costs associated with SDD 
regimens used around the country. 
An observational study was carried out at two typical British ICUs to 
obtain primary economic data on the impact of ICU-acquired pneumonia. 
The study also obtained epidemiologic data on the incidence of ICU- 
acquired pneumonias. Patient-specific (bottom-up) resource use data 
was obtained. Local unit costs for that resource use were obtained 
using rigorous methods. This provided individual patient costs, allowing 
interpatient variation to be investigated. The advantages of this 
evidence over that available prior to this study are that it is the first 
British evidence on the impact of ICU-acquired pneumonia on patient 
cost. 
Two operational issues were highlighted by this study. The first 
concerned the retrieval of data. It was necessary to access multiple 
sources of data on a regular basis, which made the study labour 
intensive. This suggested that this type of study, whilst providing 
detailed data, could not be carried out on a routine basis until hospital 
recording systems are better integrated. The lack of computerised 
records at DGH, in particular, significantly compromised the quality of 
resource use data that could be obtained. 
The data from this study were used to determine the impact of ICU- 
acquired pneumonia on economic parameters (Chapter Seven). This 
was carried out using multiple regression analysis, to control for factors 
other than ICU-acquired pneumonia that can affect cost. These other 
factors included the use of haemodialysis and the insertion of pulmonary 
artery catheters. This analysis suggested that ICU-acquired pneumonia 
increased ICU length of stay at both centres. An increase in treatment 
intensity was also detected at LTH. 
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The economic evidence obtained from Chapters Five to Seven was used 
in an economic evaluation of SDD at each ICU, reported In Chapter 
Eight. The epidemiologic and economic data for each contra was 
incorporated into the decision-analytic model developed in Chapter Four. 
The theoretical economic impact of SDD, if it were implemented at the 
two ICUs, was investigated. This analysis suggested that both contras 
would theoretically have improved outcomes at lower costs, that is, 
SDD was shown to be the dominant therapy at both ICUs. 
The subsequent sensitivity analyses showed that these conclusions 
were robust through variation of the underlying clinical and economic 
parameters. ICU-specific information on base pneumonia rates and 
patient costs meant that these parameters were associated with much 
less uncertainty. The robustness of the conclusion that SDD is a 
dominant therapy varied between the two centres. For example, SDD 
remained dominant at LTH at much lower levels of effectiveness than at 
DGH. This was explained by the higher pneumonia incidence at LTH. In 
this analysis, the uncertainty around the LYGs and dQALYs gained, as 
defined by this thesis, did not affect the robustness of the conclusion 
that SDD was dominant. However, until further evidence on the long 
term impact of intensive care is available, cost/LYG and cost/QALY 
ratios for SDD can only be very tentative. 
So, the economic evaluation described in Chapter Eight has suggested 
that SDD is a dominant therapy across a wide range of clinical, 
epidemiologic and economic conditions. However, according the survey 
described in Chapter Five, the large majority of ICU clinicians in the UK 
do not use SDD. The two main reasons are that they do not believe 
that it has any effect on mortality and that it is too expensive. The 
economic evaluations of SDD reported in this thesis do not add now 
evidence to the debate on mortality reduction by SDD, although 
examination of published evidence suggests there is a link. However, 
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these economic evaluations have illustrated that although SDD has cost 
implications of its own, the reduction in incidence of ICU-acquired 
pneumonia results in a reduction in overall cost. Tho recommendation 
from this economic evaluation is that SOD Implementation on ICUs 
should be considered again by policy-makers, in light of this now 
evidence. 
The conclusions from this economic evaluation have implications for 
future policies concerning the implementation of SDD in particular, and, 
more generally, implications for the use of modelling in economic 
evaluation. In policy terms, a therapy that has been demonstrated to be 
so generally dominant should be recommended for implementation. As 
discussed in Chapter Eight, policy-makers considering the 
implementation of SDD on their ICU have three options on how they use 
the evidence presented in this thesis. Firstly, they could directly apply 
the evidence to their local setting. Secondly, they could substitute local 
epidemiologic and economic evidence into the decision-analytic model. 
The third option is to implement SOD in their ICU, and carry out a study 
on patient outcome, with an associated economic evaluation. Each of 
these three options has successively larger resource use implications. 
To improve upon the economic evaluation reported in Chapter Eight, it 
would be necessary to implement SDD at the two centres to explore the 
real impact of SDD. The advantages of this would be the ability to 
measure SDD's effectiveness in a practice setting, rather than rely on 
published efficacy data. The actual local costs of implementing SDD 
could also be determined. However, the ideal economic evaluation is 
not necessarily one linked to an RCT. This does not reflect a normal 
practice setting so the resource use does not reflect practice either. 
Economic evaluations should ideally be carried out in more naturalistic 
settings to reflect normal practice more closely, with some degree of 
randomisation to allow comparison. Also, the cost effectiveness of SDD 
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should be considered in the context of other infection control methods 
in intensive care. Finally, the local organisational context needs to be 
considered, as shown by this thesis. 
More generally, this thesis has illustrated how modelling can be used 
successfully in economic evaluation in intensive care. Modelling in 
economic evaluation has three purposes. 
Firstly, it can be used as a preliminary exercise to assess whether 
prospective economic evaluation is warranted in a specific area. There 
are many areas that could be investigated and economic evaluation has 
resource use implications of its own, so priorities for research need to 
be identified. 
The second situation where modelling can be used is when an economic 
evaluation attached to an RCT powered to detect economic differences 
is considered 'infeasible or unethical', a use recommended by the 
Standing Group on Health Technology [19941. This thesis has 
highlighted many reasons why RCT-linked economic evaluations are not 
widely used in intensive care. Therefore, the way forward for the 
assessment of many technologies is through the use of modelling 
techniques like those described in this thesis. It is essential, therefore, 
that standard methods are developed so that confidence can be placed 
in the conclusions drawn from them. 
The third use for modelling techniques in economic evaluation is to 
make an existing economic evaluation more relevant to a specific 
setting. This is done by substituting local clinical, economic or 
organisational evidence into an evaluation. The usefulness of this is 
demonstrated by this thesis. The difference between the theoretical 
economic impact and that which would be realised in practice needs to 
be examined in the context of the effect of local clinical, economic and 
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organisational factors. This type of modelling will always be necessary 
in some form as it would be undesirable for RCT-linked economic 
evaluations to be carried out locally for all interventions. 
New technologies should only be introduced into ICU practice once their 
cost and benefit has been evaluated. The use of modelling techniques, 
in conjunction with good quality clinical and economic evidence, has 
been shown to enable derivation of robust conclusions. Of course, 
whether SOD is implemented is dependent upon factors other than cost 
effectiveness. However, cost effectiveness is a major component of a 
policy decision-making process. This thesis has contributed evidence 
that suggests SDD is cost effective, which can only bettor inform the 
decision-making process. 
In conclusion, further research into the technical and allocativo 
efficiency of intensive care is urgently required to identify which 
intensive care interventions are cost effective in which groups of 
patients. Wider social debate is required to address what levels of ICU 
provision can be considered optimal, or supportable. It is suggested by 
this thesis that the modelling techniques used here can allow economic 
evaluation to make a valuable contribution to that debate. 
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Appendix 2.1 Classification of Intensive Care Patients (Cullen of a/, 
19741 
Prior to the introduction of severity of illness scoring systems such as 
APACHE II, the following system was devised by Cullen of a/ (19741 to 
classify intensive care patients. 
Class I: Surgical patients admitted to the routine recovery room for 
wake-up from anaesthesia and do not require intensive care 
Class II: Patients physiologically stable requiring prophylactic overnight 
observation 
Class III: Patients physiologically stable requiring intensive monitoring 
and nursing (frequently of an invasive nature); their condition is 
expected to remain stable or improve with possible return to general 
ward care the following day 
Class IV: Patients physiologically unstable requiring intensive nursing 
and physician care with frequent observations and change of orders by 
surgeons, anaesthetists and internists; these patients usually have one 
or more of their organ systems disordered by disease processes and 
their prognoses are unpredictable and unstable. 
The TISS scores of the four groups increase with the severity of illness 
of the patient: 
Class TISS Score (SEM) 
5 (0.2) 
11 11 (0.7) 
III 23 (1.0) 
IV 43 (1.0) 
3 81 
Appendix 2.2 Intensive Care Society Nurse Dependency Scoring 
System [ICS Audit, 1992/931 
The following scores are attributed to each ICU patient at the end of 
each nursing shift: 
Dependency Patient Type 
score 
C Closed bed 
0 Staffed but empty bed 
0.5 Spontaneously breathing for simple monitoring, 
perhaps post operative with opiate epidural or 
similar. 
1 Artificially ventilated patient. 
1.5 Ventilated patient receiving multiple infusions or 
requiring complex monitoring or needing very 
frequent endotracheal suction 
2 As above but with very unstable cardiovascular 
system requiring frequent intervention, or, as above 
but with the addition of dialysis, haemofiltration, 
plasma exchange or other extracorporeal circuitry. 
382 
Appendix 2.3 Summary of Published Quality of Life Studies of Intensive 
Care 
First Details of Quality of Life Results reported 
Author Measures 
Cullen 4 unvalidated functional At 12 months: Patient condition: 
[19761 states measured prospectively 41 % full recovery 
US 1,3,6,12 months post Mental status: 89% fully alert 
n=62 admission by Functional state: 55% freely 
telephone interview. ambulatory 
Degree of productivity: 42% 
functioning as before illness 
Barns Unvalidated degree of Functional status at 2 years: 
[19851 capacity measured 74% returned to work 
Holland retrospectively 2 years post 10% handicapped, but self-reliant 
n=238 discharge. Information from 1.3% dependent on others 
GP. 
Sage SIP (validated objective Post ICU quality of life 
[19851 measure) and Uniscale Mean SIP score: 6.8% (sd=0.7°x) 
US (validated subjective measure) Physical subscore: 4.5% (sd-0.7%) 
n=337 measured prospectively 16 to Psychosocial subscore: 6.4% 
20 months post discharge by (sd-0.8%) 
postal questionnaire. Mean Uniscale score: 7.6 (sd = 0.3) 
Slatyer Spitzer QL Index' (validated QL"Index: little or no decrease. 
[1986], objective and subjective) Cullen (19761 outcome assessment: 
Australia measured retrospectively 1 Patient condition: 31 % full recovery 
n=100 month before admission and Mental status: 55% fully alert 
prospectively 1 month Functional state: 52% freely 
afterwards by interview. ambulatory 
4 unvalidated functional Degree of productivity: 28% 
states [Cullen, 19761 functioning as before Illness 
measured by interview. 
Loes Safar Overall Performance OPC 1: 72.2% 
[19871, Indicators' (previously OPC 2: 24.7% 
Norway reported measure) Patient 95.6% 'completely satisfied'. 
n=419 satisfaction (unvalidated) 66% regarded themselves as 
measured 20 months post completely recovered. 
discharge by telephone 
Thoner 4 functional categories (not Patients in each category: 
[19871, validated) measured 49 Group I and II: 58.7% 
Norway months post discharge by Group 111: 27.4% 
n=109 postal questionnaire' Group IV: 15.1 % 
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Appendix 2.3 (cont. ) 
First Details of Quality of Life Measures Results reported 
Author 
Zaren Disability ranking (unvalidated Patients living at home before 
[19871 modification Glasgow Outcome and after ICU (90% vs 86%), 
Sweden Scale'), working status leading an independent life (94% 
n=717 retrospectively 3 months before vs 88%). 
12 months post discharge 
Jacobs Housing, drug use, hospital Before ICU vs After ICU: 
[19881, admissions, physical condition, Drug use: 37% vs 56% 
Holland functional status (unvalidated) (p-0.02) Hosp admissions: 22% 
n=118 retrospectively before admission 2 vs 39% p<0.01 
years post discharge (postal) Physical complaints: 21 % 
deteriorated, 77% unchanged, 
2% Improved. 
Patrick SIP (validated objective measure) SIP mean score: 15 (sd =14), 
[1988), PGWB schedule" (validated general population score: 3.5 
US affective measure) PGWB mean score: 37.7 
n=69 PQOLB (subjective measure (sd - 9), population score: 39.1 
validated by this study) measured PGWB: 59% rated health 'fair to 
19 months post discharge by very poor' compared with 30% 
interview general population. 
PQOL: mean score: 75 (sd -18), 
population score: 79 (sd - 14) 
Mundt Employment status and modified Changes pre and 6 months post 
[19891, unvalidated SIP (physical, discharge: Working: 50% vs 
US psychological, social measure) 36% 
n=887 preadmission and 6 months post Decrease in ability to think 
discharge by postal questionnaire clearly and concentrate, 
decrease in ability to do 
housework, deterioration in all 
social variables (p<0.05) 
Shiell NHP Rosser and Kind QoL Index Comparison with population: 
[19891, (validated) measured post 31 % problems with work vs 7% 
UK n=82 discharge by postal questionnaire 45% social life problems vs 10% 
22% disability, 18% distress 
Appendix 2.3 (cont. ) 
First Author I Details of Quality of Life 
Measures 
Yinnon Karnofsky Index' (physical 
[1989), performance measure); 
Israel Linear analogue self 
n=126 assessment (LASA)'; Sleep 
index'; Employment; Sexual 
activity. 
Ridley Rosser's disability categories 
[19901, UK Patrick's perceived quality of 
n=129 life score 
Katz's activities of daily living 
measured by postal 
questionnaire pro admission 
and post discharge 
Vasquez 
[19921, 
Spain 
n=444 
Bell [1994] 
UK n=60 
Kerridge 
[1995] 
Australia 
n=136 
Previously published quality of 
life tool1° (functional measure) 
postal questionnaire pre 
admission and 12 months 
post discharge 
NHP measured on admission 
(in elective patients) and 
postal questionnaire 3 months 
post discharge 
Unstructured questionnaire 
Rosser questionnaire both by 
interview and by 
telephone/post 3 years post 
discharge. 
Results reported 
Pro admission vs 8 month post 
discharge moan scores (sd): 
Karnofsky: 8.2 (1.7) vs 7.9 (2.0) 
LASA: 68 (15) vs 71 (20) 
Sleep index: 2.4 (0.5) vs 2.5 (0.4) 
Groups suffering decrease in QoL 
(p<0.05) 
Disability categories I or II (good 
QoL) Employment status (fully 
employed) 
Patients < 30 years old 
Trauma victims 
No other groups showed changes. 
Patients at each QoL level t%) 
Level Pro admission After 1 
year 
1 28.2 12.4 
II 37.6 42.6 
III 23.9 28.2 
IV 10.4 16.2 
No significance tests reported 
No significant changes in 
functional ability. 
32% patients rated health 
'worsened' 
77% patients employment status 
no change 
Health problems: None: 25%; 
minor: 48%; major: 16%; severe: 
13%. 
Psychological sequelae: some: 
26%; lots of: 6%. 
Rosser QoL Index: range 0.70 to 
0.99 
Footnotes to Appendix 2.3 
'Spitzer QL-Index: contains five dimensions: activity (involvement in 
own occupation); activities of daily living; perception of one's own 
health; support of family and friends; outlook on life. 
2 Safar Overall Performance Categories 
OPC 1: Good overall performance: healthy, alert, capable of normal 
life 
OPC 2: Moderate overall disability: conscious, moderate cerebral 
disability or moderate disability from non-cerebral system 
dysfunction alone, or both. Performs independent activities 
of daily life, but is disabled for competitive work. 
OPC 3: Severe overall disability: conscious, severe cerebral 
disability or severe disability from non-cerebral organ 
systems dysfunction alone, or both. Dependent on 
others for daily support. 
OPC 4: Coma or vegetative state. 
OPC 5: Brain death. 
I Thoner functional categories: 
Group I: In good health. No sequelae 
Group II: Minor physical or mental disturbance without occupational 
limitation. Some temporary economical support. 
Group III: Moderate physical and/or mental disturbance(s) with 
occupational limitation. Permanent economical support. 
Group IV: Severe physical and/or mental disturbance(s). 
Institutionalised. 
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"Modified Glasgow Outcome Scale 
Three stages of increasing disability: 
1. Good health, no limitation in daily activities; 
2. Some limitations in daily activities but able to live an 
independent life; 
3. Severe limitations in daily activities, not able to live an 
independent life. 
5PGWB Schedule [Dupuy, 19841: Psychological general well-being 
schedule used to assess patient's affective status. The PGWB consists 
of ten questions about perceptions of well-being during the month prior 
to interview such as happiness, sadness and control of mood that are 
measured on a five-point scale. A single summated score ranging from 
0 (highly negative affect) to 50 (highly positive affect) was calculated. 
General health perceptions are also measured using a five-point self- 
rating of health during the preceding month, ranging from excellent to 
very poor. 
6PQOL: Perceived Quality of Life Scale developed by Patrick (19881. 
This is a cognitive measure of life quality or need satisfaction. 
Respondents are asked to rate their satisfaction on a scale from 0 to 
100, with 11 items describing fundamental needs of daily living. Higher 
scores indicate greater satisfaction. An average of these summated 
ratings, the PQOL score, is calculated for each respondent. 
Example: 'How satisfied are you on a scale of 0-100 with..... ' 
1. The health of your body 
2. Your ability to think and remember 
387 
'Karnofsky Scale 
Measures physical activity with scores ranging from 10 for normally 
active patients to 0 for the patient completely dependent on outside 
help. Limited physical activity means that the patient is unable to 
engage in strenuous physical activity but can perform regular daily 
activities such as walking and is fully independent in activities involved 
in self care. Minimal physical activity means that the patient is unable 
to perform normal physical activity but is partially able to take care of 
themselves in activities such as feeding, washing or use of the toilet 
without help. 
'Linear Analogue Self-Assessment (LASA) score 
This is a subjective score first introduced for use in cancer patients 
receiving chemotherapy. A position is indicated by the patient using a 
scale ranging from 0 (very bad) to 100 (very good) in relation to the 
following variables: general feeling of wellbeing, mood, level of social 
activity, pain, nausea, appetite, perceived ability to perform housework, 
level of anxiety and the patient's own perception of response to 
treatment. The mathematical expression of the mean LASA score 
ranges from 0 to 100. 
'Sleep Index 
Evaluated by three variables: duration ranging from more than 6 hours 
(3 points), 4 to 6 hours (2 points) or less than 4 hours (1 point): and 
depth of sleep ranging from sound (3 points), intermediate (2 points) 
and light (1 point). The mathematical average of these three variables in 
a given patient was designated the sleep index. A sleep index below 2 
was considered to indicate sleep of poor quality. 
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''Quality of Life Questionnaire [Vasquez, 19921 
Consists of seven items: 
The ability to have oral communication (0 to 8 points) 
Sphincter control (0 to 6 points) 
Capacity for making precise movements (0 to 3 points) 
Capacity for physical exercise (0 to 3 points) 
Mobility and dependence on others (0 to 12 points) 
The need for regular medication (0 to 2 points) 
Capacity to work or to perform activities usual for the retired (0 to 3 
points). 
Level I (total score 0), quality of life is normal 
Level lI (total score 1 to 5), there is mild deterioration in the quality of 
life, with regular use of medication as the most characteristic feature. 
Level III (total score 6 to 10), there is significant deterioration in quality 
of life, usually implying changes in employment or in the activities of the 
retired, along with deterioration in capacity for physical effort. 
Level IV (total score > 10), scores usually correspond to a major 
handicap. 
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Appendix 4.1 Trials Excluded from Extraction of Clinical Data 
First author of study Reason(s) for Exclusion of Study 
Stoutenbeek 1984, Holland Not RCT (historical control) 
Ledingham 1988, UK Not RCT (consecutive control) 
Flaherty 1990, US Not RCT (cross over study) 
McClelland 1990, UK Not RCT (historical control) 
Tetteroo 1990, Holland Atypical patient group (oesophageal resection for 
oesophageal cancer) 
Fox 1991, UK Not RCT (historical and consecutive controls) 
Hartenauer 1991, Germany Not RCT (consecutive control cross over study) 
Zobel 1991, Austria Atypical patient group (paediatric) 
de Champs 1993, France Not RCT (consecutive control) 
Unusual component (erythromycin) 
Gow 1993, UK Not RCT (consecutive control) 
Martinez-Pelluz 1993, Spain No clinical outcome measures (endotoxaemia & 
cytokine activation study) 
Nardi 1993, Italy Not RCT (consecutive control) 
No clinical outcome measures (tracheal 
colonisation & bacterial resistance study) 
Rolando 1993, UK Atypical patient group (fulminant liver failure) 
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Appendix 4.2 Summary Table of SDD Trials Included in Systematic 
Review 
Trial author, date of publication and 
country of origin 
Inclusion in systematic review models 
Unertl [1987], Germany' All, Mixed, Trauma2 
Kerver [1988], Holland All, Mixed, Trauma 
Aerdts [1989], Holland All, Mixed 
Brun-Buisson [1989), France All 
Ulrich [1989), Holland All, Mixed 
Godard [1990], France All, Mixed 
Rodriguez-Roldan (19901, Spain All, Mixed 
Blair [1991), UK All, Mixed, Trauma 
Gaussorgues [1991], France All 
Palomar 119911, Spain All, Mixed 
Pugin [19911, Switzerland All, Mixed 
Cerra [1992), USA All, Mixed, Trauma 
Cockerill [1992], USA All, Mixed, Trauma 
Gastinne [1992], France All, Mixed, Trauma 
Hammond [1992], South Africa All 
Jacobs [1992), UK All, Mixed 
Rocha [1992], Spain All, Mixed, Trauma 
cont... 
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Summary Table of SDD Trials Included in Systematic Review (cont. ) 
Trial author, date of publication and 
country of origin 
Inclusion in systematic review models 
Verhaegen $ [19921, Belgium All, Mixed, Trauma 
Verhaegen II [19921, Belgium All, Mixed, Trauma 
Winter [19921, UK All, Mixed 
Ferrer [19931, Spain All 
Garcia [19931, Spain All 
Korinek [19931, France All, Mixed, Trauma 
Suter [19931, Switzerland All 
' For more detail on individual trial design, refer to Chapter Three, Appendix 3.1. 
I 'All': trial included in 'All ICU' model 
'Mixed': trial included in 'Mixed ICU' model 
'Trauma': trial included in 'Surgery/trauma ICU' model 
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Appendix 4.3 Fixed Effects Statistical Methods for Pooling Clinical Data 
(Colton [1991]) 
1. Pooled means and 95% confidence intervals for continuous 
variables. 
Using binomial approximation to the normal distribution: 
Mean of all studies =1 /N F(nk xk) 
Confidence intervals = mean +/- t,, 2 standard error of mean 
(SEM) 
SEM =1 /N , /Tnk2 Sk2 
Where N= total number of observations: n, + n2 + ..... nk (where n= 
sample size) 
x= sample mean 
s= sample standard deviation 
The conditions for use of this expression are that nk is more than or 
equal to 5 and that the sample means are independent of one another. 
2. Pooled means and 95% confidence intervals for non continuous 
variables. 
Using binomial approximation to the normal distribution, the same 
expressions as above are used and the same conditions apply. Non- 
continuous variables such as proportions do not have variance in the 
same way as continuous normally distributed variables. The sample 
variance (s2) can be derived from the following expression: 
s2=n(1-n) 
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where fl is the observed sample proportion or rate. 
Therefore, SEM =1 /N /nk2 ((l(1-n)k) 
3. Effect size and 95% confidence intervals for non continuous 
variables. 
Mean effect size = 1/N F(nk (n, -n, )) 
where Il= = sample proportion of treated group 
nc = sample proportion of control group 
For each sample: 
Standard error of effect size =f , 
[lt t. + Il (1-ný) 
nt nc 
For pooled values, 
95% Confidence intervals = mean effect size +/- te, 2 standard 
error of effect size 
where standard error of mean effect size = 
1/N IEnk2(tl 1-n, ) +n 1-n 
nt nc 
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Appendix 4.4 Inclusion Criteria in Clinical Trials Groups 
This table summarises inclusion criteria for patients in SDD trials. 
Inclusion criteria for 
patients in SDD 
trials 
All trials 
No. trials 
Mixed ICU 
model 
No. trials 
Surgery/trauma 
model 
No. trials 
All admissions 1 1 0 
Vent. admissions 2 1 0 
LOS >= 1 day 1 (1) 1 (1) 1 (1) 
LOS >=2 days 6 (3) 4 (2) 3 (2) 
LOS >=3 days 4 (3) 3 (2) 1 (0) 
LOS >=4 days 1 (1) 1 (1) 0(0) 
LOS >=5 days 7 (5) 6 (4) 4 (3) 
LOS>= 6 days 1 (1) 1 (1) 1 (1) 
*Numbers in parentheses indicate number of trials where the patients had to be 
ventilated to be included in the trial. 
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Appendix 4.5 Synthesis of Mortality Probabilities 
This appendix summarises the algebraic method used to synthesise 
mortality probabilities from published evidence. 
Let x= probability of mortality if infected 
Let y =probability of mortality if uninfected. 
In the 'all ICU' model, the base pneumonia rate is 29.4% and the base 
mortality is 29.5%. 
If 1000 patients are admitted to ICU, 
294 contract ICU-acquired pneumonia and x% die. 
706 do not contract ICU-acquired pneumonia and y% die. 
This can be expressed as: 294x + 706y = overall mortality (29.5%) 
In the 'all ICU' model, the SDD treated pneumonia rate is 13.8% and 
the mortality is 26.7%. 
if 1000 patients are admitted to ICU, 
Assuming that the mortality from infection once it is acquired does not 
change between SDD-treated and non-SDD treated groups: 
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138 contract ICU-acquired pneumonia and x% die. 
862 do not contract ICU-acquired pneumonia and y% die. 
This can be expressed as: 138x + 862y = overall mortality (26.7%) 
Solving these two equations for x and y produces an infected mortality 
of 42.3% and an uninfected mortality of 24.2%. 
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Appendix 4.6 Details of General Study Design in Clinical Trials Groups 
Parameter All trials Mixed ICU Surgery/ 
n=24 model trauma model 
n=18 n=10 
No. trials using 14 11 6 
parenteral therapy 
No. trials using 13 11 7 
therapy for LOS 
Trials using SDD 8 4 1 
whilst ventilated 
No. trials using PSB 9 6 3 
No. blinded trials 11 6 4 
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Appendix 4.7 Details of SDD Pharmaceutical Regimens in Clinical Trials 
Groups 
Treatment details All trials Mixed ICU 
model 
Surgery/ 
trauma model 
No. trials using PTA paste & liquid 10 8 5 
No. trials using PTA gel & liquid 4 3 1 
Gentamicin substitution 4 1 1 
Polymixin B substitution 3 2 0 
Nalidixic acid substitution 1 1 0 
Ofloxacin substitution 1 1 0 
4 trials added in vancomycin to cover for MRSA. 
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Appendix 4.8 Details of Cefotaxime Protocols in Clinical Trials Groups 
Cefotaxime 
dose details 
All trials Mixed ICU 
model 
Surgery/ 
trauma model 
lg tds 3 days 2 1 1 
1g qds 4 days 3 3 2 
1g qds 5-7 days 1 1 1 
lg tds 4 days 1 1 0 
2g tds 4 days 1 1 1 
2g qds 4 days 1 0 0 
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Appendix 4.9 Costs of SDD Regimes Reported by SDD Trials 
Aerdts (Hol/and, 1989): SDD (paste and liquid) and systemic cefotaxime 
per patient DFI 857 (439-1772) (one DFI = $0.50) 
Flaherty (US, 1990): $54 per patient (Colistin, gentamicin, nystatin 
paste and liquid qds for entire ICU stay, no IV therapy, LOS not 
reported) 
Gastinne (France, 1992): US$66.50 per day, mean charge per patient 
$694 +/-544 (information supplied by Pharmacie Centrale des Hopitaux 
de Paris) PTA paste and liquid until extubated, no IV therapy. 
Hammond (South Africa, 1992): US$500 per patient (PTA gel and liquid 
qds until 48 hours after extubation, cefotaxime 1g tds for 3 days). 
Rocha (Spain, 1992): US$26 per day (1989 $), (PTA paste and liquid 
qds for entire ICU stay, cefotaxime 6g/day for 4 days) 
Verhaegen (Belgium, 1992): 33793 BEF per patient (=22.4 days SDD 
PTA paste and liquid qds for entire ICU stay and cefotaxime 1g qds for 
4 days). 
Labour costs in SDD production per patient: 112 BEF 
Winter (UK, 1992): £25 per day (1991 prices) PTA gel and liquid qds for 
entire ICU stay 
Korinek (France, 1993): US$70 per day (US, 1989); PTA and 
vancomycin paste and liquid qds for 15 days. 
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Appendix 4.10 Microbiological Surveillance Reported in the 24 Included 
SDD RCTs 
Culture site On admission 2x week 3x week 
Oropharyngeal 16 9 5 
Rectal 15 10 5 
Urine 14 5 3 
Tracheal aspirate 14 8 5 
Gastric aspirate 10 9 3 
Blood 4 1 0 
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Appendix 4.11 British Costs for Microbiological Surveillance (financial 
year 1994/5): 
Swab site Costs (1994/95)£ 
Oropharyngeal swab 4.96 
Faecal/stool 12.13 
Nose 3.58 
Tracheal aspirate 8.82 
Wound 7.72 
Urine 4.41 
Blood 11.03 
Tobramycin level 12.68 
NB: These are costs to the microbiology department only and include 
culturing for antibiotic sensitivity. Therefore, the decrease in positive 
cultures and subsequent decrease in need for susceptibility testing from 
SDD is not going to be reflected if these costs are used. The figures 
quoted are the prices charged by the microbiology department to 
external users of their services. 
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Appendix 4.12 Synthesis of Pneumonia-Attributable Length of Stay 
This appendix summarises the algebraic method used to synthesise 
length of ICU stay attributable to pneumonia from published evidence. 
14 trials report lengths of ICU stay for SDD-treated and non-SDD-treated 
patients. The weighted means are 18.03 days (sd = 9.85) for non-SDD 
treated and 17.51 days (sd = 10.62), calculated from 1309 patients. 
Let x= length of ICU stay if infected 
Let y =length of ICU stay if uninfected 
The base pneumonia rate is 29.4% and the base length of stay is 18.0 
days. 
If 1000 patients are admitted to ICU, 
294 contract pneumonia, 706 do not contract pneumonia and the mean 
length of stay is 18.0 days. 
This can be expressed as: 294x + 706y = 18.0 days x 1000 patients 
The SDD treated pneumonia rate is 13.8% and the length of stay is 
17.5 days. 
If 1000 patients are admitted to ICU, 
138 contract pneumonia, 862 do not contract pneumonia and the mean 
length of stay is 17.5 days. 
This can be expressed as: 138x + 862y = 17.5 days x 1000 patients 
Solving these two equations for x and y produces an infected length of 
stay of 20.2 days and an uninfected length of stay of 17.1 days. The 
derived infection-attributable length of stay is 3.1 days. 
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Appendix 5.1 Clinician Questionnaire 
Selective Decontamination of the Digestive Tract 
1. How many admissions do you have in one year? 
2. How many of your patients stay longer than 3 days? 
3. Please indicate the percentage of your patients that are surgical: 
4. Do you use 'protected specimen brush technique' for obtaining sputum samples as a diagnostic 
technique? Yes / No 
SDD is a form of infection control that is used to eliminate endogenous gut bacteria. It can 
consist of antimicrobial oropharyngeal pastes or gels, oral liquids or intravenous antibiotics, or a 
combination of two or all of these. It is also called SPEAR (Selective Parenteral and Enteral 
Antisepsis Regime). 
5. Does your unit currently use SDD at all? Yes / No 
If you have answered 'yes' to this question, please carry on to question 
6. Otherwise go to question 8 on the other side of this sheet. 
6. Do you give SDD to a) All patients Yes / No 
If 'no', please outline inclusion or exclusion criteria: 
(eg do you only use in mechanically ventilated, trauma, adult or other subsets of patients? ) 
7. How long has the unit been using SDD? 
........................... Don't Know 
Go on to question 9 on the other side of this sheet. 
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Appendix 5.1 cont. 
8. a) Has your unit, to your knowledge, ever used SDD? 
b) If you have ever used SDD, when did you stop? 
....................................... Don't know 
c) Tick the three main reasons why you do not use SDD: 
No clearly proven benefit at the moment 
Q 
Financial constraints 
Q 
It is impractical and time consuming 
Q 
i 
Q 
stance Microbiologist res 
Nursing resistance 
Q 
Did not know about it 
Q 
Other ................................................ 
9. Do you think that SDD: 
a) Decreases respiratory 
infection incidence? 
b) Decreases length of stay? 
c) Decreases mortality? 
d) Increases outbreaks of 
multiresistant bacteria? 
e) Makes people more likely 
to follow other infection 
control policies? 
Yes I No / Don't know 
Agree Don't Disagree 
Know 
QQQ 
Q Q Q 
Q Q Q 
Q Q Q 
Q Q Q 
10. Does your unit carry out any of the following? (tick all boxes that apply) 
a) Monitoring infection rates 
Q 
b) Severity of illness scoring and outcome audit 
Q 
c) Audit of SDD costs and/or outcomes. 
Q 
11. Have you seen the recent meta-analysis on selective digestive decontamination in the 
British Medical Journal (28th August 1993) Yes / No 
Thank you very much for completing this questionnaire. 
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Appendix 5.2 Pharmacist Questionnaire 
Selective Decontamination of the Digestive Tract (SDD) 
1. Does your unit routinely use any of the following ulcer prophylaxis? 
Please tick which you use and indicate frequency: 
Usually Sometimes Never 
Ranitidine 
Q Q Q 
Cimetidine 
Q Q Q 
Sucralfate 
Q Q Q 
Omeprazole 
Q Q Q 
Antacids 
Q Q Q 
No prophylaxis 
Q Q Q 
Other 
(please give details) 
2. Which three antibiotic regimes would you most commonly use for a suspected gram negative 
infection? 
I ................... 2 .................. 
3 .................... 
SDD is a form of infection control that is used to eliminate endogenous gut bacteria. It can 
consist of antimicrobial oropharyngeal pastes or gels, oral liquids or intravenous antibiotics, or a 
combination of two or all of these. It is also called SPEAR (Selective Parenteral and Enteral 
Antisepsis Regime). 
3. Does your intensive care unit currently use SDD at all? Yes / No 
If you have answered 'no' to this question, you do not need to continue 
with the questionnaire beyond question 3. 
Otherwise go to question 4. 
4. This question requires information about which SDD formulations you use. 
Indicate whether you use an oral paste/gel and/or an oral liquid. 
Our SDD regime contains: 
(tick appropriate boxes) 
an oral paste 
Q 
an oral gel 
Q 
an oral liquid 
Q 
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Appendix 5.2 cont. 
5. Tick the constituents in your oral paste/gel and oral liquid, giving details of doses if you know 
them. If the system you use is not on the list, please give de tails at the bottom. 
Antibiotic Paste/Gel Dose Oral Liquid Dose 
Tobramycin 
Q 
........... 
Q 
............ 
Gentamicin 
Q 
........... 
Q 
............ 
Amphotericin 
Q 
........... 
Q 
............ 
Nystatin 
Q 
........... 
Q 
............ 
Polymixin EQ........... 
Q 
............ 
(Colistin) 
Neomycin 
Q 
........... 
Q 
............ 
Others 
Q 
........... 
Q 
............ 
6. How many times a day does the patient receive this treatment? .................. 
7. How long does the patient have this topical treatment? 
(tick appropriate box and give extra details if necessary) 
All the time they are on the intensive care unit 
Q 
A specified length of time from ICU admission 
Q 
(give details) 
8. How do you obtain these preparations? (Tick appropriate boxes) 
* If you supply individual ingredients for the suspension please indicate which ones they are and 
how they are supplied. 
Bought ready made 
Paste/gel 
Q 
Suspension: Complete formulation 
Q 
*Constituent 1 .............. 
Q 
*Constituent 2 .............. 
Q 
*Constituent 3 .............. 
Q 
Manufactured by pharmacy 
F-I 
F-I 
9. a) Do you use intravenous antibiotics in your SDD regime? Yes / No 
b) If 'yes', please outline which antibiotic(s), usual dose and length of course 
Thank you very much for completing this questionnaire. 
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Appendix 6.1 a Data Collected for Admissions Database 
The data collected for each patient was: 
Name 
Hospital number 
Sex 
Origin 
APACHE II score 
Presence & source of infection 
NHS number 
Date of birth 
Race 
GP address and telephone no. 
GCS score 
Presence & source of cancer 
Elective admission? Smoker (present, past, non) 
Weight Surgical admission 
Readmission to ICU (within last 6 months) 
Date of hospital admission 
Date and time of ICU admission 
Admitting specialty 
CPR? 
Date and time of ICU discharge 
Date of hospital discharge 
Diagnosis 
Chronic conditions 
Admitting consultant 
latrogenic events in surgery? 
Destination on ICU discharge 
Destination on hospital discharge 
Reason for admission 
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Appendix 6.1b, Data Collected for Daily Resource Use Database 
Whilst the patient was on ICU, the following interventions and resource 
use associated with their stay was recorded daily: 
1. Type of intubation and ventilation mode 
2. Daily TISS score 
3. Drugs, nutrition and blood products 
4. Chemical pathology, haematology, microbiology' and radiology' 
tests 
5. Physiotherapy and chest suction frequency 
6. Intensity of monitoring (ie number of peripheral and central 
intravenous lines, arterial lines, pulmonary artery catheters, 
drains, nasogastric tube, urinary catheter, epidural catheter, ICP 
(intracranial pressure) bolt. Insertion and maintenance of these 
lines is recorded. 
7. Events (surgery, haemodialysis, intubation, cardiac arrest, post 
mortem care, haemorrhage, ECG, EEG) 
8. Daily APACHE II scores (LTH only) 
9. Dependency scores for each shift (LTH only) 
10. Infection status3 
' Retrieved from the hospital computer system at LTH. At DGH, the results were 
notified by printed summaries in the notes. 
Retrieved retrospectively from radiology departments. 
3 Obtained from the medical notes, microbiological reports and discussion with medical 
staff. 
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Appendix 6.2 Summary of Admitting Diagnoses (Knaus of al [19851 
APACHE II categories) 
Diagnosis DGH/% LTH/% 
Post peripheral vascular surgery 29 (21.0) 35 (16.5) 
Post GI surgery for neoplasm 4 (2.9) 19 (9.0) 
Post neurosurgery 0 (0.0) 26 (12.3) 
Respiratory insufficiency post op 24 (17.4) 19 (9.0) 
GI complications post op 8 (5.8) 14 (6.6) 
Multiple/head trauma post op 5 (3.6) 12 (5.7) 
Sepsis post op 5 (3.6) 7 (3.3) 
Miscellaneous post op 6 (4.3) 9 (4.2) 
Cardiac complications post op 6 (4.3) 8 (3.7) 
Neurosurgery nonoperative 6 (4.3) 11 (5.2) 
Resp insufficiency due to infection 11 (8.0) 11 (5.2) 
Respiratory insufficiency (other) 9 (3.6) 11 (5.2) 
Multiple/head trauma nonoperative 5 (3.6) 8 (3.7) 
Sepsis nonoperative 0 (0.0) 4 (1.9) 
Miscellaneous nonoperative 8 (5.8) 13 (6.1) 
Cardiac complications nonoperative 12 (8.9) 5 (2.4) 
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Appendix 6.3 Cost per Nursing Shift at LTH and DGH 
Nursing 
Grades 
Cost 
(DGH)/£ 
Cost 
(LTH)/E 
Nursing Grades Cost 
(DGH)/E 
Cost 
(LTH)1£ 
D 61.88 63.68 D long day 103.14 106.12 
E 70.14 74.78 E long day 116.90 124.62 
F 78.56 86.48 F long day 130.88 144.12 
G 89.30 89.48 G long day 149.00 149.12 
H 95.03 95.10 H long day 164.16 158.50 
D night 86.64 89.15 E bank Mon-Fri' 57.34 61.13 
E night 98.20 104.69 E bank Sat 71.90 76.65 
F night 109.99 121.07 E bank nights 100.67 107.31 
G night 125.09 125.27 E bank Sun 86.40 92.10 
H night 132.89 133.14 E bank half 45.87 48.90 
D half 49.51 50.94 E bank half Sat 57.52 61.32 
E half 56.11 59.82 E bank half Sun 69.12 73.68 
F half 62.85 69.18 E bank long day 95.98 101.88 
G half 71.30 71.58 E bank long Sat 119.85 127.76 
' 'Bank' indicates an internal hospital bank nursing system. The costs for these shift 
types were also derived for D grade bank nurses and D and E grades employed from 
external nursing agencies. 
Appendix 6.4 Medical Staff Costs at LTH and DGH 
1. LTH ICU 
Financial year: 1994/95 (Costs include wages, London allowances and 
employer contributions): 
i. Fifteen consultant sessions per week plus 2 sessions per 
weekend = 17 consultant sessions/week: £104 per session; 
ii. 1 full time Senior registrar (mid grade, including 20 class 3 
ADHs): £691 per week; 
iii. 4 full time Senior house officers (mid grade, including 20 class 3 
ADHs): £547 per week. 
Total cost per annum: £241644 
Total patient days per annum: 1830 
Total cost per patient day (24 hours) stay: £132. 
2. DGH ICU 
Financial year: 1994/95 (Costs include wages, London allowances and 
employer contributions): 
i. Fourteen consultant sessions per week plus 2 sessions per 
weekend =16 consultant sessions/week: £104 per session; 
ii. 1 whole time equivalent registrar (mid grade): £612 per week; 
iii. 1 whole time equivalent senior house officer (mid grade): £547 
per week. 
Total cost per annum: £135980 
Total patient days per annum: 1110 
Total cost per patient day (24 hours) stay: £124. 
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Appendix 6.5 Derivation of Drug Costs at DGH and LTH 
Non-drug overheads for the pharmacy departments were available from 
both centres. These were allocated to each drug dose, independent of 
the acquisition cost of the drug. Pharmacy overhead per original pack 
dispensed was derived by calculating the total number of drug items 
dispensed for the month of July, 1994 (a month in the middle of the 
study). The cost per original pack dispensed was £1.10 at LTH and 
£1.48 at DGH. One ampoule of drug used from a box of ten ampoules 
is given an overhead cost of £0.11 or £O. 148. 
The drug costs derived include the acquisition cost of the drug provided 
by the pharmacy department; the pharmacy overhead cost; the costs of 
disposables used in reconstitution (needles, fluids, syringes), disposables 
used in setting up and maintaining an infusion (infusion giving sets, 
intravenous fluids). These costs were obtained from contract prices and 
the NHS Supplies Catalogue November 1994 (North Thames Anglia 
Division). An example is illustrated below (LTH) 
Fusidic acid 500mg iv 
Drug acquisition cost 
Pharmacy overhead cost 
Sodium chloride 0.9% 500ml 
Pharmacy overhead cost 
Maintaining infusion (cost per dose) 
Total cost per day: 
4.78 
1.10 
0.67 
0.11 
0.29 
£6.95 per dose + 0.79 per day 
(infusion setting up cost) 
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Appendix 6.6 Resource Use and Costs Associated with Monitoring and 
Interventions at LTH and DGH 
The main areas of resource use are physiotherapy, respiratory and renal 
support, insertion and maintenance of vascular access and rental of 
special beds (LTH only). An example of the components of costs listed 
is provided. 
Physiotherapy Costs 
Physiotherapy constitutes the largest staff cost to ICU after nursing and 
medical staff. At LTH, the physiotherapy department record how many 
15 minute of physiotherapist time are spent with each patient. Cost to 
the hospital of employing a physiotherapist for 15 minutes on ICU was 
reported as £7.00. At DGH, the physiotherapist recorded if she treated 
the patient only. Cost to the hospital was reported as £20.00 per 
session. 
Cost of Respiratory Therapy 
(Costs listed are those for interventions at LTH. These costs were also 
derived for DGH) 
Blood gas measurement 0.19 
Minitracheostomy 16.62 
Oral intubation: 12.17 
Percutaneous tracheostomy 123.51 
Suction 0.87 
Tracheostomy tube changes 16.74 
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Daily ventilation maintenance costs vary depending on type of 
ventilation used: 
Intubated (dry breathing system) 3.82 
Intubated (wet breathing system) 13.40 
Maintenance of tracheostomy 7.58 
Intubated on CPAP 8.00 
Self ventilating on CPAP 14.27 
Self ventilating on oxygen mask 4.06 
Cost of Insertion of Lines 
Arterial cannula 15.56 
Epidural catheter 23.51 
Nasogastric tube 4.98 
Peripheral catheter 5.12 
Pulmonary artery catheter 108.43 
Quadruple lumen central intravenous catheter 42.24 
Triple lumen central intravenous catheter 36.50 
Urine catheter 6.87 
Cost of Insertion of Drains 
Abdominal drain 16.98 
Chest drain 18.59 
Intracranial bolt 306.69 
Cost of Renal Replacement (Continuous haemodialysis and 
haemofiltration) 
Insertion of bilumen 'vascath' catheter 43.34 
Installation of dialysis filter and circuit 76.74 
Dialysis fluid (pharmacy cost) 8.50 
Replacement fluid (pharmacy cost) 8.50 
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Monitoring costs include ECGs, blood sugar tests, eye and mouth care. 
Other interventions include DC cardioversion, management of 
bradycardic arrest, rental of special beds, brain stem death tests and 
post mortem care. 
Example of Components of Resource Use and Cost Associated with an 
ICU Intervention 
Insertion of quadruple lumen central intravenous catheter (LTH): 
Component Cost/£ 
Quadruple lumen catheter 24.95 
Sterile gloves 1.00 
4 3-way taps 1.16 
Tegaderm 0.40 
Dressing pack 0.27 
Scalpel (disposable) 0.16 
Suture 8.69 
Lignocaine 1%1 Oml 0.43 
Hepsal 2 vials 0.44 
2 1Oml syringe 0.08 
3 needles 0.03 
Sterile gown 1.15 
Large sterile towel 0.26 
Incopad 0.08 
Single transducer 10.44 
Total 49.64 
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Appendix 7.1 Derivation of Logit Regression Models to Explain ICU and 
Hospital Mortality at DGH and LTH 
A7.1.1 Derivation of Logit Regression Model to Explain ICU Mortality at 
LTH 
The development of a logit regression model to explain ICU mortality at 
LTH using patient admission characteristics is described in this section. 
All covariates investigated in individual analysis were included in a 
preliminary generalized logit model, Model A. Table A7.1.1 summarizes 
the logit regression analysis carried out on ICU mortality. PROC 
CATMOD within the SAS statistics package was used. The estimates 
of coefficients of covariates, their errors and individual significance are 
listed. If the coefficient estimate is not significant (p>0.05), the 
covariate does not have a significant effect on mortality. Table A7.1.1 
indicates that Model A approximates to a logistic distribution as the 
likelihood ratio test is non-significant. However, the presence of so 
many non-significant covariates (p>0.05, so it cannot be excluded that 
the estimate of coefficient of covariate is zero) introduces uncertainty. 
The variation in the error terms of the nonsignificant covariates 
decreases the robustness of the model. The aim of this analysis is to 
derive a model with a significant intercept and estimates of coefficients, 
minimal interaction between covariates, whilst fitting a logistic 
distribution. 
Table A7.1.2 summarizes the correlation between the covariates in 
Model A. Correlation between covariates exists for this data set 
(n = 207,5 missing APACHE II scores) if the correlation coefficient (p) is 
greater than the critical value of 0.164 (p < 0.01). There is significant 
interaction between covariates. Some interaction is artefactual, such as 
the high correlation between surgical categories. Some correlation is 
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intuitively correct, such as the correlation between elective admissions 
and patients with cancer (due to the elective curative and palliative 
surgery carried out at this centre). Some correlation has probably 
occurred by chance, such as the negative correlation of surgical 
iatrogenic events with presence of cancer. Significantly correlating pairs 
investigated were: ELECT*CANCER; AGE*VASCULAR; AGE*GENERAL; 
VASCULAR*ELECT; NEURO*INFECT. These composite covariates were 
put back into a reduced logit model to assess their combined 
explanatory effect and to assess their correlation with other single 
covariates. 
The first step was to remove non-significant, non-interacting covariates 
one by one and assess the impact on the model. For example, removal 
of the covariate SEX results in a loss of 3 degrees of freedom and a 
decrease of 2.43 in the maximum likelihood ratio (2 distribution, 
p>0.25). Therefore, this reduced model is not significantly different 
from Model A. This approach was used to produce the 'best' model 
possible from the dataset, testing for interaction at each level. 
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Table A7.1 Logit Regression on Patient Admission Factors Explaining 
ICU Mortality (Analysis of Maximum Likelihood Estimates and Analysis 
of Variance) Generalized Model A 
Source Estimate Standard DF X, P 
Intercept (/30) 4.854 1.725 1 7.92 0.0049 
Sex 0.118 0.202 1 0.34 0.5604 
CANCER -0.006 0.288 1 0.00 0.9838 
CPR 0.533 0.354 1 2.26 0.1324 
Age' 0.003 0.013 1 0.06 0.8118 
APACHE II' -0.141 0.035 1 16.38 0.0001 
ELECT -0.121 0.306 1 0.16 0.6921 
VENT 0.242 0.286 1 0.72 0.3963 
NEURO 0.125 0.287 1 0.19 0.6639 
GENERAL -0.203 0.317 1 0.41 0.5225 
VASCULAR -0.213 0.397 1 0.29 0.5908 
TRAUMA -0.882 0.608 1 2.10 0.1472 
OTHER -1.286 0.643 1 3.99 0.0456 
IATRO -0.090 0.299 1 0.09 0.7630 
CHRONIC -0.131 0.224 1 0.34 0.5592 
CARDIAC 0.525 0.322 1 2.66 0.1027 
INFECT 0.069 0.257 1 0.07 0.7894 
Likelihood ratio - - 185 170.39 0.7720 
' Continuous variables converted to categories to reduce number of populations 
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The most robust model derived from the dataset using the methods 
described is outlined in Table A7.1.3. The intercept and all covariat©s 
included are individually significant and there is no interaction between 
covariates. Model B also is not significantly different from Model A. 
This was shown by the likelihood ratio test. The loss of 182 degrees of 
freedom results in a drop of 165.66 in the likelihood ratio. The 
likelihood ratio has a XI distribution, so its associated p-value is 0.70, 
indicating that the two models are not significantly different. 
Table A7.1.3: Logit Regression on Patient Admission Factors Explaining 
ICU Mortality (Analysis of Maximum Likelihood Estimates and Analysis 
of Variance) Reduced Model B 
Source Estimate 
(ßJ 
Standard 
error of ßý 
DF X, 4) 2 P 
Intercept (fo) -2.715 0.776 1 12.24 0.06 0.0005 
CPR 0.757 0.321 1 5.55 2.13 0.0185 
APACHE II' 16-18 0.580 0.278 1 4.35 1.79 0.0370 
APACHE II 19-20 0.912 0.263 1 12.02 2.49 0.0005 
APACHE II 21-30 1.096 0.240 1 20.94 2.99 <0.00005 
APACHE 11 31-44 1.571 0.600 1 6.96 4.81 0.0083 
Likelihood ratio - - 3 4.73 - 0.1926 
' Continuous variables converted to categories to reduce number of populations, 
categories compared with APACHE II score 0-15. 
2 Log odds ratio 
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The logit expression of Model B is expressed by the following equation: 
Logit (ICU mortality) = -2.715 + 0.757(CPR) + 
0.580(APACHE 16-18) + 
+ 0.912(APACHE 19-20) 
1.096(APACHE 21-26) + 
1.571 (APACHE 27-44) 
The test of how well a logit model fits the data from which it is derived 
is to assess its sensitivity (correct prediction of death), specificity 
(correct prediction of survival), false positive rate (predicted to die, but 
lived) and overall correct prediction rate (see table A7.1.4). 
Table A7.1.4 Fit of Logit Model B (Explanation of LTH ICU Mortality by 
Admission Characteristics) to Parent Dataset 
Model Parameter Results of running logit 
on parent dataset (%) 
Sensitivity 100 
Specificity 98.1 
False positive rate 1.9' 
Overall correct 
prediction rate 
98.6 
'Three patients who lived were predicted to die on the ICU. 
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A7.1.2 Logit Regression Analysis of Hospital Mortality at LTH 
Model C was developed for explanation of hospital mortality, 
summarised in Table A7.1.5. 
Table A7.1.5 Logit Regression on Factors Explaining Hospital Mortality 
(Reduced Model C) 
Source Estimate 
(19") 
Standard 
error of 
A 
DF X2 y2 P 
Intercept (ß0) -4.898 0.893 1 30.06 0.01 <0.0005 
PA catheter on ICU 0.517 0.198 1 6.82 1.68 0.0090 
Neurosurgery 0.714 0.246 1 8.44 2.04 0.0037 
CPR 0.950 0.454 1 4.37 1.57 0.0365 
APACHE II' 16-18 0.679 0.227 1 8.90 1.97 0.0029 
APACHE II 19-20 1.018 0.256 1 15.76 2.77 0.0001 
APACHE II 21-26 1.483 0.423 1 12.28 4.41 0.0005 
APACHE II 27-44 1.925 0.552 1 12.19 6.86 0.0005 
Likelihood ratio - - 20 19.98 - 0.4591 
Continuous variables converted to categories to reduce number of populations, 
categories compared with APACHE II score 0-15. 
2 Log odds ratio 
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Table A7.1.6 Fit of Logit Model C (Explanation of LTH Hospital 
Mortality) to Parent Dataset 
Model Parameter Results of running logit on 
parent dataset (%) 
Sensitivity 100.0 
Specificity 95.3 
False positive rate 4.7 
Overall correct prediction rate 97.0 
Although the covariate 'NEURO' was independently significant in Model 
C, removing it improved the 'fit' of the model so that specificity was 
99.2% and overall correct prediction was 99.5%. Removal of any of 
the other covariates in Model C rendered the restricted logit model 
significantly different from the unrestricted model. 
A7.1.3 Derivation of Logit Regression Model to Explain ICU Mortality at 
DGH 
This section assesses to what extent the outcome of patients can be 
predicted on their admission to ICU at DGH. A correlation matrix was 
derived for all the covariates in the analysis. This detected the extent of 
two-dimensional interaction between the covariates. Marginally 
significant multicollinearity (n=137, critical p=0.220, p=0.05) was 
detected between many combinations of covariates but none produced 
independently significant principal components. The resulting model D 
is summarised in Table A7.1.7. 
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Table A7.1.7 Logit Regression on Patient Admission Factors to Explain 
ICU Mortality at DGH (Reduced Model D) 
Source Estimate 
(/3n) 
Standard 
error of 
DF x2 4) 2 P 
Intercept (/0) 2.045 0.396 1 26.69 7.73 <0.00005 
MEDICAL 1.280 0.397 1 10.38 3.60 0.0013 
APACHE II score 
> 20' 
0.776 0.298 1 6.77 2.17 0.0093 
Likelihood ratio - - 1 0.01 - 0.9258 
' Continuous variables converted to categories to reduce number of populations: 
category compared with APACHE II score 0 to 20. 
2 Log odds ratio 
Table A7.1.8 Fit of Logit Model D (Explanation of DGH ICU Mortality) 
to Parent Dataset 
Model Parameter Results of running logit on 
parent dataset (%1 
Sensitivity 100.0 
Specificity 100.0 
False positive rate 0.0 
Overall correct prediction rate 100.0 
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A7.1.4 Derivation of Logit Regression Model to Explain Hospital 
Mortality at DGH 
This section investigated which factors affect hospital mortality. The 
resultant model E is described in Table A7.1.9. 
Table A7.1.9 Logit Regression on Factors to Explain Hospital Mortality 
(Reduced Model E) 
Source Estimate 
(/3) 
Standard 
error of 
Qn 
DF X2 ty P 
Intercept (/30) 0.884 0.371 1 5.69 2.42 0.0171 
ELECT -0.603 0.279 1 4.66 0.55 0.0309 
VENT 0.622 0.265 1 5.52 1.86 0.0188 
APACHE II score 
> 201 
0.495 0.237 1 4.37 1.64 0.0365 
HOSPLOS >6 days2 -0.554 0.259 1 4.58 0.57 0.0324 
Likelihood ratio - - 9 13.98 - 0.1231 
' Continuous variables converted to categories to reduce number of populations: 
category compared with APACHE II score 0-20. 
2 Continuous variables converted to categories to reduce number of populations: 
category compared with length of hospital stay of 0 to 6 days. 
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Table A7.1.10 Fit of Logit Model E (Explanation of DGH Hospital 
Mortality) to Parent Dataset 
Model Parameter Results of running logit 
on parent dataset (%) 
Sensitivity 87.2 
Specificity 100.0 
False positive rate 0.0 
Overall correct prediction rate 96.1 
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Appendix 7.2 Effect of Centre on ICU, Hospital and 6 Month Mortality: 
Logit models 
Datasets from the two centres were merged. The LTH logit models 
were run on the combined dataset to assess the effect of centre on six 
month mortality. 
A7.2.1 Logit Regression Analysis of 6 Month Mortality of the Two 
Centres 
Model Al was developed for explanation of 6 month mortality. The 
covariates summarised in Table A7.2.1 were found to retain 
independent significance. 
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Table A7.2.1 Analysis of Maximum Likelihood Estimates and Analysis 
of Variance (Reduced model Al) 
Source Estimate 
(ß) 
Standard 
error of 8 
DF x2 4'' P 
Intercept (/ 0) -2.843 0.562 1 25.64 0.06 <0.00005 
PA catheter on ICU 0.327 0.146 1 4.98 1.39 0.0256 
Hospital LOS 6-11 
days' 
-1.015 0.278 1 13.34 0.33 0.0003 
Hospital LOS > 11 
days 
-1.300 0.229 1 32.22 0.27 <0.00005 
Presence of cancer 0.636 0.170 1 13.99 2.89 0.0002 
APACHE 112 16-18 0.574 0.206 1 7.79 1.77 0.0053 
APACHE II 19-20 0.882 0.212 1 17.37 2.42 <0.00005 
APACHE II 21-30 0.997 0.301 1 10.95 2.71 0.0009 
APACHE II 31-44 1.244 0.252 1 24.31 3.47 <0.00005 
LTH admission 0.272 0.148 1 3.38 1.31 0.0659 
Likelihood ratio - - 57 76.84 - 0.0410 
' Continuous variables converted to categories to reduce number of populations, 
categories compared with hospital LOS of less than 6 days. 
2 Continuous variables converted to categories to reduce number of populations, 
categories compared with APACHE II score 0-15. 
3 Log odds ratio 
This model suggests that centre has a marginal effect on 6 month 
mortality. However, the model was significantly different from the 
unrestricted model. On investigation, it was found that when 'ELECT' 
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was controlled for, the centre lost significance. This model is 
summarised in Table A7.2.2. 
Table A7.2.2 Reduced model A2 (Explanation of Six Month Mortality) 
Source Estimate 
(ßn) 
Standard 
error of ß 
DF X2 4) 3 P 
Intercept (ß0) -2.297 0.585 1 15.40 0.10 0.0001 
PA catheter on ICU 0.350 0.148 1 5.57 1.42 0.0183 
Hospital LOS 6-11 
days' 
-0.944 0.280 1 11.37 0.39 0.0007 
Hospital LOS > 11 
days 
-1.199 0.228 1 27.75 0.30 <0.00005 
Presence of cancer 0.735 0.173 1 17.97 2.08 <0.00005 
APACHE 112 16-18 0.470 0.210 1 5.03 1.60 0.0250 
APACHE II 19-20 0.749 0.217 1 11.87 2.11 0.0006 
APACHE II 21-30 0.792 0.302 1 6.87 2.21 0.0087 
APACHE II 31-44 1.058 0.250 1 17.98 2.88 <0.00005 
ELECT -0.471 0.158 1 8.89 0.62 0.0029 
Likelihood ratio - - 48 59.24 - 0.1281 
' Continuous variables converted to categories to reduce number of populations, 
categories compared with hospital LOS of less than 6 days. 
2 Continuous variables converted to categories to reduce number of populations, 
categories compared with APACHE II score 0-15. 
1 Log odds ratio 
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Table A7.2.3 Fit of Logit Model A2 (Explanation of 6 Month Mortality) 
to Parent Dataset 
Model Parameter Results of running logit 
on parent dataset (%) 
Sensitivity 99.3 
Specificity 97.7 
False positive rate 2.3' 
Overall correct prediction rate 98.5 
' Four patients predicted to die within 6 months of discharge, who lived. 
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